Name,SMILES,Target,SMILES_Canonical
"1,2-Benzodiazepine",N1N=CC=CC2=CC=CC=C12,,C1=Cc2ccccc2NN=C1
"1,2-Distearoyllecithin",CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC
"1,2-icosapentoyl-sn-glycero-3-phosphoserine",[H]C(N)(COP(O)(=O)OCC([H])(COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(=O)CCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(O)=O,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC(COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OCC(N)C(=O)O
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)),CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OCC(O)CO
"2,2'-Dibenzothiazyl disulfide",S(SC1=NC2=CC=CC=C2S1)C1=NC2=CC=CC=C2S1,,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
2-mercaptobenzothiazole,S=C1NC2=C(S1)C=CC=C2,,S=c1[nH]c2ccccc2s1
4-(Isopropylamino)diphenylamine,CC(C)NC1=CC=C(NC2=CC=CC=C2)C=C1,,CC(C)Nc1ccc(Nc2ccccc2)cc1
5-O-phosphono-alpha-D-ribofuranosyl diphosphate,O[C@H]1[C@@H](O)[C@@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O,,O=P(O)(O)OC[C@H]1O[C@H](OP(=O)(O)OP(=O)(O)O)[C@H](O)[C@@H]1O
Abacavir,NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1,Gag-Pol polyprotein;Reverse transcriptase/RNaseH;Reverse transcriptase,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1
Abametapir,CC1=CC=C(N=C1)C1=CC=C(C)C=N1,C-C chemokine receptor type 5;C-C chemokine receptor type 1;C-C chemokine receptor type 8,Cc1ccc(-c2ccc(C)cn2)nc1
Abarelix,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,Gonadotropin-releasing hormone receptor,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Abemaciclib,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1,Potassium voltage-gated channel subfamily H member 2;Cyclin-dependent kinase 1;Cyclin-dependent kinase 9;Cyclin-dependent kinase 7;Cyclin-dependent kinase 6;Cyclin-dependent kinase 4,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1
Abiraterone,[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,Corticosteroid-binding globulin;Sex hormone-binding globulin;Glucose-6-phosphate 1-dehydrogenase,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
Abrocitinib,CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1,Tyrosine-protein kinase JAK3;AP2-associated protein kinase 1;BMP-2-inducible protein kinase;Cyclin-G-associated kinase;Non-receptor tyrosine-protein kinase TYK2;Tyrosine-protein kinase JAK1;Tyrosine-protein kinase JAK2,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1,Receptor tyrosine-protein kinase erbB-2;Tyrosine-protein kinase Lyn;Receptor tyrosine-protein kinase erbB-4;Cytoplasmic tyrosine-protein kinase BMX;Tyrosine-protein kinase Tec;Tyrosine-protein kinase TXK;Tyrosine-protein kinase BTK,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12
Acamprosate,CC(=O)NCCCS(O)(=O)=O,GABA-A receptor alpha-1/beta-3/gamma-2;Glutamate [NMDA] receptor,CC(=O)NCCCS(=O)(=O)O
Acarbose,[H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO,"Maltase-glucoamylase, intestinal;Pancreatic alpha-amylase;Alpha-amylase 1;Lysosomal alpha-glucosidase;Sucrase-isomaltase, intestinal;Alpha-amylase;Oligo-1,6-glucosidase",C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@@H]([C@H](O)[C@@H](O)C=O)[C@H](O)CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
Acebutolol,CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
Aceclidine,CC(=O)OC1CN2CCC1CC2,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Muscarinic acetylcholine receptor,CC(=O)OC1CN2CCC1CC2
Aceclofenac,OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Transthyretin;Aldose reductase;Mitogen-activated protein kinase 1;Prostaglandin G/H synthase 2,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Acemetacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Lactoylglutathione lyase,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Acenocoumarol,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O,Vitamin K epoxide reductase complex subunit 1,CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O
Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,,CC(=O)Nc1ccc(O)cc1
Acetarsol,CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O,,CC(=O)Nc1cc([As](=O)(O)O)ccc1O
Acetazolamide,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,"Carbonic anhydrase 2, isoform A; LD26647p;Carbonic anhydrase 1; GH09688p;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Aquaporin-1;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Endochitinase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase V;Carbonic anhydrase, alpha family;Carbonate dehydratase;Carbonic anhydrase-related protein 11",CC(=O)Nc1nnc(S(N)(=O)=O)s1
Acetic acid,CC(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CC(=O)O
Acetohexamide,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,"Sulfonylurea receptor 1, Kir6.2",CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
Acetohydroxamic acid,CC(=O)NO,Carbonic anhydrase 2;Bacterial urease;Urease;Urease subunit beta,CC(=O)NO
Acetophenazine,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,D(2) dopamine receptor;Androgen receptor,CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2
Acetyl sulfisoxazole,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1,Dihydropteroate synthase;Endothelin-1 receptor;Endothelin B receptor,CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1
Acetylcarnitine,CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C,"Carnitine O-palmitoyltransferase 1, liver isoform;Carnitine O-palmitoyltransferase 1, muscle isoform;Carnitine palmitoyltransferase 2",CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C
Acetylcholine,CC(=O)OCC[N+](C)(C)C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Neuronal acetylcholine receptor subunit alpha-7;Acetylcholine-binding protein;Acetylcholine receptor subunit delta;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Muscarinic acetylcholine receptor;Nicotinic acetylcholine receptor alpha8 subunit,CC(=O)OCC[N+](C)(C)C
Acetylcysteine,CC(=O)N[C@@H](CS)C(O)=O,"Cytochrome c;Vascular endothelial growth factor A;Superoxide dismutase [Mn], mitochondrial;Glutathione synthetase;Cystine/glutamate transporter",CC(=O)N[C@@H](CS)C(=O)O
Acetyldigitoxin,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,Sodium/potassium-transporting ATPase,CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O
Acetylene,C#C,,C#C
Acetylsalicylic acid,CC(=O)OC1=CC=CC=C1C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Acidic phospholipase A2 3;Gamma-glutamyltranspeptidase 1;Acid-sensing ion channel 3;Nicotinate phosphoribosyltransferase,CC(=O)Oc1ccccc1C(=O)O
Acipimox,CC1=[N+]([O-])C=C(N=C1)C(O)=O,Hydroxycarboxylic acid receptor 2,Cc1cnc(C(=O)O)c[n+]1[O-]
Acitretin,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1,Retinoic acid receptor alpha;Bile salt export pump;Retinoic acid receptor gamma,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Aclidinium,OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1
Acrivastine,[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O,Multidrug resistance protein 1;Histamine H1 receptor,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1
Activated charcoal,[C],,[C]
Acyclovir,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,Purine nucleoside phosphorylase;Thymidine kinase;DNA polymerase catalytic subunit,Nc1nc(=O)c2ncn(COCCO)c2[nH]1
Adagrasib,[H][C@@]1(COC2=NC3=C(CCN(C3)C3=CC=CC4=C3C(Cl)=CC=C4)C(=N2)N2CCN(C(=O)C(F)=C)[C@@]([H])(CC#N)C2)CCCN1C,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Adapalene,COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2,Glycine receptor subunit alpha-1;Retinoic acid receptor alpha;Retinoic acid receptor beta;Retinoic acid receptor gamma,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Adefovir dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C,Protein P;DNA polymerase subunit gamma-1;Capsid protein,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C
Ademetionine,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N,Protein arginine N-methyltransferase 1;S-adenosylmethionine decarboxylase proenzyme;Met repressor;Phenylethanolamine N-methyltransferase;Protein-beta-aspartate methyltransferase,C[S+](CC[C@H](N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O
Adenine,NC1=C2NC=NC2=NC=N1,"Xanthine dehydrogenase/oxidase;Phosphatidylinositol 4-kinase, PI4K",Nc1ncnc2nc[nH]c12
Adenosine,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,"Adenosine receptor A2a;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;Adenosine kinase;Adenosine deaminase;Mitogen-activated protein kinase kinase kinase 7;Adenosylhomocysteinase;Adenosine A2 receptor;Phosphatidylinositol 4-kinase type 2-alpha;Phosphatidylinositol 4-kinase type 2-beta;Glyceraldehyde-3-phosphate dehydrogenase liver;cAMP-dependent protein kinase A;Histone-lysine N-methyltransferase, H3 lysine-79 specific",Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Adenosine phosphate,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1,"Fructose-1,6-bisphosphatase 1;Proto-oncogene tyrosine-protein kinase Src;Transient receptor potential cation channel subfamily M member 2;Transient receptor potential cation channel subfamily M member 4;Pol polyprotein;Alcohol dehydrogenase;L-lactate dehydrogenase A chain;Ketopantoate reductase;Adenylate kinase 2;2'-deoxynucleoside 5'-phosphate N-hydrolase 1",Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O
Adiphenine,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,Histamine H1 receptor;Muscarinic acetylcholine receptor,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1
Afamelanotide,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,Adenosine deaminase;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3;Melanocyte-stimulating hormone receptor,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C
Afatinib,CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1,"Tyrosine-protein kinase ABL1;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Receptor-type tyrosine-protein kinase FLT3;Receptor tyrosine-protein kinase erbB-2;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Tyrosine-protein kinase HCK;Receptor tyrosine-protein kinase erbB-4;Mitogen-activated protein kinase 10;Hepatocyte growth factor receptor;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Serine/threonine-protein kinase 10;Serine/threonine-protein kinase 17A;Ephrin type-A receptor 6;Casein kinase I isoform epsilon;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;STE20-like serine/threonine-protein kinase;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Tyrosine-protein kinase receptor UFO;Ribosomal protein S6 kinase alpha-6;Tyrosine-protein kinase TXK;Dual specificity tyrosine-phosphorylation-regulated kinase 1B;MAP kinase-interacting serine/threonine-protein kinase 1;Tyrosine-protein kinase Blk;Citron Rho-interacting kinase;Dual specificity tyrosine-phosphorylation-regulated kinase 1A;Dual specificity tyrosine-phosphorylation-regulated kinase 2;Ephrin type-B receptor 6;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Receptor tyrosine-protein kinase erbB-3;Serine/threonine-protein kinase SBK1;Dual specificity mitogen-activated protein kinase kinase 5",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1
Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;Melatonin receptor;5-hydroxytryptamine receptor 2C;Melatonin receptor type 1A;Melatonin receptor type 1B,COc1ccc2cccc(CCNC(C)=O)c2c1
Ajmaline,[H][C@]12C[C@]34[C@H](O)C1[C@@]1([H])C[C@]([H])(N2[C@H](O)[C@H]1CC)[C@]3([H])N(C)C1=CC=CC=C41,Sodium channel protein type 5 subunit alpha;Cytochrome P450 2D6;Potassium voltage-gated channel subfamily D member 3;Potassium voltage-gated channel subfamily A member 5,CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)c5ccccc5[C@]45C[C@@H](C2[C@H]5O)N3[C@@H]1O
Alatrofloxacin,[H][C@@]12CN(C[C@]1([H])[C@H]2NC(=O)[C@H](C)NC(=O)[C@H](C)N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=CC=C(F)C=C1F)C(O)=O,Topoisomerase IV;DNA gyrase,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]21
Albendazole,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,Tubulin alpha chain;Tubulin,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
Alcaftadine,CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12,Histamine H1 receptor,CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1
Alclofenac,OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,C=CCOc1ccc(CC(=O)O)cc1Cl
Alclometasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C,,C[C@@H]1C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl
Alcloxa,[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)[N-]C1=O,,NC(=O)NC1NC(=O)[N-]C1=O.[Al+3].[Al+3].[Cl-].[OH-].[OH-].[OH-].[OH-]
Alectinib,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O,Vascular endothelial growth factor receptor 2;SRSF protein kinase 1;Proto-oncogene tyrosine-protein kinase ROS;ALK tyrosine kinase receptor;Proto-oncogene tyrosine-protein kinase receptor Ret,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
Alendronic acid,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,,NCCCC(O)(P(=O)(O)O)P(=O)(O)O
Alfacalcidol,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,Sodium-dependent noradrenaline transporter;Vitamin D3 receptor,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Alfentanil,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O,Mu-type opioid receptor;Multidrug resistance protein 1;Opioid receptor,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1
Alfuzosin,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1,Alpha-1A adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Acetylcholinesterase;Solute carrier family 22 member 1,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC
Alimemazine,CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12,Histamine H1 receptor;FAD-linked sulfhydryl oxidase ALR,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21
Aliskiren,COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1,Cytochrome P450 3A4;Multidrug resistance protein 1;Renin;Renin-1;Protease,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC
Alitretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O,Retinoic acid receptor alpha;Retinoic acid receptor RXR-alpha;Retinoic acid receptor RXR-beta;Retinoic acid receptor RXR-gamma;Retinoic acid receptor beta;Retinoic acid receptor gamma;Nuclear receptor ROR-gamma;Nuclear receptor subfamily 4 group A member 1;Oxysterols receptor LXR-beta;Oxysterols receptor LXR-alpha,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Allantoin,NC(=O)NC1NC(=O)NC1=O,,NC(=O)NC1NC(=O)NC1=O
Alloin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(CO)C=C2O,,O=C1c2c(O)cccc2C([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c2cc(CO)cc(O)c21
Allopurinol,OC1=NC=NC2=C1C=NN2,Xanthine dehydrogenase/oxidase;Hypoxanthine-guanine phosphoribosyltransferase;Shiga toxin subunit A,Oc1ncnc2[nH]ncc12
Almasilate,O.[Mg++].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-],,O.[Al+3].[Al+3].[Mg+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-]
Almitrine,FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1,"Sodium channel protein type 5 subunit alpha;Sigma non-opioid intracellular receptor 1;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha;5-hydroxytryptamine receptor 3A;Sodium channel protein type 10 subunit alpha;Dihydrofolate reductase;Sodium channel alpha subunits; brain (Types I, II, III);Sodium channel protein type X alpha subunit",C=CCNc1nc(NCC=C)nc(N2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)n1
Almotriptan,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1F,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12
Alogliptin,CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O,Dipeptidyl peptidase 4,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O
Alosetron,CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2,Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 3A;Cytochrome P450 1A2,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
Alpelisib,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1
Alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,Cytochrome P450 3A4;Platelet-activating factor receptor;Cholecystokinin receptor type A;Bromodomain-containing protein 4;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
Alprostadil,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,Prostaglandin E2 receptor EP1 subtype;Prostaglandin E2 receptor EP3 subtype;Prostacyclin receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Cation channel sperm-associated protein 1;Cation channel sperm-associated protein 2;Cation channel sperm-associated protein 3;Cation channel sperm-associated protein 4,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
Altretamine,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,Cytochrome P450 1A2,CN(C)c1nc(N(C)C)nc(N(C)C)n1
Aluminium,[Al],,[Al]
Aluminium phosphate,[Al+3].[O-]P([O-])([O-])=O,"Ribonucleoside-diphosphate reductase large subunit;Ribonucleoside-diphosphate reductase subunit M2;Carbonic anhydrase 5A, mitochondrial;Adenosine receptor A1;Adenosine receptor A2a;Adenosine receptor A3;DNA polymerase alpha catalytic subunit",O=P([O-])([O-])[O-].[Al+3]
Aluminum acetate,[Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O,,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Al+3]
Aluminum chloride,Cl[Al](Cl)Cl,,[Cl][Al]([Cl])[Cl]
Aluminum chlorohydrate,O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-],,O.[Al+3].[Al+3].[Cl-].[OH-].[OH-].[OH-].[OH-].[OH-]
Aluminum hydroxide,[OH-].[OH-].[OH-].[Al+3],,[Al+3].[OH-].[OH-].[OH-]
Aluminum oxide,[O--].[O--].[O--].[Al+3].[Al+3],,[Al+3].[Al+3].[O-2].[O-2].[O-2]
Aluminum subacetate,CC(=O)O[Al](O)OC(C)=O,,CC(=O)[O][Al]([OH])[O]C(C)=O
Aluminum sulfate,[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,Bifunctional epoxide hydrolase 2,O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Al+3].[Al+3]
Aluminum zirconium octachlorohydrex gly,O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O,,NCC(=O)[O-].O.O.[Al+3].[Cl-].[Zr+4]
Alverine,CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1,Acetylcholinesterase;Cholinesterase;Gamma-glutamyltranspeptidase 1;Asc-type amino acid transporter 1;Amino acid transporter,CCN(CCCc1ccccc1)CCCc1ccccc1
Alvimopan,C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Amantadine,NC12CC3CC(CC(C3)C1)C2,Sigma non-opioid intracellular receptor 1;Multidrug and toxin extrusion protein 1;Matrix protein 2;Glutamate [NMDA] receptor,NC12CC3CC(CC(C3)C1)C2
Ambenonium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl,Acetylcholinesterase,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Endothelin B receptor;Endothelin-1 receptor,COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O
Ambroxol,NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1,Sodium-dependent serotonin transporter;Cytochrome P450 2D6;Sodium channel protein type 10 subunit alpha;Glucosylceramidase,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1
Amcinonide,[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Amifampridine,NC1=CC=NC=C1N,Voltage-gated potassium channel,Nc1ccncc1N
Amifostine,NCCCNCCSP(O)(O)=O,"D(3) dopamine receptor;Alkaline phosphatase, tissue-nonspecific isozyme",NCCCNCCSP(=O)(O)O
Amikacin,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
Amiloride,NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N,"Amiloride-sensitive sodium channel subunit alpha;Urokinase-type plasminogen activator;Adenosine receptor A2a;Amine oxidase [flavin-containing] A;Sodium/hydrogen exchanger 1;Solute carrier family 22 member 1;Acid-sensing ion channel 2;Acid-sensing ion channel 1;Membrane primary amine oxidase;Acid-sensing ion channel 3;Amiloride-sensitive sodium channel, ENaC;Sodium/hydrogen exchanger;Sodium/hydrogen exchanger 5;Sodium/hydrogen exchanger 2",N=C(N)NC(=O)c1nc(Cl)c(N)nc1N
Amiloxate,COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1,,COc1ccc(/C=C/C(=O)OCCC(C)C)cc1
Aminobenzoic acid,NC1=CC=C(C=C1)C(O)=O,,Nc1ccc(C(=O)O)cc1
Aminocaproic acid,NCCCCCC(O)=O,,NCCCCCC(=O)O
Aminoglutethimide,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1,"Aromatase;Thromboxane-A synthase;Cholesterol side-chain cleavage enzyme, mitochondrial;Cytochrome P450 11A1",CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
Aminohippuric acid,NC1=CC=C(C=C1)C(=O)NCC(O)=O,,Nc1ccc(C(=O)NCC(=O)O)cc1
Aminolevulinic acid,NCC(=O)CCC(O)=O,,NCC(=O)CCC(=O)O
Aminophenazone,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Nicotinate phosphoribosyltransferase,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C
Aminophylline,NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;cAMP-specific 3',5'-cyclic phosphodiesterase 4B",Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN
Aminosalicylic acid,NC1=CC(O)=C(C=C1)C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Acidic phospholipase A2 3;Gamma-glutamyltranspeptidase 1;Acid-sensing ion channel 3;Nicotinate phosphoribosyltransferase,Nc1ccc(C(=O)O)c(O)c1
Amiodarone,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,"Beta-1 adrenergic receptor;Sodium channel protein type 5 subunit alpha;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Thyroid hormone receptor alpha;Thyroid hormone receptor beta;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;D(4) dopamine receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Cytochrome P450 2C9;Voltage-dependent T-type calcium channel subunit alpha-1H;Endothelin-1 receptor;Squalene monooxygenase;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Squalene synthase;C-C chemokine receptor type 2;Substance-K receptor;Androgen receptor;Lethal factor;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Potassium voltage-gated channel subfamily A member 7;5-hydroxytryptamine receptor 1B;B2 bradykinin receptor;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3;C-C chemokine receptor type 4;Membrane-associated progesterone receptor component 1;C-8 sterol isomerase;Cruzipain;THAP domain-containing protein 1;Lysine-specific demethylase PHF2;Lysine-specific demethylase 5A;Lysine-specific demethylase 7A",CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
Amisulpride,CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;D(3) dopamine receptor;D(2) dopamine receptor,CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC
Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,Sodium channel protein type 5 subunit alpha;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 9 subunit alpha;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Proto-oncogene tyrosine-protein kinase receptor Ret;High affinity nerve growth factor receptor;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Transporter;Solute carrier family 22 member 2;Muscarinic acetylcholine receptor;G protein-activated inward rectifier potassium channel 2,CN(C)CCC=C1c2ccccc2CCc2ccccc21
Amitriptylinoxide,CN(C)(=O)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,Proto-oncogene tyrosine-protein kinase receptor Ret,C[N+](C)([O-])CCC=C1c2ccccc2CCc2ccccc21
Amlexanox,CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1,Inhibitor of nuclear factor kappa-B kinase subunit epsilon;Serine/threonine-protein kinase TBK1;G-protein coupled receptor 35;Phosphodiesterase 4,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1
Amlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Aldehyde oxidase;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Voltage-dependent calcium channel gamma-1 subunit;Voltage-dependent L-type calcium channel subunit alpha-1C;Carbonic anhydrase 1;Voltage-dependent calcium channel subunit alpha-2/delta-1;Voltage-dependent L-type calcium channel subunit alpha-1D;Voltage-dependent T-type calcium channel subunit alpha-1H;Potassium channel subfamily K member 2,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
Ammonia N-13,[13NH3],,[13NH3]
Ammonium carbonate,[NH4+].[NH4+].[O-]C([O-])=O,,O=C([O-])[O-].[NH4+].[NH4+]
Ammonium chloride,[NH4+].[Cl-],,[Cl-].[NH4+]
Ammonium lactate,[NH4+].CC(O)C([O-])=O,,CC(O)C(=O)[O-].[NH4+]
Amobarbital,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
Amodiaquine,CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1,Potassium voltage-gated channel subfamily H member 2;Histamine N-methyltransferase;Heparanase;Amyloid beta A4 protein,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
Amorolfine,[H]C(C)(CN1C[C@]([H])(C)O[C@]([H])(C)C1)CC1=CC=C(C=C1)C(C)(C)CC,"Angiotensin-converting enzyme;Glutamate receptor ionotropic, NMDA 1",CCC(C)(C)c1ccc(CC(C)CN2C[C@@H](C)O[C@@H](C)C2)cc1
Amoxapine,ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 3A;Sodium- and chloride-dependent glycine transporter 2;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;GABA-A receptor alpha-1/beta-2/gamma-2,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
Amoxicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
Amphetamine,CC(N)CC1=CC=CC=C1,"Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Histamine H1 receptor;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Nischarin;Adrenergic receptor alpha-2;Sodium channel alpha subunits; brain (Types I, II, III)",CC(N)Cc1ccccc1
Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,,C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O
Ampicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,Penicillin-binding protein 1A;Angiopoietin-1 receptor;Transient receptor potential cation channel subfamily M member 4;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Amprenavir,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Cytochrome P450 3A4;Gag-Pol polyprotein;Thromboxane-A synthase;Cathepsin D;Pol polyprotein;Protease,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
Amrinone,NC1=CC(=CNC1=O)C1=CC=NC=C1,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;Dual specificity protein kinase TTK;cGMP-inhibited 3',5'-cyclic phosphodiesterase B;Phosphodiesterase 4",Nc1cc(-c2ccncc2)c[nH]c1=O
Amsacrine,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1,"Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 2D6;DNA topoisomerase 2-alpha;DNA topoisomerase I, mitochondrial;DNA topoisomerase 1;DNA topoisomerase 2-beta;Solute carrier family 22 member 1;DNA topoisomerase II",COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
Amyl Nitrite,CCCCCON=O,,CCCCCON=O
Amylmetacresol,CCCCCC1=CC=C(C)C=C1O,,CCCCCc1ccc(C)cc1O
Amylocaine,CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1,"Sodium channel alpha subunits; brain (Types I, II, III)",CCC(C)(CN(C)C)OC(=O)c1ccccc1
Anagrelide,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;cGMP-dependent 3',5'-cyclic phosphodiesterase",O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1
Anastrozole,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,Aromatase,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
Anethole,COC1=CC=C(\C=C\C)C=C1,,C/C=C/c1ccc(OC)cc1
Anethole trithione,COC1=CC=C(C=C1)C1=CC(=S)SS1,,COc1ccc(-c2cc(=S)ss2)cc1
Anidulafungin,[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,"Beta-1,3-glucan synthase catalytic subunit 1",CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1
Anileridine,CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1,Mu-type opioid receptor,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1
Anisindione,COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,Vitamin K-dependent gamma-carboxylase;Arachidonate 5-lipoxygenase,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1
Anisotropine methylbromide,[Br-].CCCC(CCC)C(=O)O[C@H]1CC2CCC(C1)[N+]2(C)C,,CCCC(CCC)C(=O)OC1CC2CCC(C1)[N+]2(C)C.[Br-]
Antazoline,C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1,Histamine H1 receptor,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1
Anthralin,OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2,,O=C1c2c(O)cccc2Cc2cccc(O)c21
Antipyrine,CN1N(C(=O)C=C1C)C1=CC=CC=C1,,Cc1cc(=O)n(-c2ccccc2)n1C
Antrafenine,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1,D(1A) dopamine receptor;D(2) dopamine receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Epidermal growth factor receptor;C-C chemokine receptor type 5;Tyrosine-protein kinase Fyn;Cytochrome P450 2J2;Substance-K receptor;Potassium voltage-gated channel subfamily H member 1;Alpha-1B adrenergic receptor;Heat shock protein HSP 90-alpha;Adrenergic receptor alpha-1;Transcriptional activator protein luxR,O=C(OCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1ccccc1Nc1ccnc2cc(C(F)(F)F)ccc12
Apalutamide,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F,Androgen receptor,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Prothrombin;Coagulation factor X,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Apomorphine,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Solute carrier family 22 member 1;Transient receptor potential cation channel subfamily A member 1;5-hydroxytryptamine receptor 7;Zinc finger protein mex-5;Opioid receptor;Serotonin (5-HT) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Adrenergic receptor alpha-1;Mannose-6-phosphate isomerase;Cytoplasmic zinc-finger protein;E3 ubiquitin-protein ligase Mdm2,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3
Apraclonidine,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1,Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Adrenergic receptor alpha-1,Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1
Apremilast,CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;cAMP-specific 3',5'-cyclic phosphodiesterase 4C;cAMP-specific 3',5'-cyclic phosphodiesterase 4D",CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
Aprepitant,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,Cytochrome P450 3A4;Substance-P receptor;Neuromedin-K receptor,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Apronalide,CC(C)C(CC=C)C(=O)NC(N)=O,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 7;Adrenergic receptor alpha-2;Dopamine receptor;Cerebral cortex alpha adrenergic receptor;D(1A) dopamine receptor,C=CCC(C(=O)NC(N)=O)C(C)C
Arbutamine,O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1,Beta-1 adrenergic receptor,Oc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1
Arbutin,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,Tyrosinase;Polyphenol oxidase 2,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O
Arformoterol,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,Beta-3 adrenergic receptor;Beta-2 adrenergic receptor;Beta-1 adrenergic receptor,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1
Argatroban,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2,Prothrombin;Coagulation factor X;Tissue-type plasminogen activator;Cationic trypsin,CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;5-hydroxytryptamine receptor 1A;Histone H1.0,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Aripiprazole lauroxil,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12,5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 7;D(4) dopamine receptor;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 2C;D(3) dopamine receptor;Histamine H1 receptor;5-hydroxytryptamine receptor 1A,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21
Armodafinil,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1,D(2) dopamine receptor;D(3) dopamine receptor;Sodium-dependent dopamine transporter;Alpha-1B adrenergic receptor;Cytochrome P450 1A2;Cytochrome P450 2C19,NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1
Arsenic trioxide,O=[As]O[As]=O,"Potassium voltage-gated channel subfamily H member 2;Thioredoxin reductase 1, cytoplasmic",O=[As]O[As]=O
Artemether,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4,,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3
Artemotil,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OCC)[C@@H]2C)O4,,CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3
Artenimol,[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4,,C[C@@H]1CC[C@H]2[C@@H](C)C(O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4
Artesunate,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4,,C[C@H]1[C@H](OC(=O)CCC(=O)O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3
Articaine,CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC,"Sodium channel alpha subunits; brain (Types I, II, III)",CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC
Arzoxifene,COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,"Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Aldehyde oxidase;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Nuclear receptor subfamily 1 group I member 2;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Estrogen receptor;Delta-type opioid receptor;Acetylcholinesterase;Cytochrome P450 2C9;Estrogen receptor beta;G-protein coupled estrogen receptor 1;Interleukin-6;Tyrosine-protein kinase Fyn;Bile acid receptor;Substance-K receptor;Phospholipase D1;Phospholipase D2;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;C-8 sterol isomerase;Cruzipain;Complement C5;HLA class I histocompatibility antigen, A-3 alpha chain",COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1
Asciminib,O[C@@H]1CCN(C1)C1=C(C=C(C=N1)C(=O)NC1=CC=C(OC(F)(F)Cl)C=C1)C1=CC=NN1,"Multidrug resistance protein 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2A;Histamine H2 receptor;Carbonic anhydrase 2;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Ribosyldihydronicotinamide dehydrogenase [quinone];Carbonic anhydrase 9;Carbonic anhydrase 12;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 2;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Insulin receptor;Thromboxane-A synthase;Mitogen-activated protein kinase 8;Carbonic anhydrase 3;Carbonic anhydrase 6;Mitogen-activated protein kinase 10;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase SYK;Ephrin type-A receptor 8;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Carbonic anhydrase 14;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase PLK4;Abelson tyrosine-protein kinase 2;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase 17A;Tyrosine-protein kinase Fgr;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Cyclin-G-associated kinase;Ephrin type-B receptor 1;Dual specificity protein kinase CLK4;Mitogen-activated protein kinase 9;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Lysine--tRNA ligase;Carbonic anhydrase 13;Carbonic anhydrase 15;Non-receptor tyrosine-protein kinase TYK2;Mitogen-activated protein kinase kinase kinase MLT;Maternal embryonic leucine zipper kinase;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Tyrosine-protein kinase Blk;Cyclin-dependent kinase 19;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;Platelet-derived growth factor receptor;Tyrosine-protein kinase ABL;Bcr/Abl fusion protein",O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2ccn[nH]2)c1
Ascorbic acid,[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO,,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
Asenapine,CN1CC2C(C1)C1=C(OC3=CC=C(Cl)C=C23)C=CC=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1
Asparagine,N[C@@H](CC(N)=O)C(O)=O,Amino acid transporter,NC(=O)C[C@H](N)C(=O)O
Aspartic acid,N[C@@H](CC(O)=O)C(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,N[C@@H](CC(=O)O)C(=O)O
Astemizole,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,"Sodium/nucleoside cotransporter 1;Beta-1 adrenergic receptor;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 3A;Kappa-type opioid receptor;ATP-binding cassette sub-family G member 2;Glycine receptor subunit alpha-1;Calmodulin;Delta-type opioid receptor;Somatostatin receptor type 5;Epidermal growth factor receptor;Substance-P receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Substance-K receptor;Potassium voltage-gated channel subfamily H member 1;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Multidrug and toxin extrusion protein 1;Protein farnesyltransferase;Polycomb protein EED;HLA class I histocompatibility antigen, A-3 alpha chain;Transmembrane protein 97;Histamine H1 receptor",COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
Asunaprevir,COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2,NS3;Genome polyprotein,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1
Ataluren,OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Atazanavir,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Cytochrome P450 3A4;Multidrug resistance protein 1;Cytochrome P450 2C9;Cytochrome P450 1A2;Gag-Pol polyprotein;Pol polyprotein;Reverse transcriptase/RNaseH;UDP-glucuronosyltransferase 1-1;Protease,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
Atenolol,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Adenosine receptor A3;5-hydroxytryptamine receptor 1A,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
Atogepant,C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=C4C=CC=N2)C(=O)N1CC(F)(F)F)C1=C(F)C(F)=CC=C1F,Calcitonin gene-related peptide type 1 receptor,C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
Atomoxetine,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;G protein-activated inward rectifier potassium channel 2;Transporter;Kir3.1/Kir3.2;Kir3.1/Kir3.4;Krueppel-like factor 10,CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Atorvastatin,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,Nuclear receptor subfamily 1 group I member 3;Cytochrome P450 3A4;3-hydroxy-3-methylglutaryl-coenzyme A reductase;Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 6,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Atosiban,[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O,Vasopressin V1a receptor;Vasopressin V1b receptor;Vasopressin V2 receptor;Oxytocin receptor,CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1
Atovaquone,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O,"Dihydroorotate dehydrogenase (quinone), mitochondrial;Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial;Cytochrome b;Dihydroorotate dehydrogenase",O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Atracurium besylate,[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2,,COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1
Atropine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-1D adrenergic receptor;Solute carrier family 22 member 1;Acetylcholinesterase;Muscarinic receptor M1;Muscarinic acetylcholine receptor;Nicotinic acetylcholine receptor alpha 5 subunit,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2
Attapulgite,[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[H]O[H].[H]O[H].[H]O[H].[H]O[H],,O.O.O.O.[Al+3].[Mg+2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-].[Si+4].[Si+4].[Si+4].[Si+4]
Auranofin,CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,"Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Glucocorticoid receptor;Adenosine receptor A3;D(4) dopamine receptor;Arachidonate 5-lipoxygenase;Thioredoxin reductase 1, cytoplasmic;Tyrosine-protein kinase Fyn;Transient receptor potential cation channel subfamily A member 1",CC[P](CC)(CC)=[Au][S][C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
Aurothioglucose,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,"5-hydroxytryptamine receptor 3A;Thioredoxin reductase 1, cytoplasmic;5-hydroxytryptamine receptor 3B;Sulfide:quinone oxidoreductase, mitochondrial",OC[C@H]1O[C@H]([S][Au])[C@H](O)[C@@H](O)[C@@H]1O
Avacopan,CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F,,Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F
Avanafil,COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1,"cGMP-specific 3',5'-cyclic phosphodiesterase;Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'",COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl
Avapritinib,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1,Mast/stem cell growth factor receptor Kit;Platelet-derived growth factor receptor alpha,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Avatrombopag,OC(=O)C1CCN(CC1)C1=C(Cl)C=C(C=N1)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1,Thrombopoietin receptor,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1
Avibactam,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O,Penicillin-binding protein 2;Beta-lactamase,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Avobenzone,COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C,Tyrosinase,COc1ccc(C(=O)CC(=O)c2ccc(C(C)(C)C)cc2)cc1
Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1,"Tyrosine-protein kinase JAK3;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Mitogen-activated protein kinase 8;Fibroblast growth factor receptor 3;Mitogen-activated protein kinase 10;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Myosin light chain kinase 2, skeletal/cardiac muscle;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;AP2-associated protein kinase 1;Hepatocyte growth factor receptor;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase 10;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Fibroblast growth factor receptor 2;TRAF2 and NCK-interacting protein kinase;Tyrosine-protein kinase Fgr;Aurora kinase A;BMP-2-inducible protein kinase;Mitogen-activated protein kinase kinase kinase kinase 5;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Cyclin-dependent kinase 16;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;STE20-like serine/threonine-protein kinase;Calcium/calmodulin-dependent protein kinase kinase 2;Calcium/calmodulin-dependent protein kinase kinase 1;Epithelial discoidin domain-containing receptor 1;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase ITK/TSK;Tyrosine-protein kinase receptor UFO;Serine/threonine-protein kinase N2;Serine/threonine-protein kinase 3;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Mitogen-activated protein kinase kinase kinase MLT;Serine/threonine-protein kinase RIO1;Tyrosine-protein kinase receptor Tie-1;Tyrosine-protein kinase TXK;Casein kinase II subunit alpha';Serine/threonine-protein kinase RIO3;SRSF protein kinase 1;Activin receptor type-2B;Ankyrin repeat and protein kinase domain-containing protein 1;Discoidin domain-containing receptor 2;Mitogen-activated protein kinase kinase kinase kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Mitogen-activated protein kinase kinase kinase kinase 4;Tyrosine-protein kinase Mer;Mitogen-activated protein kinase kinase kinase 9;Serine/threonine-protein kinase MRCK beta;Myosin-IIIa;Serine/threonine-protein kinase PAK 4;Serine/threonine-protein kinase SIK1;Dual specificity testis-specific protein kinase 1;Interferon-induced, double-stranded RNA-activated protein kinase;Receptor-interacting serine/threonine-protein kinase 1;Proto-oncogene tyrosine-protein kinase ROS;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Cyclin-dependent kinase-like 2;Ephrin type-B receptor 6;G protein-coupled receptor kinase 4;Hormonally up-regulated neu tumor-associated kinase;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 3;SRSF protein kinase 3;Serine/threonine-protein kinase ULK2;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Receptor-interacting serine/threonine-protein kinase 4;Bone morphogenetic protein receptor type-1B;Mitogen-activated protein kinase kinase kinase 12;Dual specificity mitogen-activated protein kinase kinase 5;Myosin light chain kinase 3;Leucine-rich repeat serine/threonine-protein kinase 2",CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Azacitidine,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,DNA (cytosine-5)-methyltransferase 1;DNA (cytosine-5)-methyltransferase 3A,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Azatadine,CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2,Histamine H1 receptor,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1
Azathioprine,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O,ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 5;Multidrug resistance-associated protein 4;Ras-related C3 botulinum toxin substrate 1;Thiopurine S-methyltransferase,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
Azelaic acid,OC(=O)CCCCCCCC(O)=O,,O=C(O)CCCCCCCC(=O)O
Azelastine,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Alpha-1B adrenergic receptor;Histamine H3 receptor,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
Azilsartan medoxomil,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1,Type-1 angiotensin II receptor,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1
Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Motilin receptor,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
Azlocillin,[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1,Penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O,Peptidoglycan synthase FtsI;Penicillin-binding protein 1A;Penicillin-binding protein 1B;Beta-lactamase;AmpC;Efflux transporter; SugE,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-]
Bacampicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC,Bacterial penicillin-binding protein,CCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C
Bacitracin,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC,Epidermal growth factor receptor;Tyrosine-protein kinase Lck;5-hydroxytryptamine receptor 1B;Undecaprenyl-diphosphatase,CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
Baclofen,NCC(CC(O)=O)C1=CC=C(Cl)C=C1,GABA B receptor;GABA-B receptor;Adenosine receptor A3;GABA-A receptor; anion channel,NCC(CC(=O)O)c1ccc(Cl)cc1
Baloxavir marboxil,[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12,Polymerase acidic protein,COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O
Balsalazide,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Arachidonate 5-lipoxygenase;Peroxisome proliferator-activated receptor gamma,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
Baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,Tyrosine-protein kinase JAK3;AP2-associated protein kinase 1;BMP-2-inducible protein kinase;Cyclin-G-associated kinase;Non-receptor tyrosine-protein kinase TYK2;Tyrosine-protein kinase JAK1;Tyrosine-protein kinase JAK2,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Barium sulfate,[Ba++].[O-]S([O-])(=O)=O,Bifunctional epoxide hydrolase 2,O=S(=O)([O-])[O-].[Ba+2]
Bazedoxifene,CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1,Estrogen receptor;Estrogen receptor beta,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12
Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Interleukin-5;Mineralocorticoid receptor;Progesterone receptor;Matrix metalloproteinase-9;Androgen receptor;Probable G-protein coupled receptor 97,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
Bedaquiline,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2,Potassium voltage-gated channel subfamily H member 2;ATP synthase;ATP synthase subunit c,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12
Belinostat,ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1,Histone deacetylase 5;Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 3;Histone deacetylase 6;Histone deacetylase 7;Histone deacetylase 8;Histone deacetylase 9;Histone deacetylase 10;Histone deacetylase;Histone deacetylase 11;Bromodomain-containing protein 4;Histone deacetylase 4,O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
Belumosudil,CC(C)NC(=O)COC1=CC=CC(=C1)C1=NC2=C(C=CC=C2)C(NC2=CC=C3NN=CC3=C2)=N1,,CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1
Belzutifan,CS(=O)(=O)C1=CC=C(OC2=CC(=CC(F)=C2)C#N)C2=C1[C@H](O)[C@H](F)[C@@H]2F,,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F
Bemotrizinol,CCCCC(CC)COC1=CC(O)=C(C=C1)C1=NC(=NC(=N1)C1=CC=C(OC)C=C1)C1=C(O)C=C(OCC(CC)CCCC)C=C1,,CCCCC(CC)COc1ccc(-c2nc(-c3ccc(OC)cc3)nc(-c3ccc(OCC(CC)CCCC)cc3O)n2)c(O)c1
Bempedoic acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O
Benazepril,[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
Bendamustine,CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl,Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 3;Histone deacetylase 6;Histone deacetylase 8;Histone deacetylase 10,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21
Bendazac,OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,Prostaglandin D2 receptor 2,O=C(O)COc1nn(Cc2ccccc2)c2ccccc12
Bendroflumethiazide,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F,Carbonic anhydrase 2;Solute carrier family 12 member 3;Carbonic anhydrase 1;Carbonic anhydrase 4;Calcium-activated potassium channel subunit alpha-1,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O
Benfotiamine,C\C(N(CC1=CN=C(C)N=C1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1=CC=CC=C1,Solute carrier family 22 member 1;Beta-1 adrenergic receptor,C/C(=C(\CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N
Benorilate,CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1,,CC(=O)Nc1ccc(OC(=O)c2ccccc2OC(C)=O)cc1
Benoxaprofen,CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1,Arachidonate 5-lipoxygenase;Bile salt export pump,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
Benperidol,OC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2A;D(3) dopamine receptor;D(4) dopamine receptor,O=C(CCCN1CCC(n2c(O)nc3ccccc32)CC1)c1ccc(F)cc1
Benserazide,NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1,Aromatic-L-amino-acid decarboxylase;Estrogen receptor beta;Zinc finger protein mex-5;SUMO-activating enzyme;Cytoplasmic zinc-finger protein;Genome polyprotein [Cleaved into: P1; Capsid protein VP0;Hexokinase-2,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O
Benzatropine,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Sodium-dependent neutral amino acid transporter B(0)AT1,CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2
Benzethonium,CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Acetylcholinesterase;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Substance-K receptor;Membrane-associated progesterone receptor component 1;KiSS-1 receptor,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1
Benzhydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1,Mu-type opioid receptor;Kappa-type opioid receptor,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@H]4[C@@H](C2)N(C)CC[C@]314
Benziodarone,CCC1=C(C(=O)C2=CC(I)=C(O)C(I)=C2)C2=CC=CC=C2O1,Baculoviral IAP repeat-containing protein 5;Eyes absent homolog 3,CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1
Benznidazole,[O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1,3-oxoacyl-[acyl-carrier-protein] synthase 3,O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1
Benzocaine,CCOC(=O)C1=CC=C(N)C=C1,Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha;Sodium channel protein type 11 subunit alpha;Sodium channel protein type 10 subunit alpha;Sodium channel protein type 7 subunit alpha;Sodium channel protein type 5 subunit alpha,CCOC(=O)c1ccc(N)cc1
Benzoic acid,OC(=O)C1=CC=CC=C1,,O=C(O)c1ccccc1
Benzoin,OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1,Liver carboxylesterase 1;Cocaine esterase,O=C(c1ccccc1)C(O)c1ccccc1
Benzonatate,CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,Sodium channel protein type 5 subunit alpha,CCCCNc1ccc(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)cc1
Benzoyl peroxide,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,,O=C(OOC(=O)c1ccccc1)c1ccccc1
Benzphetamine,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1,Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor;Synaptic vesicular amine transporter,C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1
Benzthiazide,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O,Carbonic anhydrase 2;Solute carrier family 12 member 3;Carbonic anhydrase 1;Carbonic anhydrase 4;Calcium-activated potassium channel subunit alpha-1,NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O
Benzydamine,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,Soluble guanylate cyclase,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
Benzyl alcohol,OCC1=CC=CC=C1,,OCc1ccccc1
Benzyl benzoate,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1,,O=C(OCc1ccccc1)c1ccccc1
Benzylparaben,OC1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1,Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 7;Carbonic anhydrase 14,O=C(OCc1ccccc1)c1ccc(O)cc1
Benzylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,Penicillin-binding protein 1A;Beta-lactamase TEM;Beta-lactamase;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O
Bepotastine,OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Histamine H1 receptor,O=C(O)CCCN1CCC(OC(c2ccc(Cl)cc2)c2ccccn2)CC1
Bepridil,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,"Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Voltage-dependent P/Q-type calcium channel subunit alpha-1A;Voltage-dependent T-type calcium channel subunit alpha-1H;Lethal factor;Potassium voltage-gated channel subfamily KQT member 4;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Voltage-dependent L-type calcium channel subunit alpha-1C;Sodium channel alpha subunits; brain (Types I, II, III);Potassium channel subfamily T member 1;Voltage-dependent L-type calcium channel subunit alpha-1D",CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
Berberine,COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;5-hydroxytryptamine receptor 1D;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1E;5-hydroxytryptamine receptor 1B,COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
Berotralstat,NCC1=CC(=CC=C1)N1N=C(C=C1C(=O)NC1=CC(=CC=C1F)[C@H](NCC1CC1)C1=CC=CC(=C1)C#N)C(F)(F)F,Plasma kallikrein,N#Cc1cccc([C@@H](NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1
Besifloxacin,N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O,Topoisomerase IV;DNA gyrase,N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1
Beta carotene,C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C,Core protein,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C)C(C)(C)CCC1
Betahistine,CNCCC1=CC=CC=N1,Histamine H3 receptor,CNCCc1ccccn1
Betaine,C[N+](C)(C)CC([O-])=O,Acetylcholine receptor subunit alpha;Glutamate [NMDA] receptor;Glutamate NMDA receptor;Glutamate receptor ionotropic AMPA,C[N+](C)(C)CC(=O)[O-]
Betamethasone,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Annexin A1,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Betamethasone phosphate,[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Glucocorticoid receptor,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
Betaxolol,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1
Betazole,NCCC1=CC=NN1,Histamine H2 receptor,NCCc1ccn[nH]1
Bethanechol,CC(C[N+](C)(C)C)OC(N)=O,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor;Muscarinic receptor 2,CC(C[N+](C)(C)C)OC(N)=O
Bethanidine,CN\C(NCC1=CC=CC=C1)=N/C,Sodium-dependent noradrenaline transporter,C/N=C(\NC)NCc1ccccc1
Betiatide,OC(=O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)C1=CC=CC=C1,Integrin alpha-IIb/beta-3,O=C(O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)c1ccccc1
Betrixaban,COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1,Potassium voltage-gated channel subfamily H member 2;Prothrombin;Coagulation factor X,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1
Betulinic Acid,[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2,Type IV secretion-like conjugative transfer relaxase protein TraI,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
Bexarotene,CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C,Retinoic acid receptor alpha;Peroxisome proliferator-activated receptor gamma;Retinoic acid receptor RXR-alpha;Retinoic acid receptor RXR-beta;Retinoic acid receptor RXR-gamma;Retinoic acid receptor beta;Retinoic acid receptor gamma;Cytochrome P450 26A1;Cytochrome P450 26B1;Oxysterols receptor LXR-beta;Oxysterols receptor LXR-alpha,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C
Bezafibrate,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O,"Lipoprotein lipase;Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma;Peroxisome proliferator-activated receptor delta;Fatty acid-binding protein, intestinal;Fatty acid-binding protein, liver;3-hydroxy-3-methylglutaryl-coenzyme A reductase",CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,Androgen receptor;Cytochrome P450 2C19;Progesterone receptor,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
Bicisate,CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC,,CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC
Bictegravir,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O,Integrase,O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2
Bifonazole,C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1,"Cytochrome P450 3A4;Steroid 17-alpha-hydroxylase/17,20 lyase;Lanosterol 14-alpha demethylase;Indoleamine 2,3-dioxygenase 1",c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1
Biguanide,NC(=N)NC(N)=N,Voltage-gated potassium channel,N=C(N)NC(=N)N
Bilastine,CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1,Histamine H1 receptor,CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21
Bimatoprost,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1,Aldo-keto reductase family 1 member C3;Prostaglandin F2-alpha receptor,CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Binimetinib,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO,Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21
Bioallethrin,CC(C)=CC1C(C(=O)OC2CC(=O)C(CC=C)=C2C)C1(C)C,,C=CCC1=C(C)C(OC(=O)C2C(C=C(C)C)C2(C)C)CC1=O
Biotin,[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2,Insulin-degrading enzyme,O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21
Biperiden,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Neuronal acetylcholine receptor subunit alpha-2,OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2
Bisacodyl,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1,Sodium-dependent dopamine transporter;Kappa-type opioid receptor;Cytochrome P450 2C9,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
Bismuth subcitrate potassium,[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,,O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].[Bi+3].[K+].[K+].[K+].[K+].[K+]
Bismuth subgallate,O[Bi]1OC2=CC(=CC(O)=C2O1)C(O)=O,Cyclooxygenase,O=C(O)c1cc(O)c2c(c1)[O][Bi]([OH])[O]2
Bismuth subnitrate,[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O--].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,Cyclooxygenase,O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-2].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-]
Bismuth subsalicylate,O[Bi]1OC(=O)C2=CC=CC=C2O1,Cyclooxygenase,O=C1[O][Bi]([OH])[O]c2ccccc21
Bisoctrizole,CC(C)(C)CC(C)(C)C1=CC(CC2=C(O)C(=CC(=C2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)=C(O)C(=C1)N1N=C2C=CC=CC2=N1,,CC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1
Bisoprolol,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1
Bisoxatin,OC1=CC=C(C=C1)C1(OC2=CC=CC=C2NC1=O)C1=CC=C(O)C=C1,,O=C1Nc2ccccc2OC1(c1ccc(O)cc1)c1ccc(O)cc1
Bisphenol A diglycidyl ether,CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1,,CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1
Bithionol,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl,Sodium/potassium-transporting ATPase subunit alpha-2;Mu-type opioid receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Estrogen receptor;Estrogen receptor beta;Epidermal growth factor receptor;Tyrosine-protein kinase Lck;Receptor tyrosine-protein kinase erbB-2;Thromboxane-A synthase;Mitogen-activated protein kinase 14;Solute carrier family 22 member 1;Substance-K receptor;Mitogen-activated protein kinase 1;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;M1-family alanyl aminopeptidase;Envelope glycoprotein gp160;Potassium channel subfamily T member 1;N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
Bivalirudin,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O,Prothrombin,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Bleomycin,[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O,Transient receptor potential cation channel subfamily V member 1;Lethal factor;Lecithin retinol acyltransferase;Menin;Extracellular calcium-sensing receptor,Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1
Boceprevir,[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,"Neutrophil elastase;Cathepsin B;Cathepsin L1;Chymase;Lysosomal protective protein;Cathepsin L2;Cathepsin K;Cathepsin S;Cathepsin F;Hepatitis C virus serine protease, NS3/NS4A;Nonstructural protein NS3-4A",CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
Boric acid,OB(O)O,,OB(O)O
Bortezomib,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Prothrombin;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Cytochrome P450 2C19;26S proteasome non-ATPase regulatory subunit 1;Proteasome subunit alpha type-1;Neutrophil elastase;Carbonic anhydrase 3;Carbonic anhydrase 6;Cathepsin G;Carbonic anhydrase 14;Chymase;Chymotrypsinogen B;Proteasome subunit beta type-8;Lysosomal protective protein;Carbonic anhydrase 13;Carbonic anhydrase 15;Proteasome subunit beta type-1;Proteasome subunit beta type-2;Proteasome subunit beta type-5;Beta-carbonic anhydrase 1;PH and SEC7 domain-containing protein 1;Nuclear factor NF-kappa-B complex;Alpha-chymotrypsin;Proteasome subunit beta;Proteasome subunit beta type-9;Proteasome subunit beta type-10",CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
Bortezomib D-mannitol,[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1O[C@H]([C@H](O)CO)[C@@H]([C@H](O)CO)O1
Boscalid,ClC1=CC=C(C=C1)C1=C(NC(=O)C2=C(Cl)N=CC=C2)C=CC=C1,Cholecystokinin receptor type A;Gastrin/cholecystokinin type B receptor;Cholecystokinin receptor,O=C(Nc1ccccc1-c1ccc(Cl)cc1)c1cccnc1Cl
Bosentan,COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1,Nuclear receptor subfamily 1 group I member 2;Bile salt export pump;Endothelin-1 receptor;Endothelin B receptor,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO
Bosutinib,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,"Tyrosine-protein kinase JAK3;Macrophage-stimulating protein receptor;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Receptor tyrosine-protein kinase erbB-2;Ribosomal protein S6 kinase alpha-3;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Myosin light chain kinase, smooth muscle;Rho-associated protein kinase 1;Focal adhesion kinase 1;Tyrosine-protein kinase HCK;Serine/threonine-protein kinase PLK1;Receptor tyrosine-protein kinase erbB-4;High affinity nerve growth factor receptor;Protein kinase C delta type;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Tyrosine-protein kinase SYK;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Ephrin type-A receptor 8;Calcium/calmodulin-dependent protein kinase type II subunit gamma;AP2-associated protein kinase 1;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Serine/threonine-protein kinase Nek2;Ribosomal protein S6 kinase alpha-2;5'-AMP-activated protein kinase catalytic subunit alpha-1;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Protein kinase C epsilon type;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 5;Ephrin type-A receptor 4;Serine/threonine-protein kinase N1;Protein kinase C theta type;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;ALK tyrosine kinase receptor;Serine/threonine-protein kinase 36;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Dual specificity protein kinase CLK2;Dual specificity protein kinase CLK3;Mitogen-activated protein kinase kinase kinase kinase 5;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Calcium/calmodulin-dependent protein kinase type 1D;Cyclin-dependent kinase 16;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;STE20-like serine/threonine-protein kinase;Dual specificity protein kinase CLK4;Calcium/calmodulin-dependent protein kinase kinase 2;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Testis-specific serine/threonine-protein kinase 1;Cyclin-dependent kinase 15;Dual specificity mitogen-activated protein kinase kinase 7;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase ITK/TSK;Tyrosine-protein kinase ZAP-70;Tyrosine-protein kinase BTK;Tyrosine-protein kinase Tec;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Tyrosine-protein kinase receptor TYRO3;Ephrin type-B receptor 2;Cyclin-dependent kinase 7;Ribosomal protein S6 kinase beta-1;Serine/threonine-protein kinase N2;Serine/threonine-protein kinase DCLK3;Serine/threonine-protein kinase 3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TYK2;Serine/threonine-protein kinase Chk1;Serine/threonine-protein kinase PAK 3;Cyclin-dependent kinase 14;Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha;Wee1-like protein kinase;Serine/threonine-protein kinase 25;Mitogen-activated protein kinase kinase kinase MLT;Protein-tyrosine kinase 2-beta;Serine/threonine-protein kinase RIO1;Casein kinase I isoform alpha-like;Casein kinase I isoform delta;Tyrosine-protein kinase receptor Tie-1;Serine/threonine-protein kinase tousled-like 1;Serine/threonine-protein kinase tousled-like 2;NT-3 growth factor receptor;Tyrosine-protein kinase TXK;Inhibitor of nuclear factor kappa-B kinase subunit epsilon;Dual specificity mitogen-activated protein kinase kinase 3;Serine/threonine-protein kinase 26;Serine/threonine-protein kinase NLK;Eukaryotic translation initiation factor 2-alpha kinase 4;Serine/threonine-protein kinase RIO3;Serine/threonine-protein kinase SIK2;Serine/threonine-protein kinase 33;Serine/threonine-protein kinase TNNI3K;Ankyrin repeat and protein kinase domain-containing protein 1;Discoidin domain-containing receptor 2;Myotonin-protein kinase;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;NUAK family SNF1-like kinase 1;Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase;Mitogen-activated protein kinase kinase kinase kinase 3;Tyrosine-protein kinase Blk;Bone morphogenetic protein receptor type-2;Mitogen-activated protein kinase kinase kinase kinase 4;Dual specificity mitogen-activated protein kinase kinase 4;Dual specificity mitogen-activated protein kinase kinase 6;Tyrosine-protein kinase Mer;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 11;Serine/threonine-protein kinase 24;Citron Rho-interacting kinase;Myosin-IIIa;Myosin-IIIb;Serine/threonine-protein kinase PAK 1;Serine/threonine-protein kinase PAK 2;Serine/threonine-protein kinase SIK1;Tyrosine-protein kinase Srms;Ephrin type-A receptor 1;Ephrin type-B receptor 3;Mitogen-activated protein kinase 7;Serine/threonine-protein kinase D3;Tyrosine-protein kinase Fes/Fps;Casein kinase I isoform alpha;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Interleukin-1 receptor-associated kinase 4;Serine/threonine-protein kinase Chk2;Ephrin type-B receptor 6;G protein-coupled receptor kinase 4;G protein-coupled receptor kinase 7;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Homeodomain-interacting protein kinase 4;Hormonally up-regulated neu tumor-associated kinase;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Microtubule-associated serine/threonine-protein kinase 1;Serine/threonine-protein kinase NIM1;SRSF protein kinase 3;STE20/SPS1-related proline-alanine-rich protein kinase;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Serine/threonine-protein kinase ULK1;Serine/threonine-protein kinase ULK2;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Homeodomain-interacting protein kinase 1;Serine/threonine-protein kinase PLK2;Serine/threonine-protein kinase 35;Megakaryocyte-associated tyrosine-protein kinase;Receptor tyrosine-protein kinase erbB-3;Mitogen-activated protein kinase kinase kinase 1;Serine/threonine-protein kinase SIK3;Wee1-like protein kinase 2;Serine/threonine-protein kinase 32A;Peripheral plasma membrane protein CASK;Serine/threonine-protein kinase VRK2;Mitogen-activated protein kinase kinase kinase 12;Eukaryotic translation initiation factor 2-alpha kinase 1;Serine/threonine-protein kinase TAO2;Dual specificity mitogen-activated protein kinase kinase 5;Serine/threonine-protein kinase Nek11;Leucine-rich repeat serine/threonine-protein kinase 2;Dual serine/threonine and tyrosine protein kinase;Serine/threonine-protein kinase PknB;NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor);Tyrosine-protein kinase ABL;Bcr/Abl fusion protein",COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Bretylium,CC[N+](C)(C)CC1=CC=CC=C1Br,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sodium-dependent noradrenaline transporter,CC[N+](C)(C)Cc1ccccc1Br
Brexanolone,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O,Glucose-6-phosphate 1-dehydrogenase;GABA-A receptor alpha-1/beta-2/gamma-2;GABA A receptor alpha-4/beta-3/delta;GABA-A receptor alpha-6/beta-3/delta,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Brexpiprazole,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,D(2) dopamine receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;5-hydroxytryptamine receptor 1B;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1
Brigatinib,COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1,Epidermal growth factor receptor;Receptor-type tyrosine-protein kinase FLT3;Insulin-like growth factor 1 receptor;Insulin receptor;Proto-oncogene tyrosine-protein kinase ROS;ALK tyrosine kinase receptor,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1
Brilliant blue G,[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\C=C/C(/C=C2C)=[N+](/CC)CC2=CC(=CC=C2)S([O-])(=O)=O)\C2=C(C)C=C(C=C2)N(CC)CC2=CC(=CC=C2)S([O-])(=O)=O)C=C1,,CCOc1ccc(Nc2ccc(/C(=C3/C=C/C(=[N+](/CC)Cc4cccc(S(=O)(=O)[O-])c4)C=C3C)c3ccc(N(CC)Cc4cccc(S(=O)(=O)[O-])c4)cc3C)cc2)cc1.[Na+]
Brilliant green cation,CCN(CC)C1=CC=C(C=C1)C(C1=CC=CC=C1)=C1C=CC(C=C1)=[N+](CC)CC,,CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2ccccc2)cc1
Brimonidine,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,Brc1c(NC2=NCCN2)ccc2nccnc12
Brincidofovir,CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O,DNA polymerase catalytic subunit,CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)Cn1ccc(N)nc1=O
Brinzolamide,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
Brivaracetam,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,Synaptic vesicle glycoprotein 2A,CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1
Brivudine,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(\C=C\Br)C(=O)NC1=O,"Thymidine kinase;Thymidine kinase, cytosolic",O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br
Bromazepam,BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1,GABA-A receptor alpha-1/beta-2/gamma-2,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1
Bromfenac,NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cyclooxygenase,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
Bromhexine,CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1,Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Cytochrome P450 2D6;Membrane-associated progesterone receptor component 1,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
Bromocriptine,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Androgen receptor;5-hydroxytryptamine receptor 7;Vesicular glutamate transporter 3;Adrenergic receptor alpha-2;Dopamine receptor;Cerebral cortex alpha adrenergic receptor,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Bromodiphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1,"Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Cytochrome P450 2D6;Solute carrier family 22 member 2;Sodium channel alpha subunits; brain (Types I, II, III);Sodium-dependent serotonin transporter;Sodium-dependent dopamine transporter",CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1
Bromothalonil,BrCC(Br)(CCC#N)C#N,,N#CCCC(Br)(C#N)CBr
Bromotheophylline,CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O,"Adenosine receptor A2a;cGMP-inhibited 3',5'-cyclic phosphodiesterase A;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Alkaline phosphatase, tissue-nonspecific isozyme;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Uncharacterized protein;Adenosine A2 receptor;Adenosine A2b receptor;Adenosine receptor;Heart phosphodiesterase;Adenosine A2a receptor;Transmembrane domain-containing protein TMIGD3",Cn1c(=O)c2[nH]c(Br)nc2n(C)c1=O
Bromperidol,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;Alpha-1A adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;D(4) dopamine receptor,O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1
Brompheniramine,CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1,"Potassium voltage-gated channel subfamily H member 2;Histamine H1 receptor;Sodium channel alpha subunits; brain (Types I, II, III)",CN(C)CCC(c1ccc(Br)cc1)c1ccccn1
Bronopol,OCC(Br)(CO)[N+]([O-])=O,,O=[N+]([O-])C(Br)(CO)CO
Bucetin,CCOC1=CC=C(NC(=O)CC(C)O)C=C1,"Prostaglandin G/H synthase 2;Urokinase-type plasminogen activator;Multidrug resistance protein 1;Adenosine receptor A3;D(4) dopamine receptor;Carbonic anhydrase 2;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Carbonic anhydrase 1;Cytochrome P450 2C8;Calmodulin;Carbonic anhydrase 4;Beta-lactamase;Acetylcholinesterase;Amine oxidase [flavin-containing] B;Cholinesterase;Xanthine dehydrogenase/oxidase;Amine oxidase [flavin-containing] A;Aldose reductase;Carbonic anhydrase 9;Aromatase;Carbonic anhydrase 12;Arachidonate 5-lipoxygenase;Prothrombin;Epidermal growth factor receptor;Vasopressin V2 receptor;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Tyrosine-protein phosphatase non-receptor type 1;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Dipeptidyl peptidase 4;Myeloperoxidase;72 kDa type IV collagenase;Cyclin-dependent kinase 1;Cyclin-dependent kinase 2;Serine/threonine-protein kinase pim-1;Insulin-like growth factor 1 receptor;Lactoylglutathione lyase;Alpha-amylase 1;Neutrophil elastase;Focal adhesion kinase 1;Arachidonate 15-lipoxygenase;Carbonic anhydrase 3;Stromelysin-1;Serine/threonine-protein kinase PLK1;Carbonic anhydrase 6;Estradiol 17-beta-dehydrogenase 2;Tyrosine-protein kinase SYK;Prolyl endopeptidase;Arachidonate 12-lipoxygenase, 12S-type;Hepatocyte growth factor receptor;Serine/threonine-protein kinase Nek2;Carbonic anhydrase 14;Calcium/calmodulin-dependent protein kinase type II subunit beta;Matrix metalloproteinase-9;Serine/threonine-protein kinase N1;Phospholipase A2;ALK tyrosine kinase receptor;RAC-alpha serine/threonine-protein kinase;Macrophage metalloelastase;Collagenase 3;Chymotrypsinogen B;Beta-secretase 1;Glycogen synthase kinase-3 beta;Alcohol dehydrogenase [NADP(+)];Bifunctional epoxide hydrolase 2;Glycogen phosphorylase, liver form;Lysine--tRNA ligase;Cationic trypsin;C-C chemokine receptor type 4;Integrase;Carbonic anhydrase 13;Adenosine receptor A1;Adenosine receptor A2a;Cyclin-dependent kinase 6;Enoyl-[acyl-carrier-protein] reductase [NADH] FabI;Enoyl-acyl-carrier protein reductase;Polyphenol oxidase 2;Aldo-keto reductase family 1 member C21;Tyrosine-protein kinase receptor UFO;Neuraminidase;C-X-C chemokine receptor type 1;Casein kinase II subunit alpha;NUAK family SNF1-like kinase 1;Aurora kinase B;Death-associated protein kinase 1;Sialidase;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;G-protein coupled receptor 35;Proteasome subunit beta type-5;Cytochrome P450 1B1;Malate dehydrogenase;5'-nucleotidase;3-oxoacyl-acyl-carrier protein reductase;Beta-hydroxyacyl-ACP dehydratase; Fatty acid synthesis protein;Phosphatidylinositol 3-kinase regulatory subunit alpha;NADPH oxidase 4;Replicase polyprotein 1ab;Lactoperoxidase;Lysine-specific histone demethylase 1A;D-alanine--D-alanine ligase;Serine/threonine-protein kinase Nek6;Arginase;Cyclin-dependent kinase 1/cyclin B1;Cyclin-dependent kinase 5/CDK5 activator 1;Cyclin-dependent kinase 1/cyclin B;Cyclin-dependent kinase 4/cyclin D1;Glycogen synthase kinase-3;Short transient receptor potential channel 5;Nitric oxide synthase, inducible;Sorbitol dehydrogenase;Chymotrypsin C;Cell division protein kinase 5;Hypoxia-inducible factor 1-alpha inhibitor;D-alanylalanine synthetase;Lymphocyte differentiation antigen CD38;Phosphodiesterase 2A;Cytosol aminopeptidase;Glutathione reductase;Amyloid beta A4 protein;Cytochrome P450 1A1;Solute carrier family 2, facilitated glucose transporter member 2;ELAV-like protein 3;ELAV-like protein 1;Solute carrier family 2, facilitated glucose transporter member 4;Inositol polyphosphate multikinase;Inositol hexakisphosphate kinase 2",CCOc1ccc(NC(=O)CC(C)O)cc1
Buclizine,CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1,Histamine H1 receptor,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1
Budesonide,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Multidrug resistance protein 1;Glucocorticoid receptor;Interleukin-5;Interferon gamma;Mineralocorticoid receptor;Progesterone receptor;Matrix metalloproteinase-9;Androgen receptor,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Bufexamac,CCCCOC1=CC=C(CC(=O)NO)C=C1,Histone deacetylase 6;Histone deacetylase 10;Arachidonate 5-lipoxygenase;M1-family alanyl aminopeptidase,CCCCOc1ccc(CC(=O)NO)cc1
Bumadizone,CCCCC(C(O)=O)C(=O)N(NC1=CC=CC=C1)C1=CC=CC=C1,"Aldehyde oxidase;Glutathione reductase, mitochondrial;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Indoleamine 2,3-dioxygenase 1;M-phase inducer phosphatase 2;Trypanothione reductase;Dual specificity phosphatase Cdc25C;Ubiquitin carboxyl-terminal hydrolase isozyme L3;Dual specificity phosphatase Cdc25A;Dual specificity protein phosphatase 6;Dual specificity protein phosphatase 1;M-phase inducer phosphatase 1",CCCCC(C(=O)O)C(=O)N(Nc1ccccc1)c1ccccc1
Bumetanide,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O,Solute carrier family 12 member 1;Sodium/potassium-transporting ATPase subunit alpha-1;Solute carrier family 12 member 2;G-protein coupled receptor 35,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
Bupivacaine,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 4 subunit alpha;Prostaglandin E2 receptor EP1 subtype;Cytochrome P450 2D6;5-hydroxytryptamine receptor 3A;Potassium voltage-gated channel subfamily D member 3;Potassium voltage-gated channel subfamily A member 5;Potassium channel subfamily K member 3,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Buprenorphine,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,Mu-type opioid receptor;Potassium voltage-gated channel subfamily H member 2;Kappa-type opioid receptor;Delta-type opioid receptor;Nociceptin receptor,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
Bupropion,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Neuronal acetylcholine receptor subunit alpha-7;Cytochrome P450 2C19;Membrane-associated progesterone receptor component 1;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha3/beta2,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
Buserelin,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1,Lutropin-choriogonadotropic hormone receptor;Gonadotropin-releasing hormone receptor,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1
Buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;D(3) dopamine receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;5-hydroxytryptamine receptor 7;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Adrenergic receptor alpha-1;Serotonin 2 (5-HT2) receptor,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,Matrix metalloproteinase-9,CS(=O)(=O)OCCCCOS(C)(=O)=O
Butabarbital,CCC(C)C1(CC)C(=O)NC(=O)NC1=O,GABA-A receptor alpha-1/beta-2/gamma-2,CCC(C)C1(CC)C(=O)NC(=O)NC1=O
Butacaine,CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1,"Sodium channel alpha subunits; brain (Types I, II, III)",CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1
Butalbital,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,GABA-A receptor alpha-1/beta-3/gamma-2,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O
Butamben,CCCCOC(=O)C1=CC=C(N)C=C1,,CCCCOC(=O)c1ccc(N)cc1
Butaperazine,CCCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,Gamma-aminobutyric acid receptor subunit beta,CCCC(=O)c1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2
Butenafine,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Cytochrome P450 2D6;Acetylcholinesterase;Squalene epoxidase;Membrane-associated progesterone receptor component 1;Enoyl-[acyl-carrier-protein] reductase [NADH];Squalene monooxygenase,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
Butobarbital,CCCCC1(CC)C(=O)NC(=O)NC1=O,Gamma-aminobutyric acid receptor subunit beta-3;Potassium voltage-gated channel subfamily H member 2;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-2/beta-2/gamma-2,CCCCC1(CC)C(=O)NC(=O)NC1=O
Butoconazole,ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1,Lanosterol 14-alpha demethylase,Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1
Butorphanol,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
Butylene glycol,CC(O)CCO,,CC(O)CCO
Butylparaben,CCCCOC(=O)C1=CC=C(O)C=C1,Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 7;Carbonic anhydrase 14,CCCCOC(=O)c1ccc(O)cc1
Butylscopolamine,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Muscarinic receptor M1;Muscarinic acetylcholine receptor DM1;Muscarinic acetylcholine receptor,CCCC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Cabazitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C,Tubulin beta,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
Cabergoline,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Cabotegravir,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N1[C@@H](C)CO2,Integrase,C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
Cabozantinib,COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2,Macrophage-stimulating protein receptor;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 3;Fibroblast growth factor receptor 1;Aurora kinase A;Tyrosine-protein kinase receptor UFO;Mast/stem cell growth factor receptor Kit;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Angiopoietin-1 receptor;Hepatocyte growth factor receptor,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Caffeine,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,"Adenosine receptor A2a;Potassium voltage-gated channel subfamily H member 2;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;Acetylcholinesterase;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Glycogen phosphorylase, muscle form;Adenosine A2 receptor;Adenosine receptor;Guanine deaminase;Adenosine A2a receptor",Cn1c(=O)c2c(ncn2C)n(C)c1=O
Calcifediol,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,Vitamin D3 receptor,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12
Calcipotriol,O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;Vitamin D3 receptor;Vitamin D 25-hydroxylase;Vitamin D-binding protein;Vitamin D3 receptor A",C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Calcitriol,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;Vitamin D3 receptor;Vitamin D 25-hydroxylase;Vitamin D-binding protein;Vitamin D3 receptor A",C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Calcium Phosphate,[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O,,O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
Calcium acetate,[Ca++].CC([O-])=O.CC([O-])=O,,CC(=O)[O-].CC(=O)[O-].[Ca+2]
Calcium ascorbate,[Ca++].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-],,O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Ca+2]
Calcium carbimide,[Ca++].[N-]=C=[N-],,[Ca+2].[N-]=C=[N-]
Calcium carbonate,[Ca++].[O-]C([O-])=O,,O=C([O-])[O-].[Ca+2]
Calcium chloride,[Cl-].[Cl-].[Ca++],,[Ca+2].[Cl-].[Cl-]
Calcium citrate,[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2]
Calcium glubionate anhydrous,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,,O=C([O][Ca][O]C(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Calcium glucoheptonate,[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O,,O=C([O-])C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]
Calcium gluconate,[Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]
Calcium glycerophosphate,[Ca++].OCC(CO)OP([O-])([O-])=O,,O=P([O-])([O-])OC(CO)CO.[Ca+2]
Calcium lactate,[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O,,CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]
Calcium levulinate,[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,,CC(=O)CCC(=O)[O-].CC(=O)CCC(=O)[O-].[Ca+2]
Calcium phosphate dihydrate,O.O.[Ca++].OP([O-])([O-])=O,,O.O.O=P([O-])([O-])O.[Ca+2]
Calcium saccharate,[Ca++].[H][C@](O)(C([O-])=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)C([O-])=O,,O=C([O-])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)[O-].[Ca+2]
Calcium threonate,[Ca++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)CO.[Ca+2]
Calcium undecylenate,[Ca++].[O-]C(=O)CCCCCCCCC=C.[O-]C(=O)CCCCCCCCC=C,,C=CCCCCCCCCC(=O)[O-].C=CCCCCCCCCC(=O)[O-].[Ca+2]
Camphor,[H][C@@]12CC[C@@](C)(C(=O)C1)C2(C)C,Acetylcholinesterase;Transient receptor potential cation channel subfamily A member 1,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2
Canagliflozin,[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1,Sodium/glucose cotransporter 2;Sodium/glucose cotransporter 1;Protease,Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1
Candesartan cilexetil,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1,Thromboxane-A synthase;Type-1 angiotensin II receptor;Cruzipain;DNULL polymerase kappa;DNULL polymerase iota;DNULL polymerase eta;Cytochrome P450 3A4;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;Beta-3 adrenergic receptor;Adenosine receptor A3;Cytochrome P450 2C9;Epidermal growth factor receptor;Receptor tyrosine-protein kinase erbB-2,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Candicidin,CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1,Histamine H2 receptor;Acetylcholinesterase;Multidrug and toxin extrusion protein 1,CC1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)CC(O)C(C(=O)O)C(O)CC(=O)CC(O)CC(O)CC(O)CC(=O)CCCC(=O)CC(=O)OC1C(C)CC(C)C(O)CC(=O)c1ccc(N)cc1
Cangrelor,CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1,P2Y purinoceptor 13;Uracil nucleotide/cysteinyl leukotriene receptor;P2Y purinoceptor 12,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O
Cannabidiol,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,Cannabinoid receptor 1;Cannabinoid receptor 2;N-arachidonyl glycine receptor;Fatty-acid amide hydrolase 1;Transient receptor potential cation channel subfamily V member 2;Transient receptor potential cation channel subfamily V member 1;G-protein coupled receptor 55,C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Canrenoic acid,[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O
Cantharidin,[H][C@]12CC[C@]([H])(O1)[C@]1(C)C(=O)OC(=O)[C@]21C,Telomerase reverse transcriptase;Reverse transcriptase,C[C@@]12C(=O)OC(=O)[C@]1(C)[C@H]1CC[C@@H]2O1
Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,Thymidylate synthase,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
Capmatinib,CNC(=O)C1=C(F)C=C(C=C1)C1=NN2C(CC3=CC4=C(C=C3)N=CC=C4)=CN=C2N=C1,Hepatocyte growth factor receptor,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F
Capreomycin,[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O,Outer membrane porin protein OmpD,C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H]([C@H]2CCN=C(N)N2)NC(=O)/C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O.NCCC[C@H](N)CC(=O)NC[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@H]([C@H]2CCN=C(N)N2)NC(=O)/C(=C\NC(N)=O)NC1=O
Capsaicin,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,"Transient receptor potential cation channel subfamily V member 1;Prostaglandin G/H synthase 1;Cytochrome P450 1A2;Arachidonate 5-lipoxygenase;Potassium voltage-gated channel subfamily A member 1;Tyrosine--tRNA ligase, cytoplasmic;NADH-ubiquinone oxidoreductase chain 1 ;Transient receptor potential cation channel subfamily M member 8;Potassium voltage-gated channel subfamily A member 7;Potassium voltage-gated channel subfamily A member 2",COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Angiotensin-converting enzyme;Prothrombin;Renin;Leukotriene A-4 hydrolase;Succinyl-diaminopimelate desuccinylase;Beta-lactamase;Beta-lactamase II;Beta-lactamase class B VIM-2;Beta-lactamase NDM-1,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,Sodium channel protein type 5 subunit alpha;Sodium-dependent serotonin transporter;Histamine H1 receptor;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 9 subunit alpha;Nuclear receptor subfamily 1 group I member 2;GABA-A receptor alpha-1/beta-2/gamma-2;Neuronal acetylcholine receptor; alpha2/beta4;Frizzled-8,NC(=O)N1c2ccccc2C=Cc2ccccc21
Carbamide peroxide,OO.NC(N)=O,,NC(N)=O.OO
Carbamoylcholine,C[N+](C)(C)CCOC(N)=O,,C[N+](C)(C)CCOC(N)=O
Carbenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Carbetocin,[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC,Vasopressin V1a receptor;Vasopressin V2 receptor;Oxytocin receptor,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Carbidopa,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,Aromatic-L-amino-acid decarboxylase;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Lysine-specific demethylase 4E,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
Carbimazole,CCOC(=O)N1C=CN(C)C1=S,Lactoperoxidase;Thyroid peroxidase,CCOC(=O)n1ccn(C)c1=S
Carbinoxamine,CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Histamine H1 receptor,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1
Carbocisteine,N[C@@H](CSCC(O)=O)C(O)=O,,N[C@@H](CSCC(=O)O)C(=O)O
Carbocromen,CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2,,CCOC(=O)COc1ccc2c(C)c(CCN(CC)CC)c(=O)oc2c1
Carbon dioxide,O=C=O,,O=C=O
Carboplatin,[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H],,[NH3]->[Pt]1(<-[NH3])[O]C(=O)C2(CCC2)C(=O)[O]1
Carboprost tromethamine,NC(CO)(CO)CO.CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,,CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO
Carboxin,CC1=C(SCCO1)C(=O)NC1=CC=CC=C1,,CC1=C(C(=O)Nc2ccccc2)SCCO1
Carfilzomib,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Potassium voltage-gated channel subfamily H member 2;Cathepsin B;Proteasome subunit beta type-8;Proteasome subunit beta type-1;Proteasome subunit beta type-2;Glutathione S-transferase omega-1;Proteasome subunit beta type-9;Proteasome subunit beta type-10;Proteasome subunit beta type-5,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
Carglumic acid,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,,NC(=O)N[C@@H](CCC(=O)O)C(=O)O
Carindacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O,Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Cariprazine,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,D(1A) dopamine receptor;Potassium voltage-gated channel subfamily H member 2;D(1B) dopamine receptor;D(4) dopamine receptor;D(2) dopamine receptor;D(3) dopamine receptor;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 7;Histamine H1 receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,CCCC(C)(COC(N)=O)COC(=O)NC(C)C
Carmustine,ClCCNC(=O)N(CCCl)N=O,"Glutathione reductase, mitochondrial",O=NN(CCCl)C(=O)NCCCl
Carprofen,CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Fatty-acid amide hydrolase 1;Complement C5,CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12
Carteolol,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2
Carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,Ryanodine receptor 2;5-hydroxytryptamine receptor 4;Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Potassium channel subfamily K member 2;Solute carrier family 22 member 1;Potassium channel subfamily K member 10;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Toll-like receptor 4;Amyloid beta A4 protein,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Caspofungin,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@]([H])(C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O,"Beta-1,3-glucan synthase catalytic subunit 1;1,3-beta-glucan synthase catalytic subunit FksP;1,3-beta-D-glucan synthase catalytic subunit",CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O
Cedazuridine,OC[C@H]1O[C@@H](N2CC[C@@H](O)NC2=O)C(F)(F)[C@@H]1O,,O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Cefaclor,[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,Penicillin-binding protein 1A;Streptokinase A;Bacterial penicillin-binding protein,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1
Cefadroxil,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,Solute carrier family 15 member 1;Bacterial penicillin-binding protein,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1
Cefalotin,[H][C@@]1(NC(=O)CC2=CC=CS2)C(=O)N2C(C(O)=O)=C(COC(C)=O)CS[C@]12[H],Prostaglandin G/H synthase 2;Penicillin-binding protein 1A;Solute carrier family 22 member 8;Matrix metalloproteinase-9;Solute carrier family 22 member 11;Somatostatin receptor type 4;Tyrosine-protein phosphatase non-receptor type 7;Bacterial penicillin-binding protein,CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1
Cefamandole,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,Solute carrier family 15 member 1,Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](O)c3ccccc3)[C@H]2SC1
Cefamandole nafate,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O,Bacterial penicillin-binding protein,Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1
Cefapirin,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O,Cannabinoid receptor 1;Mu-type opioid receptor;D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;D(3) dopamine receptor;Histamine H2 receptor;Penicillin-binding protein 1A;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Substance-P receptor;Nischarin;Interstitial collagenase;Substance-K receptor;Cytochrome P450 3A5;Somatostatin receptor type 4;Bacterial penicillin-binding protein,CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1
Cefazolin,[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,"Pencillin binding protein 2a; Penicillin binding protein 2'; Penicillin binding protein, PBP2; Penicillin-binding protein 2; Penicillin-binding protein 2'; Peptidase;Penicillin-binding protein 3;Zinc finger protein mex-5;Bacterial penicillin-binding protein;Cytoplasmic zinc-finger protein",C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1
Cefditoren,[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1
Cefepime,CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1,Bacterial penicillin-binding protein,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1
Cefiderocol,[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,"Peptidoglycan synthase FtsI;Penicillin-binding protein 1A;Penicillin-binding protein 1B;Peptidoglycan D,D-transpeptidase MrdA;Peptidoglycan D,D-transpeptidase FtsI;Penicillin-binding protein 4",CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CS[C@H]12)c1csc(N)n1)C(=O)O
Cefixime,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O,"D(2) dopamine receptor;Streptokinase A;Bacterial penicillin-binding protein;1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1",C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1
Cefmenoxime,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,Bacterial penicillin-binding protein,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1
Cefmetazole,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein;Insulin-degrading enzyme,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
Cefonicid,[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,Prostaglandin G/H synthase 2;Penicillin-binding protein 1A;Matrix metalloproteinase-9;Somatostatin receptor type 4;Bacterial penicillin-binding protein,O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12
Cefoperazone,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O
Ceforanide,[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,NCc1ccccc1CC(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3CC(=O)O)CS[C@H]12
Cefotaxime,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,Peptidoglycan synthase FtsI;Penicillin-binding protein 1A;Penicillin-binding protein 1B;Beta-lactamase;Penicillin-binding protein 2,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
Cefotetan,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,Prostaglandin G/H synthase 2;Penicillin-binding protein 1A;72 kDa type IV collagenase;Catechol O-methyltransferase;Matrix metalloproteinase-9;Interstitial collagenase;Bacterial penicillin-binding protein,CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)O)S2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
Cefotiam,[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O,Penicillin-binding protein 1A;Matrix metalloproteinase-9;Vasoactive intestinal polypeptide receptor 1;Bacterial penicillin-binding protein,CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1
Cefoxitin,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O,Penicillin-binding protein 1A;Beta-lactamase;Streptokinase A;Bacterial penicillin-binding protein,CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21
Cefpiramide,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O,Bacterial penicillin-binding protein,Cc1cc(O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)cn1
Cefpirome,[H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C([O-])=O,Bacterial penicillin-binding protein,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1
Cefpodoxime,[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,Acetylcholinesterase,COCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)c3csc(N)n3)[C@H]2SC1
Cefprozil,[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,Penicillin-binding protein 1A,CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1
Cefradine,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O,Penicillin-binding protein 1A;Matrix metalloproteinase-9;Somatostatin receptor type 4;Bacterial penicillin-binding protein,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1
Ceftaroline fosamil,[H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O,Bacterial penicillin-binding protein,CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1
Ceftazidime,[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1,Peptidoglycan synthase FtsI;Penicillin-binding protein 1A;Penicillin-binding protein 1B,CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O
Ceftibuten,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,Penicillin-binding protein;Penicillin-binding protein 3;Bacterial penicillin-binding protein,Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1
Ceftizoxime,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,Penicillin-binding protein 1A;Beta-lactamase;Bacterial penicillin-binding protein,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
Ceftobiprole,[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1,,Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1
Ceftobiprole medocaril,[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCN(C1)C(=O)OCC1=C(C)OC(=O)O1,MecA,Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N\O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1
Ceftolozane,CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O,,Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c3nsc(N)n3)[C@H]2SC1
Ceftriaxone,[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,Peptidoglycan synthase FtsI;Penicillin-binding protein 1A;Penicillin-binding protein 1B;Penicillin-binding protein 2;D-amino-acid oxidase,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1
Cefuroxime,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O,Penicillin-binding protein 1A;Carbonic anhydrase 2;72 kDa type IV collagenase;Matrix metalloproteinase-9;Bacterial penicillin-binding protein,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1
Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;D(1A) dopamine receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;cGMP-specific 3',5'-cyclic phosphodiesterase;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Histone deacetylase 1;Histone deacetylase 6;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Mitogen-activated protein kinase 14;Cytochrome c oxidase subunit 2;3-phosphoinositide-dependent protein kinase 1;Progesterone receptor;Cyclooxygenase 2; Prostaglandin G/H synthase-2; Uncharacterized protein;Carbonic anhydrase;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Prostaglandin E synthase;Cytochrome c oxidase subunit 1;Carbonic anhydrase, alpha family;Carbonate dehydratase",Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Celiprolol,CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O,Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A;Beta-1 adrenergic receptor,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1
Cenobamate,NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1,Gamma-aminobutyric acid receptor subunit alpha-4;Gamma-aminobutyric acid receptor subunit alpha-6,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl
Cephalexin,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,Penicillin-binding protein 3;Solute carrier family 15 member 2;Bacterial penicillin-binding protein,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
Cephaloglycin,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,Bacterial penicillin-binding protein,CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1,Tyrosine-protein kinase JAK3;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Platelet-derived growth factor receptor alpha;Cyclin-dependent kinase 2;Fibroblast growth factor receptor 3;Tyrosine-protein kinase JAK1;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Tyrosine-protein kinase SYK;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Fibroblast growth factor receptor 2;Tyrosine-protein kinase Fgr;MAP kinase-interacting serine/threonine-protein kinase 2;Tyrosine-protein kinase ZAP-70;Tyrosine-protein kinase BTK;BDNF/NT-3 growth factors receptor;Fibroblast growth factor receptor 4;Proto-oncogene tyrosine-protein kinase ROS;Cyclin-dependent kinase 4;Transcription factor ETV6;Insulin-like growth factor 1 receptor;Insulin receptor;Testis-specific serine/threonine-protein kinase 1;ALK tyrosine kinase receptor,Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1
Cerivastatin,COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C,Nuclear receptor subfamily 1 group I member 3;3-hydroxy-3-methylglutaryl-coenzyme A reductase,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
Ceruletide,[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Cholecystokinin receptor type A,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Cetalkonium,CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,Microtubule-associated protein tau;Zinc finger protein mex-5,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1
Cetirizine,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Potassium voltage-gated channel subfamily H member 2;Histamine H1 receptor;Angiopoietin-1 receptor,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Cetrimonium,CCCCCCCCCCCCCCCC[N+](C)(C)C,Dynamin-1,CCCCCCCCCCCCCCCC[N+](C)(C)C
Cetrorelix,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,Lutropin-choriogonadotropic hormone receptor;Gonadotropin-releasing hormone receptor,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Cetyl alcohol,CCCCCCCCCCCCCCCCO,,CCCCCCCCCCCCCCCCO
Cetylpyridinium,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1,High affinity choline transporter 1;Caspase-2,CCCCCCCCCCCCCCCC[n+]1ccccc1
Cevimeline,CC1O[C@@]2(CS1)CN1CCC2CC1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CC1O[C@@]2(CS1)CN1CCC2CC1
Chenodeoxycholic acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Chloral hydrate,OC(O)C(Cl)(Cl)Cl,,OC(O)C(Cl)(Cl)Cl
Chlorambucil,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl,Delta-type opioid receptor;Cathepsin D;Aldose reductase;Cathepsin E;Disintegrin and metalloproteinase domain-containing protein 9,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
Chloramphenicol,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,Cytochrome P450 3A4;Chloramphenicol acetyltransferase;Streptokinase A;Probable HTH-type transcriptional regulator TtgR,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl
Chloramphenicol palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,Cytochrome P450 3A4;Chloramphenicol acetyltransferase;Streptokinase A;Probable HTH-type transcriptional regulator TtgR,CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1
Chloramphenicol succinate,O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O,Cytochrome P450 3A4;Chloramphenicol acetyltransferase;Streptokinase A;Probable HTH-type transcriptional regulator TtgR,O=C(O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1
Chlorcyclizine,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Apoptosis regulator Bcl-2,CN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Chlordiazepoxide,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,Histamine H1 receptor;Thyrotropin-releasing hormone receptor;Acetylcholinesterase;Translocator protein;Cholinesterase;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;Cholecystokinin receptor,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1
Chlorhexidine,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,72 kDa type IV collagenase;Matrix metalloproteinase-9;Solute carrier family 22 member 1;Trypanothione reductase;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;CAAX prenyl protease 2;Synaptojanin-2,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1
Chloric acid,[H]O[Cl](=O)=O,,[O-][Cl+2]([O-])O
Chlormerodrin,COC(CNC(N)=O)C[Hg]Cl,,COC(CNC(N)=O)[CH2][Hg][Cl]
Chlormerodrin Hg-197,[Cl-].COC(C[197Hg+])CNC(N)=O,,COC([CH2][197Hg+])CNC(N)=O.[Cl-]
Chlormezanone,CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O,Sodium/potassium-transporting ATPase subunit alpha-2;Glucocorticoid receptor;Cytochrome P450 2C19;Androgen receptor;Progesterone receptor,CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1
Chlorobutanol,CC(C)(O)C(Cl)(Cl)Cl,,CC(C)(O)C(Cl)(Cl)Cl
Chloroform,ClC(Cl)Cl,,ClC(Cl)Cl
Chloroprocaine,CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1,Sodium channel protein type 10 subunit alpha,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl
Chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Ribosyldihydronicotinamide dehydrogenase [quinone];Beta-secretase 1;Major prion protein;Histidine-rich protein PFHRP-II;Riboflavin-binding protein;Dihydrofolate reductase;Amyloid beta A4 protein;Transmembrane protein 97;Cysteine proteinase falcipain 2a,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Chlorothiazide,NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,Carbonic anhydrase 2;Solute carrier family 12 member 3,NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O
Chloroxine,OC1=C(Cl)C=C(Cl)C2=C1N=CC=C2,"Arachidonate 5-lipoxygenase;Arachidonate 15-lipoxygenase;Arachidonate 12-lipoxygenase, 12S-type;Botulinum neurotoxin type A;Arachidonate 15-lipoxygenase, type II",Oc1c(Cl)cc(Cl)c2cccnc12
Chloroxylenol,CC1=CC(O)=CC(C)=C1Cl,5-hydroxytryptamine receptor 2B;Amine oxidase [flavin-containing] A,Cc1cc(O)cc(C)c1Cl
Chlorphenesin,OCC(O)COC1=CC=C(Cl)C=C1,Sodium-dependent serotonin transporter;Sodium-dependent dopamine transporter,OCC(O)COc1ccc(Cl)cc1
Chlorphenesin carbamate,NC(=O)OCC(O)COC1=CC=C(Cl)C=C1,,NC(=O)OCC(O)COc1ccc(Cl)cc1
Chlorpheniramine,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,"Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2B;Histamine H1 receptor;Histamine H4 receptor;Cytochrome P450 2D6;Sodium channel alpha subunits; brain (Types I, II, III);Lethal(3)malignant brain tumor-like protein 1;Lethal(3)malignant brain tumor-like protein 3;MBT domain-containing protein 1;Chloroquine resistance transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter",CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
Chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,"Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;Kappa-type opioid receptor;Calmodulin;Delta-type opioid receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;Epidermal growth factor receptor;Potassium channel subfamily K member 2;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Ryanodine receptor 1;Major prion protein;Solute carrier family 22 member 1;Substance-K receptor;Trypanothione reductase;Arachidonate 15-lipoxygenase;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3;Membrane-associated progesterone receptor component 1;Transient receptor potential cation channel subfamily V member 1;Pleiotropic ABC efflux transporter of multiple drugs;Solute carrier family 22 member 2;Acetylcholine receptor subunit alpha;Glutamate [NMDA] receptor;Glutamate NMDA receptor;Muscarinic acetylcholine receptor;Dopamine receptor;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;Adenylate cyclase;FAD-linked sulfhydryl oxidase ALR;Sphingomyelin phosphodiesterase",CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
Chlorpropamide,CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1,"Solute carrier family 22 member 6;Sulfonylurea receptor 1, Kir6.2",CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
Chlorprothixene,CN(C)CC\C=C1\C2=CC=CC=C2SC2=CC=C(Cl)C=C12,D(1A) dopamine receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 6;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;D(4) dopamine receptor;Solute carrier family 22 member 1;5-hydroxytryptamine receptor 7;Pleiotropic ABC efflux transporter of multiple drugs,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
Chlorquinaldol,CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O,Botulinum neurotoxin type A,Cc1ccc2c(Cl)cc(Cl)c(O)c2n1
Chlortetracycline,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Major prion protein;Protein-arginine deiminase type-4",CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12
Chlorthalidone,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,"Carbonic anhydrase 2;Solute carrier family 12 member 3;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13",NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
Chlorzoxazone,ClC1=CC2=C(OC(=O)N2)C=C1,"Intermediate conductance calcium-activated potassium channel protein 4;Nitric oxide synthase, inducible;Nitric oxide synthase, brain;Nitric oxide synthase, endothelial;Small conductance calcium-activated potassium channel protein 2;Calcium-activated potassium channel subunit alpha-1",O=c1[nH]c2cc(Cl)ccc2o1
Cholecalciferol,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,"Glycine receptor subunit alpha-1;25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;Vitamin D3 receptor;Vitamin D 25-hydroxylase;Sterol 26-hydroxylase, mitochondrial",C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12
Cholesterol,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C,Estrogen receptor;Estrogen receptor beta,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Cholic Acid,[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C,Bile acid receptor;G-protein coupled bile acid receptor 1,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Choline,C[N+](C)(C)CCO,Acetylcholine receptor subunit delta;High affinity choline transporter 1;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Creatine transporter,C[N+](C)(C)CCO
Choline C 11,[Cl-].C[N+](C)([11CH3])CCO,High affinity choline transporter 1,C[N+](C)([11CH3])CCO.[Cl-]
Choline C-11,C[N+](C)([11CH3])CCO,High affinity choline transporter 1,C[N+](C)([11CH3])CCO
Choline magnesium trisalicylate,[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O,,C[N+](C)(C)CCO.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.[Mg+2]
Choline salicylate,C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O,,C[N+](C)(C)CCO.O=C([O-])c1ccccc1O
Chromic chloride,[Cl-].[Cl-].[Cl-].[Cr+3],,[Cl-].[Cl-].[Cl-].[Cr+3]
Chromic nitrate,[Cr+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,,O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Cr+3]
Chromium,[Cr],,[Cr]
Chromium Cr-51,[51Cr],,[51Cr]
Chromium gluconate,[Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cr+3]
Chromium nicotinate,[Cr+3].[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1,,O=C([O-])c1cccnc1.O=C([O-])c1cccnc1.O=C([O-])c1cccnc1.[Cr+3]
Chromium picolinate,[Cr+3].[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1,,O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3]
Chromous sulfate,[Cr++].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[Cr+2]
Cianidanol,O[C@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Prothrombin;Mast/stem cell growth factor receptor Kit;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Beta-secretase 1;Polyphenol oxidase 2;Carbonic anhydrase 13;Carbonic anhydrase 15;Arginase;Amyloid beta A4 protein;Dihydroorotate dehydrogenase",Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2
Ciclesonide,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C,Glucocorticoid receptor,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Ciclopirox,CC1=CC(=O)N(O)C(=C1)C1CCCCC1,Poly [ADP-ribose] polymerase 1;Deoxyhypusine hydroxylase,Cc1cc(C2CCCCC2)n(O)c(=O)c1
Cidofovir,NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1,DNA polymerase catalytic subunit,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1
Cilastatin,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,Dipeptidase 1,CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O
Cilazapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O
Cilostazol,O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;Cytochrome P450 2C9;cGMP-inhibited 3',5'-cyclic phosphodiesterase B",O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1
Cimetidine,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,5-hydroxytryptamine receptor 2A;Histamine H2 receptor;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2,CN/C(=N/C#N)NCCSCc1nc[nH]c1C
Cinacalcet,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,Cytochrome P450 2D6;Glycine receptor subunit alpha-1;Extracellular calcium-sensing receptor;Metabotropic glutamate receptor 5,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12
Cinchocaine,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,"Sodium channel protein type 5 subunit alpha;Sodium channel protein type 10 subunit alpha;Sodium channel alpha subunits; brain (Types I, II, III)",CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1
Cinnamaldehyde,O=C\C=C\C1=CC=CC=C1,,O=C/C=C/c1ccccc1
Cinnamyl alcohol,OC\C=C\C1=CC=CC=C1,,OC/C=C/c1ccccc1
Cinnarizine,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,"Mu-type opioid receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Sodium channel alpha subunits; brain (Types I, II, III)",C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
Cinoxacin,CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,Carbonic anhydrase 2;DNA gyrase,CCn1nc(C(=O)O)c(=O)c2cc3c(cc21)OCO3
Cinoxate,CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1,,CCOCCOC(=O)/C=C/c1ccc(OC)cc1
Ciprofibrate,CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O,Peroxisome proliferator-activated receptor alpha,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
Ciprofloxacin,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,DNA topoisomerase 4 subunit A;DNA gyrase subunit A;Histamine H3 receptor;GABA-A receptor; anion channel;DNA topoisomerase II;Multidrug resistance protein mdtK,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
Cisapride,CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 7;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;3-hydroxy-3-methylglutaryl-coenzyme A reductase;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Serotonin 3 (5-HT3) receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Serotonin 2 (5-HT2) receptor,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC
Cisatracurium,COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2,Acetylcholine receptor,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC
Cisplatin,[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],Sodium/potassium-transporting ATPase subunit alpha-2;D(3) dopamine receptor;Muscarinic acetylcholine receptor M5;Canalicular multispecific organic anion transporter 1;Adenosine receptor A3;Multidrug resistance-associated protein 6;Multidrug resistance-associated protein 5;Epidermal growth factor receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;C-X-C chemokine receptor type 2;Thromboxane-A synthase;C-C chemokine receptor type 2;Mitogen-activated protein kinase 3;Melanocortin receptor 5,[NH3]->[Pt](<-[NH3])([Cl])[Cl]
Citalopram,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;5-hydroxytryptamine receptor 1A;Transporter,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Citicoline,C[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O,Acetylcholine receptor subunit delta;High affinity choline transporter 1;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Creatine transporter,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O
Citric acid,OC(=O)CC(O)(CC(O)=O)C(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(O)CC(O)(CC(=O)O)C(=O)O
Cladribine,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1,"Deoxycytidine kinase;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Adenosine receptor A1;Adenosine receptor A2a",Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
Clarithromycin,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC,Potassium voltage-gated channel subfamily H member 2,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Clascoterone,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Androgen receptor,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Clavulanic acid,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO,,O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
Clemastine,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Cytochrome P450 2C19;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Transmembrane protein 97,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
Clenbuterol,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1
Clevidipine,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1D,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
Clidinium,C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,C[N@+]12CC[C@H](CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2
Clindamycin,[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]1([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,50S ribosomal protein L10,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1
Clioquinol,OC1=C(I)C=C(Cl)C2=C1N=CC=C2,Catechol O-methyltransferase;Botulinum neurotoxin type A;Carbonic anhydrase 15;Amyloid beta A4 protein,Oc1c(I)cc(Cl)c2cccnc12
Clobazam,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,GABA-A receptor alpha-1/beta-2/gamma-2,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21
Clobetasol,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;CAAX prenyl protease 1;CAAX prenyl protease 2,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl
Clobetasol propionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Annexin A1;Bile salt export pump;Androgen receptor;Cytochrome P450 3A5;Progesterone receptor,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Clobetasone,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl
Clocortolone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Clodronic acid,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,,O=P(O)(O)C(Cl)(Cl)P(=O)(O)O
Clofarabine,[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12,"DNA polymerase alpha catalytic subunit;Ribonucleoside-diphosphate reductase large subunit;Ribonucleoside-diphosphate reductase subunit M2;Ribose-phosphate pyrophosphokinase 1;Uridine-cytidine kinase 1;Uridine-cytidine kinase 2;cGMP-dependent 3',5'-cyclic phosphodiesterase",Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Clofazimine,CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1,Uncharacterized oxidoreductase CzcO-like;Cruzipain,CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1
Clofedanol,CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl,,CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl
Clofibrate,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,"Peroxisome proliferator-activated receptor alpha;Fatty acid-binding protein, liver",CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
Clomifene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1,"Prostaglandin G/H synthase 1;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3;Estrogen receptor;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Substance-K receptor;Androgen receptor;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;C-8 sterol isomerase",CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1
Clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Glutathione S-transferase P;Solute carrier family 22 member 1;Trypanothione reductase;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Serotonin (5-HT) receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Serotonin 2 (5-HT2) receptor;G protein-activated inward rectifier potassium channel 2,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
Clonazepam,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor; anion channel,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
Clonidine,ClC1=CC=CC(Cl)=C1NC1=NCCN1,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Nischarin;Solute carrier family 22 member 1;Beta-1 adrenergic receptor;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Adrenergic receptor alpha-2;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,Clc1cccc(Cl)c1NC1=NCCN1
Clopidogrel,[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,Sodium-dependent serotonin transporter;P2Y purinoceptor 12;Cytochrome P450 2B6,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
Clorazepic acid,OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O
Clothiapine,CN1CCN(CC1)C1=NC2=CC=CC=C2SC2=C1C=C(Cl)C=C2,D(2) dopamine receptor;D(1A) dopamine receptor;Muscarinic acetylcholine receptor;Serotonin 2 (5-HT2) receptor,CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1
Clotiazepam,CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl,"Fatty acid-binding protein, liver;GABA-A receptor alpha-1/beta-3/gamma-2",CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl
Clotrimazole,ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,"Beta-1 adrenergic receptor;Prostaglandin G/H synthase 2;Nuclear receptor subfamily 1 group I member 3;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Glucocorticoid receptor;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A1;Adenosine receptor A3;Intermediate conductance calcium-activated potassium channel protein 4;Nuclear receptor subfamily 1 group I member 2;D(4) dopamine receptor;Carbonic anhydrase 2;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Lanosterol 14-alpha demethylase;Delta-type opioid receptor;Beta-lactamase;Acetylcholinesterase;Cytochrome P450 2C9;Platelet-activating factor receptor;Aromatase;Cysteinyl leukotriene receptor 1;Epidermal growth factor receptor;Vasopressin V2 receptor;Substance-P receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Potassium voltage-gated channel subfamily A member 3;Cytochrome P450 2C19;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Thromboxane-A synthase;Bile acid receptor;Solute carrier family 22 member 1;Substance-K receptor;Androgen receptor;5-hydroxytryptamine receptor 1B;C-C chemokine receptor type 4;Progesterone receptor;Alpha-1A adrenergic receptor;C-X-C chemokine receptor type 1;14-alpha sterol demethylase Cyp51A;14-alpha sterol demethylase;Indoleamine 2,3-dioxygenase 2;Mycocyclosin synthase;Transitional endoplasmic reticulum ATPase;Malate dehydrogenase cytoplasmic ;Putative cytochrome P450 130;Alpha-chymotrypsin;Indoleamine 2,3-dioxygenase 1;7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
Cloxacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O,Penicillin-binding protein 1A;Beta-lactamase TEM;Beta-lactamase;Efflux transporter; SugE;Penicillin-binding protein,Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Clozapine,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;UDP-glucuronosyltransferase 1-4;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Transporter;Histamine H3 receptor;Serotonin 3 (5-HT3) receptor;Muscarinic acetylcholine receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Serotonin 2 (5-HT2) receptor;Adenylate cyclase;Histone H1.0;Calmodulin;Calmodulin-1,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
Cobalt,[Co],,[Co]
Cobalt chloride,[Cl-].[Cl-].[Co++],,[Cl-].[Cl-].[Co+2]
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Cytochrome P450 3A,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Cobimetinib,OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1,Serine/threonine-protein kinase B-raf;Dual specificity mitogen-activated protein kinase kinase 2;Dual specificity mitogen-activated protein kinase kinase 1,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1
Cocaine,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C,"Sodium channel protein type 5 subunit alpha;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor;Histamine H1 receptor;5-hydroxytryptamine receptor 1B;Sodium-dependent dopamine transporter;5-hydroxytryptamine receptor 3A;Sodium- and chloride-dependent GABA transporter 1;Sodium channel protein type 11 subunit alpha;Kappa-type opioid receptor;Cocaine- and amphetamine-regulated transcript protein;Muscarinic acetylcholine receptor M1;Transporter;Serotonin 3 receptor (5HT3);Sodium channel alpha subunits; brain (Types I, II, III);Dopamine transporter",COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C
Cocarboxylase,CC1=C(CCO[P@](O)(=O)O[P@](O)([O-])=O)SC=[N+]1CC1=CN=C(C)N=C1N,,Cc1ncc(C[n+]2csc(CCO[P@@](=O)(O)O[P@@](=O)([O-])O)c2C)c(N)n1
Codeine,[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Opioid receptor,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
Coenzyme M,OS(=O)(=O)CCS,,O=S(=O)(O)CCS
Colchiceine,COC1=C(OC)C(OC)=C2C(CCC(NC(C)=O)C3=CC(=O)C(O)=CC=C23)=C1,Cytochrome P450 3A4;Multidrug resistance protein 1;Multidrug resistance-associated protein 1;Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;Tubulin beta chain;Serine/threonine-protein kinase pim-1;Tubulin alpha-1A chain;Tubulin beta-2B chain;Bromodomain-containing protein 4;Tubulin polymerization-promoting protein;Tubulin beta-4B chain;Tubulin,COc1cc2c(c(OC)c1OC)-c1ccc(O)c(=O)cc1C(NC(C)=O)CC2
Colchicine,COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1[C@H](CC2)NC(C)=O,Cytochrome P450 3A4;Multidrug resistance protein 1;Multidrug resistance-associated protein 1;Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;Tubulin beta chain;Serine/threonine-protein kinase pim-1;Tubulin alpha-1A chain;Tubulin beta-2B chain;Bromodomain-containing protein 4;Tubulin polymerization-promoting protein;Tubulin beta-4B chain;Tubulin,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Colfosceril palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
Colistimethate,CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O,,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS(=O)(=O)[O-])NC1=O)C(C)O
Colistin,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
Conivaptan,CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1,Vasopressin V1a receptor;Vasopressin V2 receptor;Oxytocin receptor,Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2
Copanlisib,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21,"Serine/threonine-protein kinase mTOR;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21
Copper,[Cu],,[Cu]
Copper Cu-64,[64Cu],,[64Cu]
Copper gluconate,[Cu++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2]
Copper oxodotreotide Cu-64,[64Cu++].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[64Cu+2]
Cortisone acetate,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Cytochrome P450 3A4;Androgen receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 17A1",CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
Creatine,CN(CC(O)=O)C(N)=N,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Acetylcholinesterase;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Substance-K receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Histamine H1 receptor,CN(CC(=O)O)C(=N)N
Crisaborole,OB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2,"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A;High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A;Phosphodiesterase 4",N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
Crizotinib,C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl,"Tyrosine-protein kinase JAK3;Macrophage-stimulating protein receptor;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Macrophage colony-stimulating factor 1 receptor;Insulin-like growth factor 1 receptor;Insulin receptor;Fibroblast growth factor receptor 3;Rho-associated protein kinase 1;Focal adhesion kinase 1;Tyrosine-protein kinase JAK1;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Tyrosine-protein kinase SYK;Angiopoietin-1 receptor;Ephrin type-A receptor 8;AP2-associated protein kinase 1;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;LIM domain kinase 1;5'-AMP-activated protein kinase catalytic subunit alpha-1;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Serine/threonine-protein kinase PLK4;Aurora kinase C;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 5;Ephrin type-A receptor 4;Ephrin type-A receptor 6;Tyrosine-protein kinase Fgr;Aurora kinase A;ALK tyrosine kinase receptor;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Tyrosine-protein kinase FRK;Mitogen-activated protein kinase kinase kinase kinase 5;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;Ephrin type-A receptor 7;STE20-like serine/threonine-protein kinase;Calcium/calmodulin-dependent protein kinase kinase 2;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Activin receptor type-1B;Activin receptor type-1;Inhibitor of nuclear factor kappa-B kinase subunit beta;Tyrosine-protein kinase ITK/TSK;Tyrosine-protein kinase ZAP-70;Tyrosine-protein kinase BTK;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Tyrosine-protein kinase receptor TYRO3;Cyclin-dependent kinase 7;Serine/threonine-protein kinase D1;Ribosomal protein S6 kinase beta-1;Serine/threonine-protein kinase 3;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha;Protein-tyrosine kinase 2-beta;Serine/threonine-protein kinase RIO1;Tyrosine-protein kinase receptor Tie-1;NT-3 growth factor receptor;Tyrosine-protein kinase TXK;Inhibitor of nuclear factor kappa-B kinase subunit epsilon;LIM domain kinase 2;Dual specificity mitogen-activated protein kinase kinase 3;Serine/threonine-protein kinase 26;Serine/threonine-protein kinase Nek7;Insulin receptor-related protein;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase RIO3;Serine/threonine-protein kinase SIK2;SRSF protein kinase 1;Serine/threonine-protein kinase TNNI3K;Ankyrin repeat and protein kinase domain-containing protein 1;Myotonin-protein kinase;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Tyrosine-protein kinase Mer;Cyclin-dependent kinase 11B;Cyclin-dependent kinase 11A;Muscle, skeletal receptor tyrosine-protein kinase;Serine/threonine-protein kinase DCLK1;Serine/threonine-protein kinase DCLK2;Serine/threonine-protein kinase Nek9;AarF domain-containing protein kinase 4;Dual specificity testis-specific protein kinase 1;TGF-beta receptor type-1;Ephrin type-A receptor 1;Mitogen-activated protein kinase 7;Serine/threonine-protein kinase D3;Interferon-induced, double-stranded RNA-activated protein kinase;Receptor-interacting serine/threonine-protein kinase 1;Tyrosine-protein kinase Fes/Fps;Proto-oncogene tyrosine-protein kinase ROS;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Interleukin-1 receptor-associated kinase 4;Cyclin-dependent kinase-like 2;Dual specificity tyrosine-phosphorylation-regulated kinase 2;Ephrin type-B receptor 6;G protein-coupled receptor kinase 4;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Serine/threonine-protein kinase NIM1;SRSF protein kinase 3;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Serine/threonine-protein kinase ULK1;Serine/threonine-protein kinase ULK2;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Mitogen-activated protein kinase kinase kinase 15;Receptor-interacting serine/threonine-protein kinase 4;Uncharacterized serine/threonine-protein kinase SBK3;Serine/threonine-protein kinase 35;Mitogen-activated protein kinase kinase kinase 1;Bone morphogenetic protein receptor type-1B;Serine/threonine-protein kinase SBK1;Peripheral plasma membrane protein CASK;Mitogen-activated protein kinase kinase kinase 12;Serine/threonine-protein kinase TAO2;Dual serine/threonine and tyrosine protein kinase;NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor);Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2;Receptor-interacting serine/threonine-protein kinase 3;Mixed lineage kinase domain-like protein",C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
Cromoglicic acid,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O,,O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
Crotamiton,CCN(C(=O)C=CC)C1=CC=CC=C1C,5-hydroxytryptamine receptor 4;Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 7;Gastrin/cholecystokinin type B receptor;Cholecystokinin A receptor;Adenylate cyclase,CC=CC(=O)N(CC)c1ccccc1C
Cupric Chloride,Cl[Cu]Cl,Sodium-dependent noradrenaline transporter;Carbonic anhydrase 2;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Androgen receptor;Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform;G-protein coupled receptor 39;G protein-coupled receptor 39-1b;Ubiquitin-conjugating enzyme E2 T,[Cl][Cu][Cl]
Cupric oxide,[O--].[Cu++],Soluble guanylate cyclase,[Cu+2].[O-2]
Cupric sulfate,[Cu++].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[Cu+2]
Curcumin,COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O,,COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O
Cyanocobalamin,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2,"Methionine synthase;Methionine synthase reductase;Protein amnionless;Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial;Methylmalonic aciduria type A protein, mitochondrial;Transcobalamin-2;Transcobalamin-1",C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[N]4[Co+][C]#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O
Cyanocobalamin Co-57,[57Co+3].[C-]#N.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]\C1=C(C)/C1=N/C(=C\C3=N\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)\[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)/C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=[NH]C2=C1C=C(C)C(C)=C2,"Methionine synthase;Methionine synthase reductase;Protein amnionless;Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial;Methylmalonic aciduria type A protein, mitochondrial;Transcobalamin-2;Transcobalamin-1",
Cyanocobalamin Co-60,[60Co+3].[C-]#N.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]\C1=C(C)/C1=N/C(=C\C3=N\C(=C(C)/C4=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)\[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)/C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2,"Methionine synthase;Methionine synthase reductase;Protein amnionless;Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial;Methylmalonic aciduria type A protein, mitochondrial;Transcobalamin-2;Transcobalamin-1",C/C1=C2/[N-]C([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[60Co+3].[C-]#N
Cyclacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(=O)O
Cyclandelate,CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1,,CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1
Cyclizine,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Amine oxidase [flavin-containing] B;Alpha-1B adrenergic receptor,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
Cyclobenzaprine,CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Aldehyde oxidase;Proto-oncogene tyrosine-protein kinase receptor Ret,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21
Cycloguanil,CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1,Dihydrofolate reductase;Bifunctional dihydrofolate reductase-thymidylate synthase,CC1(C)N=C(N)N=C(N)N1c1ccc(Cl)cc1
Cyclopenthiazide,NS(=O)(=O)C1=CC2=C(NC(CC3CCCC3)NS2(=O)=O)C=C1Cl,"Solute carrier family 12 member 3;Glutamate receptor 1;Glutamate receptor 2;Glutamate receptor 4;Glutamate receptor 3;Glutamate receptor ionotropic, AMPA",NS(=O)(=O)c1cc2c(cc1Cl)NC(CC1CCCC1)NS2(=O)=O
Cyclopentolate,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,Muscarinic acetylcholine receptor M3,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1
Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,Cytochrome P450 3A4,O=P1(N(CCCl)CCCl)NCCCO1
Cycloserine,N[C@@H]1CONC1=O,"Glutamate receptor ionotropic, NMDA 2A;Cytochrome P450 3A4;Glutamate receptor ionotropic, NMDA 3A;Glutamate receptor ionotropic, NMDA 2B;Glutamate receptor ionotropic, NMDA 2C;Glutamate receptor ionotropic, NMDA 2D;Alanine racemase;Glutamate receptor ionotropic, NMDA 1;Glutamate receptor ionotropic, NMDA 3B;D-alanine--D-alanine ligase;Glutamate NMDA receptor",N[C@@H]1CONC1=O
Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,"Glutamate receptor ionotropic, NMDA 2A;Cytochrome P450 3A4;Glutamate receptor ionotropic, NMDA 3A;Glutamate receptor ionotropic, NMDA 2B;Glutamate receptor ionotropic, NMDA 2C;Glutamate receptor ionotropic, NMDA 2D;Alanine racemase;Glutamate receptor ionotropic, NMDA 1;Glutamate receptor ionotropic, NMDA 3B;D-alanine--D-alanine ligase;Glutamate NMDA receptor",C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
Cyclothiazide,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2,"Solute carrier family 12 member 3;Glutamate receptor 1;Glutamate receptor 2;Glutamate receptor 4;Glutamate receptor 3;Glutamate receptor ionotropic, AMPA",NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O
Cycrimine,OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1,OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1
Cyproheptadine,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Calmodulin;5-hydroxytryptamine receptor 1B;Muscarinic acetylcholine receptor;Dopamine receptor;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;Histone-lysine N-methyltransferase SETD7",CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
Cyproterone acetate,[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H],"Cytochrome P450 3A4;Androgen receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 17A1",CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
Cysteamine,NCCS,Cystine/glutamate transporter,NCCS
Cysteine,N[C@@H](CS)C(O)=O,Cystine/glutamate transporter,N[C@@H](CS)C(=O)O
Cystine,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,Cystine/glutamate transporter,N[C@@H](CSSC[C@H](N)C(=O)O)C(=O)O
Cytarabine,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Prostatic acid phosphatase;Enoyl-[acyl-carrier-protein] reductase [NADH];DNA polymerase beta;DNA polymerase (alpha/delta/epsilon);E3 ubiquitin-protein ligase Mdm2,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
D-Methionine,CSCC[C@@H](N)C(O)=O,S-ribosylhomocysteine lyase,CSCC[C@@H](N)C(=O)O
D-Serine,N[C@H](CO)C(O)=O,Acetylcholinesterase;Cholinesterase;Gamma-glutamyltranspeptidase 1;Asc-type amino acid transporter 1;Amino acid transporter,N[C@H](CO)C(=O)O
D-alpha-Tocopherol acetate,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(C)=O)=C(C)C(C)=C2O1,,CC(=O)Oc1c(C)c(C)c2c(c1C)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
D-glucose,[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O,,O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
DL-Methylephedrine,C[C@@H]([C@H](O)C1=CC=CC=C1)N(C)C,,C[C@@H]([C@H](O)c1ccccc1)N(C)C
DL-alpha tocopheryl acetate,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(O1)C(C)=C(C)C(OC(C)=O)=C2C,,CC(=O)Oc1c(C)c(C)c2c(c1C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2
DL-alpha-Tocopherol,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1,,Cc1c(C)c2c(c(C)c1O)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2
DL-dimyristoylphosphatidylcholine,CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC
DL-dimyristoylphosphatidylglycerol,CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC
Dabigatran,CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1,Prothrombin;Coagulation factor X;Tissue-type plasminogen activator;Cationic trypsin,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21
Dabigatran etexilate,CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1,Ribosyldihydronicotinamide dehydrogenase [quinone];Plasminogen;Prothrombin;Coagulation factor X;Tissue-type plasminogen activator;Vitamin K-dependent protein C;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Trypsin;Serine protease hepsin;Thrombin,CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1
Dabrafenib,CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1,RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-interacting serine/threonine-protein kinase 2;TGF-beta receptor type-1;Receptor-interacting serine/threonine-protein kinase 1;Dual serine/threonine and tyrosine protein kinase;Serine/threonine-protein kinase A-Raf;GTPase KRas;Receptor-interacting serine/threonine-protein kinase 3,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Dacarbazine,CN(C)\N=N\C1=C(N=CN1)C(N)=O,Matrix metalloproteinase-9;DNA polymerase alpha subunit B,CN(C)/N=N/c1[nH]cnc1C(N)=O
Daclatasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Potassium voltage-gated channel subfamily H member 2;Nonstructural protein 5A;Genome polyprotein,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
Dacomitinib,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,Tyrosine-protein kinase JAK3;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Epidermal growth factor receptor;Receptor tyrosine-protein kinase erbB-2;Receptor tyrosine-protein kinase erbB-4,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1
Dactinomycin,[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C,Growth factor receptor-bound protein 2;Discoidin domain-containing receptor 2;Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O
Dalfampridine,NC1=CC=NC=C1,Voltage-gated potassium channel;Potassium voltage-gated channel subfamily C member 1;Potassium voltage-gated channel subfamily C member 2,Nc1ccncc1
Dalfopristin,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC(=CO1)C2=O,,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12
Danazol,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3,Mu-type opioid receptor;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M3;Glucocorticoid receptor;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Kappa-type opioid receptor;Estrogen receptor;Androgen receptor;Progesterone receptor;Cytochrome P450 2C9;Steryl-sulfatase;Sex hormone-binding globulin;Substance-K receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
Dantrolene,[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,Ryanodine receptor 1;Ryanodine receptor 3;CDGSH iron-sulfur domain-containing protein 1,O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1
Dantron,OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O,Ryanodine receptor 1;Ryanodine receptor 3;CDGSH iron-sulfur domain-containing protein 1,O=C1c2cccc(O)c2C(=O)c2c(O)cccc21
Dapagliflozin,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1,Sodium/glucose cotransporter 2;Sodium/glucose cotransporter 1;Sodium/myo-inositol cotransporter 2;Low affinity sodium-glucose cotransporter,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Dapiprazole,CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
Dapsone,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,"Cytochrome P450 3A4;5-hydroxytryptamine receptor 6;Dihydropteroate synthase 1;Dihydrofolate reductase;Myeloperoxidase;Glucose-6-phosphate 1-dehydrogenase;Dihydropteroate synthetase, putative;6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase",Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1
Daptomycin,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,Outer membrane porin protein OmpD,CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C
Daridorexant,COC1=CC(C(=O)N2CCC[C@@]2(C)C2=NC3=C(N2)C=CC(Cl)=C3C)=C(C=C1)N1N=CC=N1,,COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1
Darifenacin,NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1
Darolutamide,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O,Androgen receptor;Progesterone receptor,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1
Darunavir,[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Multidrug resistance protein 1;Gag-Pol polyprotein;Pol polyprotein;Protease,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1
Dasabuvir,COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C,NS5B protein,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C
Dasatinib,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,"Tyrosine-protein kinase JAK3;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Serine/threonine-protein kinase mTOR;Breakpoint cluster region protein;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Receptor tyrosine-protein kinase erbB-2;Fibroblast growth factor receptor 3;Tyrosine-protein kinase HCK;Receptor tyrosine-protein kinase erbB-4;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase SYK;Myosin light chain kinase 2, skeletal/cardiac muscle;Tyrosine-protein kinase CSK;Ephrin type-A receptor 8;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Serine/threonine-protein kinase Nek2;LIM domain kinase 1;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase 10;Abelson tyrosine-protein kinase 2;Mitogen-activated protein kinase 11;Ephrin type-A receptor 5;Ephrin type-A receptor 4;Fibroblast growth factor receptor 2;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;Aurora kinase A;Serine/threonine-protein kinase 36;Ephrin type-A receptor 3;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Mitogen-activated protein kinase kinase kinase kinase 5;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;STE20-like serine/threonine-protein kinase;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Activin receptor type-1B;Serine/threonine-protein kinase receptor R3;Activin receptor type-1;TGF-beta receptor type-2;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase ITK/TSK;Protein-tyrosine kinase 6;Proto-oncogene tyrosine-protein kinase LCK;Tyrosine-protein kinase BTK;Tyrosine-protein kinase Tec;Ephrin type-B receptor 2;Non-receptor tyrosine-protein kinase TYK2;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Wee1-like protein kinase;Serine/threonine-protein kinase 25;Mitogen-activated protein kinase kinase kinase MLT;Tyrosine-protein kinase TXK;LIM domain kinase 2;Serine/threonine-protein kinase 26;Serine/threonine-protein kinase NLK;Eukaryotic translation initiation factor 2-alpha kinase 4;Serine/threonine-protein kinase SIK2;Activin receptor type-2A;Activin receptor type-2B;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Myotonin-protein kinase;Chaperone activity of bc1 complex-like, mitochondrial;Serine/threonine-protein kinase MRCK gamma;Mitogen-activated protein kinase kinase kinase kinase 1;Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Bone morphogenetic protein receptor type-1A;Mitogen-activated protein kinase kinase kinase kinase 4;Serine/threonine-protein kinase MRCK alpha;Serine/threonine-protein kinase MRCK beta;Serine/threonine-protein kinase SIK1;Tyrosine-protein kinase Srms;Dual specificity testis-specific protein kinase 1;TGF-beta receptor type-1;Ephrin type-A receptor 1;Ephrin type-B receptor 3;Tubulin alpha-1A chain;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Ephrin type-B receptor 6;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO3;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Serine/threonine-protein kinase 35;Receptor tyrosine-protein kinase erbB-3;Serine/threonine-protein kinase SIK3;Wee1-like protein kinase 2;Bone morphogenetic protein receptor type-1B;Quinolone resistance protein NorA;Serine/threonine-protein kinase SBK1;Serine/threonine-protein kinase VRK2;Serine/threonine-protein kinase TAO2;Dual specificity mitogen-activated protein kinase kinase 5;Serine/threonine-protein kinase Nek11;Calcium-dependent protein kinase 1;MAP kinase p38;Dual specificity mitogen-activated protein kinase kinase; MEK1/2;Bcr/Abl fusion protein;Myelin transcription factor 1",Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Daunorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O,Multidrug resistance protein 1;DNA topoisomerase 2-alpha;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 6;72 kDa type IV collagenase;ORF 73,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Debrisoquine,NC(=N)N1CCC2=CC=CC=C2C1,Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A,N=C(N)N1CCc2ccccc2C1
Decamethonium,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,Muscarinic acetylcholine receptor M2;Acetylcholinesterase;Histamine H3 receptor;Neuronal acetylcholine receptor; alpha4/beta2;Muscle-type nicotinic acetylcholine receptor,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
Decitabine,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,DNA (cytosine-5)-methyltransferase 1;DNA (cytosine-5)-methyltransferase 3A,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,,O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1
Deferiprone,CN1C=CC(=O)C(O)=C1C,Deoxyhypusine hydroxylase,Cc1c(O)c(=O)ccn1C
Deferoxamine,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Hypoxia-inducible factor 1-alpha;Deoxyhypusine hydroxylase,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Deflazacort,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
Degarelix,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,Gonadotropin-releasing hormone receptor,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Dehydrocholic acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC(=O)[C@]12C
Delafloxacin,NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F,DNA gyrase subunit A;Cytochrome P450 1A2;DNA gyrase subunit B,Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F
Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O,,C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1
Delavirdine,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2,Histamine H4 receptor;Beta-lactamase;Gag-Pol polyprotein;Reverse transcriptase/RNaseH;Reverse transcriptase;Malate dehydrogenase cytoplasmic ,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1
Demecarium,CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,Acetylcholinesterase,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1
Demeclocycline,[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O,30S ribosomal protein S4;30S ribosomal protein S9;Estrogen receptor beta,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12
Deoxycholic acid,[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Dequalinium,CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2,Protein kinase C alpha type;Small conductance calcium-activated potassium channel protein 3;Small conductance calcium-activated potassium channel protein 1;Small conductance calcium-activated potassium channel protein 2;cGMP-gated cation channel alpha-1;Cyclic nucleotide-gated olfactory channel,Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21
Deserpidine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,Synaptic vesicular amine transporter,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
Desflurane,FC(F)OC(F)C(F)(F)F,Potassium channel subfamily K member 2;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9;Potassium channel subfamily K member 10;Potassium channel subfamily K member 18;Glycine receptor (alpha-1/beta);GABA-A receptor; anion channel,FC(F)OC(F)C(F)(F)F
Desipramine,CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;Sodium-dependent dopamine transporter;Voltage-dependent calcium channel gamma-1 subunit;Solute carrier family 22 member 1;Transporter;Serotonin (5-HT) receptor;Sodium channel alpha subunits; brain (Types I, II, III);Equilibrative nucleoside transporter 4;G protein-activated inward rectifier potassium channel 4;G protein-activated inward rectifier potassium channel 2",CNCCCN1c2ccccc2CCc2ccccc21
Deslanoside,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Sodium/potassium-transporting ATPase,C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1
Desloratadine,ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1,Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Alpha-1B adrenergic receptor,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
Desmopressin,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O,Vasopressin V1a receptor;Vasopressin V1b receptor;Oxytocin receptor;Vasopressin V2 receptor,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Desogestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],Progesterone receptor;Sex hormone-binding globulin,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC
Desonide,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Desoximetasone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Annexin A1;Progesterone receptor,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Desoxycorticosterone acetate,[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Mineralocorticoid receptor,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Desvenlafaxine,CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1
Deucravacitinib,[2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C2CC2)N=N1,Non-receptor tyrosine-protein kinase TYK2;Tyrosine-protein kinase JAK3;Tyrosine-protein kinase JAK1;Tyrosine-protein kinase JAK2,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Deutetrabenazine,[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Synaptic vesicular amine transporter,[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Prostaglandin G/H synthase 2;Glucocorticoid receptor;Annexin A1;Interleukin-5;Mineralocorticoid receptor;Interleukin-4;Androgen receptor;Progesterone receptor;Fatty acid-binding protein, liver;Nuclear receptor subfamily 1 group I member 2",C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Dexamethasone acetate,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Fatty acid-binding protein, liver",CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Dexamethasone metasulfobenzoate,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Fatty acid-binding protein, liver",C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)c1cccc(S(=O)(=O)O)c1
Dexbrompheniramine,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1,Histamine H1 receptor,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1
Dexchlorpheniramine maleate,OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
Dexfenfluramine,CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F,Beta-1 adrenergic receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1B adrenergic receptor,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
Dexibuprofen,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
Dexketoprofen,[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Dexlansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,Potassium-transporting ATPase;Cytosolic endo-beta-N-acetylglucosaminidase;Sterile alpha and TIR motif-containing protein 1,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1
Dexmedetomidine,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1,Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Dexmethylphenidate,[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Transporter;Dopamine receptor,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1
Dexpanthenol,CC(C)(CO)[C@@H](O)C(=O)NCCCO,,CC(C)(CO)[C@@H](O)C(=O)NCCCO
Dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
Dextroamphetamine,C[C@H](N)CC1=CC=CC=C1,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Trace amine-associated receptor 1;Synaptic vesicular amine transporter,C[C@H](N)Cc1ccccc1
Dextromethorphan,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,"Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Cytochrome P450 2D6;Glutamate receptor ionotropic, NMDA 3A;Glutamate receptor ionotropic, NMDA 2C;Solute carrier family 22 member 1;Glutamate NMDA receptor;Sodium channel alpha subunits; brain (Types I, II, III);Taste receptor type 2 member 46",COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
Dextropropoxyphene,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1,"Sodium channel protein type 5 subunit alpha;Mu-type opioid receptor;Glutamate receptor ionotropic, NMDA 3A",CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C
Dextrothyroxine,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,Thyroid hormone receptor beta;Thyroid hormone receptor;Glutamate NMDA receptor,N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O
Dezocine,[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N,Mu-type opioid receptor;Kappa-type opioid receptor,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N
Diacerein,CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O,Caspase-3;Caspase-7;Female germline-specific tumor suppressor gld-1;N-acylethanolamine-hydrolyzing acid amidase,CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O
Diacetyl benzoyl lathyrol,C[C@H]1C[C@@]2(OC(C)=O)[C@H]([C@H]1OC(=O)C1=CC=CC=C1)[C@@H](OC(C)=O)C(=C)CC[C@H]1[C@@H](\C=C(C)\C2=O)C1(C)C,,C=C1CC[C@H]2[C@@H](/C=C(\C)C(=O)[C@@]3(OC(C)=O)C[C@H](C)[C@H](OC(=O)c4ccccc4)[C@@H]3[C@H]1OC(C)=O)C2(C)C
Diaminopropanol tetraacetic acid,OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O,,O=C(O)CN(CC(=O)O)CC(O)CN(CC(=O)O)CC(=O)O
Diamorphine,[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,D(2) dopamine receptor;D(1A) dopamine receptor;D(3) dopamine receptor,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
Diatrizoate,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
Diazepam,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,"GABA A receptor alpha-5/beta-2/gamma-3;Gamma-aminobutyric acid receptor subunit alpha-5;Cytochrome P450 3A4;Alpha-1A adrenergic receptor;Adenosine receptor A3;Aldo-keto reductase family 1 member C1;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Fatty acid-binding protein, liver;Acetylcholinesterase;Translocator protein;Thyrotropin-releasing hormone receptor;Cholinesterase;Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-3;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-6/beta-2/gamma-2;GABA-A receptor; alpha-1/beta-2/gamma-2;GABA A receptor alpha-2/beta-2/gamma-2;GABA A receptor alpha-5/beta-3/gamma-2;GABA A receptor alpha-3/beta-2/gamma-3;GABA A receptor alpha-5/beta-3/gamma-3;GABA A receptor alpha-5/beta-2/gamma-2",CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
Diazolidinylurea,OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O,,O=C1C(N(CO)C(=O)NCO)N(CO)C(=O)N1CO
Diazoxide,CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2,"Nicotinamide phosphoribosyltransferase;Sulfonylurea receptor 1, Kir6.2;ATP-sensitive inward rectifier potassium channel 11",CC1=NS(=O)(=O)c2cc(Cl)ccc2N1
Dibekacin,NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",NC[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)O1
Dibenzepin,CN(C)CCN1C2=CC=CC=C2N(C)C2=CC=CC=C2C1=O,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Adenosine receptor A3;Muscarinic receptor M1;Muscarinic acetylcholine receptor;Muscarinic acetylcholine receptor DM1,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21
Dichloralphenazone,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,"Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2B;Histamine H1 receptor;Histamine H4 receptor;Cytochrome P450 2D6;Sodium channel alpha subunits; brain (Types I, II, III);Lethal(3)malignant brain tumor-like protein 1;Lethal(3)malignant brain tumor-like protein 3;MBT domain-containing protein 1;Chloroquine resistance transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter",Cc1cc(=O)n(-c2ccccc2)n1C.OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl
Dichloroacetic acid,OC(=O)C(Cl)Cl,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(O)C(Cl)Cl
Dichlorobenzyl alcohol,OCC1=C(Cl)C=C(Cl)C=C1,,OCc1ccc(Cl)cc1Cl
Dichromate,[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O,,[O]=[Cr](=[O])([O-])[O][Cr](=[O])(=[O])[O-]
Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Transthyretin;Aldo-keto reductase family 1 member C3;Peroxisome proliferator-activated receptor gamma;Fatty acid-binding protein, liver;Interleukin-8;Transient receptor potential cation channel subfamily A member 1;Aldo-keto reductase family 1 member B10;Acid-sensing ion channel 3;C-X-C chemokine receptor type 1;UDP-glucuronosyltransferase 1-1;UDP-glucuronosyltransferase 1-7;UDP-glucuronosyltransferase 1-6;UDP-glucuronosyltransferase 1-9;UDP-glucuronosyltransferase 1-10;Transient receptor potential cation channel subfamily M member 3",O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Diclofenamide,NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Cytochrome P450 2C9;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1
Dicloxacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O,"Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Penicillin-binding protein 1A;Sodium-dependent dopamine transporter;Bile salt export pump;cGMP-dependent 3',5'-cyclic phosphodiesterase;Streptokinase A;Penicillin-binding protein",Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Dicoumarol,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,Cytochrome P450 2C9;NAD(P)H dehydrogenase [quinone] 1;Aldose reductase;Mitogen-activated protein kinase 1;Proprotein convertase subtilisin/kexin type 7;G-protein coupled receptor 35;Enoyl-[acyl-carrier-protein] reductase [NADH];Urease;ATP phosphoribosyltransferase;NULLD(P)H dehydrogenase [quinone] 1;Vitamin K epoxide reductase complex subunit 1,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O
Dicyclomine,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,"Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Membrane-associated progesterone receptor component 1;SMR1-alpha2;Sodium channel alpha subunits; brain (Types I, II, III)",CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,Reverse transcriptase/RNaseH,O=c1nc[nH]c2c1ncn2[C@H]1CC[C@@H](CO)O1
Didecyldimethylammonium,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC,,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC
Dienestrol,[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1,Estrogen receptor,C/C=C(C(=C/C)/c1ccc(O)cc1)\c1ccc(O)cc1
Dienogest,[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H],Progesterone receptor,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N
Diethylamino hydroxybenzoyl hexyl benzoate,CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(C=C1O)N(CC)CC,,CCCCCCOC(=O)c1ccccc1C(=O)c1ccc(N(CC)CC)cc1O
Diethylcarbamazine,CCN(CC)C(=O)N1CCN(C)CC1,Prostaglandin G/H synthase 1;Arachidonate 5-lipoxygenase;Nematode GABA-A receptor,CCN(CC)C(=O)N1CCN(C)CC1
Diethylpropion,CCN(CC)C(C)C(=O)C1=CC=CC=C1,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter,CCN(CC)C(C)C(=O)c1ccccc1
Diethylstilbestrol,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,Sodium/nucleoside cotransporter 1;Beta-1 adrenergic receptor;Prostaglandin G/H synthase 1;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Glucocorticoid receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A1;Adenosine receptor A3;Nuclear receptor subfamily 1 group I member 2;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Estrogen receptor;Delta-type opioid receptor;Acetylcholinesterase;Estrogen receptor beta;Estrogen-related receptor gamma;Cysteinyl leukotriene receptor 1;Vasopressin V1a receptor;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Steroid hormone receptor ERR2;Mitogen-activated protein kinase 14;Substance-K receptor;Androgen receptor;Arachidonate 15-lipoxygenase;Progesterone receptor;Alpha-1A adrenergic receptor;UDP-glucose 4-epimerase;Steroid hormone receptor ERR1,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
Diethyltoluamide,CCN(CC)C(=O)C1=CC(C)=CC=C1,,CCN(CC)C(=O)c1cccc(C)c1
Difelikefalin,CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O,,CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1
Difenoxin,OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,Mu-type opioid receptor,N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1
Diflorasone,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Diflunisal,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Carbonic anhydrase 2;Transthyretin;Carbonic anhydrase 1;Dihydrofolate reductase,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
Difluocortolone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Androgen receptor;Progesterone receptor,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Difluprednate,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Digitoxin,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,Sodium/potassium-transporting ATPase subunit alpha-2;Potassium voltage-gated channel subfamily H member 2;Sodium/potassium-transporting ATPase subunit alpha-1;Signal transducer and activator of transcription 3;Sodium/potassium-transporting ATPase,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,Sodium/potassium-transporting ATPase subunit alpha-2;Potassium voltage-gated channel subfamily H member 2;Nuclear receptor ROR-gamma;Sodium/potassium-transporting ATPase subunit alpha-1;Signal transducer and activator of transcription 3;Sodium/potassium-transporting ATPase,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
Dihydralazine,NNC1=C2C=CC=CC2=C(NN)N=N1,Aldehyde oxidase;Voltage-dependent L-type calcium channel subunit alpha-1C;DNA (cytosine-5)-methyltransferase 1;DNA (cytosine-5)-methyltransferase 3A;DNA (cytosine-5)-methyltransferase 3B;Myeloperoxidase;Arachidonate 15-lipoxygenase;Acetylcholinesterase;Cholinesterase;Lactoperoxidase;Ryanodine receptor 2,NNc1nnc(NN)c2ccccc12
Dihydro-alpha-ergocryptine,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 7,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Dihydrocodeine,[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC,Mu-type opioid receptor,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341
Dihydroergocornine,[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,5-hydroxytryptamine receptor 4;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Beta-3 adrenergic receptor;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Cytochrome P450 2C9;Cytochrome P450 2C19;5-hydroxytryptamine receptor 1B,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Dihydroergocristine,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,5-hydroxytryptamine receptor 4;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Beta-3 adrenergic receptor;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Cytochrome P450 2C9;Cytochrome P450 2C19;5-hydroxytryptamine receptor 1B,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
Dihydroergotamine,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Gastrin/cholecystokinin type B receptor;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Adrenergic receptor alpha-2,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Dihydrostreptomycin,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO,30S ribosomal protein S12,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O
Dihydrotachysterol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C,Vitamin D3 receptor,CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]12C
Diiodohydroxyquinoline,OC1=C2N=CC=CC2=C(I)C=C1I,Adenosine receptor A3;Epidermal growth factor receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Mitogen-activated protein kinase 3;Mitogen-activated protein kinase 14;Angiotensin-converting enzyme;Mitogen-activated protein kinase 1;Catechol O-methyltransferase,Oc1c(I)cc(I)c2cccnc12
Diloxanide furoate,CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1,,CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1
Diltiazem,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,"Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Multidrug resistance protein 1;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 3A;Voltage-dependent calcium channel gamma-1 subunit;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent L-type calcium channel subunit alpha-1S;Solute carrier family 22 member 1;Voltage-dependent L-type calcium channel subunit alpha-1D;Sodium channel alpha subunits; brain (Types I, II, III);Voltage-gated L-type calcium channel;Potassium voltage-gated channel subfamily C member 1;Potassium voltage-gated channel subfamily A member 7;Voltage-dependent L-type calcium channel subunit alpha-1F",COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
Dimazole,CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C,Thyroid peroxidase;Lactoperoxidase;Dopamine beta-hydroxylase,CCN(CC)CCOc1ccc2nc(N(C)C)sc2c1
Dimenhydrinate,CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor,CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2nc(Cl)[nH]c2n(C)c1=O
Dimercaprol,OCC(S)CS,,OCC(S)CS
Dimercaptosuccinic acid,OC(=O)C(S)C(S)C(O)=O,,O=C(O)C(S)C(S)C(=O)O
Dimethyl fumarate,[H]\C(=C(\[H])C(=O)OC)C(=O)OC,Hydroxycarboxylic acid receptor 2;Kelch-like ECH-associated protein 1,COC(=O)/C=C/C(=O)OC
Dimethyl sulfoxide,CS(C)=O,,CS(C)=O
Dimetindene,CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1,Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1
Dimetotiazine,CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(=O)(=O)N(C)C)N(C)C,D(2) dopamine receptor;D(3) dopamine receptor;Histamine H1 receptor,CC(CN1c2ccccc2Sc2ccc(S(=O)(=O)N(C)C)cc21)N(C)C
Dinoprost,[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)CCCCC,Prostaglandin E2 receptor EP1 subtype;Prostaglandin D2 receptor 2;Prostaglandin E2 receptor EP3 subtype;Thromboxane A2 receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Prostaglandin F2-alpha receptor,CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O
Dinoprost tromethamine,NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,,CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO
Dinoprostone,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,Prostaglandin E2 receptor EP1 subtype;Prostaglandin D2 receptor 2;Prostaglandin E2 receptor EP3 subtype;Prostacyclin receptor;Thromboxane A2 receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Prostaglandin F2-alpha receptor;Solute carrier family 22 member 6;Solute carrier family 22 member 20;Cation channel sperm-associated protein 1;Cation channel sperm-associated protein 2;Cation channel sperm-associated protein 3;Cation channel sperm-associated protein 4,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O
Dioctyldimonium,CCCCCCCC[N+](C)(C)CCCCCCCC,,CCCCCCCC[N+](C)(C)CCCCCCCC
Diosmin,COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1,Lysine-specific histone demethylase 1A,COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O
Dioxybenzone,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O,Hormone-sensitive lipase,COc1ccc(C(=O)c2ccccc2O)c(O)c1
Dipentamethylenethiuram disulfide,S=C(SSC(=S)N1CCCCC1)N1CCCCC1,,S=C(SSC(=S)N1CCCCC1)N1CCCCC1
Diphemanil,C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1
Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,"Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Cytochrome P450 2D6;Solute carrier family 22 member 2;Sodium channel alpha subunits; brain (Types I, II, III);Sodium-dependent serotonin transporter;Sodium-dependent dopamine transporter",CN(C)CCOC(c1ccccc1)c1ccccc1
Diphenidol,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,"D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 2A;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Cytochrome P450 2D6;Alpha-1B adrenergic receptor;Sodium channel alpha subunits; brain (Types I, II, III)",OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
Diphenoxylate,CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,Mu-type opioid receptor;Potassium voltage-gated channel subfamily A member 3,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
Diphenylguanidine,N=C(NC1=CC=CC=C1)NC1=CC=CC=C1,"Sigma non-opioid intracellular receptor 1;Lysosomal Pro-X carboxypeptidase;Glutamate receptor ionotropic, NMDA 1;Glutamate receptor ionotropic, NMDA 2C;Cholinesterase;Acetylcholine receptor subunit alpha;Glutamate [NMDA] receptor;Glutamate NMDA receptor;Glutamate NMDA receptor; GRIN1/GRIN2B;Glutamate NMDA receptor; GRIN1/GRIN2A;Muscarinic acetylcholine receptor",N=C(Nc1ccccc1)Nc1ccccc1
Diphenylpyraline,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Sodium-dependent dopamine transporter;Cytochrome P450 2D6,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1
Dipivefrin,CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1,Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1
Dipotassium phosphate,[K+].[K+].OP([O-])([O-])=O,DNA topoisomerase 2-alpha,O=P([O-])([O-])O.[K+].[K+]
Dipyridamole,OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1,"Sodium/nucleoside cotransporter 1;cGMP-specific 3',5'-cyclic phosphodiesterase;Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Equilibrative nucleoside transporter 1;High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B;cGMP-dependent 3',5'-cyclic phosphodiesterase;cAMP-specific 3',5'-cyclic phosphodiesterase 7B;High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A;Arachidonate 15-lipoxygenase;Cyclic nucleotide phosphodiesterase PDE3A;Cyclic AMP-specific phosphodiesterase SSPDE4A1A;Phosphodiesterase 3;Phosphodiesterase 7;Phosphodiesterase 6;Phosphodiesterase 1;Equilibrative nucleoside transporter 4;Protein prune homolog;ORF 73;Replicase polyprotein 1ab",OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
Dipyrithione,[O-][N+]1=CC=CC=C1SSC1=CC=CC=[N+]1[O-],"Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;FAD-linked sulfhydryl oxidase ALR;Protein-lysine 6-oxidase;Lysyl oxidase homolog 3;Lysyl oxidase homolog 4;Lysyl oxidase homolog 2",[O-][n+]1ccccc1SSc1cccc[n+]1[O-]
Diroximel fumarate,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,Hydroxycarboxylic acid receptor 2;Kelch-like ECH-associated protein 1,COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O
Disopyramide,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;G protein-activated inward rectifier potassium channel 4;Solute carrier family 22 member 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
Disperse Blue 106,CCN(CCO)C1=CC=C(\N=N\C2=NC=C(S2)N(=O)=O)C(C)=C1,,CCN(CCO)c1ccc(/N=N/c2ncc([N+](=O)[O-])s2)c(C)c1
Distearyldimonium,CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC,,CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC
Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,"Sodium/nucleoside cotransporter 1;Mu-type opioid receptor;Translocator protein;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;D(4) dopamine receptor;Kappa-type opioid receptor;Cytochrome P450 1A2;Amine oxidase [flavin-containing] A;Aldehyde dehydrogenase, mitochondrial;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;C-C chemokine receptor type 5;C-X-C chemokine receptor type 2;C-C chemokine receptor type 2;Mitogen-activated protein kinase 3;Arachidonate 15-lipoxygenase;5-hydroxytryptamine receptor 1B;C-C chemokine receptor type 4;Membrane-associated progesterone receptor component 1;Monoglyceride lipase;Bifunctional protein GlmU;Protein-lysine 6-oxidase;Lysine-specific demethylase 5A;Lysyl oxidase homolog 3;Lysyl oxidase homolog 4;Histone-lysine N-methyltransferase EHMT2;Histone-lysine N-methyltransferase EHMT1;Lysyl oxidase homolog 2;Gasdermin-D",CCN(CC)C(=S)SSC(=S)N(CC)CC
Ditiocarb zinc,[Zn++].CCN(CC)C([S-])=S.CCN(CC)C([S-])=S,,CCN(CC)C(=S)[S-].CCN(CC)C(=S)[S-].[Zn+2]
Dobutamine,CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1,"Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Sodium-dependent dopamine transporter;Carbonic anhydrase 2;Alpha-1D adrenergic receptor;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Epidermal growth factor receptor;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Catechol O-methyltransferase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Solute carrier family 22 member 1;Arachidonate 15-lipoxygenase;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Carbonic anhydrase 13;Carbonic anhydrase 15",CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1
Docetaxel,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Cytochrome P450 3A4;Multidrug resistance protein 1;Multidrug resistance-associated protein 7;Epidermal growth factor receptor;Substance-K receptor;Growth hormone-releasing hormone receptor;Tubulin beta;Nucleotide-binding oligomerization domain-containing protein 2,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C
Doconexent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,Aromatase;Retinoic acid receptor RXR-alpha;Free fatty acid receptor 1;Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Oxoeicosanoid receptor 1;Transient receptor potential cation channel subfamily A member 1,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O
Docosanol,CCCCCCCCCCCCCCCCCCCCCCO,Envelope glycoprotein,CCCCCCCCCCCCCCCCCCCCCCO
Docusate,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O,,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O
Dofetilide,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,Potassium voltage-gated channel subfamily H member 2;Potassium channel subfamily K member 2;Potassium voltage-gated channel subfamily H member 1,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1
Dolasetron,[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2,Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 3A,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12
Dolutegravir,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2,Sigma non-opioid intracellular receptor 1;Vesicular acetylcholine transporter;Integrase;Sigma intracellular receptor 2,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
Domiphen,CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1,,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1
Domperidone,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2,Mu-type opioid receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Aldehyde oxidase;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Kappa-type opioid receptor;Calmodulin;Retinoic acid receptor RXR-alpha;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
Donepezil,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1,Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Acetylcholinesterase;Amine oxidase [flavin-containing] B;Cholinesterase;Histamine H3 receptor;Beta-secretase 1;Butyrylcholinesterase; Protein Bche;Choline O-acetyltransferase;Butyrylcholinesterase,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2
Dopamine,NCCC1=CC(O)=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;D(1B) dopamine receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;Trace amine-associated receptor 1;Melatonin receptor type 1A;Melatonin receptor type 1B;Lysine-specific demethylase 4E;Dopamine beta-hydroxylase;Opioid receptor;Adrenergic receptor alpha-2;Dopamine receptor;Adrenergic receptor alpha-1;Adenylate cyclase;Adenosine A2b receptor;FAD-linked sulfhydryl oxidase ALR;M18 aspartyl aminopeptidase,NCCc1ccc(O)c(O)c1
Dopexamine,OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1,Beta-2 adrenergic receptor;D(1A) dopamine receptor,Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O
Doravirine,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,Reverse transcriptase;Reverse transcriptase/RNaseH,Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Bacterial penicillin-binding protein,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12
Dorzolamide,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
Dosulepin,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter,CN(C)CC/C=C1\c2ccccc2CSc2ccccc21
Dotatate,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O
Dotatate gallium Ga-68,[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[68Ga+3]
Doxacurium,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,Muscarinic acetylcholine receptor M2;Neuronal acetylcholine receptor subunit alpha-2;Acetylcholine receptor,COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC
Doxapram,CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,Cytochrome P450 2D6;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
Doxazosin,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1,"5-hydroxytryptamine receptor 4;Beta-2 adrenergic receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Interstitial collagenase;HLA class I histocompatibility antigen, A-3 alpha chain",COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
Doxepin,[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;Solute carrier family 22 member 2;Serotonin (5-HT) receptor;Histamine H1 receptor,CN(C)CCC=C1c2ccccc2COc2ccccc21
Doxercalciferol,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C,Vitamin D3 receptor,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Doxorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,5-hydroxytryptamine receptor 4;Multidrug resistance protein 1;Muscarinic acetylcholine receptor M1;Canalicular multispecific organic anion transporter 1;DNA topoisomerase 2-alpha;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 6;Caspase-1;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;72 kDa type IV collagenase;DNA topoisomerase 1;Telomerase reverse transcriptase;DNA topoisomerase 2-beta;Aurora kinase A;Ribonuclease pancreatic;Arachidonate 15-lipoxygenase;5-hydroxytryptamine receptor 1B;Integrase;Reverse transcriptase;Type-2 restriction enzyme HindIII;Type-2 restriction enzyme ScaI;ORF 73;UDP-galactopyranose mutase;CDGSH iron-sulfur domain-containing protein 1,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Doxycycline,[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,"50S ribosomal protein L10;72 kDa type IV collagenase;Stromelysin-1;Neutrophil collagenase;Collagenase 3;Tetracycline resistance protein, class B;Zinc finger protein mex-5;Matrilysin",C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
Doxylamine,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1,Histamine H1 receptor,CN(C)CCOC(C)(c1ccccc1)c1ccccn1
Drometrizole trisiloxane,CC(CC1=C(O)C(=CC(C)=C1)N1N=C2C=CC=CC2=N1)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C,,Cc1cc(CC(C)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C)c(O)c(-n2nc3ccccc3n2)c1
Dronabinol,[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1,Cannabinoid receptor 1;D(3) dopamine receptor;Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;Cannabinoid receptor 2;Glycine receptor subunit alpha-3;N-arachidonyl glycine receptor;Transient receptor potential cation channel subfamily A member 1;G-protein coupled receptor 55;Cannabinoid receptor;Transient receptor potential cation channel subfamily V member 2,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21
Dronedarone,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2,Thyroid hormone receptor alpha;Potassium voltage-gated channel subfamily H member 2;Voltage-dependent calcium channel gamma-1 subunit;Potassium voltage-gated channel subfamily KQT member 2;Potassium voltage-gated channel subfamily A member 5;THAP domain-containing protein 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1
Droperidol,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12,"5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Sodium channel alpha subunits; brain (Types I, II, III)",O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
Drospirenone,[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21,Mineralocorticoid receptor;Androgen receptor;Progesterone receptor,C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12
Drostanolone propionate,[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C,Androgen receptor,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C
Drotaverine,CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B;Voltage-dependent L-type calcium channel subunit alpha-1C",CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
Droxidopa,N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O,Muscarinic acetylcholine receptor M1;Adrenergic receptor,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1
Duloxetine,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,"Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Histamine H1 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Sodium-dependent dopamine transporter;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Transporter;Serine hydroxymethyltransferase, mitochondrial",CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
Dutasteride,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F,Glycine receptor subunit alpha-1;3-oxo-5-alpha-steroid 4-dehydrogenase 2;3-oxo-5-alpha-steroid 4-dehydrogenase 1,C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CC[C@@H]12
Duvelisib,C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
Dyclonine,CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1,Acetylcholinesterase;Sodium channel protein type 10 subunit alpha,CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1
Dydrogesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C,Progesterone receptor;Nuclear receptor subfamily 2 group E member 1,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C
Dyphylline,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,"Adenosine receptor A2a;cGMP-inhibited 3',5'-cyclic phosphodiesterase A;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Alkaline phosphatase, tissue-nonspecific isozyme;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Uncharacterized protein;Adenosine A2 receptor;Adenosine A2b receptor;Adenosine receptor;Heart phosphodiesterase;Adenosine A2a receptor;Transmembrane domain-containing protein TMIGD3",Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
Ebastine,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Acetylcholinesterase;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Substance-K receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Histamine H1 receptor,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
Ecamsule,CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC1=CC=C(C=C2C3CCC(CS(O)(=O)=O)(C2=O)C3(C)C)C=C1,,CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1
Echothiophate,CCOP(=O)(OCC)SCC[N+](C)(C)C,Acetylcholinesterase,CCOP(=O)(OCC)SCC[N+](C)(C)C
Econazole,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,"Beta-1 adrenergic receptor;Cannabinoid receptor 1;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A1;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Lanosterol 14-alpha demethylase;Delta-type opioid receptor;Beta-lactamase;Acetylcholinesterase;Cytochrome P450 2C9;Cytochrome P450 1A2;Epidermal growth factor receptor;Substance-P receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 2C19;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Thromboxane-A synthase;Matrix metalloproteinase-9;Indoleamine 2,3-dioxygenase 1;Substance-K receptor;Androgen receptor;5-hydroxytryptamine receptor 1B;Melanocortin receptor 5;Melanocortin receptor 3;Neuropeptide Y receptor type 2;Membrane-associated progesterone receptor component 1;Progesterone receptor;Alpha-1A adrenergic receptor;Cholinesterase;Indoleamine 2,3-dioxygenase 2;Mycocyclosin synthase;Malate dehydrogenase cytoplasmic ;Calcium release-activated calcium channel protein 1;7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
Edaravone,CC1=NN(C(=O)C1)C1=CC=CC=C1,Polyunsaturated fatty acid lipoxygenase ALOX15,CC1=NN(c2ccccc2)C(=O)C1
Edetate calcium disodium anhydrous,[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Ca+2].[Na+].[Na+]
Edetate disodium anhydrous,[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O,,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CC(=O)O.[Na+].[Na+]
Edetic acid,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O
Edotreotide gallium Ga-68,[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Somatostatin receptor type 2,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O.[68Ga+3]
Edoxaban,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1,Coagulation factor X,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Edoxudine,CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O,Thymidine kinase,CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O
Edrophonium,CC[N+](C)(C)C1=CC(O)=CC=C1,Acetylcholinesterase,CC[N+](C)(C)c1cccc(O)c1
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,Cytochrome P450 3A4;Nuclear receptor subfamily 1 group I member 2;Gag-Pol polyprotein;Reverse transcriptase/RNaseH;Reverse transcriptase;Reverse transcriptase protein,O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1
Efinaconazole,C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,Lanosterol 14-alpha demethylase,C=C1CCN([C@H](C)[C@](O)(Cn2cncn2)c2ccc(F)cc2F)CC1
Eflornithine,NCCCC(N)(C(F)F)C(O)=O,Ornithine decarboxylase,NCCCC(N)(C(=O)O)C(F)F
Elagolix,COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O,Gonadotropin-releasing hormone receptor,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
Elbasvir,[H][C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=NC=C(N1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CN=C(N3)[C@]3([H])CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1,Nonstructural protein 5A;Genome polyprotein,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C
Eletriptan,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12
Elexacaftor,C[C@@H]1CN(C2=NC(=CC=C2C(=O)NS(=O)(=O)C2=CN(C)N=C2C)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(C)(C)C1,Cystic fibrosis transmembrane conductance regulator,Cc1nn(C)cc1S(=O)(=O)NC(=O)c1ccc(-n2ccc(OCC(C)(C)C(F)(F)F)n2)nc1N1C[C@@H](C)CC1(C)C
Eliglustat,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,Ceramide glucosyltransferase,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2
Eltrombopag,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1,Potassium voltage-gated channel subfamily H member 2;Thrombopoietin receptor,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
Eluxadoline,COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O,Mu-type opioid receptor;Delta-type opioid receptor;Kappa-type opioid receptor,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O
Elvitegravir,[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2,Gag-Pol polyprotein;Integrase;Reverse transcriptase,COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C
Emedastine,CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1,Histamine H1 receptor,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1,Sodium/glucose cotransporter 4;Sodium/glucose cotransporter 5;Sodium/glucose cotransporter 1;Sodium/myo-inositol cotransporter 2;Sodium/glucose cotransporter 2,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
Emtricitabine,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,Reverse transcriptase/RNaseH,Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F
Enalapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
Enalaprilat,[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O,Angiotensin-converting enzyme;Angiotensin-converting enzyme 2,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Enasidenib,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F,"Isocitrate dehydrogenase [NADP] cytoplasmic;Isocitrate dehydrogenase [NADP], mitochondrial",CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Encainide,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,Sodium channel protein type 5 subunit alpha;Sodium channel subunit beta-1;Sodium channel subunit beta-2;Sodium channel subunit beta-3;Sodium channel subunit beta-4,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1
Encorafenib,COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C,Mitogen-activated protein kinase 14;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Enflurane,FC(F)OC(F)(F)C(F)Cl,Glycine receptor subunit alpha-1;Potassium channel subfamily K member 2;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9;Potassium channel subfamily K member 10;Potassium channel subfamily K member 18,FC(F)OC(F)(F)C(F)Cl
Enoxacin,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,"DNA gyrase subunit A;V-type proton ATPase subunit B, brain isoform;Topoisomerase IV;DNA gyrase",CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
Enoximone,CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;Phosphodiesterase 4",CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1
Enprofylline,CCCN1C2=C(NC=N2)C(=O)NC1=O,"Adenosine receptor A2a;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;cAMP-specific 3',5'-cyclic phosphodiesterase 4B;Adenosine A2a receptor",CCCn1c(=O)[nH]c(=O)c2[nH]cnc21
Ensulizole,OS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1,"cGMP-specific 3',5'-cyclic phosphodiesterase;Phosphodiesterase 3",O=S(=O)(O)c1ccc2nc(-c3ccccc3)[nH]c2c1
Entacapone,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N,Catechol O-methyltransferase;G-protein coupled receptor 35;Alpha-ketoglutarate-dependent dioxygenase FTO,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1
Entecavir,NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C,Protein P;Capsid protein,C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)nc(N)[nH]c21
Entrectinib,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1,Tyrosine-protein kinase JAK3;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Insulin-like growth factor 1 receptor;Insulin receptor;Focal adhesion kinase 1;Tyrosine-protein kinase JAK1;Aurora kinase A;Protein-tyrosine kinase 6;Aurora kinase B;Tyrosine-protein kinase JAK2;Activated CDC42 kinase 1;High affinity nerve growth factor receptor;ALK tyrosine kinase receptor;BDNF/NT-3 growth factors receptor;NT-3 growth factor receptor;Proto-oncogene tyrosine-protein kinase ROS,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1
Enzacamene,CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1,,Cc1ccc(/C=C2/C(=O)C3(C)CCC2C3(C)C)cc1
Enzalutamide,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F,Androgen receptor,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
Ephedrine,CN[C@@H](C)[C@H](O)C1=CC=CC=C1,Beta-2 adrenergic receptor,CN[C@@H](C)[C@H](O)c1ccccc1
Epicriptine,[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;Glycine receptor subunit beta;Glycine receptor subunit alpha-3,CC[C@@H](C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
Epinastine,NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;5-hydroxytryptamine receptor 2A;Alpha-1A adrenergic receptor;Histamine H1 receptor;Histamine H2 receptor;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2,NC1=NCC2c3ccccc3Cc3ccccc3N12
Epinephrine,CNC[C@H](O)C1=CC(O)=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Arachidonate 15-lipoxygenase;Mu-type opioid receptor;Adrenergic receptor alpha-2;Adrenergic receptor beta;M18 aspartyl aminopeptidase,CNC[C@H](O)c1ccc(O)c(O)c1
Epirubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,5-hydroxytryptamine receptor 4;Tyrosine-protein kinase Fyn;NS3,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
Eplerenone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,Glucocorticoid receptor;Mineralocorticoid receptor;Progesterone receptor,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13
Epoprostenol,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,Prostaglandin E2 receptor EP1 subtype;P2Y purinoceptor 12;Prostacyclin receptor;Prostaglandin E2 receptor EP4 subtype,CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O
Eprosartan,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O,Type-1 angiotensin II receptor;Type-1B angiotensin II receptor;Type-2 angiotensin II receptor;Angiotensin II receptor (AT-1) type-1;Angiotensin II receptor,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1
Eravacycline,[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,30S ribosomal protein S4;30S ribosomal protein S9,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12
Erdafitinib,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1,Vascular endothelial growth factor receptor 2;Fibroblast growth factor receptor 3;Fibroblast growth factor receptor 1;Fibroblast growth factor receptor 2;Fibroblast growth factor receptor 4,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1
Erdosteine,OC(=O)CSCC(=O)NC1CCSC1=O,,O=C(O)CSCC(=O)NC1CCSC1=O
Ergocalciferol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;Vitamin D3 receptor;Vitamin D 25-hydroxylase",C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12
Ergometrine,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;5-hydroxytryptamine receptor 1D;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1E;5-hydroxytryptamine receptor 1B,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Ergosterol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;D(3) dopamine receptor;Beta-3 adrenergic receptor;Heat shock protein HSP 90-alpha,CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Ergotamine,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O,5-hydroxytryptamine receptor 4;Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 7;Gastrin/cholecystokinin type B receptor;Cholecystokinin A receptor;Adenylate cyclase,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Eribulin,[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@H]7O[C@@]8(C[C@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2,Tubulin beta,C=C1C[C@@H]2CC[C@@]34C[C@@H]5O[C@@H]6[C@@H](O[C@H]7CC[C@H](CC(=O)C[C@@H]8[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]8C[C@H]8O[C@@H](CC[C@@H]1O2)C[C@@H](C)C8=C)O[C@@H]7[C@@H]6O3)[C@H]5O4
Erlotinib,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,"Tyrosine-protein kinase JAK3;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Platelet-derived growth factor receptor alpha;Receptor tyrosine-protein kinase erbB-2;Death-associated protein kinase 3;Focal adhesion kinase 1;Tyrosine-protein kinase HCK;Receptor tyrosine-protein kinase erbB-4;Mitogen-activated protein kinase 10;Tyrosine-protein kinase JAK2;Calcium/calmodulin-dependent protein kinase type II subunit delta;Myosin light chain kinase 2, skeletal/cardiac muscle;Tyrosine-protein kinase CSK;Ephrin type-A receptor 8;AP2-associated protein kinase 1;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Serine/threonine-protein kinase PLK4;Aurora kinase C;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 5;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase 17A;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;Aurora kinase A;ALK tyrosine kinase receptor;Serine/threonine-protein kinase 36;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Tyrosine-protein kinase FRK;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Ephrin type-A receptor 7;STE20-like serine/threonine-protein kinase;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Epithelial discoidin domain-containing receptor 1;Solute carrier family 22 member 1;Ephrin type-B receptor 4;Serine/threonine-protein kinase ULK3;Tyrosine-protein kinase receptor UFO;Tyrosine-protein kinase receptor TYRO3;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Casein kinase I isoform delta;Tyrosine-protein kinase receptor Tie-1;Tyrosine-protein kinase TXK;MAP kinase-interacting serine/threonine-protein kinase 1;Eukaryotic translation initiation factor 2-alpha kinase 4;Serine/threonine-protein kinase SIK2;Serine/threonine-protein kinase TNNI3K;Myotonin-protein kinase;Chaperone activity of bc1 complex-like, mitochondrial;Serine/threonine-protein kinase MRCK gamma;Leukocyte tyrosine kinase receptor;Aurora kinase B;Tyrosine-protein kinase Blk;Tyrosine-protein kinase Mer;Citron Rho-interacting kinase;AarF domain-containing protein kinase 4;Tubulin alpha-1A chain;Mitogen-activated protein kinase 4;Interferon-induced, double-stranded RNA-activated protein kinase;Ribosomal protein S6 kinase alpha-4;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Dual specificity tyrosine-phosphorylation-regulated kinase 2;Ephrin type-B receptor 6;G protein-coupled receptor kinase 4;Homeodomain-interacting protein kinase 4;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;SRSF protein kinase 3;Mitogen-activated protein kinase kinase kinase 19;Receptor-interacting serine/threonine-protein kinase 4;Receptor tyrosine-protein kinase erbB-3;Serine/threonine-protein kinase SBK1;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Dual specificity mitogen-activated protein kinase kinase 5;Leucine-rich repeat serine/threonine-protein kinase 2;Solute carrier organic anion transporter family member 2B1",C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
Ertapenem,[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Penicillin-binding protein 2;Penicillin-binding protein 4;D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5;Penicillin-binding protein 1;D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6;D-alanyl-D-alanine carboxypeptidase DacB;Penicillin-binding protein 1A;Penicillin-binding protein 1B,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12
Ertugliflozin,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1,Sodium/glucose cotransporter 2;Low affinity sodium-glucose cotransporter;Sodium/glucose cotransporter 1,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1
Erythrityl tetranitrate,[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O,,O=[N+]([O-])OC[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]
Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Potassium voltage-gated channel subfamily H member 2;Aldehyde oxidase;Bile salt export pump;Motilin receptor;Cytochrome P450 1B1,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Escitalopram,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Sodium-dependent dopamine transporter;Transporter,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Esculin,OC[C@H]1O[C@@H](OC2=C(O)C=C3OC(=O)C=CC3=C2)[C@H](O)[C@@H](O)[C@@H]1O,,O=c1ccc2cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)cc2o1
Esketamine,CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl,Glutamate NMDA receptor,CN[C@]1(c2ccccc2Cl)CCCCC1=O
Eslicarbazepine,NC(=O)N1C2=C(C[C@H](O)C3=C1C=CC=C3)C=CC=C2,Sodium channel protein type 5 subunit alpha;Sodium-dependent serotonin transporter;Histamine H1 receptor;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 9 subunit alpha;Nuclear receptor subfamily 1 group I member 2;GABA-A receptor alpha-1/beta-2/gamma-2;Neuronal acetylcholine receptor; alpha2/beta4;Frizzled-8,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21
Eslicarbazepine acetate,CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12,,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21
Esmolol,COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
Esomeprazole,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,Potassium-transporting ATPase,COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1
Estazolam,ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1,GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2
Estetrol,[H][C@@]12[C@@H](O)[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H],Estrogen receptor;Estrogen receptor beta,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O
Estradiol,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,Sodium-dependent serotonin transporter;Aldehyde oxidase;Glucocorticoid receptor;Sodium-dependent dopamine transporter;Estrogen receptor;Androgen receptor;Calcium-activated potassium channel subunit alpha-1;Estrogen receptor beta;G-protein coupled estrogen receptor 1;Corticosteroid-binding globulin;Steryl-sulfatase;Sex hormone-binding globulin;Steroid hormone receptor ERR1;Steroid hormone receptor ERR2;Arachidonate 15-lipoxygenase;Progesterone receptor;Cytochrome P450 1B1,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
Estradiol acetate,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H],Estrogen receptor,CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12
Estradiol benzoate,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C,Estrogen receptor,C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
Estradiol cypionate,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,Sodium-dependent serotonin transporter;Glucocorticoid receptor;Estrogen receptor;Estrogen receptor beta;Corticosteroid-binding globulin;Sex hormone-binding globulin;Arachidonate 15-lipoxygenase;Lanosterol 14-alpha demethylase;Olfactory receptor 51E2,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
Estradiol dienanthate,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C,,CCCCCCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](OC(=O)CCCCCC)CC[C@@H]12
Estradiol valerate,[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,Estrogen receptor,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C
Estramustine,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H],Histamine H1 receptor,C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
Estramustine phosphate,[H][C@@]12CC[C@H](OP(O)(O)=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)N(CCCl)CCCl)C=C3,Estrogen receptor beta;Tyrosine-protein phosphatase non-receptor type 1;Tyrosine-protein phosphatase non-receptor type 11;Protein-tyrosine phosphatase 1C,C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O
Estriol,[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,Sodium-dependent serotonin transporter;Glucocorticoid receptor;Estrogen receptor;Estrogen receptor beta;Corticosteroid-binding globulin;Sex hormone-binding globulin;Arachidonate 15-lipoxygenase;Lanosterol 14-alpha demethylase;Olfactory receptor 51E2,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O
Estrone,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2B;Estrogen receptor;Estrogen receptor beta;Aromatase;Corticosteroid-binding globulin;Steryl-sulfatase;Sex hormone-binding globulin;Estradiol 17-beta-dehydrogenase 1;Androgen receptor;Arachidonate 15-lipoxygenase;Progesterone receptor,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O
Estrone sulfate,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OS(O)(=O)=O)C=C3,Steryl-sulfatase;Solute carrier family 22 member 20;Estrogen receptor;Estrogen receptor beta,C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O
Eszopiclone,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-4;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-3;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-3/beta-2/gamma-3;GABA A receptor alpha-5/beta-2/gamma-2;GABA A receptor alpha-5/beta-2/gamma-3,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1
Etacrynic acid,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl
Etafedrine,CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1,Sodium-dependent noradrenaline transporter;Aldehyde oxidase;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Acetylcholinesterase;Acetylcholine receptor subunit epsilon;Solute carrier family 22 member 1;Alpha-1A adrenergic receptor;Muscarinic acetylcholine receptor M2;Butyrylcholinesterase; Protein Bche;Choline O-acetyltransferase;Muscarinic acetylcholine receptor M1;Amine oxidase [flavin-containing] A;Cholinesterase;Histamine N-methyltransferase;Butyrylcholinesterase;Glutamate NMDA receptor; GRIN1/GRIN2B;Glutamate NMDA receptor; GRIN1/GRIN2A;Muscarinic acetylcholine receptor;Amyloid beta A4 protein,CCN(C)[C@@H](C)[C@H](O)c1ccccc1
Etelcalcetide,C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O,Extracellular calcium-sensing receptor,CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O
Ethambutol,CC[C@@H](CO)NCCN[C@@H](CC)CO,Cytochrome P450 3A4;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Probable arabinosyltransferase A;Probable arabinosyltransferase B;Probable arabinosyltransferase C;Cytochrome P450 3A5,CC[C@@H](CO)NCCN[C@@H](CC)CO
Ethanol,CCO,"Glutamate receptor ionotropic, NMDA 3A;Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;GABA A receptor alpha-4/beta-2/delta",CCO
Ethanolamine oleate,NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O,,CCCCCCCC/C=C\CCCCCCCC(=O)O.NCCO
Ethchlorvynol,CCC(O)(\C=C\Cl)C#C,GABA-A receptor alpha-1/beta-3/gamma-2,C#CC(O)(/C=C/Cl)CC
Ethinamate,NC(=O)OC1(CCCCC1)C#C,Thyroid peroxidase;Lactoperoxidase;Dopamine beta-hydroxylase,C#CC1(OC(N)=O)CCCCC1
Ethinylestradiol,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,5-hydroxytryptamine receptor 4;Nuclear receptor subfamily 1 group I member 3;Mu-type opioid receptor;Adenosine receptor A2a;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Aldehyde oxidase;Glucocorticoid receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Kappa-type opioid receptor;Estrogen receptor;Androgen receptor;Estrogen receptor beta;Sex hormone-binding globulin;Arachidonate 15-lipoxygenase;Progesterone receptor;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
Ethionamide,CCC1=NC=CC(=C1)C(N)=S,Catalase-peroxidase;Enoyl-[acyl-carrier-protein] reductase [NADH];Polyphenol oxidase 2,CCc1cc(C(N)=S)ccn1
Ethoheptazine,CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1,,CCOC(=O)C1(c2ccccc2)CCCN(C)CC1
Ethosuximide,CCC1(C)CC(=O)NC1=O,Voltage-dependent T-type calcium channel subunit alpha-1G,CCC1(C)CC(=O)NC1=O
Ethotoin,CCN1C(=O)NC(C1=O)C1=CC=CC=C1,Sodium channel alpha subunit,CCN1C(=O)NC(c2ccccc2)C1=O
Ethyl chloride,CCCl,,CCCl
Ethyl ferulate,[H]\C(=C(\[H])C1=CC(OC)=C(O)C=C1)C(=O)OCC,,CCOC(=O)/C=C/c1ccc(O)c(OC)c1
Ethyl hydroxybenzoate,CCOC(=O)C1=CC=C(O)C=C1,Carbonic anhydrase 2;Estrogen receptor;Carbonic anhydrase 1;Estrogen receptor beta;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 7;Carbonic anhydrase 14,CCOC(=O)c1ccc(O)cc1
Ethyl salicylate,CCOC(=O)C1=CC=CC=C1O,Cyclooxygenase,CCOC(=O)c1ccccc1O
Ethylenediamine,NCCN,,NCCN
Ethylhexyl methoxycrylene,CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=C(OC)C=C1,,CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccc(OC)cc1
Ethynodiol diacetate,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H],,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C
Etidocaine,CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C,Sodium channel protein type 5 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 4 subunit alpha;Potassium channel subfamily K member 3,CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C
Etidronic acid,CC(O)(P(O)(O)=O)P(O)(O)=O,,CC(O)(P(=O)(O)O)P(=O)(O)O
Etilefrine,CCNCC(O)C1=CC=CC(O)=C1,Beta-1 adrenergic receptor,CCNCC(O)c1cccc(O)c1
Etodolac,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Etofamide,CCOCCN(CC1=CC=C(OC2=CC=C(C=C2)[N+]([O-])=O)C=C1)C(=O)C(Cl)Cl,"Arachidonate 15-lipoxygenase;Sulfonylurea receptor 1, Kir6.2",CCOCCN(Cc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1)C(=O)C(Cl)Cl
Etomidate,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1,"Gamma-aminobutyric acid receptor subunit alpha-1;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial;Acetylcholine receptor subunit delta;GABA-A receptor alpha-1/beta-2/gamma-2;GABA A receptor alpha-2/beta-2/gamma-2",CCOC(=O)c1cncn1[C@H](C)c1ccccc1
Etonogestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],Estrogen receptor;Progesterone receptor;Sex hormone-binding globulin,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC
Etoposide,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O,Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Nuclear receptor subfamily 1 group I member 2;DNA topoisomerase 2-alpha;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 6;Canalicular multispecific organic anion transporter 2;DNA topoisomerase 2-beta;Arachidonate 15-lipoxygenase,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Etoricoxib,CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Prostaglandin E2 receptor EP2 subtype;Mitogen-activated protein kinase 14,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Etravirine,CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N,Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Canalicular multispecific organic anion transporter 2;Gag-Pol polyprotein;Reverse transcriptase/RNaseH;Cruzipain;Reverse transcriptase;Reverse transcriptase protein,Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br
Eugenol,COC1=C(O)C=CC(CC=C)=C1,Prostaglandin G/H synthase 1;Arachidonate 5-lipoxygenase,C=CCc1ccc(O)c(OC)c1
Everolimus,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,Multidrug resistance protein 1;Peptidyl-prolyl cis-trans isomerase FKBP1A;Serine/threonine-protein kinase mTOR,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
Exametazime,C[C@@H](NCC(C)(C)CN[C@H](C)C(\C)=N\O)C(\C)=N\O,,C/C(=N\O)[C@@H](C)NCC(C)(C)CN[C@H](C)/C(C)=N/O
Exemestane,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C,Androgen receptor;Aromatase,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12
Ezetimibe,[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1,Niemann-Pick C1-like protein 1,O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N
Famciclovir,CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O,DNA polymerase catalytic subunit,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O
Famotidine,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,"Histamine H2 receptor;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Heat shock protein HSP 90-alpha;Solute carrier family 22 member 3",NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1
Favipiravir,NC(=O)C1=NC(F)=CN=C1O,,NC(=O)c1nc(F)cnc1O
Febuxostat,CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N,Potassium voltage-gated channel subfamily H member 2;Xanthine dehydrogenase/oxidase,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O
Fedratinib,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C,"Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;Serine/threonine-protein kinase B-raf;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Ribosomal protein S6 kinase alpha-3;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Insulin-like growth factor 1 receptor;Myosin light chain kinase, smooth muscle;Insulin receptor;Death-associated protein kinase 3;Calcium/calmodulin-dependent protein kinase type 1;Mitogen-activated protein kinase 8;Fibroblast growth factor receptor 3;Rho-associated protein kinase 1;Focal adhesion kinase 1;Tyrosine-protein kinase HCK;Serine/threonine-protein kinase PLK1;Receptor tyrosine-protein kinase erbB-4;Mitogen-activated protein kinase 10;Death-associated protein kinase 2;High affinity nerve growth factor receptor;Rho-associated protein kinase 2;Tyrosine-protein kinase SYK;Calcium/calmodulin-dependent protein kinase type II subunit delta;Myosin light chain kinase 2, skeletal/cardiac muscle;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Ephrin type-A receptor 8;Calcium/calmodulin-dependent protein kinase type II subunit gamma;AP2-associated protein kinase 1;Serine/threonine-protein kinase MARK2;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Serine/threonine-protein kinase Nek2;LIM domain kinase 1;Ribosomal protein S6 kinase alpha-2;5'-AMP-activated protein kinase catalytic subunit alpha-1;Calcium/calmodulin-dependent protein kinase type II subunit beta;Fibroblast growth factor receptor 1;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Protein kinase C epsilon type;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 4;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase N1;Serine/threonine-protein kinase 17A;Ephrin type-A receptor 6;Tyrosine-protein kinase Fgr;Aurora kinase A;ALK tyrosine kinase receptor;Serine/threonine-protein kinase 36;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Dual specificity protein kinase CLK2;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Calcium/calmodulin-dependent protein kinase type 1D;Cyclin-dependent kinase 16;Activated CDC42 kinase 1;Ephrin type-A receptor 7;Ribosomal protein S6 kinase alpha-5;STE20-like serine/threonine-protein kinase;Dual specificity protein kinase CLK4;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Calcium/calmodulin-dependent protein kinase kinase 2;MAP/microtubule affinity-regulating kinase 3;Calcium/calmodulin-dependent protein kinase kinase 1;Calcium/calmodulin-dependent protein kinase type 1G;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Testis-specific serine/threonine-protein kinase 1;Activin receptor type-1B;Serine/threonine-protein kinase receptor R3;Activin receptor type-1;Cyclin-dependent kinase 15;Inhibitor of nuclear factor kappa-B kinase subunit beta;TGF-beta receptor type-2;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase ITK/TSK;Tyrosine-protein kinase ZAP-70;Cyclin-dependent kinase 9;Protein-tyrosine kinase 6;Tyrosine-protein kinase BTK;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Ephrin type-B receptor 2;Cyclin-dependent kinase 7;Ribosomal protein S6 kinase beta-1;Serine/threonine-protein kinase DCLK3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Serine/threonine-protein kinase Chk1;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Cyclin-dependent kinase 17;Cyclin-dependent kinase 18;Cyclin-dependent kinase 14;Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha;Phosphatidylinositol 5-phosphate 4-kinase type-2 beta;Myosin light chain kinase family member 4;Wee1-like protein kinase;Serine/threonine-protein kinase 25;Mitogen-activated protein kinase kinase kinase MLT;Protein-tyrosine kinase 2-beta;Serine/threonine-protein kinase RIO1;Tyrosine-protein kinase receptor Tie-1;Serine/threonine-protein kinase tousled-like 1;Serine/threonine-protein kinase tousled-like 2;NT-3 growth factor receptor;Tyrosine-protein kinase TXK;Casein kinase II subunit alpha;Casein kinase II subunit alpha';Dual specificity tyrosine-phosphorylation-regulated kinase 1B;Inhibitor of nuclear factor kappa-B kinase subunit epsilon;LIM domain kinase 2;Serine/threonine-protein kinase STK11;Dual specificity mitogen-activated protein kinase kinase 3;Maternal embryonic leucine zipper kinase;MAP kinase-interacting serine/threonine-protein kinase 1;Serine/threonine-protein kinase 26;Serine/threonine-protein kinase Nek7;Eukaryotic translation initiation factor 2-alpha kinase 4;Insulin receptor-related protein;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase RIO3;Serine/threonine-protein kinase SIK2;SRSF protein kinase 1;SRSF protein kinase 2;Serine/threonine-protein kinase 33;Serine/threonine-protein kinase TNNI3K;5'-AMP-activated protein kinase catalytic subunit alpha-2;Ankyrin repeat and protein kinase domain-containing protein 1;Discoidin domain-containing receptor 2;Myotonin-protein kinase;Chaperone activity of bc1 complex-like, mitochondrial;Serine/threonine-protein kinase LATS2;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;Serine/threonine-protein kinase PAK 6;Serine/threonine-protein kinase PAK 7;NUAK family SNF1-like kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Bone morphogenetic protein receptor type-2;Serine/threonine-protein kinase MARK1;MAP/microtubule affinity-regulating kinase 4;Dual specificity mitogen-activated protein kinase kinase 4;Tyrosine-protein kinase Mer;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 10;Mitogen-activated protein kinase kinase kinase 11;Muscle, skeletal receptor tyrosine-protein kinase;Citron Rho-interacting kinase;Death-associated protein kinase 1;Serine/threonine-protein kinase DCLK1;Serine/threonine-protein kinase DCLK2;Serine/threonine-protein kinase Nek5;Serine/threonine-protein kinase Nek9;Serine/threonine-protein kinase PAK 1;Serine/threonine-protein kinase PAK 2;Serine/threonine-protein kinase PAK 4;AarF domain-containing protein kinase 4;Serine/threonine-protein kinase SIK1;Tyrosine-protein kinase Srms;Dual specificity testis-specific protein kinase 1;Ephrin type-A receptor 1;Serine/threonine-protein kinase PLK3;Mitogen-activated protein kinase 6;Mitogen-activated protein kinase 7;Mitogen-activated protein kinase 15;Serine/threonine-protein kinase D3;cGMP-dependent protein kinase 2;Interferon-induced, double-stranded RNA-activated protein kinase;Receptor-interacting serine/threonine-protein kinase 1;Tyrosine-protein kinase Fes/Fps;Fibroblast growth factor receptor 4;Proto-oncogene tyrosine-protein kinase ROS;Ribosomal protein S6 kinase alpha-1;Ribosomal protein S6 kinase alpha-4;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Interleukin-1 receptor-associated kinase 4;Cyclin-dependent kinase 4;Cyclin-dependent kinase-like 2;Ephrin type-B receptor 6;Serine/threonine-protein kinase/endoribonuclease IRE1;G protein-coupled receptor kinase 4;G protein-coupled receptor kinase 7;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Homeodomain-interacting protein kinase 4;Serine/threonine-protein kinase ICK;Inhibitor of nuclear factor kappa-B kinase subunit alpha;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Serine/threonine-protein kinase 38;Serine/threonine-protein kinase NIM1;Serine/threonine-protein kinase RIO2;SRSF protein kinase 3;STE20/SPS1-related proline-alanine-rich protein kinase;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Serine/threonine-protein kinase ULK1;Serine/threonine-protein kinase ULK2;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Homeodomain-interacting protein kinase 1;Serine/threonine-protein kinase PLK2;Receptor-interacting serine/threonine-protein kinase 4;Uncharacterized serine/threonine-protein kinase SBK3;Cyclin-dependent kinase-like 5;Megakaryocyte-associated tyrosine-protein kinase;Phosphatidylinositol 4-kinase beta;Serine/threonine-protein kinase SIK3;Wee1-like protein kinase 2;Bone morphogenetic protein receptor type-1B;Serine/threonine-protein kinase SBK1;Serine/threonine-protein kinase Nek3;Peripheral plasma membrane protein CASK;Serine/threonine-protein kinase PRP4 homolog;Mitogen-activated protein kinase kinase kinase 12;Serine/threonine-protein kinase Sgk3;Eukaryotic translation initiation factor 2-alpha kinase 1;Serine/threonine-protein kinase TAO2;SNF-related serine/threonine-protein kinase;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Dual specificity mitogen-activated protein kinase kinase 5;Serine/threonine-protein kinase Nek11;Myosin light chain kinase 3;Leucine-rich repeat serine/threonine-protein kinase 2;Dual serine/threonine and tyrosine protein kinase;Calcium-dependent protein kinase 1;Bromodomain-containing protein 4;Serine/threonine-protein kinase PknB;Serine/threonine-protein kinase Nek6;cGMP-dependent protein kinase 1;Serine/threonine-protein kinase Nek4;Bromodomain testis-specific protein;Serine/threonine-protein kinase Nek1;Tyrosine-protein kinase JAK3;Tyrosine-protein kinase JAK1;Non-receptor tyrosine-protein kinase TYK2;Receptor-type tyrosine-protein kinase FLT3;Tyrosine-protein kinase JAK2",Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Felbamate,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,"Glutamate receptor ionotropic, NMDA 2A;Glutamate receptor ionotropic, NMDA 2B",NC(=O)OCC(COC(N)=O)c1ccccc1
Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC,"Aldehyde oxidase;Adenosine receptor A3;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1D;Cytochrome P450 2C9;Voltage-dependent T-type calcium channel subunit alpha-1H;Bile acid receptor;Cystic fibrosis transmembrane conductance regulator;Sodium channel alpha subunits; brain (Types I, II, III)",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
Fenbufen,OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1,Prostaglandin G/H synthase 1;Prostaglandin G/H synthase 2,O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1
Fenfluramine,CCNC(C)CC1=CC=CC(=C1)C(F)(F)F,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1B adrenergic receptor,CCNC(C)Cc1cccc(C(F)(F)F)c1
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,"Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;D(3) dopamine receptor;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Acetylcholinesterase;Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma;Fatty acid-binding protein, liver;Cruzipain",CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
Fenofibric acid,CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O,,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O
Fenoldopam,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12,D(1A) dopamine receptor;D(2) dopamine receptor;D(1B) dopamine receptor;D(4) dopamine receptor;Lysine-specific demethylase 4E;Adrenergic receptor alpha-1;Adenosine A2b receptor;FAD-linked sulfhydryl oxidase ALR,Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1
Fenoprofen,CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cyclooxygenase;Sodium-coupled monocarboxylate transporter 1,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
Fenoterol,CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1,Beta-2 adrenergic receptor,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1
Fenpropidin,CC(CN1CCCCC1)CC1=CC=C(C=C1)C(C)(C)C,Trypsin-1;Acrosin,CC(Cc1ccc(C(C)(C)C)cc1)CN1CCCCC1
Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,Mu-type opioid receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Kappa-type opioid receptor;Delta-type opioid receptor;Solute carrier family 22 member 1;Histamine H1 receptor;Opioid receptor;Monoamine oxidase,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
Ferric ammonium citrate,N.[Fe+3].OC(=O)CC(O)(CC(O)=O)C(O)=O,,N.O=C(O)CC(O)(CC(=O)O)C(=O)O.[Fe+3]
Ferric cation,[Fe+3],,[Fe+3]
Ferric chloride,Cl[Fe](Cl)Cl,,[Cl][Fe]([Cl])[Cl]
Ferric derisomaltose,[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O.[Fe+3]
Ferric glycerophosphate,[Fe++].[Fe++].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O,,O=P([O-])([O-])OC(CCO)CCO.O=P([O-])([O-])OCC(O)CO.[Fe+2].[Fe+2]
Ferric maltol,[Fe+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1,,Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].[Fe+3]
Ferric pyrophosphate citrate,[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=P(O)(O)OP(=O)(O)O.O=P(O)(O)OP(=O)(O)O.O=P([O-])([O-])OP(=O)([O-])O.[Fe+3].[Fe+3].[Fe+3].[Fe+3]
Ferric sulfate,O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,,O.O.O.O.O.O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Fe+3].[Fe+3]
Ferrous ascorbate,[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-],,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1[O-].[Fe+2]
Ferrous bisglycinate,[Fe++].NCC([O-])=O.NCC([O-])=O,,NCC(=O)[O-].NCC(=O)[O-].[Fe+2]
Ferrous cysteine glycinate,[Fe++].NCC(O)=O.[H][C@](N)(CS)C(O)=O.[H][C@](N)(C[S-])C([O-])=O,,NCC(=O)O.N[C@@H](CS)C(=O)O.N[C@@H](C[S-])C(=O)[O-].[Fe+2]
Ferrous fumarate,[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O,,O=C([O-])/C=C/C(=O)[O-].[Fe+2]
Ferrous gluconate,[Fe++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Fe+2]
Ferrous glycine sulfate,[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O,,NCC(=O)[O-].NCC(=O)[O-].O=S(=O)(O)O.[Fe+2]
Ferrous succinate,[Fe++].[O-]C(=O)CCC([O-])=O,Sodium-dependent serotonin transporter;Glucocorticoid receptor;Estrogen receptor;Estrogen receptor beta;Corticosteroid-binding globulin;Sex hormone-binding globulin;Arachidonate 15-lipoxygenase;Lanosterol 14-alpha demethylase;Olfactory receptor 51E2,O=C([O-])CCC(=O)[O-].[Fe+2]
Ferrous sulfate anhydrous,[Fe++].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[Fe+2]
Ferumoxytol,[O--].[O--].[O--].[O--].[Fe++].[Fe+3].[Fe+3],,[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2]
Fesoterodine,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1
Fexinidazole,CSC1=CC=C(OCC2=NC=C(N2C)[N+]([O-])=O)C=C1,3-oxoacyl-[acyl-carrier-protein] synthase 3,CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1
Fexofenadine,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Histamine H1 receptor;Solute carrier organic anion transporter family member 1A2,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
Fidaxomicin,[H][C@@]1(O[C@@H]2[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\C(=O)O[C@@H](C\C=C(/C)\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O,DNA-directed RNA polymerase,CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@@H]3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)/C(C)=C/C(C)=C/C[C@@H]([C@@H](C)O)OC2=O)O[C@@H]1C
Filgotinib,O=C(NC1=NN2C(C=CC=C2C2=CC=C(CN3CCS(=O)(=O)CC3)C=C2)=N1)C1CC1,Potassium voltage-gated channel subfamily H member 2;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Tyrosine-protein kinase JAK3;Tyrosine-protein kinase JAK2;Non-receptor tyrosine-protein kinase TYK2;Tyrosine-protein kinase JAK1,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Finafloxacin,[H][C@]12CN(C[C@]1([H])OCCN2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O,DNA gyrase subunit B;DNA topoisomerase 4 subunit A,N#Cc1c(N2C[C@@H]3NCCO[C@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
Finasteride,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,Cytochrome P450 2C9;Cytochrome P450 2C19;3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;3-oxo-5-alpha-steroid 4-dehydrogenase 1;3-oxo-5-alpha-steroid 4-dehydrogenase 2;Steroid 5-alpha-reductase,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
Finerenone,CCOC1=NC=C(C)C2=C1[C@H](C1=CC=C(C=C1OC)C#N)C(C(N)=O)=C(C)N2,Mineralocorticoid receptor,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2
Fingolimod,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Sphingosine-1-phosphate lyase 1;Sphingosine 1-phosphate receptor 1;Sphingosine 1-phosphate receptor 5;Sphingosine 1-phosphate receptor 4;Sphingosine 1-phosphate receptor 3;Transient receptor potential cation channel subfamily M member 7,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1
Flavin adenine dinucleotide,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2,,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](=O)(O)O[P@](=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)c2cc1C
Flavin mononucleotide,CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C1=NC(=O)NC(=O)C1=N2,,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C
Flavone,O=C1C=C(OC2=CC=CC=C12)C1=CC=CC=C1,,O=c1cc(-c2ccccc2)oc2ccccc12
Flavoxate,CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1,Potassium voltage-gated channel subfamily H member 2;Phosphodiesterase 4;Phosphodiesterase 7;Phosphodiesterase 8,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
Flecainide,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Sodium channel protein type 4 subunit alpha;Potassium voltage-gated channel subfamily A member 5;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Potassium voltage-gated channel subfamily A member 7;Potassium voltage-gated channel subfamily D member 2;Potassium voltage-gated channel subfamily C member 1,O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
Flibanserin,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1,5-hydroxytryptamine receptor 1A;D(2) dopamine receptor;D(3) dopamine receptor;D(4) dopamine receptor;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 2A,O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1
Floctafenine,OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C=CC=C12)C(F)(F)F,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2c(C(F)(F)F)cccc12
Florbetaben (18F),CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1,Amyloid beta A4 protein,CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])cc2)cc1
Florbetapir (18F),[H]N(C1=C([H])C([H])=C(\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H],Amyloid beta A4 protein,CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])nc2)cc1
Flortaucipir F-18,[18F]C1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1,Microtubule-associated protein tau,[18F]c1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1
Flosequinan,CN1C=C(C(=O)C2=C1C=C(F)C=C2)S(C)=O,,Cn1cc(S(C)=O)c(=O)c2ccc(F)cc21
Floxuridine,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O,Thymidylate synthase,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F
Fluciclovine (18F),N[C@]1(C[C@H]([18F])C1)C(O)=O,,N[C@]1(C(=O)O)C[C@@H]([18F])C1
Fluclorolone acetonide,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CO)O1
Flucloxacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1F)C(O)=O,Penicillin-binding protein 1A;Beta-lactamase TEM;Beta-lactamase;Efflux transporter; SugE;Penicillin-binding protein,Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,Cytochrome P450 3A4;Lanosterol 14-alpha demethylase;Cytochrome P450 2C9;Cytochrome P450 2C19;14-alpha sterol demethylase Cyp51A;14-alpha sterol demethylase;Mycocyclosin synthase;Sterol 14-alpha demethylase,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
Flucytosine,NC1=C(F)C=NC(=O)N1,5-hydroxytryptamine receptor 2A;Thymidylate synthase;ATP-dependent molecular chaperone HSP82,Nc1[nH]c(=O)ncc1F
Fludarabine,NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"DNA polymerase catalytic subunit;Deoxycytidine kinase;DNA polymerase alpha catalytic subunit;Ribonucleoside-diphosphate reductase large subunit;Ribonucleoside-diphosphate reductase subunit M2;Deoxyguanosine kinase, mitochondrial;Ribose-phosphate pyrophosphokinase 1;Dipeptidyl peptidase 4;Adenylate cyclase type V;Adenosylhomocysteinase ",Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Fludeoxyglucose (18F),[H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO,,O=C[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO
Fludrocortisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Glucocorticoid receptor;Annexin A1;Mineralocorticoid receptor;Nitric oxide synthase, inducible;Corticosteroid-binding globulin;Sex hormone-binding globulin",C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Flufenamic acid,OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F,,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1
Fluindione,FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,Arachidonate 5-lipoxygenase,O=C1c2ccccc2C(=O)C1c1ccc(F)cc1
Flumazenil,CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1,Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-5;Gamma-aminobutyric acid receptor subunit alpha-4;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-6/beta-2/gamma-2;GABA-A receptor; alpha-1/beta-2/gamma-2;GABA-A receptor alpha-6/beta-3/gamma-2,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
Flumethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Mu-type opioid receptor;Potassium voltage-gated channel subfamily H member 2;Kappa-type opioid receptor;Glutamate receptor ionotropic, NMDA 3A;Neuronal acetylcholine receptor subunit alpha-10;Delta-type opioid receptor;Opioid receptor",C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Flunarizine,FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,"Cannabinoid receptor 1;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium channel protein type 1 subunit alpha;Sodium-dependent dopamine transporter;Adenosine receptor A3;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Voltage-dependent N-type calcium channel subunit alpha-1B;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Sodium channel protein type 2 subunit alpha;Sodium channel alpha subunits; brain (Types I, II, III);CAAX prenyl protease 2;Potassium channel subfamily K member 2;Voltage-dependent T-type calcium channel subunit alpha-1G;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent T-type calcium channel subunit alpha-1I",Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
Flunisolide,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,Glucocorticoid receptor;Progesterone receptor,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Flunitrazepam,CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F,Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-5;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-3;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-3/beta-2/gamma-3;GABA A receptor alpha-5/beta-3/gamma-3;GABA A receptor alpha-5/beta-2/gamma-2;GABA A receptor alpha-5/beta-2/gamma-3,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21
Fluocinolone acetonide,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Fluocinonide,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O,Glucocorticoid receptor;Progesterone receptor,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Fluocortolone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Androgen receptor;Progesterone receptor,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
Fluorescein,OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1,Cytochrome P450 2C19;Protein arginine N-methyltransferase 1;Solute carrier family 22 member 6;Solute carrier family 22 member 20,O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21
Fluoride ion,[F-],Sodium-dependent noradrenaline transporter;Carbonic anhydrase 2;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Androgen receptor;Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform;G-protein coupled receptor 39;G protein-coupled receptor 39-1b;Ubiquitin-conjugating enzyme E2 T,[F-]
Fluoride ion F-18,[18F-],,[18F-]
Fluorodopa (18F),N[C@@H](CC1=CC(O)=C(O)C=C1[18F])C(O)=O,,N[C@@H](Cc1cc(O)c(O)cc1[18F])C(=O)O
Fluoroestradiol F-18,[H][C@@]12C[C@@H]([18F])[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,Estrogen receptor,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H]([18F])[C@@H]2O
Fluorometholone,[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Androgen receptor;Progesterone receptor,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Fluorouracil,FC1=CNC(=O)NC1=O,Thymidylate synthase;Multidrug resistance-associated protein 5;ATP-binding cassette sub-family C member 11;Uracil phosphoribosyltransferase,O=c1[nH]cc(F)c(=O)[nH]1
Fluoxetine,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Beta-1 adrenergic receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Acetylcholinesterase;Potassium channel subfamily K member 2;Histamine H3 receptor;Transporter;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Equilibrative nucleoside transporter 4;Potassium voltage-gated channel subfamily C member 1;G protein-activated inward rectifier potassium channel 2,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
Fluoxymesterone,[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Androgen receptor,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Flupentixol,[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,D(1A) dopamine receptor;D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;Alpha-1A adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;D(4) dopamine receptor;Potassium channel subfamily K member 2;Solute carrier family 22 member 1;Dopamine receptor,OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
Fluphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,"Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Kappa-type opioid receptor;Delta-type opioid receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;Epidermal growth factor receptor;Potassium channel subfamily K member 2;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Substance-K receptor;Androgen receptor;Trypanothione reductase;Melanocortin receptor 5;Membrane-associated progesterone receptor component 1;Pleiotropic ABC efflux transporter of multiple drugs;Sodium channel alpha subunits; brain (Types I, II, III);Adenylate cyclase",OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
Fluprednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Flurandrenolide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Somatostatin receptor type 2;Somatostatin receptor type 3;Somatostatin receptor type 5;Somatostatin receptor type 4;Somatostatin receptor type 1,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Flurazepam,CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F,Solute carrier family 22 member 2;GABA-A receptor alpha-1/beta-2/gamma-2,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21
Flurbiprofen,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Fatty acid-binding protein, intestinal;Fatty acid-binding protein, liver",CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Fluspirilene,FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Glycine receptor subunit alpha-1;5-hydroxytryptamine receptor 1E;Nociceptin receptor,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2
Flutamide,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,5-hydroxytryptamine receptor 4;5-hydroxytryptamine receptor 6;Androgen receptor;Cytochrome P450 1A2;Bile salt export pump,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
Flutemetamol (18F),CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1,Amyloid beta A4 protein,CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F]
Fluticasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF
Fluticasone furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Mineralocorticoid receptor;Progesterone receptor;Androgen receptor,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF
Fluticasone propionate,[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Mineralocorticoid receptor;Progesterone receptor;Cytosolic phospholipase A2,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Fluvastatin,CC(C)N1C(\C=C\C(O)CC(O)CC(O)=O)=C(C2=CC=CC=C12)C1=CC=C(F)C=C1,Nuclear receptor subfamily 1 group I member 3;Cytochrome P450 2C9;Retinoic acid receptor RXR-alpha;3-hydroxy-3-methylglutaryl-coenzyme A reductase;Sodium/bile acid cotransporter,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
Fluvoxamine,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F,Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Cytochrome P450 1A2,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1
Folic acid,NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1,,Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1
Fomepizole,CC1=CNN=C1,Alcohol dehydrogenase,Cc1cn[nH]c1
Fondaparinux,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,Antithrombin-III,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
Formaldehyde,[H]C([H])=O,,C=O
Formestane,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,Aromatase,C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Formoterol,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;D(3) dopamine receptor;Beta-3 adrenergic receptor;Heat shock protein HSP 90-alpha,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1
Fosamprenavir,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Gag-Pol polyprotein;Pol polyprotein,CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
Fosaprepitant,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,Substance-P receptor,C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Foscarnet,OC(=O)P(O)(O)=O,DNA polymerase catalytic subunit;Reverse transcriptase/RNaseH;Reverse transcriptase,O=C(O)P(=O)(O)O
Fosdenopterin,[H][C@@]12COP(O)(=O)O[C@]1([H])C(O)(O)[C@]1([H])NC3=C(NC(N)=NC3=O)N[C@]1([H])O2,Molybdenum cofactor biosynthesis protein 1,Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2
Fosfomycin,C[C@@H]1O[C@@H]1P(O)(O)=O,UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1;UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2;UDP-N-acetylglucosamine 1-carboxyvinyltransferase,C[C@@H]1O[C@@H]1P(=O)(O)O
Fosinopril,CCC(=O)O[C@@H](OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C,Angiotensin-converting enzyme,CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
Fosnetupitant,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1,Substance-P receptor,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Fosphenytoin,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,Sodium channel protein type 5 subunit alpha,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O
Fospropofol,CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O,GABA-A receptor,CC(C)c1cccc(C(C)C)c1OCOP(=O)(O)O
Fostamatinib,COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC,Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Adenosine receptor A3;Tyrosine-protein kinase SYK,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC
Fostemsavir,COC1=CN=C(N2C=NC(C)=N2)C2=C1C(=CN2COP(O)(O)=O)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1,Envelope glycoprotein gp160,COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O
Framycetin,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,Transient receptor potential cation channel subfamily V member 1;30S ribosomal protein S12;Phenylalanine--tRNA ligase alpha subunit;Phenylalanine--tRNA ligase beta subunit;Lethal factor;Lecithin retinol acyltransferase;Menin;Extracellular calcium-sensing receptor,NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O
Frovatriptan,CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D,CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1
Fructose,OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,Glycine receptor subunit alpha-1,OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O
Fulvestrant,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H],Nuclear receptor subfamily 1 group I member 2;Beta-lactamase TEM;Estrogen receptor;Progesterone receptor;Estrogen receptor beta;G-protein coupled estrogen receptor 1;Bile acid receptor;Steroid hormone receptor ERR1;Bifunctional epoxide hydrolase 2,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O
Furosemide,NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O,"Solute carrier family 12 member 1;Sodium/potassium-transporting ATPase subunit alpha-1;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 6;Carbonic anhydrase 14;Corticosteroid 11-beta-dehydrogenase isozyme 1;Solute carrier family 12 member 2;Carbonic anhydrase 13;G-protein coupled receptor 35;Holo-[acyl-carrieir-protein] synthase;CDGSH iron-sulfur domain-containing protein 1",NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
Fursultiamine,C\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\CCO)SSCC1CCCO1,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 9;Carbonic anhydrase 6;Carbonic anhydrase 15;Carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",C/C(=C(/CCO)SSCC1CCCO1)N(C=O)Cc1cnc(C)nc1N
Fusafungine,[H]C1(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C(=O)C([H])(OC(=O)[C@]([H])(C(C)C)N(C)C1=O)C(C)C)C(C)C)C(C)C,,CC(C)C1OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C1=O
Fusidic acid,[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O,,CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\CCC=C(C)C)C(=O)O
Futibatinib,COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2,"Multidrug resistance protein 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2A;Histamine H2 receptor;Carbonic anhydrase 2;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Ribosyldihydronicotinamide dehydrogenase [quinone];Carbonic anhydrase 9;Carbonic anhydrase 12;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 2;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Insulin receptor;Thromboxane-A synthase;Mitogen-activated protein kinase 8;Carbonic anhydrase 3;Carbonic anhydrase 6;Mitogen-activated protein kinase 10;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase SYK;Ephrin type-A receptor 8;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Carbonic anhydrase 14;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase PLK4;Abelson tyrosine-protein kinase 2;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase 17A;Tyrosine-protein kinase Fgr;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Cyclin-G-associated kinase;Ephrin type-B receptor 1;Dual specificity protein kinase CLK4;Mitogen-activated protein kinase 9;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Lysine--tRNA ligase;Carbonic anhydrase 13;Carbonic anhydrase 15;Non-receptor tyrosine-protein kinase TYK2;Mitogen-activated protein kinase kinase kinase MLT;Maternal embryonic leucine zipper kinase;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Tyrosine-protein kinase Blk;Cyclin-dependent kinase 19;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;Platelet-derived growth factor receptor;Tyrosine-protein kinase ABL;Bcr/Abl fusion protein",C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1
Gabapentin,NCC1(CC(O)=O)CCCCC1,"Sodium channel protein type 5 subunit alpha;Alpha-2A adrenergic receptor;Adenosine receptor A1;Gamma-aminobutyric acid type B receptor subunit 2;Glutamate receptor ionotropic, NMDA 3A;Large neutral amino acids transporter small subunit 1;Voltage-dependent calcium channel subunit alpha-2/delta-1;Potassium voltage-gated channel subfamily KQT member 3;Potassium voltage-gated channel subfamily KQT member 5;Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit;Voltage-dependent calcium channel subunit alpha-2/delta-2",NCC1(CC(=O)O)CCCCC1
Gabapentin enacarbil,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,,CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C
Gadobenic acid,[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)O)C(COCc1ccccc1)C(=O)O.[Gd+3]
Gadobutrol,OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234,Beta-2 adrenergic receptor;Cytochrome P450 2D6;Acetylcholinesterase;Cholinesterase,O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234
Gadodiamide,[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O,Acetylcholinesterase,CNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NC)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Gadofosveset trisodium,[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O,,O=C([O-])CN(CCN(CC(=O)[O-])C[C@H](COP(=O)([O-])OC1CCC(c2ccccc2)(c2ccccc2)CC1)N(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+].[Na+].[Na+]
Gadolinium,[Gd],,[Gd]
Gadopentetic acid,[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CCN(CC(=O)[O-])CC(=O)O.[Gd+3]
Gadopiclenol,[Gd+3].OCC(O)CNC(=O)CCC(N1CCN(CC2=CC=CC(CN(CC1)C(CCC(=O)NCC(O)CO)C([O-])=O)=N2)C(CCC(=O)NCC(O)CO)C([O-])=O)C([O-])=O,,O=C(CCC(C(=O)[O-])N1CCN(C(CCC(=O)NCC(O)CO)C(=O)[O-])Cc2cccc(n2)CN(C(CCC(=O)NCC(O)CO)C(=O)[O-])CC1)NCC(O)CO.[Gd+3]
Gadoteric acid,[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC1.[Gd+3]
Gadoteridol,[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,"5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Sodium channel alpha subunits; brain (Types I, II, III)",CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3]
Gadoversetamide,[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O,,COCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Gadoxetic acid,[Gd+3].[H][C@@](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)(CC1=CC=C(OCC)C=C1)N(CC(O)=O)CC(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3]
Galactose,[H]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO,Galectin-8;Galectin-9;Galectin-3,O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO
Galantamine,[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3,Acetylcholinesterase;Cholinesterase;Butyrylcholinesterase; Protein Bche;Butyrylcholinesterase,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2
Gallamine triethiodide,[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC,,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]
Gallium Ga-68 gozetotide,[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O,Prostate-specific antigen,O=C([O-])CCc1ccc(O)c(CN(CCN(CC(=O)[O-])Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)[O-])c1.[68Ga+3]
Gallium chloride Ga-67,[Cl-].[Cl-].[Cl-].[67Ga+3],,[67Ga+3].[Cl-].[Cl-].[Cl-]
Gallium citrate Ga-67,[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[67Ga+3]
Gallium nitrate,[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O,,O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Ga+3]
Gallium-68 PSMA,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)C(O)=O)C(O)=O,,O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1
Gamolenic acid,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O
Ganaxolone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C,"Arachidonate 5-lipoxygenase;Tyrosine-protein phosphatase non-receptor type 1;Liver carboxylesterase 1;Protein kinase C eta type;Corticosteroid 11-beta-dehydrogenase isozyme 2;Corticosteroid 11-beta-dehydrogenase isozyme 1;Glycogen phosphorylase, muscle form;Cocaine esterase;Aldo-keto reductase family 1 member B10;Tyrosine-protein phosphatase non-receptor type 11;Protein-tyrosine phosphatase 1C;High mobility group protein B1;Lactoylglutathione lyase",CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C
Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,DNA polymerase catalytic subunit;Thymidine kinase;Metabotropic glutamate receptor 1;Metabotropic glutamate receptor 5;Capsid scaffolding protein;Purine nucleoside phosphorylase,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
Ganirelix,CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,Gonadotropin-releasing hormone receptor,CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC
Gatifloxacin,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1,DNA topoisomerase 4 subunit A;DNA gyrase subunit A;DNA topoisomerase 4;DNA gyrase,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
Gaxilose,OC[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C=O,,O=C[C@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O
Gefitinib,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,"ATP-binding cassette sub-family G member 2;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Tyrosine-protein kinase Lck;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Receptor tyrosine-protein kinase erbB-2;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Death-associated protein kinase 3;Tyrosine-protein kinase HCK;Receptor tyrosine-protein kinase erbB-4;Mitogen-activated protein kinase 10;Myosin light chain kinase 2, skeletal/cardiac muscle;Ephrin type-A receptor 8;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 5;Serine/threonine-protein kinase 17A;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;Serine/threonine-protein kinase 36;Ephrin type-A receptor 3;Tyrosine-protein kinase FRK;Beta-secretase 1;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Activated CDC42 kinase 1;STE20-like serine/threonine-protein kinase;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Ephrin type-B receptor 4;Serine/threonine-protein kinase ULK3;Protein-tyrosine kinase 6;Tyrosine-protein kinase receptor UFO;Cyclin-dependent kinase 7;Serine/threonine-protein kinase D1;Serine/threonine-protein kinase DCLK3;NUAK family SNF1-like kinase 2;Casein kinase I isoform delta;Tyrosine-protein kinase TXK;MAP kinase-interacting serine/threonine-protein kinase 1;Serine/threonine-protein kinase NLK;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase SIK2;Myotonin-protein kinase;Leukocyte tyrosine kinase receptor;Serine/threonine-protein kinase pim-3;Tyrosine-protein kinase Blk;Citron Rho-interacting kinase;Ephrin type-A receptor 1;Tubulin alpha-1A chain;Mitogen-activated protein kinase 6;Mitogen-activated protein kinase 4;Ribosomal protein S6 kinase alpha-4;Cruzipain;Misshapen-like kinase 1;Interleukin-1 receptor-associated kinase 4;Serine/threonine-protein kinase Chk2;Ephrin type-B receptor 6;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Mitogen-activated protein kinase kinase kinase 19;Receptor tyrosine-protein kinase erbB-3;Quinolone resistance protein NorA;Serine/threonine-protein kinase SBK1;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Dual specificity mitogen-activated protein kinase kinase 5;Proto-oncogene tyrosine-protein kinase Src",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1
Gemcitabine,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,Thymidylate synthase;Deoxycytidine kinase;Ribonucleoside-diphosphate reductase large subunit;Ribonucleoside-diphosphate reductase subunit M2;UMP-CMP kinase;DNA polymerase (alpha/delta/epsilon),Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gemeprost,CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC,,CCCCC(C)(C)[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)OC
Gemfibrozil,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,"Lipoprotein lipase;Transthyretin;Cytochrome P450 2C8;Cytochrome P450 2C9;Peroxisome proliferator-activated receptor alpha;Fatty acid-binding protein, liver;CDGSH iron-sulfur domain-containing protein 1",Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
Gemifloxacin,CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,DNA topoisomerase 4 subunit A;DNA gyrase subunit B,CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN
Gentamicin,[H][C@@]1(CN)CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.[H][C@]1(CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)C(C)N.[H][C@]1(CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)C(C)NC,Dihydrofolate reductase;Transient receptor potential cation channel subfamily A member 1,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H](N)C[C@@H]2N)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O
Gentian violet cation,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C,Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;5-hydroxytryptamine receptor 2A;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Acetylcholinesterase;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Substance-K receptor;Androgen receptor;Alpha-1B adrenergic receptor,CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
Geraniol,CC(C)=CCC\C(C)=C\CO,High affinity choline transporter 1;Creatine transporter,CC(C)=CCC/C(C)=C/CO
Gestonorone caproate,[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],,CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Gestrinone,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H],Sex hormone-binding globulin,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21CC
Gilteritinib,CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O,Proto-oncogene tyrosine-protein kinase receptor Ret;High affinity nerve growth factor receptor;ALK tyrosine kinase receptor;Tyrosine-protein kinase receptor UFO;Leukocyte tyrosine kinase receptor;Tyrosine-protein kinase Mer;Proto-oncogene tyrosine-protein kinase ROS;Receptor-type tyrosine-protein kinase FLT3,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Gimeracil,OC1=CC(=O)NC=C1Cl,Dihydropyrimidine dehydrogenase [NADP(+)],O=c1cc(O)c(Cl)c[nH]1
Glasdegib,CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N,Smoothened homolog,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Glecaprevir,[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\C=C\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1,"Plasminogen;Neutrophil elastase;Chymotrypsin-like elastase family member 1;Cathepsin B;Cathepsin L1;Chymase;Lysosomal protective protein;Cathepsin L2;Cathepsin K;Cathepsin S;Hepatitis C virus serine protease, NS3/NS4A;NS3 protease",CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O
Gliclazide,[H][C@@]12CCC[C@]1([H])CN(C2)NC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,"Sulfonylurea receptor 2, Kir6.2;Sulfonylurea receptor 1, Kir6.2",Cc1ccc(S(=O)(=O)NC(=O)NN2C[C@H]3CCC[C@H]3C2)cc1
Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,"Sulfonylurea receptor 1, Kir6.2;Sulfonylurea receptor 2, Kir6.2",CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
Glipizide,CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,"Sulfonylurea receptor 1, Kir6.2",Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
Gliquidone,COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O,"Sulfonylurea receptor 1, Kir6.2",COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C
Gluconic Acid,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O,Tyrosine-protein phosphatase non-receptor type 1;V-type proton ATPase 116 kDa subunit a isoform 3;72 kDa type IV collagenase;Matrix metalloproteinase-14;Neutrophil collagenase,O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Gluconolactone,OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O,Glucosylceramidase,O=C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
Glucosamine,N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,"Sodium channel protein type 9 subunit alpha;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Sodium channel protein type 2 subunit alpha;Carbonic anhydrase 13;Carbonic anhydrase 15;Sodium channel protein type 3 subunit alpha;Dihydropyrimidinase-related protein 2;Sodium channel protein type X alpha subunit",N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
Glutamic acid,N[C@@H](CCC(O)=O)C(O)=O,,N[C@@H](CCC(=O)O)C(=O)O
Glutathione,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,Glutathione S-transferase kappa 1,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O
Glutathione disulfide,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
Glutethimide,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,GABA-A receptor alpha-1/beta-3/gamma-2,CCC1(c2ccccc2)CCC(=O)NC1=O
Glyburide,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 7;5-hydroxytryptamine receptor 2B,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
Glycerin,OCC(O)CO,,OCC(O)CO
Glycerol phenylbutyrate,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,,O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1
Glycine,NCC(O)=O,"Glutamate receptor ionotropic, NMDA 1;Sodium- and chloride-dependent glycine transporter 1;Glutamate NMDA receptor;Olfactory receptor 51E2",NCC(=O)O
Glycol salicylate,OCCOC(=O)C1=CC=CC=C1O,,O=C(OCCO)c1ccccc1O
Glycolic acid,OCC(O)=O,,O=C(O)CO
Glycopyrronium,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1
Glycyrrhizic acid,[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O,,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12
Glymidine,COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1,Deoxycytidine kinase;Protein P;Reverse transcriptase/RNaseH,COCCOc1cnc(NS(=O)(=O)c2ccccc2)nc1
Gonadorelin,CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,Gonadotropin-releasing hormone receptor;Lutropin-choriogonadotropic hormone receptor,CC(C)CC(NC(=O)CNC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O
Goserelin,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,Lutropin-choriogonadotropic hormone receptor;Gonadotropin-releasing hormone receptor,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Gramicidin D,CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO,Sodium/potassium-transporting ATPase subunit alpha-2;Endothelin-1 receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Substance-K receptor;Melanocortin receptor 4;Melanocortin receptor 5,CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO)C(C)C)C(C)C)C(C)C
Granisetron,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2,Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 3A;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Serotonin 3 (5-HT3) receptor;Neuronal acetylcholine receptor; alpha4/beta2;5-hydroxytryptamine receptor 3B;Neuronal acetylcholine receptor subunit alpha-3,CN1[C@@H]2CCC[C@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2
Grazoprevir,COC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)O3)C(C)(C)C)N=C2C=C1,NS3;Genome polyprotein;NS3 protease,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1
Grepafloxacin,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,Potassium voltage-gated channel subfamily H member 2;DNA topoisomerase 4;DNA gyrase,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
Griseofulvin,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,Tubulin beta chain;Lanosterol 14-alpha demethylase;Solute carrier family 22 member 1;Tubulin,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
Guaiacol,COC1=C(O)C=CC=C1,Carbonic anhydrase 2;Carbonic anhydrase 1,COc1ccccc1O
Guaifenesin,COC1=CC=CC=C1OCC(O)CO,,COc1ccccc1OCC(O)CO
Guanabenz,NC(N)=NN=CC1=C(Cl)C=CC=C1Cl,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Amine oxidase [flavin-containing] A;Trace amine-associated receptor 1;Nischarin;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;Adrenergic receptor alpha-2,NC(N)=NN=Cc1c(Cl)cccc1Cl
Guanadrel,NC(N)=NCC1COC2(CCCCC2)O1,Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor,NC(N)=NCC1COC2(CCCCC2)O1
Guanethidine,NC(N)=NCCN1CCCCCCC1,Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,NC(N)=NCCN1CCCCCCC1
Guanfacine,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Nischarin;Alpha-1A adrenergic receptor;Alpha-2A adrenergic receptor,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl
Guanidine,NC(N)=N,Voltage-gated potassium channel,N=C(N)N
Guanoxan,NC(=N)NCC1COC2=C(O1)C=CC=C2,,N=C(N)NCC1COc2ccccc2O1
Halazepam,FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,GABA-A receptor; anion channel,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F
Halcinonide,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor;Androgen receptor;Progesterone receptor,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
Halofantrine,CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F,Potassium voltage-gated channel subfamily H member 2,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12
Haloperidol,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,"Beta-2 adrenergic receptor;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Calmodulin;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Potassium channel subfamily K member 2;Potassium voltage-gated channel subfamily H member 1;Membrane-associated progesterone receptor component 1;Pol polyprotein;Muscarinic acetylcholine receptor M2;Protease;C-8 sterol isomerase;Transporter;Vesicular acetylcholine transporter;AP-2 complex subunit sigma;Muscarinic acetylcholine receptor;Opioid receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;Adenylate cyclase;G protein-activated inward rectifier potassium channel 2;Histone H1.0;Transmembrane protein 97;Sigma intracellular receptor 2;Zinc finger protein 664;D(4) dopamine receptor",O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Haloprogin,ClC1=CC(Cl)=C(Cl)C=C1OCC#CI,D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Kappa-type opioid receptor;Substance-K receptor;UDP-glucose 4-epimerase,Clc1cc(Cl)c(OCC#CI)cc1Cl
Halothane,[H]C(Cl)(Br)C(F)(F)F,Potassium channel subfamily K member 2;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9;Potassium channel subfamily K member 10;Potassium channel subfamily K member 18;Glycine receptor (alpha-1/beta);GABA-A receptor; anion channel,FC(F)(F)C(Cl)Br
Helium,[He],,[He]
Hesperidin,COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O1)C=C(O[C@@H]1O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1O)C=C2O,Acetylcholinesterase;Cholinesterase,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O
Hetacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O,Penicillin-binding protein,CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
Hexachlorophene,OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl,Sodium/potassium-transporting ATPase subunit alpha-2;Prostaglandin G/H synthase 2;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2C adrenergic receptor;Adenosine receptor A3;Estrogen receptor;Acetylcholinesterase;Estrogen receptor beta;Cytochrome P450 1A2;Epidermal growth factor receptor;Cytochrome P450 2C19;D-lactate dehydrogenase;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Thromboxane-A synthase;Mitogen-activated protein kinase 3;Mitogen-activated protein kinase 14;Substance-K receptor;Androgen receptor;Mitogen-activated protein kinase 1;Enoyl-[acyl-carrier-protein] reductase [NADH] FabI;Zinc finger protein mex-5;Transitional endoplasmic reticulum ATPase;Heat shock cognate 71 kDa protein;Heat shock 70 kDa protein 1A;M1-family alanyl aminopeptidase;Cytoplasmic zinc-finger protein;Envelope glycoprotein gp160;Macrophage migration inhibitory factor;N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D;78 kDa glucose-regulated protein,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
Hexafluronium,C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2,Acetylcholinesterase;Butyrylcholinesterase,C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21
Hexamidine,NC(=N)C1=CC=C(OCCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,Urokinase-type plasminogen activator;Prothrombin;Trypsin-1;Suppressor of tumorigenicity 14 protein;Protein arginine N-methyltransferase 1,N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1
Hexaminolevulinate,[H]N([H])CC(=O)CCC(=O)OCCCCCC,,CCCCCCOC(=O)CCC(=O)CN
Hexetidine,CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1,Toll-like receptor 9;Replicase polyprotein 1ab;Beta-lactamase;Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1,CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1
Hexobendine,COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1,"Sodium channel alpha subunits; brain (Types I, II, III)",COc1cc(C(=O)OCCCN(C)CCN(C)CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC
Hexocyclium,C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1
Hexylcaine,CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1,"Sodium channel alpha subunits; brain (Types I, II, III)",CC(CNC1CCCCC1)OC(=O)c1ccccc1
Hexylresorcinol,CCCCCCC1=C(O)C=C(O)C=C1,Arachidonate 5-lipoxygenase;Tyrosinase;Polyphenol oxidase 2,CCCCCCc1ccc(O)cc1O
Histamine,NCCC1=CNC=N1,Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Trace amine-associated receptor 1;Histamine H3 receptor,NCCc1c[nH]cn1
Histrelin,CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,Gonadotropin-releasing hormone receptor,CC(=O)O.CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
Homatropine,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(O)c1ccccc1)C2
Homatropine methylbromide,[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1,,C[N+]1(C)C2CCC1CC(OC(=O)C(O)c1ccccc1)C2.[Br-]
Homosalate,CC1CC(CC(C)(C)C1)OC(=O)C1=C(O)C=CC=C1,,CC1CC(OC(=O)c2ccccc2O)CC(C)(C)C1
Huperzine A,[H][C@@]12CC3=C(C=CC(=O)N3)[C@@](N)(CC(C)=C1)\C2=C\C,,C/C=C1\[C@H]2C=C(C)C[C@]1(N)c1ccc(=O)[nH]c1C2
Hyaluronic acid,CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O,,CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC2[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]2O)O[C@@H]1C(=O)O
Hydralazine,NNC1=NN=CC2=CC=CC=C12,Aldehyde oxidase;Voltage-dependent L-type calcium channel subunit alpha-1C;DNA (cytosine-5)-methyltransferase 1;DNA (cytosine-5)-methyltransferase 3A;DNA (cytosine-5)-methyltransferase 3B;Myeloperoxidase;Arachidonate 15-lipoxygenase;Acetylcholinesterase;Cholinesterase;Lactoperoxidase;Ryanodine receptor 2,NNc1nncc2ccccc12
Hydrochlorothiazide,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,"Carbonic anhydrase 2;Solute carrier family 12 member 3;Carbonic anhydrase 1;Carbonic anhydrase 4;Calcium-activated potassium channel subunit alpha-1;Astrosclerin-3;Delta carbonic anhydrase;Carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,Mu-type opioid receptor;Kappa-type opioid receptor,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314
Hydrocortamate,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Hydrocortisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Glucocorticoid receptor;Annexin A1;Mineralocorticoid receptor;Nitric oxide synthase, inducible;Corticosteroid-binding globulin;Sex hormone-binding globulin",C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Hydrocortisone acetate,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Hydrocortisone butyrate,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Hydrocortisone cypionate,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1
Hydrocortisone phosphate,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Hydrocortisone probutate,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Hydrocortisone succinate,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O
Hydrocortisone valerate,[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor,CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Hydroflumethiazide,NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F,Solute carrier family 12 member 3,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O
Hydrogen fluoride,F,,F
Hydrogen peroxide,OO,,OO
Hydromorphone,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Opioid receptor,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
Hydroquinone,OC1=CC=C(O)C=C1,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 3;Carbonic anhydrase 14;Carbonic anhydrase 13;Acetylcholinesterase;Polyphenol oxidase 2;Carbonic anhydrase 15;Carbonic anhydrase",Oc1ccc(O)cc1
Hydrotalcite,O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O,,O.O.O.O.O.O.O.O.O.O.O.O.O=C([O-])[O-].[Al+3].[Al+3].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2]
Hydroxocobalamin,[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H],"Methionine synthase;Methionine synthase reductase;Protein amnionless;Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial;Methylmalonic aciduria type A protein, mitochondrial;Transcobalamin-2;Transcobalamin-1",CC1=C2[N]3[C@@H]4[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@H](O[C@@H]2CO)n2c[n+](c5cc(C)c(C)cc52)[Co-3]325([OH])[N+]3=C1[C@@H](CCC(N)=O)C(C)(C)C3=CC1=[N+]2C(=C(C)C2=[N+]5[C@]4(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O
Hydroxyamphetamine,CC(N)CC1=CC=C(O)C=C1,Beta-secretase 1;Trace amine-associated receptor 1,CC(N)Cc1ccc(O)cc1
Hydroxychloroquine,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Hemoglobin subunit alpha;Alpha-1D adrenergic receptor;Toll-like receptor 7;Toll-like receptor 9;Transmembrane protein 97,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Hydroxycitronellal,[H]C(=O)CC(C)CCCC(C)(C)O,,CC(CC=O)CCCC(C)(C)O
Hydroxyethyl cellulose,CC(O)COCC1OC(OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C(OCC(C)O)C1OCC(C)O,,CC(O)COCC1OC(OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C(OCC(C)O)C1OCC(C)O
Hydroxyprogesterone caproate,[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Histamine H2 receptor;Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Aldo-keto reductase family 1 member C1;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Cytochrome P450 2C19;Sex hormone-binding globulin;Estrogen receptor,CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Hydroxystilbamidine,NC(=N)C1=CC=C(\C=C\C2=C(O)C=C(C=C2)C(N)=N)C=C1,Trypsin,N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1
Hydroxyurea,NC(=O)NO,,NC(=O)NO
Hydroxyzine,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Cytochrome P450 2D6;Envelope glycoprotein gp160,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Hyoscyamine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)c1ccccc1)C2
Hypochlorite,[O-]Cl,,[O-]Cl
Ibandronate,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
Ibrexafungerp,[H][C@]12CC[C@@]3([H])[C@@]4(C)COC[C@@]3(C[C@H]([C@@H]4OC[C@](C)(N)C(C)(C)C)N3N=CN=C3C3=CC=NC=C3)C1=CC[C@@]1(C)[C@H](C(O)=O)[C@](C)(CC[C@]21C)[C@H](C)C(C)C,"Beta-1,3-glucan synthase catalytic subunit 1;1,3-Beta-D-glucan-UDP glucosyltransferase",CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5(COC[C@@]4(C)[C@@H](OC[C@](C)(N)C(C)(C)C)[C@H](n4ncnc4-c4ccncc4)C5)C3=CC[C@@]2(C)[C@@H]1C(=O)O
Ibrutinib,NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1,Potassium voltage-gated channel subfamily H member 2;Tyrosine-protein kinase ABL1;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase receptor Ret;Tyrosine-protein kinase CSK;Cytoplasmic tyrosine-protein kinase BMX;Tyrosine-protein kinase Fer;Fibroblast growth factor receptor 2;Protein-tyrosine kinase 6;Redox-regulatory protein FAM213A;Tyrosine-protein kinase Lyn;Tyrosine-protein kinase JAK3;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Tyrosine-protein kinase HCK;Receptor tyrosine-protein kinase erbB-4;Tyrosine-protein kinase Fgr;Tyrosine-protein kinase ITK/TSK;Tyrosine-protein kinase Tec;Tyrosine-protein kinase TXK;Tyrosine-protein kinase Blk;Tyrosine-protein kinase BTK,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cytochrome P450 2C9;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Arachidonate 5-lipoxygenase;Fatty acid-binding protein, liver;Interleukin-8;Prostaglandin-H2 D-isomerase;Serum albumin;Solute carrier family 22 member 6;Solute carrier family 22 member 20;Cyclooxygenase;Sodium-coupled monocarboxylate transporter 1;Dehydrogenase/reductase SDR family member 9;Acid-sensing ion channel 1",CC(C)Cc1ccc(C(C)C(=O)O)cc1
Ibutilide,CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,Potassium voltage-gated channel subfamily H member 2,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1
Icatibant,[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,B2 bradykinin receptor;B1 bradykinin receptor,N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21
Icosapent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O
Icosapent ethyl,CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC
Idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O,Multidrug resistance protein 1;DNA topoisomerase 2-alpha;Multidrug resistance-associated protein 1,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
Idebenone,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Cytochrome P450 3A4;Cytochrome P450 2D6;Cytochrome P450 2C9;Cytochrome P450 2C19,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
Idelalisib,[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,"DNA-dependent protein kinase catalytic subunit;Phosphatidylinositol 3-kinase catalytic subunit type 3;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1
Idoxuridine,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O,"Thymidine kinase, cytosolic;Thymidine kinase",O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
Ifosfamide,ClCCNP1(=O)OCCCN1CCCl,"Solute carrier family 12 member 1;Sodium/potassium-transporting ATPase subunit alpha-1;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 6;Carbonic anhydrase 14;Corticosteroid 11-beta-dehydrogenase isozyme 1;Solute carrier family 12 member 2;Carbonic anhydrase 13;G-protein coupled receptor 35;Holo-[acyl-carrieir-protein] synthase;CDGSH iron-sulfur domain-containing protein 1",O=P1(NCCCl)OCCCN1CCCl
Iloperidone,COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M4;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;Gastrin/cholecystokinin type B receptor;Serotonin 2 (5-HT2) receptor,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1
Iloprost,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O,Prostaglandin E2 receptor EP1 subtype;Prostaglandin E2 receptor EP3 subtype;Prostacyclin receptor;Thromboxane A2 receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Prostaglandin F2-alpha receptor,CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O
Imatinib,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,"Multidrug resistance protein 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2A;Histamine H2 receptor;Carbonic anhydrase 2;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Ribosyldihydronicotinamide dehydrogenase [quinone];Carbonic anhydrase 9;Carbonic anhydrase 12;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 2;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Insulin receptor;Thromboxane-A synthase;Mitogen-activated protein kinase 8;Carbonic anhydrase 3;Carbonic anhydrase 6;Mitogen-activated protein kinase 10;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase SYK;Ephrin type-A receptor 8;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Carbonic anhydrase 14;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase PLK4;Abelson tyrosine-protein kinase 2;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase 17A;Tyrosine-protein kinase Fgr;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Cyclin-G-associated kinase;Ephrin type-B receptor 1;Dual specificity protein kinase CLK4;Mitogen-activated protein kinase 9;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Lysine--tRNA ligase;Carbonic anhydrase 13;Carbonic anhydrase 15;Non-receptor tyrosine-protein kinase TYK2;Mitogen-activated protein kinase kinase kinase MLT;Maternal embryonic leucine zipper kinase;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Tyrosine-protein kinase Blk;Cyclin-dependent kinase 19;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;Platelet-derived growth factor receptor;Tyrosine-protein kinase ABL;Bcr/Abl fusion protein",Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imidurea,OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O,,O=C(NCNC(=O)NC1C(=O)NC(=O)N1CO)NC1C(=O)NC(=O)N1CO
Imipenem,[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Penicillin-binding protein 4;Penicillin-binding protein 1;Beta-lactamase;Beta-lactamase GES-13;Bacterial penicillin-binding protein,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12
Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,"D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Adenosine receptor A3;Major prion protein;Solute carrier family 22 member 1;Potassium voltage-gated channel subfamily H member 1;Transporter;Pleiotropic ABC efflux transporter of multiple drugs;Solute carrier family 22 member 2;Glutamate NMDA receptor;Muscarinic acetylcholine receptor;Serotonin (5-HT) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Adrenergic receptor alpha-1;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;G protein-activated inward rectifier potassium channel 4;G protein-activated inward rectifier potassium channel 2;Sphingomyelin phosphodiesterase",CN(C)CCCN1c2ccccc2CCc2ccccc21
Imiquimod,CC(C)CN1C=NC2=C1C1=C(C=CC=C1)N=C2N,Adenosine receptor A2a;Histamine H2 receptor;Alpha-1D adrenergic receptor;Toll-like receptor 7,CC(C)Cn1cnc2c(N)nc3ccccc3c21
Indacaterol,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;D(3) dopamine receptor,CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2
Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,"Carbonic anhydrase 2;Solute carrier family 12 member 3;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Potassium voltage-gated channel subfamily KQT member 1;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 6;Carbonic anhydrase 14;Arachidonate 15-lipoxygenase;Carbonic anhydrase 13",CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
Indecainide,CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=CC=CC=C12,Sodium channel protein type 5 subunit alpha,CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21
Indigotindisulfonic acid,OS(=O)(=O)C1=CC2=C(N\C(C2=O)=C2\NC3=C(C=C(C=C3)S(O)(=O)=O)C2=O)C=C1,,O=C1/C(=C2\Nc3ccc(S(=O)(=O)O)cc3C2=O)Nc2ccc(S(=O)(=O)O)cc21
Indinavir,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,Cytochrome P450 3A4;Gag-Pol polyprotein;Thromboxane-A synthase;Substance-K receptor;Pol polyprotein;Protease;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
Indium In-111 chloride,Cl[111In](Cl)Cl,,[Cl][111In]([Cl])[Cl]
Indium In-111 oxyquinoline,[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2,,[111In+3].[O-]c1cccc2cccnc12.[O-]c1cccc2cccnc12.[O-]c1cccc2cccnc12
Indium In-111 pentetate,[111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O,,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)O)CC(=O)O.[111In+3]
Indium In-111 pentetreotide,[111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1,,CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(Cc2ccccc2)N=C([O-])CN(CCN(CCC(C(=O)O)C(=O)O)CC(=O)[O-])CC(=O)[O-])C(O)=NC(Cc2ccccc2)C(O)=NC(Cc2c[nH]c3ccccc23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1.[111In+3]
Indocyanine green,[Na+].CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4C=CC=CC4=C3C2(C)C)N(CCCCS([O-])(=O)=O)C2=CC=C3C=CC=CC3=C12,,CC1(C)C(/C=C/C=C/C=C/C=C2/N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]
Indocyanine green acid form,CC1(C)\C(=C\C=C\C=C\C=C\C2=[N+](CCCCS(O)(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C2=C1C1=CC=CC=C1C=C2,,CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21
Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Multidrug resistance protein 1;Multidrug resistance-associated protein 1;Androgen receptor;Prostaglandin D2 receptor 2;Dehydrogenase/reductase SDR family member 9;Aldose reductase;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Peroxisome proliferator-activated receptor gamma;Prostaglandin E2 receptor EP2 subtype;Lactoylglutathione lyase;Cytochrome c oxidase subunit 2;Interleukin-8;Potassium voltage-gated channel subfamily A member 7;Prostaglandin-H2 D-isomerase;Cyclooxygenase;Prostaglandin G/H synthase (cyclooxygenase);Nitric oxide synthase, inducible;Prostaglandin E synthase;Aldo-keto reductase family 1 member C4;Nicotinate phosphoribosyltransferase",COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Indoramin,O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1,Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1
Infigratinib,CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1,Macrophage-stimulating protein receptor;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Platelet-derived growth factor receptor alpha;Insulin receptor;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase SYK;Angiopoietin-1 receptor;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;ALK tyrosine kinase receptor;Ephrin type-B receptor 1;BDNF/NT-3 growth factors receptor;Non-receptor tyrosine-protein kinase TYK2;Proto-oncogene tyrosine-protein kinase ROS;Smoothened homolog;Fibroblast growth factor receptor 3;Fibroblast growth factor receptor 2;Fibroblast growth factor receptor 4;Fibroblast growth factor receptor 1,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1
Ingenol mebutate,[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C,Protein kinase C gamma type;Protein kinase C beta type;Protein kinase C alpha type;Protein kinase C epsilon type;Serine/threonine-protein kinase D1;Protein kinase C delta type,C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C
Inosine pranobex,C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O,,CC(=O)Nc1ccc(C(=O)O)cc1.CC(=O)Nc1ccc(C(=O)O)cc1.CC(=O)Nc1ccc(C(=O)O)cc1.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.O=c1[nH]cnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O
Inositol nicotinate,O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1,,O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H]1OC(=O)c1cccnc1)c1cccnc1
Iobenguane,NC(N)=NCC1=CC(I)=CC=C1,,NC(N)=NCc1cccc(I)c1
Iobenguane sulfate I-123,OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1,,N=C(N)NCc1cccc([123I])c1.N=C(N)NCc1cccc([123I])c1.O=S(=O)(O)O
Iobitridol,CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(NC(=O)C(CO)CO)=C1I,,CN(CC(O)CO)C(=O)c1c(I)c(NC(=O)C(CO)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I
Iocetamic acid,CC(CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I)C(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CC(=O)N(CC(C)C(=O)O)c1c(I)cc(I)c(N)c1I
Iodide,[I-],,[I-]
Iodide I-123,[123I-],,[123I-]
Iodide I-131,[131I-],,[131I-]
Iodine,II,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Opioid receptor,II
Iodipamide,OC(=O)C1=C(I)C(NC(=O)CCCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;G protein-activated inward rectifier potassium channel 4;Solute carrier family 22 member 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,O=C(CCCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I
Iodixanol,CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
Iodoform,[H]C(I)(I)I,,IC(I)I
Iodohippurate sodium I-123,[Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1[123I],,O=C([O-])CNC(=O)c1ccccc1[123I].[Na+]
Iodohippurate sodium I-131,[Na+].[O-]C(=O)CNC(=O)C1=C([131I])C=CC=C1,,O=C([O-])CNC(=O)c1ccccc1[131I].[Na+]
Iofetamine I-123,CC(C)NC(C)CC1=CC=C([123I])C=C1,,CC(C)NC(C)Cc1ccc([123I])cc1
Ioflupane I-123,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF,,COC(=O)[C@H]1[C@@H](c2ccc([123I])cc2)C[C@@H]2CC[C@H]1N2CCCF
Iohexol,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
Iomeprol,CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,"Cytochrome P450 3A4;Multidrug resistance protein 1;Cytochrome P450 2C9;Cytochrome P450 1A2;Cytochrome P450 2C19;Fatty acid synthase;Potassium-transporting ATPase;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1;Glutathione S-transferase omega-1;Cytosolic endo-beta-N-acetylglucosaminidase",CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
Iopamidol,C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I,Cannabinoid receptor 1;Cannabinoid receptor 2;Fatty-acid amide hydrolase 1;G-protein coupled receptor 55,C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I
Iopanoic acid,CCC(CC1=C(I)C(N)=C(I)C=C1I)C(O)=O,,CCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O
Iophendylate,CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I,Mu-type opioid receptor;Potassium voltage-gated channel subfamily A member 3,CCOC(=O)CCCCCCCCC(C)c1ccccc1I
Iopodic acid,CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I,,CN(C)C=Nc1c(I)cc(I)c(CCC(=O)O)c1I
Iopromide,COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I
Iothalamic acid,CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,,CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
Iotrolan,CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I,,CN(C(=O)CC(=O)N(C)c1c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(C(=O)NC(CO)C(O)CO)c1I)c1c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(C(=O)NC(CO)C(O)CO)c1I
Ioversol,OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,,O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I
Ioxaglic acid,CNC(=O)C1=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C(I)C(N(C)C(C)=O)=C1I,,CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I
Ioxilan,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I,,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I
Ioxitalamic acid,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I,,CC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I
Ipratropium,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Solute carrier family 22 member 2,CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2
Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,Type-1 angiotensin II receptor;Endothelin-1 receptor;Type-1B angiotensin II receptor;Angiotensin II receptor (AT-1) type-1;Angiotensin II receptor;Sodium/bile acid cotransporter,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Irinotecan,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,Multidrug resistance protein 1;Muscarinic acetylcholine receptor M4;Canalicular multispecific organic anion transporter 1;Alpha-2C adrenergic receptor;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 4;Acetylcholinesterase;DNA topoisomerase 1;Interstitial collagenase;Solute carrier family 22 member 1;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
Iron,[Fe],,[Fe]
Iron sucrose,O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,,O.O.O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-]
Isavuconazole,C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1,"Alpha-2A adrenergic receptor;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3;Lanosterol 14-alpha demethylase;Beta-lactamase;Cytochrome P450 2C9;Cytochrome P450 1A2;Cytochrome P450 2C19;Alkaline phosphatase, tissue-nonspecific isozyme;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Bile acid receptor;Indoleamine 2,3-dioxygenase 1;Substance-K receptor;Indoleamine 2,3-dioxygenase 2;Malate dehydrogenase cytoplasmic ",C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F
Isavuconazonium,[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1,,CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1
Isoaminile,CC(C)[C@@](C[C@H](C)N(C)C)(C#N)C1=CC=CC=C1,,CC(C)[C@](C#N)(C[C@H](C)N(C)C)c1ccccc1
Isocarboxazid,CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1,Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A,Cc1cc(C(=O)NNCc2ccccc2)no1
Isoconazole,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=C(Cl)C=CC=C1Cl,"Steroid 17-alpha-hydroxylase/17,20 lyase;Indoleamine 2,3-dioxygenase 1",Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1
Isoetharine,CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1,Beta-2 adrenergic receptor,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1
Isoeugenol,COC1=CC(C=CC)=CC=C1O,Prostaglandin G/H synthase 1;Arachidonate 5-lipoxygenase,CC=Cc1ccc(O)c(OC)c1
Isoflurane,FC(F)OC(Cl)C(F)(F)F,5-hydroxytryptamine receptor 2B;Potassium channel subfamily K member 2;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9;Potassium channel subfamily K member 10;Potassium channel subfamily K member 18;Glycine receptor (alpha-1/beta);GABA-A receptor; anion channel,FC(F)OC(Cl)C(F)(F)F
Isoflurophate,CC(C)OP(F)(=O)OC(C)C,,CC(C)OP(=O)(F)OC(C)C
Isometheptene,CNC(C)CCC=C(C)C,,CNC(C)CCC=C(C)C
Isoniazid,NNC(=O)C1=CC=NC=C1,Cytochrome P450 3A4;Catalase-peroxidase;Enoyl-[acyl-carrier-protein] reductase [NADH];Myeloperoxidase;Cytochrome P450 3A5;Dihydrofolate reductase,NNC(=O)c1ccncc1
Isoprenaline,CC(C)NCC(O)C1=CC(O)=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;D(3) dopamine receptor;Beta-3 adrenergic receptor;D(4) dopamine receptor;Arachidonate 15-lipoxygenase;Taste receptor type 2 member 14;Taste receptor type 2 member 46;Taste receptor type 2 member 38;Taste receptor type 2 member 39;Taste receptor type 2 member 40;Taste receptor type 2 member 41;Taste receptor type 2 member 43;Taste receptor type 2 member 31;Taste receptor type 2 member 45;Taste receptor type 2 member 30;Taste receptor type 2 member 19;Taste receptor type 2 member 20;Taste receptor type 2 member 50;Taste receptor type 2 member 60;Taste receptor type 2 member 42;Taste receptor type 2 member 16;Taste receptor type 2 member 13;Taste receptor type 2 member 10;Taste receptor type 2 member 9;Taste receptor type 2 member 8;Taste receptor type 2 member 7;Taste receptor type 2 member 5;Taste receptor type 2 member 4;Taste receptor type 2 member 3;Taste receptor type 2 member 1,CC(C)NCC(O)c1ccc(O)c(O)c1
Isopropamide,CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C
Isopropyl alcohol,CC(C)O,,CC(C)O
Isopropyl myristate,CCCCCCCCCCCCCC(=O)OC(C)C,,CCCCCCCCCCCCCC(=O)OC(C)C
Isosorbide,[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H],,O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,Atrial natriuretic peptide receptor 1;Soluble guanylate cyclase,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
Isosorbide mononitrate,[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O,Atrial natriuretic peptide receptor 1;Soluble guanylate cyclase,O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
Isosulfan blue,CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=CC(=CC=C1S(O)(=O)=O)S(O)(=O)=O,,CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2cc(S(=O)(=O)O)ccc2S(=O)(=O)O)cc1
Isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,5-hydroxytryptamine receptor 2B;Alpha-2B adrenergic receptor;Adenosine receptor A3;Retinoic acid receptor alpha;Alcohol dehydrogenase 4;Dehydrogenase/reductase SDR family member 9;11-cis retinol dehydrogenase;17-beta-hydroxysteroid dehydrogenase type 6;Retinoic acid receptor beta;Mitogen-activated protein kinase 14;Mitogen-activated protein kinase 1;Cellular retinoic acid-binding protein 1;Olfactory receptor 51E2,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Isoxaflutole,[H]C1=NOC(=C1C(=O)C1=C(C([H])=C(C([H])=C1[H])C(F)(F)F)S(=O)(=O)C([H])([H])[H])C1([H])C([H])([H])C1([H])[H],,CS(=O)(=O)c1cc(C(F)(F)F)ccc1C(=O)c1cnoc1C1CC1
Isoxicam,CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1
Isoxsuprine,C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1,,C[C@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1
Isradipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,Potassium voltage-gated channel subfamily H member 2;Nuclear receptor subfamily 1 group I member 2;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1D;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent L-type calcium channel subunit alpha-1F,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12
Istradefylline,[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC,Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;Amine oxidase [flavin-containing] B;Adenosine receptor A2a,CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,Beta-2 adrenergic receptor;Cytochrome P450 3A4;Lanosterol 14-alpha demethylase;Vasopressin V2 receptor;Tyrosine-protein kinase Fyn;C-C chemokine receptor type 4;C-X-C chemokine receptor type 1;Cruzipain;14-alpha sterol demethylase Cyp51A;14-alpha sterol demethylase;7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
Ivabradine,COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2
Ivacaftor,CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C,Cystic fibrosis transmembrane conductance regulator,CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O
Ivermectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O.[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)[C@@H](C)CC)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O,D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Neuronal acetylcholine receptor subunit alpha-7;Bile acid receptor;Glycine Receptor;Glutamate-gated chloride channel;Sarcoplasmic/endoplasmic reticulum calcium ATPase 2;Sodium/potassium-transporting ATPase subunit alpha-1;Sarcoplasmic/endoplasmic reticulum calcium ATPase 1;P2X purinoceptor 4,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O
Ivosidenib,[H][C@@](N(C(=O)[C@]1([H])CCC(=O)N1C1=NC=CC(=C1)C#N)C1=CC(F)=CN=C1)(C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1,Isocitrate dehydrogenase [NADP] cytoplasmic,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Ixabepilone,[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1,Tubulin beta,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
Ixazomib,CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B(O)O,Proteasome subunit beta type-1;Proteasome subunit beta type-2;Proteasome subunit beta type-5,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O
Kanamycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B);3-oxoacyl-[acyl-carrier-protein] synthase 3;Gap junction beta-2 protein",NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O
Kaolin,O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-],,O.O.[Al+3].[Al+3].[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-]
Kappadione,[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1,,Cc1cc(OP(=O)([O-])[O-])c2ccccc2c1OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
Kava,COC1=CC(=O)OC(C1)\C=C\C1=CCCC=C1,,COC1=CC(=O)OC(/C=C/C2=CCCC=C2)C1
Ketamine,CNC1(CCCCC1=O)C1=CC=CC=C1Cl,Acetylcholine receptor subunit alpha;Glutamate [NMDA] receptor;Glutamate NMDA receptor;Glutamate receptor ionotropic AMPA,CNC1(c2ccccc2Cl)CCCCC1=O
Ketazolam,CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1,GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2,CC1=CC(=O)N2CC(=O)N(C)c3ccc(Cl)cc3C2(c2ccccc2)O1
Ketoconazole,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,"Sodium/nucleoside cotransporter 1;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M2;Aldehyde oxidase;Sodium-dependent dopamine transporter;Nuclear receptor subfamily 1 group I member 2;Alpha-1D adrenergic receptor;Lanosterol 14-alpha demethylase;Delta-type opioid receptor;Bile salt export pump;Cytochrome P450 2C9;Aromatase;25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;Potassium voltage-gated channel subfamily A member 10;Cytochrome P450 2C19;Thromboxane-A synthase;Indoleamine 2,3-dioxygenase 1;Solute carrier family 22 member 1;Substance-K receptor;Cytochrome P450 3A5;Arachidonate 15-lipoxygenase;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Gonadotropin-releasing hormone receptor;1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;Cytochrome P450 21;Cytochrome P450 11B1;Cytochrome P450 11A1;Cytochrome P450 24A1;Cytochrome P450 7A1;Cytochrome P450 51;Cytochrome P450 17A1;Cytochrome P450 11B2, mitochondrial;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial",CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Ketoprofen,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cyclooxygenase,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Ketorolac,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Fatty acid-binding protein, liver;Aldose reductase;Prostaglandin-H2 D-isomerase;Serine/threonine-protein kinase PAK 1",O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Ketotifen,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12,D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Multidrug resistance protein 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-1D adrenergic receptor,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
Kinetin,C(NC1=NC=NC2=C1NC=N2)C1=CC=CO1,Endochitinase,c1coc(CNc2ncnc3nc[nH]c23)c1
Krypton Kr 81m,[81Kr],,[81Kr]
L-Glutamine,N[C@@H](CCC(N)=O)C(O)=O,Amino acid transporter,NC(=O)CC[C@H](N)C(=O)O
L-Lactic acid,C[C@H](O)C(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,C[C@H](O)C(=O)O
Labetalol,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;CAAX prenyl protease 1;CAAX prenyl protease 2,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Lacidipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,Cytochrome P450 3A4;Sodium-dependent noradrenaline transporter;D(3) dopamine receptor;Adenosine receptor A3;Cytochrome P450 2C9;Cytochrome P450 2C19;Thromboxane-A synthase;Androgen receptor;Voltage-gated L-type calcium channel,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,"Sodium channel protein type 9 subunit alpha;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Sodium channel protein type 2 subunit alpha;Carbonic anhydrase 13;Carbonic anhydrase 15;Sodium channel protein type 3 subunit alpha;Dihydropyrimidinase-related protein 2;Sodium channel protein type X alpha subunit",COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1
Lactic acid,CC(O)C(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CC(O)C(=O)O
Lactitol,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,,OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)CO
Lactose,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O,Galectin-8;Galectin-9;Galectin-3,OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
Lactulose,OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,Galectin-8;Galectin-9;Galectin-3,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Deoxycytidine kinase;Protein P;Reverse transcriptase/RNaseH,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,"Sodium channel protein type 5 subunit alpha;Sigma non-opioid intracellular receptor 1;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha;5-hydroxytryptamine receptor 3A;Sodium channel protein type 10 subunit alpha;Dihydrofolate reductase;Sodium channel alpha subunits; brain (Types I, II, III);Sodium channel protein type X alpha subunit",Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
Lanreotide,[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H],Somatostatin receptor type 2;Somatostatin receptor type 3;Somatostatin receptor type 5;Somatostatin receptor type 4;Somatostatin receptor type 1,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,"Cytochrome P450 2D6;Cytochrome P450 2C19;Fatty acid synthase;Phosphoethanolamine/phosphocholine phosphatase;Microtubule-associated protein tau;Indoleamine 2,3-dioxygenase 2;Potassium-transporting ATPase;Indoleamine 2,3-dioxygenase 1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1;Cytosolic endo-beta-N-acetylglucosaminidase",Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Lanthanum carbonate,[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O,,O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3]
Lapatinib,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Tyrosine-protein kinase CSK;Mast/stem cell growth factor receptor Kit;Proto-oncogene tyrosine-protein kinase Src;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
Lapyrium,CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,"Fumarate reductase;Synaptojanin-2;Synaptojanin-1;Serine hydroxymethyltransferase, mitochondrial",CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1
Laropiprant,CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1,Prostaglandin E2 receptor EP1 subtype;Prostaglandin D2 receptor 2;Prostaglandin E2 receptor EP3 subtype;Prostacyclin receptor;Thromboxane A2 receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin F2-alpha receptor;Prostaglandin D2 receptor,CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3
Larotrectinib,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1,High affinity nerve growth factor receptor;BDNF/NT-3 growth factors receptor;NT-3 growth factor receptor,O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1
Lasmiditan,CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1,5-hydroxytryptamine receptor 1F,CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
Lasofoxifene,[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1,Estrogen receptor;Estrogen receptor beta,Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1
Latamoxef,[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O,Peptidoglycan synthase FtsI;Penicillin-binding protein 1A;Penicillin-binding protein 1B,CO[C@@]1(NC(=O)C(C(=O)O)c2ccc(O)cc2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CO[C@@H]21
Latanoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1,Prostaglandin E2 receptor EP1 subtype;Prostaglandin E2 receptor EP3 subtype;Prostaglandin F2-alpha receptor,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Latanoprostene bunod,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1,,O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
Lauric acid,CCCCCCCCCCCC(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CCCCCCCCCCCC(=O)O
Laurocapram,CCCCCCCCCCCCN1CCCCCC1=O,,CCCCCCCCCCCCN1CCCCCC1=O
Ledipasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC=C2NC(=NC2=C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C,Nonstructural protein 5A;Genome polyprotein,COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C
Lefamulin,[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)C(C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,"Sodium/nucleoside cotransporter 1;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Dihydroorotate dehydrogenase (quinone), mitochondrial;Cytochrome P450 1A2;Amine oxidase [flavin-containing] A",Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
Lemborexant,CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=NC=C(F)C=C2)C2=CC=CC(F)=C2)C(C)=N1,Potassium voltage-gated channel subfamily H member 2;Orexin receptor type 1;Orexin receptor type 2,Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Tumor necrosis factor;Cereblon isoform 4;Protein cereblon,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O
Lenvatinib,COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O,"Carbonic anhydrase 5A, mitochondrial;Platelet-derived growth factor receptor beta;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase receptor Ret;Mast/stem cell growth factor receptor Kit;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Platelet-derived growth factor receptor alpha;Fibroblast growth factor receptor 1",COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Lercanidipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1,Voltage-gated L-type calcium channel,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1
Lesinurad,OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2,Solute carrier family 22 member 11;Solute carrier family 22 member 12,O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12
Letermovir,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=CC(=CC=C1OC)C(F)(F)F,DNA terminase complex,COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1
Letrozole,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N,"Aromatase;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial",N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Leucovorin,[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2,Thymidylate synthase;Dihydrofolate reductase,Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
Leuprolide,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 7;Adrenergic receptor alpha-2;Dopamine receptor;Cerebral cortex alpha adrenergic receptor;D(1A) dopamine receptor,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
Levacetylmethadol,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,Potassium voltage-gated channel subfamily H member 2;Mu-type opioid receptor,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1
Levallorphan,[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2,Mu-type opioid receptor;Acetylcholinesterase;Opioid receptor,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
Levamisole,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1,"Acetylcholine receptor subunit alpha-type unc-63;Alkaline phosphatase, tissue-nonspecific isozyme;Nicotinic acetylcholine receptor alpha subunit;Membrane-associated progesterone receptor component 1;Intestinal-type alkaline phosphatase",c1ccc([C@H]2CN3CCSC3=N2)cc1
Levamlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC,Voltage-gated L-type calcium channel,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl
Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,Sodium channel protein type 1 subunit alpha;Voltage-dependent T-type calcium channel subunit alpha-1G;Carbonic anhydrase 1;Synaptic vesicle glycoprotein 2A,CC[C@@H](C(N)=O)N1CCCC1=O
Levmetamfetamine,CN[C@H](C)CC1=CC=CC=C1,Trace amine-associated receptor 1,CN[C@H](C)Cc1ccccc1
Levobetaxolol,CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1
Levobunolol,CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;Beta-3 adrenergic receptor,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
Levobupivacaine,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,Potassium voltage-gated channel subfamily H member 2;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 4 subunit alpha;Prostaglandin E2 receptor EP1 subtype;Cytochrome P450 2D6;5-hydroxytryptamine receptor 3A;Potassium voltage-gated channel subfamily D member 3;Potassium voltage-gated channel subfamily A member 5,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Levocabastine,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1,Multidrug resistance protein 1;Histamine H1 receptor;Neurotensin receptor type 2;Neurotensin receptor 2,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1
Levocarnitine,C[N+](C)(C)C[C@H](O)CC([O-])=O,"Carnitine O-palmitoyltransferase 1, liver isoform;Carnitine O-palmitoyltransferase 1, muscle isoform;Carnitine palmitoyltransferase 2",C[N+](C)(C)C[C@H](O)CC(=O)[O-]
Levocetirizine,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Histamine H1 receptor,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1
Levodopa,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,Large neutral amino acids transporter small subunit 1;Epidermal growth factor receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Arachidonate 15-lipoxygenase;D(1A) dopamine receptor;D(2) dopamine receptor,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
Levofloxacin,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,Potassium voltage-gated channel subfamily H member 2;DNA gyrase subunit A;Multidrug and toxin extrusion protein 1;DNA topoisomerase 4;DNA gyrase;CAAX prenyl protease 2,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Levoketoconazole,CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,"Sodium/nucleoside cotransporter 1;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M2;Aldehyde oxidase;Sodium-dependent dopamine transporter;Nuclear receptor subfamily 1 group I member 2;Alpha-1D adrenergic receptor;Lanosterol 14-alpha demethylase;Delta-type opioid receptor;Bile salt export pump;Cytochrome P450 2C9;Aromatase;25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial;Potassium voltage-gated channel subfamily A member 10;Cytochrome P450 2C19;Thromboxane-A synthase;Indoleamine 2,3-dioxygenase 1;Solute carrier family 22 member 1;Substance-K receptor;Cytochrome P450 3A5;Arachidonate 15-lipoxygenase;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Gonadotropin-releasing hormone receptor;1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial;Cytochrome P450 21;Cytochrome P450 11B1;Cytochrome P450 11A1;Cytochrome P450 24A1;Cytochrome P450 7A1;Cytochrome P450 51;Cytochrome P450 17A1;Cytochrome P450 11B2, mitochondrial;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial",CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Levoleucovorin,NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1,Thymidylate synthase;Dihydrofolate reductase,Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O
Levomefolic acid,CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2,,CN1c2c([nH]c(N)nc2=O)NC[C@@H]1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Levomenol,[H][C@@]1(CCC(C)=CC1)[C@@](C)(O)CCC=C(C)C,Neuronal acetylcholine receptor subunit alpha-7;Signal transducer and activator of transcription 3,CC(C)=CCC[C@](C)(O)[C@@H]1CC=C(C)CC1
Levomenthol,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,Transient receptor potential cation channel subfamily A member 1;Transient receptor potential cation channel subfamily M member 8,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Levomilnacipran,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1,Sodium-dependent dopamine transporter;Sodium-dependent serotonin transporter;Glutamate NMDA receptor;Sodium-dependent noradrenaline transporter,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN
Levonordefrin,C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1,Adrenergic receptor alpha-2,C[C@H](N)[C@H](O)c1ccc(O)c(O)c1
Levonorgestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],Sodium-dependent serotonin transporter;Glucocorticoid receptor;Estrogen receptor;Progesterone receptor;Sex hormone-binding globulin;Androgen receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
Levorphanol,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,"Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Solute carrier family 22 member 1;Acetylcholinesterase;Sigma non-opioid intracellular receptor 1;Glutamate [NMDA] receptor;Glutamate NMDA receptor;Opioid receptor;Sodium channel alpha subunits; brain (Types I, II, III)",CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
Levosalbutamol,CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1,Beta-2 adrenergic receptor,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1
Levosimendan,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;ATP-sensitive inward rectifier potassium channel 11;ATP-sensitive inward rectifier potassium channel 8;Troponin C, slow skeletal and cardiac muscles",C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1
Levothyroxine,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,"Thyroid hormone receptor alpha;Thyroid hormone receptor beta;Transthyretin;Bile acid receptor;THAP domain-containing protein 1;Macrophage migration inhibitory factor;Malate dehydrogenase, mitochondrial",N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O
Lidocaine,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C,"Sodium channel protein type 5 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 9 subunit alpha;5-hydroxytryptamine receptor 3A;Sodium channel protein type 10 subunit alpha;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Acetylcholine receptor;Sodium channel alpha subunits; brain (Types I, II, III);Sodium channel protein type X alpha subunit",CCN(CC)CC(=O)Nc1c(C)cccc1C
Lidoflazine,CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1,"Potassium voltage-gated channel subfamily H member 2;Equilibrative nucleoside transporter 1;Sodium channel alpha subunits; brain (Types I, II, III)",Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
Lifitegrast,CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1,Intercellular adhesion molecule 1;Integrin alpha-L/beta-2,CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1
Light green SF yellowish,[Na+].[Na+].CCN(CC1=CC(=CC=C1)S([O-])(=O)=O)C1=CC=C(C=C1)C(C1=CC=C(C=C1)S([O-])(=O)=O)=C1C=CC(C=C1)=[N+](CC)CC1=CC(=CC=C1)S([O-])(=O)=O,,CCN(Cc1cccc(S(=O)(=O)[O-])c1)c1ccc(C(=C2C=CC(=[N+](CC)Cc3cccc(S(=O)(=O)[O-])c3)C=C2)c2ccc(S(=O)(=O)[O-])cc2)cc1.[Na+].[Na+]
Linaclotide,[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,Heat-stable enterotoxin receptor,C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2
Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,Muscarinic acetylcholine receptor M1;Dipeptidyl peptidase 4;Prolyl endopeptidase FAP;Dipeptidyl peptidase 9;Dipeptidyl peptidase IV,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Lincomycin,[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,50S ribosomal protein L10,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1
Lindane,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Gamma-aminobutyric acid receptor subunit beta-3;Androgen receptor;Gamma-aminobutyric acid receptor subunit beta;Gamma-aminobutyric acid receptor subunit rho-1;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor;GABA-A receptor alpha-6/beta-3/gamma-2;GABA A receptor alpha-1/beta-1/gamma-2,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
Linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,"Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
Linoleic acid,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O
Linzagolix,COC1=C(COC2=C(OC)C=C(F)C(=C2)N2C(=O)NC3=CSC(C(O)=O)=C3C2=O)C(F)=C(F)C=C1,,COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F
Liothyronine,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O,Thyroid hormone receptor alpha;Thyroid hormone receptor beta;Adenosine receptor A1;Cytochrome P450 2C9;Proliferating cell nuclear antigen;THAP domain-containing protein 1;GABA-A receptor; anion channel,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
Liotrix,[Na+].[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C([O-])=O.N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O,,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+].[Na+]
Lipoic acid,OC(=O)CCCC[C@@H]1CCSS1,,O=C(O)CCCC[C@@H]1CCSS1
Lisdexamfetamine,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Synaptic vesicular amine transporter,C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
Lisinopril,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,Angiotensin-converting enzyme,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Lisuride,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 7;5-hydroxytryptamine receptor 2B,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Lithium carbonate,[Li+].[Li+].[O-]C([O-])=O,,O=C([O-])[O-].[Li+].[Li+]
Lithium citrate,[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]
Lithium hydroxide,[Li+].[OH-],,[Li+].[OH-]
Lodoxamide,OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N,G-protein coupled receptor 35,N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1
Lofexidine,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1,5-hydroxytryptamine receptor 1A;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Nischarin;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Alpha-2A adrenergic receptor,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1
Lomefloxacin,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12,DNA gyrase subunit A;DNA gyrase,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
Lomitapide,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12,Microsomal triglyceride transfer protein large subunit,O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1
Lomustine,ClCCN(N=O)C(=O)NC1CCCCC1,Alpha-2A adrenergic receptor,O=NN(CCCl)C(=O)NC1CCCCC1
Lonafarnib,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3=C(CCC4=C2C(Br)=CC(Cl)=C4)C=C(Br)C=N3)CC1,GTPase HRas;GTPase KRas;GTPase NRas;Protein farnesyltransferase,NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1
Loperamide,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,"Beta-2 adrenergic receptor;Sodium channel protein type 5 subunit alpha;Mu-type opioid receptor;Glutamate receptor ionotropic, NMDA 2A;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2B;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Aldehyde oxidase;Voltage-dependent P/Q-type calcium channel subunit alpha-1A;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Calmodulin;Delta-type opioid receptor;Somatostatin receptor type 5;Glutamate receptor ionotropic, NMDA 2B;Glutamate receptor ionotropic, NMDA 2C;Glutamate receptor ionotropic, NMDA 2D;Angiopoietin-1 receptor;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Cocaine esterase;Sodium channel alpha subunits; brain (Types I, II, III);Menin",CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
Lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Gag-Pol polyprotein;Pol polyprotein;CAAX prenyl protease 1 homolog;Protease,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
Loracarbef,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1
Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;5-hydroxytryptamine receptor 2B;Histamine H1 receptor;Nuclear receptor subfamily 1 group I member 2;Cytochrome P450 2C19;Potassium channel subfamily K member 9;Bile acid receptor;Sodium-dependent neutral amino acid transporter B(0)AT2,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
Lorazepam,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,"Fatty acid-binding protein, liver;GABA-A receptor alpha-1/beta-3/gamma-2",O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
Lorcaserin,C[C@H]1CNCCC2=CC=C(Cl)C=C12,Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C,C[C@H]1CNCCc2ccc(Cl)cc21
Lorlatinib,C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Tyrosine-protein kinase FRK;ALK tyrosine kinase receptor;Proto-oncogene tyrosine-protein kinase ROS;Focal adhesion kinase 1;High affinity nerve growth factor receptor;Tyrosine-protein kinase Fer;Activated CDC42 kinase 1;BDNF/NT-3 growth factors receptor;Protein-tyrosine kinase 2-beta;NT-3 growth factor receptor;Leukocyte tyrosine kinase receptor;Tyrosine-protein kinase Fes/Fps,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21
Lormetazepam,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl,"Fatty acid-binding protein, liver;GABA-A receptor alpha-1/beta-3/gamma-2",CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21
Lornoxicam,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cyclooxygenase,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
Lorpiprazole,[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;5-hydroxytryptamine receptor 1A;Histone H1.0,FC(F)(F)c1cccc(N2CCN(CCc3nnc4n3C[C@@H]3CCC[C@H]43)CC2)c1
Losartan,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,Multidrug resistance protein 1;Angiotensin-converting enzyme;Cytochrome P450 2C9;Type-1 angiotensin II receptor;Type-2 angiotensin II receptor;Type-1B angiotensin II receptor;Type-1A angiotensin II receptor;Phosphodiesterase 3;Phosphodiesterase 4;Angiotensin II receptor (AT-1) type-1;Angiotensin II receptor;Platelet glycoprotein VI,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Loteprednol,[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)OCCl
Loteprednol etabonate,[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Adenosine receptor A1;Nuclear receptor subfamily 1 group I member 2;3-hydroxy-3-methylglutaryl-coenzyme A reductase;Hydroxycarboxylic acid receptor 2;Hydroxycarboxylic acid receptor 3;Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 6;Substance-K receptor;Androgen receptor;Acetylcholinesterase;Cholinesterase;Leukocyte adhesion glycoprotein LFA-1 alpha;Acyl-CoA:cholesterol acyltransferase,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Loxapine,CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;Potassium channel subfamily K member 2;Potassium channel subfamily T member 1;5-hydroxytryptamine receptor 7;Adrenergic receptor alpha-1,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1
Loxoprofen,CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Lubiprostone,[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC,Chloride channel protein 2,CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1
Luliconazole,ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1,Lanosterol 14-alpha demethylase,N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1
Lumacaftor,CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O,Cystic fibrosis transmembrane conductance regulator,Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1
Lumateperone,[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;D(4) dopamine receptor;Alpha-1B adrenergic receptor;D(2) dopamine receptor;D(1A) dopamine receptor;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2A,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12
Lumefantrine,CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1,Potassium voltage-gated channel subfamily H member 2,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1
Lumefantrine co-artemether,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1.CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C1=CC=C(Cl)C=C1\C2=C\C1=CC=C(Cl)C=C1,,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1.CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1.CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1.CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1.CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1.CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1.CO[C@H]1O[C@@H]2O[C@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3
Lumiracoxib,CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1,Prostaglandin G/H synthase 1;Prostaglandin G/H synthase 2,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Lurasidone,[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 7;Alpha-2C adrenergic receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 2A,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1
Lurbinectedin,[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC4=CC=C(OC)C=C54)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@@]2([H])N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31,Proto-oncogene tyrosine-protein kinase Src;Nuclear receptor subfamily 1 group I member 2,COc1ccc2[nH]c3c(c2c1)CCN[C@]31CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4
Lusutrombopag,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1,Thrombopoietin receptor,CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
Lutein,C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,,CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C
Lutetium Lu 177 dotatate,[177Lu+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,Somatostatin receptor type 2,C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[177Lu+3]
Lutetium Lu-177,[177Lu],,[177Lu]
Lutetium Lu-177 vipivotide tetraxetan,[177Lu+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)CC1)C(O)=O)C(O)=O,,O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)NC[C@H]2CC[C@H](C(=O)N[C@@H](Cc3ccc4ccccc4c3)C(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)CC2)CCN(CC(=O)[O-])CC1.[177Lu+3]
Lycopene,CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C,,CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C
Lymecycline,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C,DNA repair protein RAD52 homolog,CN(C)[C@@H]1C(O)=C(C(=O)NCNCCCC[C@H](N)C(=O)O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
Lynestrenol,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Muscarinic acetylcholine receptor M2;Estrogen receptor;Androgen receptor;Acetylcholinesterase;Cytochrome P450 2C19;Progesterone receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
Lypressin,[H]N([H])C(=O)C[C@]1([H])NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)NC([H])(CCCCN)C(=O)NCC(N)=O,Vasopressin receptor,NCCCCC(NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Lysine,NCCCC[C@H](N)C(O)=O,"Glutathione reductase, mitochondrial",NCCCC[C@H](N)C(=O)O
Macimorelin,CC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=O,Growth hormone secretagogue receptor type 1,CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O
Macitentan,CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1,Endothelin-1 receptor;Endothelin B receptor,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
Mafenide,NCC1=CC=C(C=C1)S(N)(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Dihydropteroate synthase;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",NCc1ccc(S(N)(=O)=O)cc1
Magaldrate,O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,,O.O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-]
Magnesium,[MgH2],,[MgH2]
Magnesium acetate,[Mg++].CC([O-])=O.CC([O-])=O,,CC(=O)[O-].CC(=O)[O-].[Mg+2]
Magnesium acetate tetrahydrate,O.O.O.O.[Mg++].CC([O-])=O.CC([O-])=O,,CC(=O)[O-].CC(=O)[O-].O.O.O.O.[Mg+2]
Magnesium ascorbate,[Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,,O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Mg+2]
Magnesium carbonate,[Mg++].[O-]C([O-])=O,,O=C([O-])[O-].[Mg+2]
Magnesium cation,[Mg++],,[Mg+2]
Magnesium chloride,[Mg++].[Cl-].[Cl-],,[Cl-].[Cl-].[Mg+2]
Magnesium citrate,[Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2]
Magnesium gluconate,O.O.[Mg++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O,,O.O.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Mg+2]
Magnesium glycinate,[Mg++].NCC([O-])=O.NCC([O-])=O,,NCC(=O)[O-].NCC(=O)[O-].[Mg+2]
Magnesium hydroxide,[OH-].[OH-].[Mg++],,[Mg+2].[OH-].[OH-]
Magnesium malate,[Mg++].OC(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)C(=O)[O-].[Mg+2]
Magnesium oxide,[O--].[Mg++],,[Mg+2].[O-2]
Magnesium silicate,[O--].[O--].[O--].[Mg++].[Si+4],,[Mg+2].[O-2].[O-2].[O-2].[Si+4]
Magnesium sulfate,[Mg++].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[Mg+2]
Magnesium trisilicate,[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O,,O=[Si]([O-])O[Si]([O-])([O-])O[Si](=O)[O-].[Mg+2].[Mg+2]
Malathion,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,Melatonin receptor type 1A;Acetylcholinesterase,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
Mandelic acid,OC(C(O)=O)C1=CC=CC=C1,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(O)C(O)c1ccccc1
Mangafodipir,[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1,,Cc1nc(COP(=O)(O)O)cc(CN(CCN(CC(=O)[O-])Cc2cc(COP(=O)(O)O)nc(C)c2O)CC(=O)[O-])c1O.[Mn+2]
Manganese,[Mn++],,[Mn+2]
Manganese citrate,[Mn++].[Mn++].[Mn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mn+2].[Mn+2].[Mn+2]
Manganese gluconate,[Mn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Mn+2]
Manidipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,Cruzipain;Voltage-gated L-type calcium channel,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1
Mannitol,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Mannitol busulfan,CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O,,CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O
Maprotiline,CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;ATP-binding cassette sub-family G member 2;Alpha-1B adrenergic receptor;G protein-activated inward rectifier potassium channel 2;Transient receptor potential cation channel subfamily M member 3,CNCCCC12CCC(c3ccccc31)c1ccccc12
Maralixibat,CCCCC1(CCCC)CS(=O)(=O)C2=CC=C(C=C2[C@H]([C@H]1O)C1=CC=C(OCC2=CC=C(C[N+]34CCN(CC3)CC4)C=C2)C=C1)N(C)C,,CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O
Maraviroc,CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,C-C chemokine receptor type 5;Multidrug and toxin extrusion protein 1,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Maribavir,CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,Adenosine receptor A1;Adenosine kinase;Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;Cytosolic purine 5'-nucleotidase;Inosine-5'-monophosphate dehydrogenase 1;Inosine-5'-monophosphate dehydrogenase 2;DNA topoisomerase 1;NS5B protein,CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O
Masoprocol,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1,"Transthyretin;Estrogen receptor;Androgen receptor;Aromatase;Arachidonate 5-lipoxygenase;Insulin-like growth factor 1 receptor;Arachidonate 15-lipoxygenase;Estradiol 17-beta-dehydrogenase 1;Estradiol 17-beta-dehydrogenase 2;Arachidonate 12-lipoxygenase, 12S-type;Leukotriene B4 receptor 1;Transient receptor potential cation channel subfamily A member 1;Seed linoleate 13S-lipoxygenase-1;Prostaglandin G/H synthase 1;Zinc finger protein mex-5;5-lipoxygenase;Cyclooxygenase;Arachidonate 15-lipoxygenase, type II;Lipoxygenase;Cytoplasmic zinc-finger protein;Fatty acid hydroperoxide lyase, chloroplastic",C[C@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1
Mavacamten,CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O,,CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
Mazindol,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1,Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Histamine H1 receptor;Sodium-dependent dopamine transporter;Transporter,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21
Mebendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1,Tyrosine-protein kinase ABL1;Vascular endothelial growth factor receptor 2;Calmodulin-domain protein kinase 1;Tubulin,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
Mebeverine,CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1,,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1
Mebrofenin,CC1=CC(C)=C(Br)C(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O,,Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br
Mebutamate,CCC(C)C(C)(COC(N)=O)COC(N)=O,"Glutamate receptor ionotropic, NMDA 2A;Glutamate receptor ionotropic, NMDA 2B",CCC(C)C(C)(COC(N)=O)COC(N)=O
Mecamylamine,CNC1(C)C2CCC(C2)C1(C)C,Neuronal acetylcholine receptor subunit alpha-7;Acetylcholine receptor subunit alpha;Neuronal acetylcholine receptor; alpha2/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3;Neuronal acetylcholine receptor subunit alpha-3;Neuronal acetylcholine receptor subunit alpha-4;Neuronal acetylcholine receptor subunit alpha-6,CNC1(C)C2CCC(C2)C1(C)C
Mechlorethamine,CN(CCCl)CCCl,D(2) dopamine receptor;D(3) dopamine receptor;D(4) dopamine receptor,CN(CCCl)CCCl
Meclizine,CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1,Histamine H1 receptor,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1
Meclofenamic acid,CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1,,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
Mecobalamin,C1(CC[C@@]2([C@@H](CC(N)=O)[C@@]3([C@@]4([N+]5=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C(C)=C4[N+]6=C(C=C7[N+]8=C([C@H](C7(C)C)CCC(N)=O)C(C)=C2N3[Co-3]568([N+]2=CN([C@H]3O[C@@H]([C@@H](OP(O[C@@H](CN1)C)([O-])=O)[C@H]3O)CO)C1=CC(C)=C(C=C21)C)C)[C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C)[H])C)=O,"Methionine synthase;Methionine synthase reductase;Protein amnionless;Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial;Methylmalonic aciduria type A protein, mitochondrial;Transcobalamin-2;Transcobalamin-1",CC1=C2[N]3[C@@H]4[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@H](O[C@@H]2CO)n2c[n+](c5cc(C)c(C)cc52)[Co-3]325([CH3])[N+]3=C1[C@@H](CCC(N)=O)C(C)(C)C3=CC1=[N+]2C(=C(C)C2=[N+]5[C@]4(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O
Medifoxamine,CN(C)CC(OC1=CC=CC=C1)OC1=CC=CC=C1,Hypoxia-inducible factor 1-alpha;Deoxyhypusine hydroxylase,CN(C)CC(Oc1ccccc1)Oc1ccccc1
Medrogestone,[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,Progesterone receptor;Nuclear receptor subfamily 2 group E member 1,CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Medronic acid,OP(O)(=O)CP(O)(O)=O,,O=P(O)(O)CP(=O)(O)O
Medroxyprogesterone acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,Histamine H2 receptor;Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Aldo-keto reductase family 1 member C1;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Cytochrome P450 2C19;Sex hormone-binding globulin;Estrogen receptor,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Medrysone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,Glucocorticoid receptor,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
Mefenamic acid,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,,Cc1cccc(Nc2ccccc2C(=O)O)c1C
Mefloquine,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,Adenosine receptor A2a;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Adenosine receptor A1;Hemoglobin subunit alpha;Glycine receptor subunit alpha-1;Protein kinase Pfmrk,OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1
Megestrol acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Meglumine,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Amino acid transporter,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Melatonin,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1,5-hydroxytryptamine receptor 2B;Ribosyldihydronicotinamide dehydrogenase [quinone];Melatonin receptor type 1A;Melatonin receptor type 1B;Nuclear receptor ROR-alpha;Myeloperoxidase;Histamine H3 receptor;Cytochrome P450 1B1;Melatonin receptor,COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
Melphalan,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,L-type amino acid transporter 1,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
Melphalan flufenamide,CCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC1=CC=C(C=C1)N(CCCl)CCCl,,CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1
Memantine,CC12CC3CC(C)(C1)CC(N)(C3)C2,"5-hydroxytryptamine receptor 3A;Glutamate receptor ionotropic, NMDA 3A;Glutamate receptor ionotropic, NMDA 1;Solute carrier family 22 member 1;Glutamate receptor ionotropic, NMDA 2C;Glutamate NMDA receptor; GRIN1/GRIN2B;Glutamate NMDA receptor; GRIN1/GRIN2A",CC12CC3CC(C)(C1)CC(N)(C3)C2
Menadiol diphosphate,CC1=C(OP(O)(O)=O)C2=CC=CC=C2C(OP(O)(O)=O)=C1,,Cc1cc(OP(=O)(O)O)c2ccccc2c1OP(=O)(O)O
Menadione,CC1=CC(=O)C2=CC=CC=C2C1=O,"Aldehyde oxidase;Glutathione reductase, mitochondrial;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Indoleamine 2,3-dioxygenase 1;M-phase inducer phosphatase 2;Trypanothione reductase;Dual specificity phosphatase Cdc25C;Ubiquitin carboxyl-terminal hydrolase isozyme L3;Dual specificity phosphatase Cdc25A;Dual specificity protein phosphatase 6;Dual specificity protein phosphatase 1;M-phase inducer phosphatase 1",CC1=CC(=O)c2ccccc2C1=O
Menthol,CC(C)C1CCC(C)CC1O,"Glutamate receptor ionotropic, NMDA 3A;Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;GABA A receptor alpha-4/beta-2/delta",CC1CCC(C(C)C)C(O)C1
Menthyl salicylate,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1O,,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)c1ccccc1O
Mepenzolate,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Solute carrier family 22 member 1,C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1
Meperidine,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,Acetylcholinesterase;Cholinesterase,CCOC(=O)C1(c2ccccc2)CCN(C)CC1
Mephenesin,CC1=CC=CC=C1OCC(O)CO,Prostaglandin G/H synthase 1,Cc1ccccc1OCC(O)CO
Mephentermine,CNC(C)(C)CC1=CC=CC=C1,Alpha-1A adrenergic receptor,CNC(C)(C)Cc1ccccc1
Mephenytoin,CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1,Sodium channel alpha subunit,CCC1(c2ccccc2)NC(=O)N(C)C1=O
Mepivacaine,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,Sodium channel protein type 5 subunit alpha;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha,Cc1cccc(C)c1NC(=O)C1CCCCN1C
Meprednisone,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,Glucocorticoid receptor,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
Meprobamate,CCCC(C)(COC(N)=O)COC(N)=O,Multidrug resistance protein 1;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2,CCCC(C)(COC(N)=O)COC(N)=O
Mepyramine,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
Mequinol,COC1=CC=C(O)C=C1,Tyrosinase,COc1ccc(O)cc1
Meradimate,CC(C)C1CCC(C)CC1OC(=O)C1=CC=CC=C1N,,CC1CCC(C(C)C)C(OC(=O)c2ccccc2N)C1
Mercaptopurine,S=C1N=CNC2=C1NC=N2,Prostaglandin G/H synthase 1;Multidrug resistance-associated protein 5;Multidrug resistance-associated protein 4;Purine nucleoside phosphorylase;Amidophosphoribosyltransferase;Thiopurine S-methyltransferase,S=c1nc[nH]c2nc[nH]c12
Meropenem,[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H],Penicillin-binding protein 2;Penicillin-binding protein 4;D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5;Penicillin-binding protein 1;D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6;D-alanyl-D-alanine carboxypeptidase DacB;Streptokinase A;Beta-lactamase class B VIM-2;Beta-lactamase NDM-1;Beta-lactamase,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
Mesalazine,NC1=CC(C(O)=O)=C(O)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Arachidonate 5-lipoxygenase;Peroxisome proliferator-activated receptor gamma;Tumor necrosis factor;Hydroxyacid oxidase 1,Nc1ccc(O)c(C(=O)O)c1
Mesoridazine,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,D(1A) dopamine receptor;D(2) dopamine receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;D(4) dopamine receptor,CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21
Mestranol,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3,Cannabinoid receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Estrogen receptor;Androgen receptor;Progesterone receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
Metacycline,[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,DNA repair protein RAD52 homolog,C=C1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12
Metamfetamine,CN[C@@H](C)CC1=CC=CC=C1,Sigma non-opioid intracellular receptor 1,CN[C@@H](C)Cc1ccccc1
Metamizole,CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,Transient receptor potential cation channel subfamily A member 1,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C
Metaraminol,C[C@H](N)[C@H](O)C1=CC(O)=CC=C1,Alpha-1A adrenergic receptor,C[C@H](N)[C@H](O)c1cccc(O)c1
Metaxalone,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2;GABA A receptor alpha-2/beta-2/gamma-2;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-4/beta-2/delta;GABA A receptor alpha-5/beta-2/gamma-2;GABA A receptor alpha-4/beta-3/delta;GABA-A receptor alpha-6/beta-2;GABA-A receptor alpha-6/beta-2/delta;GABA-A receptor alpha-6/beta-3/delta,Cc1cc(C)cc(OCC2CNC(=O)O2)c1
Metergoline,[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@@]1([H])C[C@@H](CNC(=O)OCC1=CC=CC=C1)CN2C,5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Acetylcholinesterase;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Substance-K receptor;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;Serotonin 1 (5-HT1) receptor;Serotonin 2 (5-HT2) receptor,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
Metformin,CN(C)C(=N)NC(N)=N,5'-AMP-activated protein kinase subunit beta-1;Dipeptidyl peptidase 4;Solute carrier family 22 member 1;Solute carrier family 22 member 2;Solute carrier family 22 member 3;Mitochondrial complex I (NADH dehydrogenase),CN(C)C(=N)NC(=N)N
Methacholine,CC(C[N+](C)(C)C)OC(C)=O,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4,CC(=O)OC(C)C[N+](C)(C)C
Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,"Mu-type opioid receptor;Potassium voltage-gated channel subfamily H member 2;Kappa-type opioid receptor;Glutamate receptor ionotropic, NMDA 3A;Neuronal acetylcholine receptor subunit alpha-10;Delta-type opioid receptor;Opioid receptor",CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
Methantheline,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12,Muscarinic acetylcholine receptor,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21
Methazolamide,CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase V;Carbonic anhydrase, alpha family;Carbonate dehydratase",CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C
Methdilazine,CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1,Histamine H1 receptor,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1
Methenamine,C1N2CN3CN1CN(C2)C3,Acetylcholine receptor subunit alpha;Glutamate [NMDA] receptor;Glutamate NMDA receptor;Glutamate receptor ionotropic AMPA,C1N2CN3CN1CN(C2)C3
Methimazole,CN1C=CNC1=S,Thyroid peroxidase;Lactoperoxidase;Dopamine beta-hydroxylase,Cn1cc[nH]c1=S
Methionine,CSCC[C@H](N)C(O)=O,S-ribosylhomocysteine lyase,CSCC[C@H](N)C(=O)O
Methocarbamol,COC1=C(OCC(O)COC(N)=O)C=CC=C1,Carbonic anhydrase 1,COc1ccccc1OCC(O)COC(N)=O
Methohexital,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O,Glycine receptor subunit alpha-1;GABA-A receptor alpha-1/beta-3/gamma-2;Neuronal acetylcholine receptor; alpha2/beta2,C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O
Methotrexate,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Thymidylate synthase;Multidrug resistance-associated protein 5;Folylpolyglutamate synthase, mitochondrial;Multidrug resistance-associated protein 4;Bifunctional dihydrofolate reductase-thymidylate synthase;Dihydrofolate reductase;Folate receptor beta;Proton-coupled folate transporter;Pteridine reductase 1;Folate transporter 1;Folate receptor alpha;High mobility group protein B1",CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Methotrimeprazine,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2
Methoxamine,COC1=CC(C(O)C(C)N)=C(OC)C=C1,Alpha-1A adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Adrenergic receptor alpha-2,COc1ccc(OC)c(C(O)C(C)N)c1
Methoxsalen,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Acetylcholinesterase;Cytochrome P450 1A2;Amine oxidase [flavin-containing] A;Polyphenol oxidase 2,COc1c2occc2cc2ccc(=O)oc12
Methoxyflurane,COC(F)(F)C(Cl)Cl,Glycine receptor subunit alpha-1;GABA-A receptor; anion channel,COC(F)(F)C(Cl)Cl
Methoxyphenamine,CNC(C)CC1=CC=CC=C1OC,Alpha-1A adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Adrenergic receptor alpha-2,CNC(C)Cc1ccccc1OC
Methscopolamine,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Methscopolamine bromide,[Br-].[H][C@@]12O[C@]1([H])[C@H]1C[C@H](C[C@@H]2[N+]1(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]
Methsuximide,CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1,Voltage-dependent T-type calcium channel subunit alpha-1G,CN1C(=O)CC(C)(c2ccccc2)C1=O
Methyl aminolevulinate,COC(=O)CCC(=O)CN,,COC(=O)CCC(=O)CN
Methyl nicotinate,COC(=O)C1=CN=CC=C1,,COC(=O)c1cccnc1
Methyl salicylate,COC(=O)C1=CC=CC=C1O,,COC(=O)c1ccccc1O
Methylchloroisothiazolinone,CN1SC(Cl)=CC1=O,,Cn1sc(Cl)cc1=O
Methyldopa,C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O,Alpha-2A adrenergic receptor;Aromatic-L-amino-acid decarboxylase;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Arachidonate 15-lipoxygenase;Lysine-specific demethylase 4E,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
Methylene blue,[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1,,CN(C)c1ccc2nc3ccc(N(C)C)cc3[s+]c2c1.[Cl-]
Methylergometrine,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Cytochrome P450 2D6;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;5-hydroxytryptamine receptor 1B,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Methylnaltrexone,C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35,Mu-type opioid receptor;Cytochrome P450 2D6;Kappa-type opioid receptor;Delta-type opioid receptor,C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Methylparaben,COC(=O)C1=CC=C(O)C=C1,Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 7;Carbonic anhydrase 14,COC(=O)c1ccc(O)cc1
Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter,COC(=O)C(c1ccccc1)C1CCCCN1
Methylphenobarbital,CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1,GABA-A receptor alpha-1/beta-3/gamma-2,CCC1(c2ccccc2)C(=O)NC(=O)N(C)C1=O
Methylprednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Annexin A1;Androgen receptor;Short transient receptor potential channel 5,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Methylprednisolone aceponate,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Methylprednisolone hemisuccinate,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12
Methylprednisone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Glucocorticoid receptor;Annexin A1;Androgen receptor;Short transient receptor potential channel 5,C[C@H]1C[C@@H]2[C@H](C(=O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
Methyltestosterone,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Glucocorticoid receptor;Androgen receptor;Sex hormone-binding globulin;Progesterone receptor,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Methyprylon,CCC1(CC)C(=O)NCC(C)C1=O,GABA-A receptor alpha-1/beta-3/gamma-2,CCC1(CC)C(=O)NCC(C)C1=O
Methysergide,[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Induced myeloid leukemia cell differentiation protein Mcl-1;Bcl-2-like protein 1;5-hydroxytryptamine receptor 2A;Zinc finger protein mex-5;Serotonin 2 (5-HT2) receptor;Cytoplasmic zinc-finger protein;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C,CCC(CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
Meticillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O,Beta-lactam-inducible penicillin-binding protein;NH(3)-dependent NAD(+) synthetase;Penicillin-binding protein,COc1cccc(OC)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Meticrane,CC1=CC2=C(C=C1S(N)(=O)=O)S(=O)(=O)CCC2,Sodium channel protein type 5 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 4 subunit alpha;Potassium channel subfamily K member 3,Cc1cc2c(cc1S(N)(=O)=O)S(=O)(=O)CCC2
Metipranolol,CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C
Metixene,CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1,5-hydroxytryptamine receptor 2C;Muscarinic acetylcholine receptor M1;Cholinesterase,CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1
Metoclopramide,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,5-hydroxytryptamine receptor 4;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Aldehyde oxidase;Cytochrome P450 2D6;5-hydroxytryptamine receptor 3A;Myeloperoxidase;Solute carrier family 22 member 1;Serotonin 3 (5-HT3) receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Serotonin 2 (5-HT2) receptor;Serotonin 3 receptor (5HT3),CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
Metocurine,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,Muscarinic acetylcholine receptor M2;5-hydroxytryptamine receptor 3A;Neuronal acetylcholine receptor subunit alpha-7;Small conductance calcium-activated potassium channel protein 3;Small conductance calcium-activated potassium channel protein 2;Zinc-activated ligand-gated ion channel;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Acetylcholine receptor subunit alpha;Nicotinic acetylcholine receptor alpha 5 subunit;Neuronal acetylcholine receptor; alpha4/beta2;Acetylcholine receptor;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta4;Acetylcholine receptor; alpha1/beta1/delta/gamma;Serotonin 3 receptor (5HT3);Small conductance calcium-activated potassium channel protein 1;GABA-A receptor; anion channel,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3
Metocurine iodide,[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3.[I-].[I-]
Metolazone,CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O,Solute carrier family 12 member 1;Solute carrier family 12 member 3;Carbonic anhydrase 7,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
Metoprolol,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A;Adrenergic receptor beta,COCCc1ccc(OCC(O)CNC(C)C)cc1
Metrizoic acid,CN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I
Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,Thioredoxin reductase,Cc1ncc([N+](=O)[O-])n1CCO
Metyrapone,CC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1,"Cytochrome P450 3A4;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 11B1;Cytochrome P450 11B1, mitochondrial",CC(C)(C(=O)c1cccnc1)c1cccnc1
Metyrosine,C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O,Large neutral amino acids transporter small subunit 1,C[C@](N)(Cc1ccc(O)cc1)C(=O)O
Mexiletine,CC(N)COC1=C(C)C=CC=C1C,Sodium channel protein type 5 subunit alpha;Sodium channel subunit beta-1;Sodium channel subunit beta-2;Sodium channel subunit beta-3;Sodium channel subunit beta-4;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2B;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 9 subunit alpha;Sodium channel protein type 10 subunit alpha;Potassium channel subfamily K member 3;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Solute carrier family 22 member 2;Sodium channel protein type X alpha subunit,Cc1cccc(C)c1OCC(C)N
Mezlocillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O,"Prostaglandin G/H synthase 2;Cannabinoid receptor 1;Prostaglandin G/H synthase 1;Cytochrome P450 3A4;Penicillin-binding protein 1A;Prostaglandin E2 receptor EP1 subtype;Adenosine receptor A3;Carbonic anhydrase 2;Multidrug resistance-associated protein 1;Cytochrome P450 2C8;Prostaglandin D2 receptor 2;Cytochrome P450 2C9;Aldose reductase;Prostaglandin E2 receptor EP3 subtype;Aldo-keto reductase family 1 member C3;Arachidonate 5-lipoxygenase;Peroxisome proliferator-activated receptor gamma;Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Cannabinoid receptor 2;Thromboxane-A synthase;Serum albumin;Interleukin-8;Interleukin-1 receptor type 1;Prostaglandin-H2 D-isomerase;Bacterial penicillin-binding protein",CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
Mianserin,CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1F;Transporter;Serotonin 3 (5-HT3) receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Sodium channel alpha subunits; brain (Types I, II, III);Cerebral cortex alpha adrenergic receptor;Serotonin 2 (5-HT2) receptor;Serotonin 3 receptor (5HT3);G-protein coupled receptor",CN1CCN2c3ccccc3Cc3ccccc3C2C1
Micafungin,CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O,"Beta-1,3-glucan synthase;Beta-1,3-glucan synthase catalytic subunit 1",CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1
Miconazole,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,"Sodium/potassium-transporting ATPase subunit alpha-2;Beta-1 adrenergic receptor;Prostaglandin G/H synthase 2;Cannabinoid receptor 1;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A1;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Lanosterol 14-alpha demethylase;Delta-type opioid receptor;Beta-lactamase;Acetylcholinesterase;Cytochrome P450 2C9;Aromatase;Epidermal growth factor receptor;Substance-P receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 2C19;Alkaline phosphatase, tissue-nonspecific isozyme;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Thromboxane-A synthase;Indoleamine 2,3-dioxygenase 1;Type-2 angiotensin II receptor;Substance-K receptor;Androgen receptor;5-hydroxytryptamine receptor 1B;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3;Membrane-associated progesterone receptor component 1;Progesterone receptor;Cholinesterase;Indoleamine 2,3-dioxygenase 2;Mycocyclosin synthase;Malate dehydrogenase cytoplasmic ;Calcium release-activated calcium channel protein 1;Fatty acid hydroperoxide lyase, chloroplastic;7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
Micronomicin,CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,,CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H](N)C[C@@H]2N)O1
Midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,Cytochrome P450 3A4;Multidrug resistance protein 1;Translocator protein;Thyrotropin-releasing hormone receptor;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-3;GABA-A receptor; anion channel;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-3/beta-2/gamma-3;GABA A receptor alpha-5/beta-3/gamma-3;GABA A receptor alpha-5/beta-2/gamma-2;GABA A receptor alpha-5/beta-2/gamma-3,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Midodrine,COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1,Alpha-1A adrenergic receptor;Heat shock protein HSP 90-alpha,COc1ccc(OC)c(C(O)CNC(=O)CN)c1
Midostaurin,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1,"Tyrosine-protein kinase JAK3;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Ribosomal protein S6 kinase alpha-3;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Serine/threonine-protein kinase pim-1;Myosin light chain kinase, smooth muscle;Death-associated protein kinase 3;Calcium/calmodulin-dependent protein kinase type 1;Mitogen-activated protein kinase 8;Fibroblast growth factor receptor 3;Rho-associated protein kinase 1;Tyrosine-protein kinase HCK;Tyrosine-protein kinase JAK1;Receptor tyrosine-protein kinase erbB-4;Mitogen-activated protein kinase 10;Death-associated protein kinase 2;High affinity nerve growth factor receptor;Protein kinase C delta type;cAMP-dependent protein kinase catalytic subunit beta;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Protein kinase C alpha type;Tyrosine-protein kinase SYK;Calcium/calmodulin-dependent protein kinase type II subunit delta;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Calcium/calmodulin-dependent protein kinase type II subunit gamma;AP2-associated protein kinase 1;Serine/threonine-protein kinase MARK2;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Ribosomal protein S6 kinase alpha-2;5'-AMP-activated protein kinase catalytic subunit alpha-1;Calcium/calmodulin-dependent protein kinase type II subunit beta;Protein kinase C eta type;Fibroblast growth factor receptor 1;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Protein kinase C epsilon type;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase N1;Protein kinase C theta type;Serine/threonine-protein kinase 17A;TRAF2 and NCK-interacting protein kinase;Tyrosine-protein kinase Fgr;Aurora kinase A;ALK tyrosine kinase receptor;RAC-alpha serine/threonine-protein kinase;BMP-2-inducible protein kinase;Serine/threonine-protein kinase pim-2;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Dual specificity protein kinase CLK2;Dual specificity protein kinase CLK3;Mitogen-activated protein kinase kinase kinase kinase 5;Cyclin-G-associated kinase;Glycogen synthase kinase-3 beta;Calcium/calmodulin-dependent protein kinase type 1D;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;Ribosomal protein S6 kinase alpha-5;STE20-like serine/threonine-protein kinase;Dual specificity protein kinase CLK4;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Calcium/calmodulin-dependent protein kinase kinase 2;MAP/microtubule affinity-regulating kinase 3;Calcium/calmodulin-dependent protein kinase kinase 1;Calcium/calmodulin-dependent protein kinase type 1G;Epithelial discoidin domain-containing receptor 1;Testis-specific serine/threonine-protein kinase 1;Inhibitor of nuclear factor kappa-B kinase subunit beta;3-phosphoinositide-dependent protein kinase 1;Tyrosine-protein kinase ZAP-70;Glycogen synthase kinase-3 alpha;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Tyrosine-protein kinase receptor TYRO3;Ribosomal protein S6 kinase beta-1;Serine/threonine-protein kinase N2;RAC-beta serine/threonine-protein kinase;Serine/threonine-protein kinase 3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Serine/threonine-protein kinase Chk1;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Serine/threonine-protein kinase PAK 3;Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha;Phosphatidylinositol 5-phosphate 4-kinase type-2 beta;Myosin light chain kinase family member 4;Wee1-like protein kinase;Serine/threonine-protein kinase 25;Protein-tyrosine kinase 2-beta;Serine/threonine-protein kinase RIO1;Tyrosine-protein kinase receptor Tie-1;NT-3 growth factor receptor;Casein kinase II subunit alpha;Dual specificity tyrosine-phosphorylation-regulated kinase 1B;Inhibitor of nuclear factor kappa-B kinase subunit epsilon;Serine/threonine-protein kinase STK11;Dual specificity mitogen-activated protein kinase kinase 3;Maternal embryonic leucine zipper kinase;Eukaryotic translation initiation factor 2-alpha kinase 4;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase RIO3;Serine/threonine-protein kinase SIK2;SRSF protein kinase 1;SRSF protein kinase 2;Serine/threonine-protein kinase 33;5'-AMP-activated protein kinase catalytic subunit alpha-2;Myotonin-protein kinase;RAC-gamma serine/threonine-protein kinase;Serine/threonine-protein kinase LATS1;Serine/threonine-protein kinase LATS2;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;NUAK family SNF1-like kinase 1;Serine/threonine-protein kinase pim-3;cAMP-dependent protein kinase catalytic subunit alpha;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Serine/threonine-protein kinase BRSK1;Mitogen-activated protein kinase kinase kinase kinase 4;Serine/threonine-protein kinase MARK1;MAP/microtubule affinity-regulating kinase 4;Dual specificity mitogen-activated protein kinase kinase 4;Dual specificity mitogen-activated protein kinase kinase 6;Tyrosine-protein kinase Mer;Cyclin-dependent kinase 19;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 10;Mitogen-activated protein kinase kinase kinase 11;Death-associated protein kinase 1;Serine/threonine-protein kinase PAK 1;Serine/threonine-protein kinase PAK 2;Serine/threonine-protein kinase BRSK2;Serine/threonine-protein kinase SIK1;Tubulin alpha-1A chain;Serine/threonine-protein kinase D2;Serine/threonine-protein kinase D3;cGMP-dependent protein kinase 2;Interferon-induced, double-stranded RNA-activated protein kinase;Proto-oncogene tyrosine-protein kinase ROS;Ribosomal protein S6 kinase alpha-1;Ribosomal protein S6 kinase alpha-4;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Dual specificity tyrosine-phosphorylation-regulated kinase 1A;Ephrin type-B receptor 6;Serine/threonine-protein kinase/endoribonuclease IRE1;Rhodopsin kinase;G protein-coupled receptor kinase 4;G protein-coupled receptor kinase 7;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Homeodomain-interacting protein kinase 4;Hormonally up-regulated neu tumor-associated kinase;Serine/threonine-protein kinase ICK;Inhibitor of nuclear factor kappa-B kinase subunit alpha;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Microtubule-associated serine/threonine-protein kinase 1;U4/U6 small nuclear ribonucleoprotein Prp4;Serine/threonine-protein kinase RIO2;SRSF protein kinase 3;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Tankyrase-2;Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta;Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma;Serine/threonine-protein kinase SIK3;Serine/threonine-protein kinase 32A;Serine/threonine-protein kinase PRP4 homolog;Serine/threonine-protein kinase Sgk3;Myosin light chain kinase 3;Leucine-rich repeat serine/threonine-protein kinase 2;Dual serine/threonine and tyrosine protein kinase;Calcium-dependent protein kinase 1;cGMP-dependent protein kinase 1;cAMP-dependent protein kinase catalytic subunit PRKX;Receptor-type tyrosine-protein kinase FLT3",CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Mifamurtide,O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC,Nucleotide-binding oligomerization domain-containing protein 2,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](C=O)NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+]
Mifepristone,[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H],Mu-type opioid receptor;Sigma non-opioid intracellular receptor 1;Cytochrome P450 3A4;Alpha-2B adrenergic receptor;Glucocorticoid receptor;Nuclear receptor subfamily 1 group I member 2;Kappa-type opioid receptor;Mineralocorticoid receptor;Estrogen receptor;Androgen receptor;Progesterone receptor;Estrogen receptor beta;Tyrosine-protein kinase Fyn;Mitogen-activated protein kinase 14;Arachidonate 15-lipoxygenase;P-glycoprotein 3,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Migalastat,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,"Maltase-glucoamylase, intestinal;Lysosomal alpha-glucosidase;Non-lysosomal glucosylceramidase;Sucrase-isomaltase, intestinal;Glycogen debranching enzyme;Lactase-phlorizin hydrolase;Beta-galactosidase;Alpha-galactosidase C;Alpha-galactosidase;Alpha-galactosidase A",OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
Miglitol,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,"Maltase-glucoamylase, intestinal;Pancreatic alpha-amylase;Glucosylceramidase;Lysosomal alpha-glucosidase;Sucrase-isomaltase, intestinal;Glycogen debranching enzyme;Lactase-phlorizin hydrolase;Beta-galactosidase;Alpha-mannosidase;Alpha-glucosidase",OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
Miglustat,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,"Maltase-glucoamylase, intestinal;Ceramide glucosyltransferase;Lysosomal alpha-glucosidase;Sucrase-isomaltase, intestinal;Non-lysosomal glucosylceramidase;Glycogen debranching enzyme;Sucrase-isomaltase;Putative alpha-glucosidase;Trehalase;Uncharacterized protein",CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
Milnacipran,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1,"Glutamate receptor ionotropic, NMDA 2A;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Transporter",CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Milrinone,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1,"cGMP-inhibited 3',5'-cyclic phosphodiesterase A;cGMP-specific 3',5'-cyclic phosphodiesterase;cGMP-inhibited 3',5'-cyclic phosphodiesterase B;Cyclic nucleotide phosphodiesterase PDE3A;Cyclic AMP-specific phosphodiesterase SSPDE4A1A;Uncharacterized protein;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Phosphodiesterase 3;Phosphodiesterase 4",Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
Miltefosine,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,RAC-alpha serine/threonine-protein kinase;Dual specificity phosphatase Cdc25A,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
Minaprine,CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Acetylcholinesterase,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1
Minocycline,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,"Tetracycline resistance protein, class B;30S ribosomal protein S4;30S ribosomal protein S9",CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Minoxidil,NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1,"ATP-sensitive inward rectifier potassium channel 1;Sulfonylurea receptor 2, Kir6.2",Nc1cc(N2CCCCC2)nc(N)[n+]1[O-]
Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,Beta-3 adrenergic receptor,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1
Mirtazapine,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Alpha-2C adrenergic receptor;5-hydroxytryptamine receptor 3A;Transporter;Adrenergic receptor alpha-1,CN1CCN2c3ncccc3Cc3ccccc3C2C1
Misoprostol,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,Prostaglandin E2 receptor EP3 subtype;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin F2-alpha receptor,CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Mitapivat,O=C(N1CCN(CC2CC2)CC1)C1=CC=C(NS(=O)(=O)C2=CC=CC3=C2N=CC=C3)C=C1,,O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1
Mitomycin,[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O,"Indoleamine 2,3-dioxygenase 1",CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
Mitotane,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl,"Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 6;Sodium-dependent dopamine transporter;Adenosine receptor A3;Cytochrome P450 11B1, mitochondrial;Adrenodoxin, mitochondrial;Cholesterol side-chain cleavage enzyme, mitochondrial",Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
Mitoxantrone,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2C;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M4;Canalicular multispecific organic anion transporter 1;DNA topoisomerase 2-alpha;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Serine/threonine-protein kinase pim-1;Solute carrier family 22 member 1;DNA-(apurinic or apyrimidinic site) lyase;Arachidonate 15-lipoxygenase;Integrase;Tyrosine-protein kinase BTK;Proto-oncogene tyrosine-protein kinase ROS;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;DNA-3-methyladenine glycosylase;Dual specificity tyrosine-phosphorylation-regulated kinase 1A,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
Mivacurium,COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,Neuronal acetylcholine receptor subunit alpha-2;Acetylcholine receptor,COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2
Mizolastine,CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1,Potassium voltage-gated channel subfamily H member 2;Arachidonate 5-lipoxygenase;Histamine H1 receptor,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
Mobocertinib,COC1=C(NC2=NC=C(C(=O)OC(C)C)C(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,Tyrosine-protein kinase JAK3;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Platelet-derived growth factor receptor alpha;Cyclin-dependent kinase 2;Fibroblast growth factor receptor 3;Tyrosine-protein kinase JAK1;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Tyrosine-protein kinase SYK;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Fibroblast growth factor receptor 2;Tyrosine-protein kinase Fgr;MAP kinase-interacting serine/threonine-protein kinase 2;Tyrosine-protein kinase ZAP-70;Tyrosine-protein kinase BTK;BDNF/NT-3 growth factors receptor;Fibroblast growth factor receptor 4;Proto-oncogene tyrosine-protein kinase ROS;Cyclin-dependent kinase 4;Transcription factor ETV6;Insulin-like growth factor 1 receptor;Insulin receptor;Testis-specific serine/threonine-protein kinase 1;ALK tyrosine kinase receptor,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
Moclobemide,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1,Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
Modafinil,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,D(2) dopamine receptor;Sodium-dependent dopamine transporter;Alpha-1B adrenergic receptor;Cytochrome P450 1A2;Cytochrome P450 2C19;Transporter,NC(=O)CS(=O)C(c1ccccc1)c1ccccc1
Moexipril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O
Molindone,CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2,D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M3;Alpha-2C adrenergic receptor;D(4) dopamine receptor;D(1A) dopamine receptor,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2
Molsidomine,CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1,Estrogen receptor,CCOC(=O)[N-]c1c[n+](N2CCOCC2)no1
Molybdenum,[Mo],,[Mo]
Mometasone furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Mineralocorticoid receptor;Progesterone receptor;Androgen receptor,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl
Monobenzone,OC1=CC=C(OCC2=CC=CC=C2)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Sodium-dependent noradrenaline transporter;Tyrosinase;Arachidonate 15-lipoxygenase,Oc1ccc(OCc2ccccc2)cc1
Monomethyl fumarate,COC(=O)\C=C\C(O)=O,Hydroxycarboxylic acid receptor 2;Kelch-like ECH-associated protein 1,COC(=O)/C=C/C(=O)O
Monopotassium phosphate,[K+].OP(O)([O-])=O,DNA topoisomerase 2-alpha,O=P([O-])(O)O.[K+]
Montelukast,OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1,Beta-2 adrenergic receptor;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Cytochrome P450 2C8;Delta-type opioid receptor;Cysteinyl leukotriene receptor 1;Arachidonate 5-lipoxygenase;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Cysteinyl leukotriene receptor 2;Mitogen-activated protein kinase 14;Substance-K receptor;Uracil nucleotide/cysteinyl leukotriene receptor,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
Moricizine,CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1,Sodium channel protein type 5 subunit alpha,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2
Morphine,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,"Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Solute carrier family 22 member 1;Nociceptin receptor;Opioid receptor;Dopamine receptor;Mu opioid receptor-like OR2;Opioid receptor, delta 1b;Opioid receptor homologue",CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
Morpholinylmercaptobenzothiazole,C1CN(CCO1)SC1=NC2=CC=CC=C2S1,,c1ccc2sc(SN3CCOCC3)nc2c1
Moxidectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O,Glutamate-gated chloride channel,CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C
Moxifloxacin,[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O,DNA topoisomerase 4 subunit A;DNA gyrase subunit A;Topoisomerase IV;DNA gyrase,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
Moxisylyte,CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1,,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C
Moxonidine,COC1=NC(C)=NC(Cl)=C1NC1=NCCN1,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;Alpha-2C adrenergic receptor;Alpha-2B adrenergic receptor;Nischarin,COc1nc(C)nc(Cl)c1NC1=NCCN1
Mupirocin,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O,"Isoleucine--tRNA ligase;Isoleucine--tRNA ligase, cytoplasmic",C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O
Muzolimine,CC(N1N=C(N)CC1=O)C1=CC(Cl)=C(Cl)C=C1,,CC(c1ccc(Cl)c(Cl)c1)N1N=C(N)CC1=O
Mycophenolate mofetil,COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2
Mycophenolic acid,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C,,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
N-Acetylglucosamine,[H]C(=O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O)CO,Killer cell lectin-like receptor subfamily B member 1A,CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO
"N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine",C1CCC(CC1)NC1=CC=C(NC2=CC=CC=C2)C=C1,,c1ccc(Nc2ccc(NC3CCCCC3)cc2)cc1
N-acetyltyrosine,CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,"Cytochrome c;Vascular endothelial growth factor A;Superoxide dismutase [Mn], mitochondrial;Glutathione synthetase;Cystine/glutamate transporter",CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O
NADH,NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O,,NC(=O)C1=CN([C@@H]2O[C@H](CO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1
Nabilone,[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC,Cannabinoid receptor 1;Cannabinoid receptor 2,CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21
Nabumetone,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Sodium-dependent noradrenaline transporter;Cytochrome P450 1A2;Amine oxidase [flavin-containing] A,COc1ccc2cc(CCC(C)=O)ccc2c1
Nadolol,CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
Nafarelin,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,Gonadotropin-releasing hormone receptor,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Nafcillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O,Penicillin-binding protein 1A;Penicillin-binding protein,CCOc1ccc2ccccc2c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Naftazone,NC(=O)N\N=C1/C=CC2=CC=CC=C2C1=O,Histamine H1 receptor,NC(=O)N/N=C1\C=Cc2ccccc2C1=O
Naftifine,CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12,"Sigma non-opioid intracellular receptor 1;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Squalene monooxygenase;Squalene epoxidase;C-8 sterol isomerase;Dehydrosqualene desaturase",CN(CC=Cc1ccccc1)Cc1cccc2ccccc12
Nalbuphine,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
Naldemedine,[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O,Delta-type opioid receptor;Mu-type opioid receptor,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1
Nalidixic acid,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,,CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21
Nalmefene,OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1=C24)C(=C)CC[C@@]35O,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Naloxegol,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5,Mu-type opioid receptor,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5
Naloxone,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,Mu-type opioid receptor;Cytochrome P450 2D6;Adenosine receptor A3;Kappa-type opioid receptor;Delta-type opioid receptor;C-C chemokine receptor type 5;Opioid receptor,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Naltrexone,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O,Mu-type opioid receptor;Cytochrome P450 2D6;Kappa-type opioid receptor;Delta-type opioid receptor;Neuronal acetylcholine receptor subunit alpha-7;Neuronal acetylcholine receptor subunit alpha-4;Opioid receptor;Opioid receptors; mu and delta,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Nandrolone decanoate,[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],Estrogen receptor;Androgen receptor,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
Nandrolone phenpropionate,[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],Estrogen receptor;Androgen receptor,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1
Naphazoline,C(C1=NCCN1)C1=CC=CC2=CC=CC=C12,Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Nischarin;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Adrenergic receptor alpha,c1ccc2c(CC3=NCCN3)cccc2c1
Naproxen,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Aldo-keto reductase family 1 member C2;Aldo-keto reductase family 1 member C3;Prostaglandin-H2 D-isomerase;Hormone-sensitive lipase;Cyclooxygenase,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Naratriptan,CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1
Natamycin,[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B);3-oxoacyl-[acyl-carrier-protein] synthase 3;Gap junction beta-2 protein",C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
Nateglinide,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O,"Solute carrier family 22 member 6;Sulfonylurea receptor 1, Kir6.2;Sulfonylurea receptor 2, Kir6.2",CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
Nebivolol,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A;Beta-3 adrenergic receptor,OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1
Nedaplatin,[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H],,[NH3]->[Pt]1(<-[NH3])[O]CC(=O)[O]1
Nedocromil,CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O,Cysteinyl leukotriene receptor 1;G-protein coupled receptor 35,CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12
Nefazodone,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,D(2) dopamine receptor;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Histamine H1 receptor;Sodium-dependent dopamine transporter;Acetylcholinesterase;Bile salt export pump;Transporter,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
Nefopam,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1,Sodium channel protein type 5 subunit alpha;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Sodium-dependent dopamine transporter,CN1CCOC(c2ccccc2)c2ccccc2C1
Nelarabine,COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"DNA polymerase alpha catalytic subunit;Ribonucleoside-diphosphate reductase large subunit;Ribonucleoside-diphosphate reductase subunit M2;Ribose-phosphate pyrophosphokinase 1;Uridine-cytidine kinase 1;Uridine-cytidine kinase 2;cGMP-dependent 3',5'-cyclic phosphodiesterase",COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Nelfinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,Mu-type opioid receptor;D(1A) dopamine receptor;Cytochrome P450 3A4;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;Muscarinic acetylcholine receptor M5;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A3;Kappa-type opioid receptor;Delta-type opioid receptor;Epidermal growth factor receptor;Gag-Pol polyprotein;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Mitogen-activated protein kinase 3;Mitogen-activated protein kinase 14;Substance-K receptor;Androgen receptor;Arachidonate 15-lipoxygenase;Progesterone receptor;Pol polyprotein;Protease,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
Neon,[Ne],,[Ne]
Neostigmine,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C,Acetylcholinesterase;Cholinesterase,CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
Nepafenac,NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cyclooxygenase,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Neratinib,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N,Tyrosine-protein kinase JAK3;Macrophage-stimulating protein receptor;Tyrosine-protein kinase ABL1;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 2;Macrophage colony-stimulating factor 1 receptor;Insulin receptor;Mitogen-activated protein kinase 8;Focal adhesion kinase 1;Tyrosine-protein kinase HCK;Mitogen-activated protein kinase 10;Tyrosine-protein kinase SYK;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Serine/threonine-protein kinase Nek2;Ribosomal protein S6 kinase alpha-2;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Serine/threonine-protein kinase 17A;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;Serine/threonine-protein kinase 36;Mitogen-activated protein kinase kinase kinase kinase 5;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Calcium/calmodulin-dependent protein kinase type 1D;Cyclin-dependent kinase 16;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;STE20-like serine/threonine-protein kinase;Dual specificity mitogen-activated protein kinase kinase 7;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase BTK;Tyrosine-protein kinase receptor UFO;Cyclin-dependent kinase 7;Serine/threonine-protein kinase D1;Serine/threonine-protein kinase 3;NUAK family SNF1-like kinase 2;Serine/threonine-protein kinase Chk1;Wee1-like protein kinase;Serine/threonine-protein kinase 25;Mitogen-activated protein kinase kinase kinase MLT;Protein-tyrosine kinase 2-beta;Casein kinase I isoform gamma-2;Casein kinase I isoform gamma-3;Tyrosine-protein kinase receptor Tie-1;Tyrosine-protein kinase TXK;Maternal embryonic leucine zipper kinase;Serine/threonine-protein kinase 26;Eukaryotic translation initiation factor 2-alpha kinase 4;Insulin receptor-related protein;Serine/threonine-protein kinase SIK2;Serine/threonine-protein kinase 33;Mitogen-activated protein kinase kinase kinase kinase 1;Serine/threonine-protein kinase PAK 6;NUAK family SNF1-like kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Tyrosine-protein kinase Blk;Mitogen-activated protein kinase kinase kinase kinase 4;Tyrosine-protein kinase Mer;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 10;Mitogen-activated protein kinase kinase kinase 11;Serine/threonine-protein kinase 24;Serine/threonine-protein kinase PAK 1;Serine/threonine-protein kinase PAK 2;Serine/threonine-protein kinase SIK1;Serine/threonine-protein kinase D2;Serine/threonine-protein kinase D3;Tyrosine-protein kinase Fes/Fps;Ribosomal protein S6 kinase alpha-1;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase Chk2;Ephrin type-B receptor 6;Homeodomain-interacting protein kinase 4;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Microtubule-associated serine/threonine-protein kinase 1;Serine/threonine-protein kinase TAO3;Mitogen-activated protein kinase kinase kinase 19;Serine/threonine-protein kinase 35;Receptor tyrosine-protein kinase erbB-3;Wee1-like protein kinase 2;Serine/threonine-protein kinase Nek3;Mitogen-activated protein kinase kinase kinase 12;Dual specificity mitogen-activated protein kinase kinase 5;Dual serine/threonine and tyrosine protein kinase;Serine/threonine-protein kinase 32B;Receptor tyrosine-protein kinase erbB-4;Epidermal growth factor receptor;Receptor tyrosine-protein kinase erbB-2,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C
Netarsudil,CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1,Rho-associated protein kinase 1;Rho-associated protein kinase 2,Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1
Netilmicin,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,Dihydrofolate reductase;Transient receptor potential cation channel subfamily A member 1,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
Netupitant,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1,Substance-P receptor,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Nevirapine,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,Gag-Pol polyprotein;Pol polyprotein;Reverse transcriptase/RNaseH;Reverse transcriptase;Reverse transcriptase protein,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1
Niacin,OC(=O)C1=CN=CC=C1,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",O=C(O)c1cccnc1
Niacinamide ascorbate,NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O,,NC(=O)c1cccnc1.O=C1O[C@H](C(O)CO)C(O)=C1O
Nialamide,O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1,Androgen receptor;Cytochrome P450 2C19;Progesterone receptor,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1
Nicardipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1,Cytochrome P450 3A4;Multidrug resistance protein 1;Adenosine receptor A3;Nuclear receptor subfamily 1 group I member 2;ATP-binding cassette sub-family G member 2;Beta-lactamase;Cytochrome P450 2C9;Voltage-dependent T-type calcium channel subunit alpha-1H;Adenosine receptor A1;Adenosine receptor A2a;Equilibrative nucleoside transporter 1;Quinolone resistance protein NorA;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Voltage-gated L-type calcium channel;Malate dehydrogenase cytoplasmic ;Potassium voltage-gated channel subfamily A member 4,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
Nicergoline,[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13
Nickel sulfate,[Ni++].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[Ni+2]
Niclosamide,OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O,Cytochrome P450 2C9;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Vascular endothelial growth factor receptor 2;Tyrosine-protein kinase JAK2;Angiopoietin-1 receptor;Tyrosine-protein kinase Lyn;Fibroblast growth factor receptor 1;Aurora kinase A;RAC-alpha serine/threonine-protein kinase;Glycogen synthase kinase-3 beta;3-phosphoinositide-dependent protein kinase 1;Potassium channel subfamily T member 1;Signal transducer and activator of transcription 3;Replicase polyprotein 1ab,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O
Nicoboxil,CCCCOCCOC(=O)C1=CN=CC=C1,,CCCCOCCOC(=O)c1cccnc1
Nicorandil,[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1,ATP-sensitive inward rectifier potassium channel 11;ATP-sensitive inward rectifier potassium channel 1;Atrial natriuretic peptide receptor 1,O=C(NCCO[N+](=O)[O-])c1cccnc1
Nicotinamide,NC(=O)C1=CC=CN=C1,"Hydroxycarboxylic acid receptor 2;Hydroxycarboxylic acid receptor 3;Nicotinamide N-methyltransferase;Nicotinate-nucleotide pyrophosphorylase [carboxylating];NAD-dependent protein deacetylase sirtuin-1;NAD-dependent protein deacetylase sirtuin-2;Fatty-acid amide hydrolase 1;NAD-dependent deacetylase HST2;NAD-dependent deacetylase sirtuin 3;NAD-dependent protein deacylase sirtuin-5, mitochondrial;Putative silent information regulator 2;Sterile alpha and TIR motif-containing protein 1",NC(=O)c1cccnc1
Nicotine,CN1CCC[C@H]1C1=CN=CC=C1,Neuronal acetylcholine receptor subunit alpha-7;Potassium voltage-gated channel subfamily D member 3;Cytochrome P450 2A6;Acetylcholine-binding protein;Transient receptor potential cation channel subfamily A member 1;Acetylcholine receptor subunit delta;Neuronal acetylcholine receptor subunit alpha-4;Neuronal acetylcholine receptor subunit alpha-9;Neuronal acetylcholine receptor subunit beta-4;Neuronal acetylcholine receptor subunit alpha-3;Neuronal acetylcholine receptor subunit alpha-2;Soluble acetylcholine receptor;Acetylcholine receptor subunit alpha;Lycopene cyclase;Nicotinic acetylcholine receptor alpha 5 subunit;Acetylcholine receptor subunit beta-like 2;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Neuronal acetylcholine receptor; alpha2/beta4;Neuronal acetylcholine receptor;Serotonin 3 (5-HT3) receptor;Acetylcholine receptor; alpha1/beta1/delta/gamma;Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3;Acetylcholine receptor;Muscarinic acetylcholine receptor,CN1CCC[C@H]1c1cccnc1
Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,"Sodium/nucleoside cotransporter 1;Adenosine receptor A2a;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Adenosine receptor A1;Adenosine receptor A3;Glutathione reductase, mitochondrial;Transthyretin;Glycine receptor subunit alpha-1;Voltage-dependent L-type calcium channel subunit alpha-1D;Bile salt export pump;Voltage-dependent T-type calcium channel subunit alpha-1H;Cytochrome P450 1A2;Potassium voltage-gated channel subfamily A member 1;Voltage-dependent L-type calcium channel subunit alpha-1S;Potassium voltage-gated channel subfamily A member 5;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Glycine receptor subunit beta;Potassium voltage-gated channel subfamily A member 2;Myosin light chain kinase, smooth muscle;Thromboxane-A synthase;C-C chemokine receptor type 2;Voltage-dependent L-type calcium channel subunit alpha-1F;Glycine receptor subunit alpha-3;Arachidonate 15-lipoxygenase;Acetylcholinesterase;Voltage-dependent L-type calcium channel subunit alpha-1C;Cholinesterase;Indoleamine 2,3-dioxygenase 2;Sodium channel alpha subunits; brain (Types I, II, III);Voltage-gated L-type calcium channel;Indoleamine 2,3-dioxygenase 1;Potassium voltage-gated channel subfamily A member 7;Potassium channel subfamily K member 2",COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
Nifurtimox,CC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)[N+]([O-])=O,Macrophage migration inhibitory factor,CC1CS(=O)(=O)CCN1/N=C/c1ccc([N+](=O)[O-])o1
Nilotinib,CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Ribosyldihydronicotinamide dehydrogenase [quinone];Carbonic anhydrase 9;Carbonic anhydrase 12;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Insulin receptor;Mitogen-activated protein kinase 8;Tyrosine-protein kinase HCK;Carbonic anhydrase 3;Carbonic anhydrase 6;Mitogen-activated protein kinase 10;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Ephrin type-A receptor 8;Tyrosine-protein kinase Lyn;Cytoplasmic tyrosine-protein kinase BMX;Carbonic anhydrase 14;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase 10;Abelson tyrosine-protein kinase 2;Mitogen-activated protein kinase 11;Ephrin type-A receptor 5;Ephrin type-A receptor 4;Fibroblast growth factor receptor 2;Ephrin type-A receptor 6;Tyrosine-protein kinase Fgr;Ephrin type-A receptor 3;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Ephrin type-B receptor 1;Dual specificity protein kinase CLK4;Mitogen-activated protein kinase 9;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Carbonic anhydrase 13;Carbonic anhydrase 15;BDNF/NT-3 growth factors receptor;Ephrin type-B receptor 2;Mitogen-activated protein kinase kinase kinase MLT;Tyrosine-protein kinase receptor Tie-1;NT-3 growth factor receptor;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Mitogen-activated protein kinase kinase kinase kinase 1;Tyrosine-protein kinase Blk;Serine/threonine-protein kinase MRCK beta;Ephrin type-A receptor 1;Ephrin type-B receptor 3;Ephrin type-B receptor 6;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Dual specificity mitogen-activated protein kinase kinase 5;Calcium-dependent protein kinase 1;Bcr/Abl fusion protein",Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Nilutamide,CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,Androgen receptor,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O
Nilvadipine,COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N,Voltage-dependent calcium channel gamma-1 subunit;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1D;Voltage-gated L-type calcium channel,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
Nimesulide,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Sodium-dependent dopamine transporter;Aromatase;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Myeloperoxidase;Interstitial collagenase;Sodium-dependent neutral amino acid transporter B(0)AT1;Dipeptidyl peptidase 3",CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C,Sodium/nucleoside cotransporter 1;Cannabinoid receptor 1;Cytochrome P450 3A4;Adenosine receptor A3;Nuclear receptor subfamily 1 group I member 2;Voltage-dependent calcium channel gamma-1 subunit;Mineralocorticoid receptor;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1D;Cytochrome P450 2C9;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent L-type calcium channel subunit alpha-1S;Cytochrome P450 2C19;Bile acid receptor;Voltage-dependent L-type calcium channel subunit alpha-1F;Adenosine receptor A1;Adenosine receptor A2a,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
Nintedanib,COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1,"Tyrosine-protein kinase JAK3;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Macrophage colony-stimulating factor 1 receptor;Ribosomal protein S6 kinase alpha-3;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Cyclin-dependent kinase 2;Insulin-like growth factor 1 receptor;Myosin light chain kinase, smooth muscle;Insulin receptor;Death-associated protein kinase 3;Calcium/calmodulin-dependent protein kinase type 1;Mitogen-activated protein kinase 8;Fibroblast growth factor receptor 3;Focal adhesion kinase 1;Tyrosine-protein kinase HCK;Tyrosine-protein kinase JAK1;Mitogen-activated protein kinase 10;Death-associated protein kinase 2;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Myosin light chain kinase 2, skeletal/cardiac muscle;Angiopoietin-1 receptor;AP2-associated protein kinase 1;Serine/threonine-protein kinase MARK2;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Ribosomal protein S6 kinase alpha-2;5'-AMP-activated protein kinase catalytic subunit alpha-1;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase N1;Protein kinase C theta type;Serine/threonine-protein kinase 17A;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;ALK tyrosine kinase receptor;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Dual specificity protein kinase CLK2;Mitogen-activated protein kinase kinase kinase kinase 5;Glycogen synthase kinase-3 beta;Ephrin type-B receptor 1;Calcium/calmodulin-dependent protein kinase type 1D;Cyclin-dependent kinase 16;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;Ribosomal protein S6 kinase alpha-5;STE20-like serine/threonine-protein kinase;Dual specificity protein kinase CLK4;Calcium/calmodulin-dependent protein kinase kinase 2;MAP/microtubule affinity-regulating kinase 3;Calcium/calmodulin-dependent protein kinase kinase 1;Calcium/calmodulin-dependent protein kinase type 1G;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Testis-specific serine/threonine-protein kinase 1;Activin receptor type-1B;Serine/threonine-protein kinase receptor R3;Activin receptor type-1;3-phosphoinositide-dependent protein kinase 1;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase ITK/TSK;Tyrosine-protein kinase ZAP-70;Glycogen synthase kinase-3 alpha;Tyrosine-protein kinase BTK;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Tyrosine-protein kinase receptor TYRO3;Cyclin-dependent kinase 7;Serine/threonine-protein kinase D1;Ribosomal protein S6 kinase beta-1;Serine/threonine-protein kinase N2;Serine/threonine-protein kinase DCLK3;Serine/threonine-protein kinase 3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Serine/threonine-protein kinase Chk1;Serine/threonine-protein kinase PAK 3;Cyclin-dependent kinase 17;Cyclin-dependent kinase 18;Cyclin-dependent kinase 14;Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha;Phosphatidylinositol 5-phosphate 4-kinase type-2 beta;Myosin light chain kinase family member 4;Wee1-like protein kinase;Protein-tyrosine kinase 2-beta;Serine/threonine-protein kinase RIO1;Casein kinase I isoform delta;Tyrosine-protein kinase receptor Tie-1;NT-3 growth factor receptor;Tyrosine-protein kinase TXK;Casein kinase II subunit alpha;Casein kinase II subunit alpha';Dual specificity tyrosine-phosphorylation-regulated kinase 1B;Inhibitor of nuclear factor kappa-B kinase subunit epsilon;Serine/threonine-protein kinase STK11;Dual specificity mitogen-activated protein kinase kinase 3;Maternal embryonic leucine zipper kinase;Serine/threonine-protein kinase 26;Eukaryotic translation initiation factor 2-alpha kinase 4;Insulin receptor-related protein;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase RIO3;Serine/threonine-protein kinase SIK2;SRSF protein kinase 1;SRSF protein kinase 2;Serine/threonine-protein kinase 33;5'-AMP-activated protein kinase catalytic subunit alpha-2;Discoidin domain-containing receptor 2;Serine/threonine-protein kinase LATS1;Serine/threonine-protein kinase LATS2;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;Serine/threonine-protein kinase PAK 7;NUAK family SNF1-like kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Bone morphogenetic protein receptor type-2;Mitogen-activated protein kinase kinase kinase kinase 4;Serine/threonine-protein kinase MARK1;MAP/microtubule affinity-regulating kinase 4;Dual specificity mitogen-activated protein kinase kinase 4;Tyrosine-protein kinase Mer;Calcium/calmodulin-dependent protein kinase type IV;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 10;Mitogen-activated protein kinase kinase kinase 11;Serine/threonine-protein kinase 24;Muscle, skeletal receptor tyrosine-protein kinase;Serine/threonine-protein kinase DCLK1;Myosin-IIIb;Serine/threonine-protein kinase PAK 2;Serine/threonine-protein kinase PAK 4;Serine/threonine-protein kinase SIK1;TGF-beta receptor type-1;Ephrin type-A receptor 1;Mitogen-activated protein kinase 7;Serine/threonine-protein kinase D2;Serine/threonine-protein kinase D3;Receptor-interacting serine/threonine-protein kinase 1;Tyrosine-protein kinase Fes/Fps;Fibroblast growth factor receptor 4;Proto-oncogene tyrosine-protein kinase ROS;Ribosomal protein S6 kinase alpha-1;Ribosomal protein S6 kinase alpha-4;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Interleukin-1 receptor-associated kinase 4;Cyclin-dependent kinase 4;Cyclin-dependent kinase-like 2;Ephrin type-B receptor 6;Serine/threonine-protein kinase/endoribonuclease IRE1;Rhodopsin kinase;G protein-coupled receptor kinase 4;G protein-coupled receptor kinase 7;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Homeodomain-interacting protein kinase 4;Serine/threonine-protein kinase ICK;Inhibitor of nuclear factor kappa-B kinase subunit alpha;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Microtubule-associated serine/threonine-protein kinase 1;Serine/threonine-protein kinase OSR1;SRSF protein kinase 3;STE20/SPS1-related proline-alanine-rich protein kinase;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase ULK1;Serine/threonine-protein kinase ULK2;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Homeodomain-interacting protein kinase 1;Mitogen-activated protein kinase kinase kinase 15;Receptor-interacting serine/threonine-protein kinase 4;Uncharacterized serine/threonine-protein kinase SBK3;Serine/threonine-protein kinase 35;Serine/threonine-protein kinase SBK1;Serine/threonine-protein kinase PRP4 homolog;Mitogen-activated protein kinase kinase kinase 12;Serine/threonine-protein kinase Sgk3;Dual specificity mitogen-activated protein kinase kinase 5;Myosin light chain kinase 3;Leucine-rich repeat serine/threonine-protein kinase 2;Calcium-dependent protein kinase 1;Vascular endothelial growth factor receptor 2;Serine/threonine-protein kinase PknB;cGMP-dependent protein kinase 1;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 3;Platelet-derived growth factor receptor alpha;Fibroblast growth factor receptor 1",COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Niraparib,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1,Tankyrase-2;Tankyrase-1;Poly [ADP-ribose] polymerase 3;Poly [ADP-ribose] polymerase 4;Poly [ADP-ribose] polymerase 10;Poly [ADP-ribose] polymerase 12;Poly [ADP-ribose] polymerase 14;Poly [ADP-ribose] polymerase 15;Poly [ADP-ribose] polymerase 2;Poly [ADP-ribose] polymerase 1,NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12
Nirmatrelvir,[H][C@]12CN([C@H](C(=O)N[C@@H](C[C@]3([H])CCNC3=O)C#N)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)C(F)(F)F)C(C)(C)C,,CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C
Nisoldipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,"Adenosine receptor A2a;Potassium voltage-gated channel subfamily H member 2;Voltage-dependent P/Q-type calcium channel subunit alpha-1A;Adenosine receptor A3;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1D;Voltage-dependent T-type calcium channel subunit alpha-1H;Cytochrome P450 1A2;Sodium channel alpha subunits; brain (Types I, II, III)",COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,Aldose reductase;Pyruvate dehydrogenase [NADP(+)];Pyruvate:ferredoxin oxidoreductase;Pyruvate-flavodoxin oxidoreductase,CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1
Nitisinone,[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O,4-hydroxyphenylpyruvate dioxygenase,O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]
Nitrazepam,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1,GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor; anion channel,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
Nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,"Potassium voltage-gated channel subfamily H member 2;Adenosine receptor A3;Intermediate conductance calcium-activated potassium channel protein 4;Voltage-dependent calcium channel gamma-1 subunit;Transthyretin;Voltage-dependent L-type calcium channel subunit alpha-1D;Cytochrome P450 2C9;Voltage-dependent T-type calcium channel subunit alpha-1H;Cytochrome P450 2C19;Voltage-dependent L-type calcium channel subunit alpha-1F;Adenosine receptor A1;Adenosine receptor A2a;Voltage-dependent L-type calcium channel subunit alpha-1C;Voltage-dependent L-type calcium channel subunit alpha-1S;Platelet-activating factor receptor;Sodium channel alpha subunits; brain (Types I, II, III)",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1
Nitric Oxide,[N]=O,Soluble guanylate cyclase,[N]=O
Nitrite,[O-]N=O,,O=N[O-]
Nitrofural,NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O,,NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1
Nitrofurantoin,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,Glucose-6-phosphate 1-dehydrogenase;CDGSH iron-sulfur domain-containing protein 1,O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
Nitrogen,N#N,,N#N
Nitroglycerin,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Nitroprusside,O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N,Atrial natriuretic peptide receptor 1;Soluble guanylate cyclase,N#[C][Fe-2]([C]#N)([C]#N)([C]#N)([C]#N)[N]=O
Nitrous acid,ON=O,,O=NO
Nitrous oxide,[N-]=[N+]=O,Soluble guanylate cyclase,[N-]=[N+]=O
Nizatidine,CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O,Histamine H2 receptor;Acetylcholinesterase,CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
Nomegestrol,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,Estrogen receptor,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Nomegestrol acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H],,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Nomifensine,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;Histamine H1 receptor;Sodium-dependent dopamine transporter;Amine oxidase [flavin-containing] A;Myeloperoxidase;Transporter;Hemoglobin HbA,CN1Cc2c(N)cccc2C(c2ccccc2)C1
Nonoxynol-9,CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1,,CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1
Norelgestromin,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO,Progesterone receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=NO)CC[C@@H]4[C@H]3CC[C@@]21CC
Norepinephrine,NC[C@H](O)C1=CC(O)=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Mu-type opioid receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Adrenergic receptor alpha;Adrenergic receptor beta,NC[C@H](O)c1ccc(O)c(O)c1
Norethisterone,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],Sodium-dependent serotonin transporter;Glucocorticoid receptor;Estrogen receptor;Androgen receptor;Progesterone receptor;Sex hormone-binding globulin,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Norethynodrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3,Progesterone receptor;Androgen receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
Norfloxacin,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1,Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-5;DNA topoisomerase 4 subunit A;DNA gyrase subunit A;Gamma-aminobutyric acid receptor subunit alpha-4;Gamma-aminobutyric acid receptor subunit alpha-6;DNA topoisomerase 2-beta;Multidrug and toxin extrusion protein 1;GABA-A receptor; anion channel;Multidrug resistance protein mdtK,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
Norflurane,FCC(F)(F)F,5-hydroxytryptamine receptor 2B;Potassium channel subfamily K member 2;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9;Potassium channel subfamily K member 10;Potassium channel subfamily K member 18;Glycine receptor (alpha-1/beta);GABA-A receptor; anion channel,FCC(F)(F)F
Norgestimate,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,Progesterone receptor;Short transient receptor potential channel 3;Short transient receptor potential channel 6,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC
Norgestrel,CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C,Progesterone receptor;Sex hormone-binding globulin,C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC
Normethadone,CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,"Mu-type opioid receptor;Potassium voltage-gated channel subfamily H member 2;Kappa-type opioid receptor;Glutamate receptor ionotropic, NMDA 3A;Neuronal acetylcholine receptor subunit alpha-10;Delta-type opioid receptor;Opioid receptor",CCC(=O)C(CCN(C)C)(c1ccccc1)c1ccccc1
Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Cytochrome P450 2C19;Proto-oncogene tyrosine-protein kinase receptor Ret;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;ATP-sensitive inward rectifier potassium channel 10,CNCCC=C1c2ccccc2CCc2ccccc21
Noscapine,[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12,Cytochrome P450 2C9;Cytochrome P450 2C19;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
Novobiocin,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C,ATP-binding cassette sub-family G member 2;DNA gyrase subunit B;ParE;DNA gyrase;DNULL gyrase subunit B,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C
Noxytiolin,CNC(=S)NCO,Vasopressin V1a receptor;Vasopressin V1b receptor;Vasopressin V2 receptor;Oxytocin receptor;Oxytocin-neurophysin 1,CNC(=S)NCO
Nylidrin,CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1,,CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1
Nystatin,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\CC\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,Histamine H1 receptor,C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O
Obeticholic acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,,CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12
Octasulfur,S1SSSSSSS1,Carbonic anhydrase 2;Carbonic anhydrase 1,S1SSSSSSS1
Octinoxate,[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC,,CCCCC(CC)COC(=O)/C=C/c1ccc(OC)cc1
Octisalate,CCCCC(CC)COC(=O)C1=C(O)C=CC=C1,,CCCCC(CC)COC(=O)c1ccccc1O
Octocrylene,CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=CC=C1,,CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1
Odevixibat,CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C3=CC=C(O)C=C3)C=C2S(=O)(=O)N1,Ileal sodium/bile acid cotransporter,CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1
Ofloxacin,CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,Gamma-aminobutyric acid receptor subunit alpha-2;Sodium-dependent serotonin transporter;Muscarinic acetylcholine receptor M1;DNA gyrase subunit A;DNA gyrase subunit B;Histamine H3 receptor;Gag-Pro-Pol polyprotein;GABA-A receptor; anion channel;CAAX prenyl protease 1;Trypsin,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Oftasceine,OC(=O)CN(CC(O)=O)CC1=CC2=C(OC3=CC(O)=C(CN(CC(O)=O)CC(O)=O)C=C3C22OC(=O)C3=CC=CC=C23)C=C1O,Sodium-dependent noradrenaline transporter;Aldehyde oxidase;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Acetylcholinesterase;Acetylcholine receptor subunit epsilon;Solute carrier family 22 member 1;Alpha-1A adrenergic receptor;Muscarinic acetylcholine receptor M2;Butyrylcholinesterase; Protein Bche;Choline O-acetyltransferase;Muscarinic acetylcholine receptor M1;Amine oxidase [flavin-containing] A;Cholinesterase;Histamine N-methyltransferase;Butyrylcholinesterase;Glutamate NMDA receptor; GRIN1/GRIN2B;Glutamate NMDA receptor; GRIN1/GRIN2A;Muscarinic acetylcholine receptor;Amyloid beta A4 protein,O=C(O)CN(CC(=O)O)Cc1cc2c(cc1O)Oc1cc(O)c(CN(CC(=O)O)CC(=O)O)cc1C21OC(=O)c2ccccc21
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Arachidonate 15-lipoxygenase;Transporter;Adrenergic receptor alpha-2;Serotonin 2 (5-HT2) receptor;FAD-linked sulfhydryl oxidase ALR;Histone H1.0,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
Olaparib,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,Tankyrase-2;Poly [ADP-ribose] polymerase 4;Poly [ADP-ribose] polymerase 10;Poly [ADP-ribose] polymerase 12;Poly [ADP-ribose] polymerase 15;Poly [ADP-ribose] polymerase 6;Mono [ADP-ribose] polymerase PARP16;Tankyrase-1;Poly [ADP-ribose] polymerase 2;Poly [ADP-ribose] polymerase 1;Poly [ADP-ribose] polymerase 3,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1
Oleic Acid,CCCCCCCC\C=C\CCCCCCCC(O)=O,"Fatty-acid amide hydrolase 1;Aromatase;Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma;Fatty acid-binding protein, adipocyte;DNA topoisomerase 1;Telomerase reverse transcriptase;Fatty acid-binding protein, epidermal;Peroxisome proliferator-activated receptor delta;Free fatty acid receptor 1;Fatty acid-binding protein, liver;Seed linoleate 13S-lipoxygenase-1;Tissue factor;Free fatty acid receptor 4",CCCCCCCC/C=C/CCCCCCCC(=O)O
Oliceridine,COC1=C(CNCC[C@]2(CCOC3(CCCC3)C2)C2=NC=CC=C2)SC=C1,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Voltage-dependent L-type calcium channel subunit alpha-1C;Nociceptin receptor;Mu-type opioid receptor,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
Olmesartan,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O,Multidrug resistance protein 1;Angiotensin-converting enzyme;Cytochrome P450 2C9;Type-1 angiotensin II receptor;Type-2 angiotensin II receptor;Type-1B angiotensin II receptor;Type-1A angiotensin II receptor;Phosphodiesterase 3;Phosphodiesterase 4;Angiotensin II receptor (AT-1) type-1;Angiotensin II receptor;Platelet glycoprotein VI,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1
Olodaterol,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,Beta-1 adrenergic receptor;Beta-3 adrenergic receptor;Beta-2 adrenergic receptor,COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1
Olopatadine,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,Histamine H1 receptor,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
Olsalazine,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O,Arachidonate 5-lipoxygenase;Peroxisome proliferator-activated receptor gamma;Cyclooxygenase,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O
Olutasidenib,C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2,"Isocitrate dehydrogenase [NADP] cytoplasmic;Isocitrate dehydrogenase [NADP], mitochondrial",C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Omacetaxine mepesuccinate,[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H],,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
Omadacycline,[H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C,DNA repair protein RAD52 homolog,CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Ombitasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1,Nonstructural protein 5A;Genome polyprotein [Cleaved into: Core protein p21;Genome polyprotein,COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C
Omeprazole,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C,"Cytochrome P450 3A4;Multidrug resistance protein 1;Cytochrome P450 2C9;Cytochrome P450 1A2;Cytochrome P450 2C19;Fatty acid synthase;Potassium-transporting ATPase;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1;Glutathione S-transferase omega-1;Cytosolic endo-beta-N-acetylglucosaminidase",COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Omidenepag isopropyl,CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1,,CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1
Ondansetron,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2,Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2B;Aldehyde oxidase;5-hydroxytryptamine receptor 3A;Solute carrier family 22 member 1;5-hydroxytryptamine receptor 1B;Mu-type opioid receptor;Muscarinic acetylcholine receptor M1;Gastrin/cholecystokinin type B receptor;Sigma non-opioid intracellular receptor 1;Neuronal acetylcholine receptor subunit alpha-7;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 4;5-hydroxytryptamine receptor 1D;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;Serotonin 3 (5-HT3) receptor;Neuronal acetylcholine receptor; alpha4/beta2;Serotonin 2 (5-HT2) receptor;Serotonin 3 receptor (5HT3);5-hydroxytryptamine receptor 3B,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
Opicapone,CC1=C(C2=NOC(=N2)C2=CC(=C(O)C(O)=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl,Catechol O-methyltransferase,Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1
Orciprenaline,CC(C)NCC(O)C1=CC(O)=CC(O)=C1,Beta-2 adrenergic receptor,CC(C)NCC(O)c1cc(O)cc(O)c1
Oritavancin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Cannabinoid receptor 1;Lipoprotein lipase;Fatty acid synthase;Sn1-specific diacylglycerol lipase alpha;Fatty-acid amide hydrolase 1;Sn1-specific diacylglycerol lipase beta;Abhydrolase domain-containing protein 16A;Monoacylglycerol lipase ABHD12;Platelet-activating factor acetylhydrolase;Pancreatic triacylglycerol lipase;Monoacylglycerol lipase ABHD6;Hepatic triacylglycerol lipase;Endothelial lipase;Gastric triacylglycerol lipase,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
Ornithine,NCCC[C@H](N)C(O)=O,G-protein coupled receptor family C group 6 member A,NCCC[C@H](N)C(=O)O
Orphenadrine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C,Sodium channel protein type 5 subunit alpha;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 9 subunit alpha;Cytochrome P450 2D6;Sodium channel protein type 10 subunit alpha;Solute carrier family 22 member 1;Glutamate [NMDA] receptor,Cc1ccccc1C(OCCN(C)C)c1ccccc1
Oseltamivir,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Neuraminidase;Sialidase,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
Osilodrostat,FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12,"Aromatase;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 11B1, mitochondrial",N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1
Osimertinib,COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,Potassium voltage-gated channel subfamily H member 2;Insulin receptor;ALK tyrosine kinase receptor;Receptor tyrosine-protein kinase erbB-3;Dipeptidyl peptidase 1;Epidermal growth factor receptor,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
Ospemifene,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,Estrogen receptor,OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
Oteracil,OC(=O)C1=NC(=O)NC(=O)N1,Uridine 5'-monophosphate synthase,O=C(O)c1nc(=O)[nH]c(=O)[nH]1
Oteseconazole,O[C@@](CN1C=NN=N1)(C1=CC=C(F)C=C1F)C(F)(F)C1=CC=C(C=N1)C1=CC=C(OCC(F)(F)F)C=C1,Sodium/nucleoside cotransporter 1;5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Lanosterol 14-alpha demethylase;Acetylcholinesterase;Tyrosine-protein kinase Fyn;Heme oxygenase 2;Arachidonate 15-lipoxygenase;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1
Ouabain,[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,Sodium/potassium-transporting ATPase subunit alpha-2;Potassium voltage-gated channel subfamily H member 2;Sodium/potassium-transporting ATPase subunit alpha-1;Signal transducer and activator of transcription 3,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
Oxacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Penicillin-binding protein 1A;Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;Penicillin-binding protein",Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Oxaliplatin,[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,Cytochrome P450 3A4;Multidrug resistance protein 1;Dipeptidyl peptidase 4;Dipeptidyl peptidase 8;Dipeptidyl peptidase 9,O=C1[O][Pt]2(<-[NH2][C@@H]3CCCC[C@H]3[NH2]->2)[O]C1=O
Oxamniquine,CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O,Potassium voltage-gated channel subfamily H member 2;Histamine N-methyltransferase;Heparanase;Amyloid beta A4 protein,CC(C)NCC1CCc2cc(CO)c([N+](=O)[O-])cc2N1
Oxandrolone,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,Androgen receptor,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Oxaprozin,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;fMet-Leu-Phe receptor;Bifunctional epoxide hydrolase 2;Complement C5;Serine hydroxymethyltransferase, mitochondrial",O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
Oxatomide,O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Histamine H1 receptor,O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1
Oxazepam,OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,GABA-A receptor alpha-1/beta-3/gamma-2,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,Sodium channel protein type 5 subunit alpha,NC(=O)N1c2ccccc2CC(=O)c2ccccc21
Oxeladin,CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1,,CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1
Oxetacaine,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1,"Sodium channel alpha subunits; brain (Types I, II, III)",CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1
Oxiconazole,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1,"D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Beta-3 adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3;Lanosterol 14-alpha demethylase;Delta-type opioid receptor;Acetylcholinesterase;Cytochrome P450 2C9;Cytochrome P450 2C19;Thromboxane-A synthase;Indoleamine 2,3-dioxygenase 1;Substance-K receptor",Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
Oxidronic acid,OC(P(O)(O)=O)P(O)(O)=O,,O=P(O)(O)C(O)P(=O)(O)O
Oxilofrine,[H][C@@](C)(NC)[C@]([H])(O)C1=CC=C(O)C=C1,Beta-1 adrenergic receptor,CN[C@@H](C)[C@H](O)c1ccc(O)cc1
Oxitriptan,N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 7,N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O
Oxolamine,CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1,Histamine H1 receptor,CCN(CC)CCc1nc(-c2ccccc2)no1
Oxprenolol,CC(C)NCC(O)COC1=CC=CC=C1OCC=C,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Solute carrier family 22 member 1;5-hydroxytryptamine receptor 1A,C=CCOc1ccccc1OCC(O)CNC(C)C
Oxtriphylline,C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O
Oxybenzone,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1,Hormone-sensitive lipase,COc1ccc(C(=O)c2ccccc2)c(O)c1
Oxybuprocaine,CCCCOC1=CC(=CC=C1N)C(=O)OCCN(CC)CC,"Sodium channel protein type 10 subunit alpha;Sodium channel alpha subunits; brain (Types I, II, III)",CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N
Oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;D(3) dopamine receptor;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Cytochrome P450 2C19;Membrane-associated progesterone receptor component 1;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
Oxycodone,COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Acetylcholinesterase,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Oxygen,O=O,,O=O
Oxymetazoline,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1E;Nischarin;Alpha-1A adrenergic receptor;Adrenergic receptor alpha-2;Alpha-2 adrenergic receptor;Alpha-2B adrenergic receptor,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
Oxymetholone,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O,Estrogen receptor;Androgen receptor,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Oxymorphone,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Opioid receptor;Opioid receptors; mu and delta,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
Oxyphenbutazone,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1,fMet-Leu-Phe receptor;Prostacyclin synthase;Cyclooxygenase;Nicotinate phosphoribosyltransferase,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O
Oxyphencyclimine,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3,CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1
Oxyphenisatin acetate,CC(=O)OC1=CC=C(C=C1)C1(C(=O)NC2=CC=CC=C12)C1=CC=C(OC(C)=O)C=C1,,CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3ccccc32)cc1
Oxyphenonium,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4,CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
Oxyquinoline,OC1=CC=CC2=C1N=CC=C2,72 kDa type IV collagenase;Catechol O-methyltransferase;Methionine aminopeptidase 2;Methionine aminopeptidase 1;Bacterial leucyl aminopeptidase,Oc1cccc2cccnc12
Oxytetracycline,[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,30S ribosomal protein S4;30S ribosomal protein S9,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12
Ozanimod,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,Sphingosine 1-phosphate receptor 4;Sphingosine 1-phosphate receptor 3;Sphingosine 1-phosphate receptor 2;Sphingosine 1-phosphate receptor 1;Sphingosine 1-phosphate receptor 5,CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N
Ozenoxacin,CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O,"DNA gyrase subunit A;V-type proton ATPase subunit B, brain isoform;Topoisomerase IV;DNA gyrase",CNc1ncc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C
P-nitrobiphenyl,O=N(=O)C1=CC=C(C=C1)C1=CC=CC=C1,,O=[N+]([O-])c1ccc(-c2ccccc2)cc1
PBT-434,CCNCC1=NC2=C(C(Cl)=CC(Cl)=C2O)C(=O)N1C,,CCNCc1nc2c(O)c(Cl)cc(Cl)c2c(=O)n1C
Paclitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,Multidrug resistance protein 1;Nuclear receptor subfamily 1 group I member 2;Delta-type opioid receptor;Bile salt export pump;Multidrug resistance-associated protein 7;Tubulin beta chain;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Cholecystokinin receptor type A;Substance-K receptor;Melanocortin receptor 5;Botulinum neurotoxin type A;Tyrosine-protein kinase Mer;Tubulin beta-3 chain;Nucleotide-binding oligomerization domain-containing protein 2;Tubulin beta,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
Pacritinib,C(CN1CCCC1)OC1=CC=C2NC3=NC=CC(=N3)C3=CC(COC\C=C\COCC1=C2)=CC=C3,Tyrosine-protein kinase JAK3;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Platelet-derived growth factor receptor alpha;Cyclin-dependent kinase 2;Fibroblast growth factor receptor 3;Tyrosine-protein kinase JAK1;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Tyrosine-protein kinase SYK;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Fibroblast growth factor receptor 2;Tyrosine-protein kinase Fgr;MAP kinase-interacting serine/threonine-protein kinase 2;Tyrosine-protein kinase ZAP-70;Tyrosine-protein kinase BTK;BDNF/NT-3 growth factors receptor;Fibroblast growth factor receptor 4;Proto-oncogene tyrosine-protein kinase ROS;Cyclin-dependent kinase 4;Transcription factor ETV6;Insulin-like growth factor 1 receptor;Insulin receptor;Testis-specific serine/threonine-protein kinase 1;ALK tyrosine kinase receptor,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1
Padeliporfin,[Pd++].[H][C@]1(C)\C2=C\C3=C(C(C)=O)C(C)=C([N-]3)\C=C3/N=C(/C(/CC(=O)OC)=C4\[N-]\C(=C/C(=N2)[C@]1([H])CC)C(C)=C4C(=O)NCCS(O)(=O)=O)[C@@]([H])(CCC(O)=O)[C@]3([H])C,,CC[C@H]1c2cc3[n-]c(c(CC(=O)OC)c4nc(cc5[n-]c(cc(n2)[C@@H]1C)c(C(C)=O)c5C)[C@@H](C)[C@@H]4CCC(=O)O)c(C(=O)NCCS(=O)(=O)O)c3C.[Pd+2]
Padimate O,CCCCC(CC)COC(=O)C1=CC=C(C=C1)N(C)C,,CCCCC(CC)COC(=O)c1ccc(N(C)C)cc1
Pafolacianine,CC1(C)\C(=C/C=C2\CCCC(\C=C\C3=[N+](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC2=CC=C(C[C@H](NC(=O)C3=CC=C(NCC4=CN=C5N=C(N)NC(=O)C5=N4)C=C3)C(O)=O)C=C2)N(CCCCS(O)(=O)=O)C2=C1C=C(C=C2)S(O)(=O)=O,,CC1(C)C(/C=C/C2=C(Oc3ccc(C[C@H](NC(=O)c4ccc(NCc5cnc6nc(N)[nH]c(=O)c6n5)cc4)C(=O)O)cc3)/C(=C/C=C3/N(CCCCS(=O)(=O)O)c4ccc(S(=O)(=O)O)cc4C3(C)C)CCC2)=[N+](CCCCS(=O)(=O)O)c2ccc(S(=O)(=O)[O-])cc21
Palbociclib,CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O,Tyrosine-protein kinase JAK3;Receptor-type tyrosine-protein kinase FLT3;Cyclin-dependent kinase 9;Cyclin-dependent kinase 4/cyclin D1;CDK2/Cyclin A;CDK6/cyclin D1;Ribosomal protein S6 kinase alpha-1;Dual specificity tyrosine-phosphorylation-regulated kinase 1A;Cyclin-dependent kinase 6;Cyclin-dependent kinase 4,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
Paliperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;Prostaglandin E2 receptor EP3 subtype;D(2) dopamine receptor;5-hydroxytryptamine receptor 2A,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O
Palmitic Acid,CCCCCCCCCCCCCCCC(O)=O,,CCCCCCCCCCCCCCCC(=O)O
Palonosetron,[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2,5-hydroxytryptamine receptor 3A;Serotonin 3 receptor (5HT3),O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2
Palovarotene,CC1(C)CCC(C)(C)C2=C1C=C(CN1C=CC=N1)C(\C=C\C1=CC=C(C=C1)C(O)=O)=C2,Retinoic acid receptor alpha;Retinoic acid receptor beta;Retinoic acid receptor gamma,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Pamidronic acid,NCCC(O)(P(O)(O)=O)P(O)(O)=O,,NCCC(O)(P(=O)(O)O)P(=O)(O)O
Pancuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,Acetylcholine receptor;Neuronal acetylcholine receptor; alpha4/beta2;Acetylcholine receptor; alpha1/beta1/delta/gamma,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1
Panobinostat,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1,Histone deacetylase;Bromodomain-containing protein 4;Histone deacetylase 8;Histone deacetylase 5;Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 3;Histone deacetylase 6;Histone deacetylase 7;Histone deacetylase 4;Histone deacetylase 9;Histone deacetylase 10;Histone deacetylase 11,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1
Pantethine,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO
Panthenol,CC(C)(CO)C(O)C(=O)NCCCO,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Adenosine receptor A3;5-hydroxytryptamine receptor 1A,CC(C)(CO)C(O)C(=O)NCCCO
Pantoprazole,COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1,"Sodium/potassium-transporting ATPase subunit alpha-1;Fatty acid synthase;Indoleamine 2,3-dioxygenase 2;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Potassium-transporting ATPase;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
Pantothenic acid,CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O,,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)O
Papaverine,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1,"Potassium voltage-gated channel subfamily H member 2;cGMP-inhibited 3',5'-cyclic phosphodiesterase A;cAMP-specific 3',5'-cyclic phosphodiesterase 4B;Acetylcholinesterase;cGMP-specific 3',5'-cyclic phosphodiesterase;cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A;Cytochrome P450 2C19;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;cAMP-specific 3',5'-cyclic phosphodiesterase 4D;cGMP-dependent 3',5'-cyclic phosphodiesterase;cGMP-inhibited 3',5'-cyclic phosphodiesterase B;Protein-arginine deiminase type-4;Cyclic nucleotide phosphodiesterase PDE3A;Cyclic AMP-specific phosphodiesterase SSPDE4A1A;Phosphodiesterase 1;Serine hydroxymethyltransferase, mitochondrial",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
Parachlorophenol,OC1=CC=C(Cl)C=C1,"Indoleamine 2,3-dioxygenase 1;Solute carrier family 22 member 1;78 kDa glucose-regulated protein",Oc1ccc(Cl)cc1
Paraldehyde,CC1OC(C)OC(C)O1,,CC1OC(C)OC(C)O1
Paramethadione,CCC1(C)OC(=O)N(C)C1=O,Voltage-gated T-type calcium channel,CCC1(C)OC(=O)N(C)C1=O
Paramethasone acetate,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,"Cytochrome P450 3A4;Androgen receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 17A1",CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Parecoxib,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1,Prostaglandin G/H synthase 1;Prostaglandin G/H synthase 2,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1
Pargyline,CN(CC#C)CC1=CC=CC=C1,"Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Aldehyde dehydrogenase, mitochondrial",C#CCN(C)Cc1ccccc1
Paricalcitol,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O,Vitamin D3 receptor,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C
Paritaprevir,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1,"Plasminogen;Neutrophil elastase;Chymotrypsin-like elastase family member 1;Cathepsin B;Cathepsin L1;Chymase;Lysosomal protective protein;Cathepsin L2;Cathepsin K;Cathepsin S;Hepatitis C virus serine protease, NS3/NS4A;NS3 protease",Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1
Paromomycin,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,"Indoleamine 2,3-dioxygenase 1",NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O
Paroxetine,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,Beta-1 adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Cytochrome P450 1A2;Substance-P receptor;Myeloperoxidase;Beta-adrenergic receptor kinase 1;Transporter;Quinolone resistance protein NorA;P2X purinoceptor 4;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
Parthenolide,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,,C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21
Pasireotide,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1,Somatostatin receptor type 2;Somatostatin receptor type 3;Somatostatin receptor type 5;Somatostatin receptor type 1,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O
Patent Blue,CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=C(C=C(C(O)=C1)S(O)(=O)=O)S(O)(=O)=O,,CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2cc(O)c(S(=O)(=O)O)cc2S(=O)(=O)O)cc1
Pazopanib,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,"Tyrosine-protein kinase JAK3;Acetylcholinesterase;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Calcium/calmodulin-dependent protein kinase type 1;Mitogen-activated protein kinase 8;Fibroblast growth factor receptor 3;Tyrosine-protein kinase HCK;Mitogen-activated protein kinase 10;Tyrosine-protein kinase JAK2;Tyrosine-protein kinase SYK;Myosin light chain kinase 2, skeletal/cardiac muscle;Angiopoietin-1 receptor;AP2-associated protein kinase 1;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Serine/threonine-protein kinase Nek2;LIM domain kinase 1;Fibroblast growth factor receptor 1;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Fibroblast growth factor receptor 2;TRAF2 and NCK-interacting protein kinase;Tyrosine-protein kinase Fgr;Aurora kinase A;ALK tyrosine kinase receptor;Serine/threonine-protein kinase 36;BMP-2-inducible protein kinase;Tyrosine-protein kinase FRK;Mitogen-activated protein kinase kinase kinase kinase 5;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Cyclin-dependent kinase 16;STE20-like serine/threonine-protein kinase;MAP/microtubule affinity-regulating kinase 3;Calcium/calmodulin-dependent protein kinase type 1G;Epithelial discoidin domain-containing receptor 1;TGF-beta receptor type-2;Tyrosine-protein kinase ITK/TSK;Protein-tyrosine kinase 6;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Tyrosine-protein kinase receptor Tie-1;Tyrosine-protein kinase TXK;LIM domain kinase 2;Serine/threonine-protein kinase NLK;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase SIK2;Activin receptor type-2B;Discoidin domain-containing receptor 2;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Tyrosine-protein kinase Blk;Mitogen-activated protein kinase kinase kinase kinase 4;Dual specificity mitogen-activated protein kinase kinase 4;Dual specificity mitogen-activated protein kinase kinase 6;Tyrosine-protein kinase Mer;Cyclin-dependent kinase 11B;Cyclin-dependent kinase 11A;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 10;Mitogen-activated protein kinase kinase kinase 11;Serine/threonine-protein kinase Nek5;Serine/threonine-protein kinase SIK1;Tyrosine-protein kinase Srms;Interferon-induced, double-stranded RNA-activated protein kinase;Receptor-interacting serine/threonine-protein kinase 1;Tyrosine-protein kinase Fes/Fps;Fibroblast growth factor receptor 4;Proto-oncogene tyrosine-protein kinase ROS;Mitogen-activated protein kinase kinase kinase kinase 2;Ephrin type-B receptor 6;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 2;Serine/threonine-protein kinase RIO2;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Mitogen-activated protein kinase kinase kinase 19;Mitogen-activated protein kinase kinase kinase 1;Phosphatidylinositol 4-kinase beta;Bone morphogenetic protein receptor type-1B;Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma;Serine/threonine-protein kinase TAO2;Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma;Dual specificity mitogen-activated protein kinase kinase 5;Calcium-dependent protein kinase 1",Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Pefloxacin,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1,DNA gyrase subunit A;Cytochrome P450 1A2;DNA gyrase subunit B,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
Pemetrexed,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,"Thymidylate synthase;Dihydrofolate reductase;Folylpolyglutamate synthase, mitochondrial;Bifunctional dihydrofolate reductase-thymidylate synthase;Serine hydroxymethyltransferase, cytosolic;Folate receptor beta;Proton-coupled folate transporter;Thymidylate synthase (EC 2.1.1.45) (TS) (TSase);Folate transporter 1;Folate receptor alpha;Trifunctional purine biosynthetic protein adenosine-3",Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1
Pemigatinib,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F,Fibroblast growth factor receptor 4;Fibroblast growth factor receptor 3;Fibroblast growth factor receptor 1;Fibroblast growth factor receptor 2,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21
Pemirolast,CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;cAMP-specific 3',5'-cyclic phosphodiesterase 4C;cAMP-specific 3',5'-cyclic phosphodiesterase 4D",Cc1cccn2c(=O)c(-c3nn[nH]n3)cnc12
Pemoline,NC1=NC(=O)C(O1)C1=CC=CC=C1,Sodium-dependent dopamine transporter,NC1=NC(=O)C(c2ccccc2)O1
Penbutolol,CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A;Alpha-1-acid glycoprotein 1,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1
Penciclovir,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2,DNA polymerase catalytic subunit;Thymidine kinase,Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1
Penicillamine,[H][C@](N)(C(O)=O)C(C)(C)S,Succinyl-diaminopimelate desuccinylase,CC(C)(S)[C@@H](N)C(=O)O
Pentaerythritol tetranitrate,[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O,,O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]
Pentafluoropropane,FC(F)CC(F)(F)F,,FC(F)CC(F)(F)F
Pentagastrin,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Gastrin/cholecystokinin type B receptor;Cholecystokinin receptor type A,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Pentamidine,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;D(3) dopamine receptor;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Amine oxidase [flavin-containing] A;Plasminogen;Trypsin-1;Coagulation factor X;Suppressor of tumorigenicity 14 protein;Protein S100-B;Protein arginine N-methyltransferase 1;Solute carrier family 22 member 1;Amiloride-sensitive amine oxidase [copper-containing];Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;Glutamate NMDA receptor;Glutamate NMDA receptor; GRIN1/GRIN2A;Spermidine/spermine N(1)-acetyltransferase 1;Protein-tyrosine phosphatase 4A3;Acrosin;Protein tyrosine phosphatase type IVA 2;Protein tyrosine phosphatase type IVA 1,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1
Pentazocine,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CC=C(C)C,Mu-type opioid receptor;Sigma non-opioid intracellular receptor 1;Kappa-type opioid receptor;Delta-type opioid receptor;Opioid receptor,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
Pentetic acid,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O
Pentetreotide,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O
Pentobarbital,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,Gamma-aminobutyric acid receptor subunit beta-3;Potassium voltage-gated channel subfamily H member 2;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-2/beta-2/gamma-2,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
Pentolinium,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,Neuronal acetylcholine receptor subunit alpha-10;Neuronal acetylcholine receptor; alpha3/beta4,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
Pentosan polysulfate,O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O,,O=S(=O)(O)O[C@@H]1[C@@H](OS(=O)(=O)O)[C@H](O[C@@H]2CO[C@@H](O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)OC[C@H]1O
Pentostatin,OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O,Adenosine deaminase,OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O
Pentoxifylline,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,"Adenosine receptor A2b;cAMP-specific 3',5'-cyclic phosphodiesterase 4B;Acetylcholinesterase;cGMP-specific 3',5'-cyclic phosphodiesterase",CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
Pentoxyverine,CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1,Sigma non-opioid intracellular receptor 1;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Lysosomal Pro-X carboxypeptidase;Solute carrier family 22 member 1;Sodium-dependent dopamine transporter,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1
Peramivir,[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,Neuraminidase;Sialidase;Sialidase 2,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N
Perampanel,O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1,Glutamate receptor ionotropic AMPA,N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O
Perazine,CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1,Gamma-aminobutyric acid receptor subunit beta,CN1CCN(CCCN2c3ccccc3Sc3ccccc32)CC1
Perboric acid,OOB=O,,O=BOO
Perflexane,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
Perflubutane,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F
Perflutren,FC(F)(F)C(F)(F)C(F)(F)F,,FC(F)(F)C(F)(F)C(F)(F)F
Pergolide,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 7;Adrenergic receptor alpha-2;Dopamine receptor;Cerebral cortex alpha adrenergic receptor;D(1A) dopamine receptor,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Perhexiline,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1,"Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Cytochrome P450 2D6;Voltage-dependent T-type calcium channel subunit alpha-1G;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent T-type calcium channel subunit alpha-1I;Carnitine O-palmitoyltransferase 1, liver isoform;Carnitine O-palmitoyltransferase 2, mitochondrial;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Carnitine O-palmitoyltransferase 1, muscle isoform;Adrenergic receptor alpha-1;Carnitine palmitoyltransferase 2;Carnitine palmitoyltransferase 1A",C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
Periciazine,OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1,D(1A) dopamine receptor;Androgen receptor;Acetylcholinesterase;Cholinesterase,N#Cc1ccc2c(c1)N(CCCN1CCC(O)CC1)c1ccccc1S2
Perindopril,[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,Angiotensin-converting enzyme,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
Permethrin,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1,Sodium channel protein,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1
Perphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M3;Aldehyde oxidase;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Pleiotropic ABC efflux transporter of multiple drugs,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Pexidartinib,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Tyrosine-protein kinase Lck;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;NT-3 growth factor receptor;Cyclin-dependent kinase 19;Mast/stem cell growth factor receptor Kit;Receptor-type tyrosine-protein kinase FLT3;Macrophage colony-stimulating factor 1 receptor,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Phenacemide,NC(=O)NC(=O)CC1=CC=CC=C1,Sodium channel protein type 1 subunit alpha,NC(=O)NC(=O)Cc1ccccc1
Phenazopyridine,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1,Sodium channel alpha subunit;Snake venom metalloproteinase Bap1,Nc1ccc(/N=N/c2ccccc2)c(N)n1
Phendimetrazine,C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1,Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;Sodium-dependent dopamine transporter,C[C@H]1[C@H](c2ccccc2)OCCN1C
Phenelzine,NNCCC1=CC=CC=C1,"Cytochrome P450 3A4;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Cytochrome P450 2C8;Cytochrome P450 2C9;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Cytochrome P450 2C19;Membrane primary amine oxidase;Indoleamine 2,3-dioxygenase 1;Lysine-specific histone demethylase 1A;FAD-linked sulfhydryl oxidase ALR",NNCCc1ccccc1
Pheneticillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C)OC1=CC=CC=C1)C(O)=O,Penicillin-binding protein,CC(Oc1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
Phenformin,NC(=N)NC(=N)NCCC1=CC=CC=C1,5'-AMP-activated protein kinase subunit beta-1,N=C(N)NC(=N)NCCc1ccccc1
Phenindamine,CN1CCC2=C(C1)C(C1=CC=CC=C21)C1=CC=CC=C1,Histamine H1 receptor,CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12
Phenindione,O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1,Vitamin K epoxide reductase complex subunit 1;Prothrombin;Arachidonate 5-lipoxygenase,O=C1c2ccccc2C(=O)C1c1ccccc1
Pheniramine,CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1,"Histamine H1 receptor;Histamine H4 receptor;Sodium channel alpha subunits; brain (Types I, II, III)",CN(C)CCC(c1ccccc1)c1ccccn1
Phenmetrazine,CC1NCCOC1C1=CC=CC=C1,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Amine oxidase [flavin-containing] A,CC1NCCOC1c1ccccc1
Phenobarbital,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1,"Nuclear receptor subfamily 1 group I member 3;Nuclear receptor subfamily 1 group I member 2;GABA-A receptor alpha-1/beta-2/gamma-2;Sodium channel alpha subunits; brain (Types I, II, III)",CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
Phenol,OC1=CC=CC=C1,Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 3;Carbonic anhydrase 14;Endolysin;Carbonic anhydrase 15;Carbonic anhydrase;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Beta-carbonic anhydrase 1,Oc1ccccc1
Phenolphthalein,OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1,Thymidylate synthase,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21
Phenoxybenzamine,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1,"Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Solute carrier family 22 member 1;Dopamine receptor;Adrenergic receptor alpha-1;Sodium channel alpha subunits; brain (Types I, II, III)",CC(COc1ccccc1)N(CCCl)Cc1ccccc1
Phenoxymethylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O
Phenprocoumon,CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,Pol polyprotein;Vitamin K epoxide reductase complex subunit 1,CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Phensuximide,CN1C(=O)CC(C1=O)C1=CC=CC=C1,Voltage-gated T-type calcium channel,CN1C(=O)CC(c2ccccc2)C1=O
Phentermine,CC(C)(N)CC1=CC=CC=C1,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter,CC(C)(N)Cc1ccccc1
Phentolamine,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1,"Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Histamine H1 receptor;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Nischarin;Adrenergic receptor alpha-2;Sodium channel alpha subunits; brain (Types I, II, III)",Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Phenyl aminosalicylate,NC1=CC(O)=C(C=C1)C(=O)OC1=CC=CC=C1,,Nc1ccc(C(=O)Oc2ccccc2)c(O)c1
Phenyl salicylate,OC1=CC=CC=C1C(=O)OC1=CC=CC=C1,,O=C(Oc1ccccc1)c1ccccc1O
Phenylacetic acid,OC(=O)CC1=CC=CC=C1,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(O)Cc1ccccc1
Phenylalanine,N[C@@H](CC1=CC=CC=C1)C(O)=O,Large neutral amino acids transporter small subunit 1;Voltage-dependent calcium channel subunit alpha-2/delta-1;L-type amino acid transporter 1;Intestinal alkaline phosphatase;Probable G-protein coupled receptor 139;Intestinal-type alkaline phosphatase;E3 ubiquitin-protein ligase XIAP,N[C@@H](Cc1ccccc1)C(=O)O
Phenylbutazone,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,Prostaglandin G/H synthase 1;fMet-Leu-Phe receptor;Prostacyclin synthase;Cytochrome P450 2C9;Cyclooxygenase 2; Prostaglandin G/H synthase-2; Uncharacterized protein;Cyclooxygenase;Nicotinate phosphoribosyltransferase,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Phenylbutyric acid,OC(=O)CCCC1=CC=CC=C1,,O=C(O)CCCc1ccccc1
Phenylephrine,CNC[C@H](O)C1=CC(O)=CC=C1,Alpha-1A adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Beta-1 adrenergic receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,CNC[C@H](O)c1cccc(O)c1
Phenylethyl resorcinol,CC(C1=CC=CC=C1)C1=CC=C(O)C=C1O,Arachidonate 5-lipoxygenase;Tyrosinase;Polyphenol oxidase 2,CC(c1ccccc1)c1ccc(O)cc1O
Phenylpropanolamine,CC(N)C(O)C1=CC=CC=C1,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,CC(N)C(O)c1ccccc1
Phenyltoloxamine,CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1,D(1A) dopamine receptor;D(2) dopamine receptor;D(1B) dopamine receptor;D(4) dopamine receptor;Histamine H1 receptor,CN(C)CCOc1ccccc1Cc1ccccc1
Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,"Nuclear receptor subfamily 1 group I member 3;Sodium channel protein type 5 subunit alpha;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha;Sodium channel alpha subunits; brain (Types I, II, III)",O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
Phloxine B,[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br,"Arachidonate 5-lipoxygenase;Arachidonate 15-lipoxygenase;Arachidonate 12-lipoxygenase, 12S-type;Botulinum neurotoxin type A;Arachidonate 15-lipoxygenase, type II",O=C([O-])c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]
Pholcodine,[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Opioid receptor,CN1CC[C@]23c4c5ccc(OCCN6CCOCC6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
Phosphoric acid,OP(O)(O)=O,,O=P(O)(O)O
Phosphorus,[P],,[P]
Phthalylsulfathiazole,OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,Dihydropteroate synthase;Endothelin-1 receptor;Transcriptional activator protein LasR,O=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Phylloquinone,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 3;Carbonic anhydrase 14;Carbonic anhydrase 13;Acetylcholinesterase;Polyphenol oxidase 2;Carbonic anhydrase 15;Carbonic anhydrase",CC1=C(C/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O
Physostigmine,[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C,Cytochrome P450 2D6;Acetylcholinesterase;Cholinesterase;Butyrylcholinesterase; Protein Bche;Muscarinic acetylcholine receptor M1;Butyrylcholinesterase,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
Pibrentasvir,CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F,Nonstructural protein 5A;Genome polyprotein [Cleaved into: Core protein p21,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2cc([C@H]3CC[C@H](c4cc5nc([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)[C@@H](C)OC
Picosulfuric acid,OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1,,O=S(=O)(O)Oc1ccc(C(c2ccc(OS(=O)(=O)O)cc2)c2ccccn2)cc1
Pidolic acid,OC(=O)[C@@H]1CCC(=O)N1,,O=C1CC[C@@H](C(=O)O)N1
Piflufolastat F 18,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O,Glutamate carboxypeptidase 2,O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc([18F])nc1)C(=O)O)C(=O)O
Pilocarpine,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O,Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor DM1;Muscarinic acetylcholine receptor;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C
Pimavanserin,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1,5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 2A,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1
Pimecrolimus,[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC,Interleukin-5;Interferon gamma;Peptidyl-prolyl cis-trans isomerase FKBP1A;Interleukin-2;Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
Pimethixene,CN1CCC(CC1)=C1C2=CC=CC=C2SC2=CC=CC=C12,5-hydroxytryptamine receptor 2A;Transcriptional activator protein luxR;Histone-lysine N-methyltransferase SETD7,CN1CCC(=C2c3ccccc3Sc3ccccc32)CC1
Pimozide,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,Mu-type opioid receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M3;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Kappa-type opioid receptor;Multidrug resistance-associated protein 1;Glycine receptor subunit alpha-1;Voltage-dependent T-type calcium channel subunit alpha-1G;Calmodulin;Delta-type opioid receptor;Voltage-dependent T-type calcium channel subunit alpha-1I;Potassium channel subfamily K member 2;Potassium voltage-gated channel subfamily A member 10;Sodium channel protein type 2 subunit alpha;Solute carrier family 22 member 2;Dopamine receptor;Ubiquitin carboxyl-terminal hydrolase 1;Voltage-dependent T-type calcium channel subunit alpha-1H;G protein-activated inward rectifier potassium channel 2,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
Pinacidil,CC(N\C(NC#N)=N\C1=CC=NC=C1)C(C)(C)C,"ATP-binding cassette sub-family C member 9;Calcium-activated potassium channel subunit alpha-1;Sulfonylurea receptor 2, Kir6.2",CC(N/C(=N/c1ccncc1)NC#N)C(C)(C)C
Pinaverium,COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1,,COc1cc(Br)c(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)cc1OC
Pindolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Beta-3 adrenergic receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Serotonin 1 (5-HT1) receptor;Serotonin 2 (5-HT2) receptor,CC(C)NCC(O)COc1cccc2[nH]ccc12
Pioglitazone,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Carbonic anhydrase 2;Bile salt export pump;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma;Aldose reductase;Enoyl-[acyl-carrier-protein] reductase [NADH];CDGSH iron-sulfur domain-containing protein 1;CDGSH iron-sulfur domain-containing protein 2,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Pipecuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,Neuronal acetylcholine receptor; alpha2/beta4;Acetylcholine receptor;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1
Piperacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O,Penicillin-binding protein 1A;Beta-lactamase;Streptokinase A;Bacterial penicillin-binding protein,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H]2SC(C)(C)[C@@H]3C(=O)O)c2ccccc2)C(=O)C1=O
Piperaquine,ClC1=CC2=C(C=C1)C(=CC=N2)N1CCN(CCCN2CCN(CC2)C2=CC=NC3=C2C=CC(Cl)=C3)CC1,Gamma-aminobutyric acid receptor subunit beta,Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1
Piperazine,C1CNCCN1,Gamma-aminobutyric acid receptor subunit beta,C1CNCCN1
Piperonyl butoxide,CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC,,CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2
Pipobroman,BrCCC(=O)N1CCN(CC1)C(=O)CCBr,,O=C(CCBr)N1CCN(C(=O)CCBr)CC1
Pipotiazine,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Major prion protein;Solute carrier family 22 member 1;Trypanothione reductase;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Pleiotropic ABC efflux transporter of multiple drugs;Dopamine receptor;Sodium channel alpha subunits; brain (Types I, II, III);FAD-linked sulfhydryl oxidase ALR",CN(C)S(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2
Pipradrol,[H]N1CCCCC1C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,OC(c1ccccc1)(c1ccccc1)C1CCCCN1
Piracetam,NC(=O)CN1CCCC1=O,Synaptic vesicle glycoprotein 2A,NC(=O)CN1CCCC1=O
Pirbuterol,CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1,Beta-2 adrenergic receptor,CC(C)(C)NCC(O)c1ccc(O)c(CO)n1
Pirenzepine,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Adenosine receptor A3;Muscarinic receptor M1;Muscarinic acetylcholine receptor;Muscarinic acetylcholine receptor DM1,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1
Piretanide,NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O,Solute carrier family 12 member 1;Solute carrier family 12 member 2,NS(=O)(=O)c1cc(C(=O)O)cc(N2CCCC2)c1Oc1ccccc1
Pirfenidone,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,Beta-1 adrenergic receptor;Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2,Cc1ccc(=O)n(-c2ccccc2)c1
Piritramide,NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1,,N#CC(CCN1CCC(C(N)=O)(N2CCCCC2)CC1)(c1ccccc1)c1ccccc1
Piroxicam,CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cyclooxygenase,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
Pitavastatin,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O,3-hydroxy-3-methylglutaryl-coenzyme A reductase;Retinoic acid receptor RXR-alpha,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
Pitolisant,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,Potassium voltage-gated channel subfamily H member 2;Histamine H1 receptor;Histamine H2 receptor;Histamine H3 receptor;Cholinesterase,Clc1ccc(CCCOCCCN2CCCCC2)cc1
Pivampicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C,Penicillin-binding protein 1A;Angiopoietin-1 receptor;Transient receptor potential cation channel subfamily M member 4;Bacterial penicillin-binding protein,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C
Pivmecillinam,[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1,Penicillin-binding protein 2,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](N=CN3CCCCCC3)[C@H]2SC1(C)C
Pixantrone,NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2C;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M4;Canalicular multispecific organic anion transporter 1;DNA topoisomerase 2-alpha;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Epidermal growth factor receptor;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Serine/threonine-protein kinase pim-1;Solute carrier family 22 member 1;DNA-(apurinic or apyrimidinic site) lyase;Arachidonate 15-lipoxygenase;Integrase;Tyrosine-protein kinase BTK;Proto-oncogene tyrosine-protein kinase ROS;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Solute carrier family 22 member 3;DNA-3-methyladenine glycosylase;Dual specificity tyrosine-phosphorylation-regulated kinase 1A,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O
Pizotifen,CN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2,D(2) dopamine receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 7;Muscarinic acetylcholine receptor M1,CN1CCC(=C2c3ccccc3CCc3sccc32)CC1
Plazomicin,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O,,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O
Plecanatide,[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O,Tumor necrosis factor;Tumor necrosis factor receptor superfamily member 1A;Heat-stable enterotoxin receptor,CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)O
Plerixafor,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1,C-X-C chemokine receptor type 4;C-C chemokine receptor type 2;Stromal cell-derived factor 1;C-C chemokine receptor type 4;Atypical chemokine receptor 3,c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1
Plicamycin,CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O,50S ribosomal protein L10,CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1
Podofilox,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O,,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
Podophyllin,COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O,Cytochrome P450 3A4;Glucocorticoid receptor;Cytochrome P450 2C9;Cytochrome P450 2C19;Regulatory protein E2;Tubulin alpha-1A chain;Tubulin;Human papillomavirus regulatory protein E2,COc1cc(C2c3cc4c(cc3C(O)C(CO)C2C(=O)O)OCO4)cc(OC)c1OC.COc1cc(C2c3cc4c(cc3C(O)C(CO)C2C(=O)O)OCO4)cc(OC)c1OC.COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC.COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC
Polidocanol,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,Envelope glycoprotein,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
Polydatin,OC[C@H]1O[C@@H](OC2=CC(\C=C\C3=CC=C(O)C=C3)=CC(O)=C2)[C@H](O)[C@@H](O)[C@@H]1O,,OC[C@H]1O[C@@H](Oc2cc(O)cc(/C=C/c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
Polymyxin B,[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O
Polythiazide,CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,Solute carrier family 12 member 3,CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O
Pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,Cereblon isoform 4;Protein cereblon,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
Ponatinib,CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1,Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Breakpoint cluster region protein;Proto-oncogene tyrosine-protein kinase Src;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 2;Platelet-derived growth factor receptor alpha;Fibroblast growth factor receptor 3;Tyrosine-protein kinase CSK;Tyrosine-protein kinase Lyn;Fibroblast growth factor receptor 1;Fibroblast growth factor receptor 2;Receptor-interacting serine/threonine-protein kinase 2;Cyclin-dependent kinase 19;Cyclin-dependent kinase 8;Receptor-interacting serine/threonine-protein kinase 1;Fibroblast growth factor receptor 4;Bcr/Abl fusion protein;Receptor-interacting serine/threonine-protein kinase 3,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Ponesimod,CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C,Sphingosine 1-phosphate receptor 5;Sphingosine 1-phosphate receptor 4;Sphingosine 1-phosphate receptor 3;Sphingosine 1-phosphate receptor 1,CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1,Cytochrome P450 3A4;Lanosterol 14-alpha demethylase;14-alpha sterol demethylase Cyp51A;14-alpha sterol demethylase;Sterol 14-alpha demethylase;7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O
Potassium,[KH],,[KH]
Potassium Iodide,[K+].[I-],Carbonic anhydrase 4,[I-].[K+]
Potassium acetate,[K+].CC([O-])=O,,CC(=O)[O-].[K+]
Potassium alum,[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Al+3].[K+]
Potassium aspartate,[H+].[H+].O.[K+].[K+].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O,,N[C@@H](CC(=O)[O-])C(=O)[O-].N[C@@H](CC(=O)[O-])C(=O)[O-].O.[H+].[H+].[K+].[K+]
Potassium bicarbonate,[K+].OC([O-])=O,,O=C([O-])O.[K+]
Potassium carbonate,[K+].[K+].[O-]C([O-])=O,,O=C([O-])[O-].[K+].[K+]
Potassium cation,[K+],,[K+]
Potassium chloride,[Cl-].[K+],,[Cl-].[K+]
Potassium citrate,[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+]
Potassium gluconate,[K+].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[K+]
Potassium hydroxide,[OH-].[K+],,[K+].[OH-]
Potassium lactate,[K+].CC(O)C([O-])=O,,CC(O)C(=O)[O-].[K+]
Potassium nitrate,[K+].[O-][N+]([O-])=O,,O=[N+]([O-])[O-].[K+]
Potassium perchlorate,[K+].[O-][Cl](=O)(=O)=O,,[K+].[O-][Cl+3]([O-])([O-])[O-]
Potassium sulfate,[K+].[K+].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[K+].[K+]
Practolol,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1
Pralatrexate,NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1,Dihydrofolate reductase;Proton-coupled folate transporter;Folate transporter 1;Folate receptor alpha,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Pralidoxime,C[N+]1=C(\C=N\O)C=CC=C1,Acetylcholinesterase,C[n+]1ccccc1/C=N/O
Pralsetinib,CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1,Vascular endothelial growth factor receptor 2;Platelet-derived growth factor receptor beta;Receptor-type tyrosine-protein kinase FLT3;Tyrosine-protein kinase JAK1;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Fibroblast growth factor receptor 1;Epithelial discoidin domain-containing receptor 1;NT-3 growth factor receptor;Proto-oncogene tyrosine-protein kinase receptor Ret,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
Pramipexole,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Beta-2 adrenergic receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 7;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor,CCCN[C@H]1CCc2nc(N)sc2C1
Pramiracetam,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,Synaptic vesicle glycoprotein 2A,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C
Pramlintide,[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O,Amylin receptor AMY2;Amylin receptor AMY1;Amylin receptor AMY3,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O
Pramocaine,CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1,"Sigma non-opioid intracellular receptor 1;Membrane-associated progesterone receptor component 1;Sodium channel alpha subunits; brain (Types I, II, III)",CCCCOc1ccc(OCCCN2CCOCC2)cc1
Prasterone,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C,Corticosteroid-binding globulin;Sex hormone-binding globulin;Glucose-6-phosphate 1-dehydrogenase,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
Prasterone enantate,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(=O)CCCCCC,"Cytochrome P450 3A4;Androgen receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 17A1",CCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]32)C1
Prasugrel,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,P2Y purinoceptor 12,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Pravastatin,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC,3-hydroxy-3-methylglutaryl-coenzyme A reductase;Solute carrier family 22 member 6,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
Prazepam,ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1,GABA-A receptor alpha-1/beta-2/gamma-2,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1
Praziquantel,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,Bile salt export pump;Glutathione S-transferase class-mu 26 kDa isozyme;High voltage-activated calcium channel beta subunit CavB1;High voltage-activated calcium channel beta subunit CavB2,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1
Prazosin,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1,"Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Adenosine receptor A3;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Ribosyldihydronicotinamide dehydrogenase [quinone];Matrix metalloproteinase-9;Interstitial collagenase;Solute carrier family 22 member 1;Mu-type opioid receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 1A;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;Alpha-2 adrenergic receptor;Beta-casein",COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
Prednicarbate,[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Prednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Glucocorticoid receptor;Annexin A1;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Corticosteroid-binding globulin;Interleukin-6;G-protein coupled bile acid receptor 1;Fatty acid-binding protein, liver;Glutamine synthetase;Disintegrin and metalloproteinase domain-containing protein 17",C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Prednisolone acetate,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Corticosteroid-binding globulin;Interleukin-6;G-protein coupled bile acid receptor 1;Fatty acid-binding protein, liver;Glutamine synthetase;Disintegrin and metalloproteinase domain-containing protein 17",CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Prednisolone phosphate,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Fructose-1,6-bisphosphatase 1;Proto-oncogene tyrosine-protein kinase Src;Transient receptor potential cation channel subfamily M member 2;Transient receptor potential cation channel subfamily M member 4;Pol polyprotein;Alcohol dehydrogenase;L-lactate dehydrogenase A chain;Ketopantoate reductase;Adenylate kinase 2;2'-deoxynucleoside 5'-phosphate N-hydrolase 1",C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O
Prednisolone tebutate,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Corticosteroid-binding globulin;Interleukin-6;G-protein coupled bile acid receptor 1;Fatty acid-binding protein, liver;Glutamine synthetase;Disintegrin and metalloproteinase domain-containing protein 17",CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Prednisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Sodium/nucleoside cotransporter 1;Glucocorticoid receptor;Annexin A1,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
Prednisone acetate,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,"Glucocorticoid receptor;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Corticosteroid-binding globulin;Interleukin-6;G-protein coupled bile acid receptor 1;Fatty acid-binding protein, liver;Glutamine synthetase;Disintegrin and metalloproteinase domain-containing protein 17",CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@@]21C
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Large neutral amino acids transporter small subunit 1;Voltage-dependent calcium channel subunit alpha-2/delta-1;Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit;Voltage-dependent calcium channel subunit alpha-2/delta-2,CC(C)C[C@H](CN)CC(=O)O
Pregnenolone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Prenylamine,CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1,"Sodium channel alpha subunits; brain (Types I, II, III);Voltage-gated L-type calcium channel;Calmodulin",CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1
Pretomanid,[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1,Solute carrier family 12 member 1;Solute carrier family 12 member 2,O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2
Prilocaine,CCCNC(C)C(=O)NC1=CC=CC=C1C,"Sodium channel alpha subunits; brain (Types I, II, III)",CCCNC(C)C(=O)Nc1ccccc1C
Primaquine,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1,"Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Hemoglobin subunit alpha;Amine oxidase [flavin-containing] B;Ribosyldihydronicotinamide dehydrogenase [quinone];Cytochrome P450 1A2;Amine oxidase [flavin-containing] A;Glucose-6-phosphate 1-dehydrogenase;Heat shock protein HSP 90-alpha;Reverse transcriptase;Aryl hydrocarbon receptor;Chloroquine resistance transporter;Serine hydroxymethyltransferase, mitochondrial",COc1cc(NC(C)CCCN)c2ncccc2c1
Primidone,CCC1(C(=O)NCNC1=O)C1=CC=CC=C1,GABA-A receptor alpha-1/beta-2/gamma-2;Transient receptor potential cation channel subfamily M member 3,CCC1(c2ccccc2)C(=O)NCNC1=O
Probenecid,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O,Carbonic anhydrase 2;Carbonic anhydrase 9;Carbonic anhydrase 12;Solute carrier family 22 member 6;Solute carrier family 22 member 8;Solute carrier family 22 member 11;Solute carrier family 22 member 12;Solute carrier family 22 member 20;UDP-glucuronosyltransferase 1-7;Transient receptor potential cation channel subfamily V member 2,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
Probucol,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C,Potassium voltage-gated channel subfamily H member 2;Arachidonate 15-lipoxygenase;ATP-binding cassette sub-family A member 1;Serine protease hepsin;Trypsin,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
Procainamide,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,Potassium voltage-gated channel subfamily H member 2;Muscarinic acetylcholine receptor M2;Acetylcholinesterase;DNA (cytosine-5)-methyltransferase 1;DNA (cytosine-5)-methyltransferase 3A;DNA (cytosine-5)-methyltransferase 3B;Sodium channel alpha subunit,CCN(CC)CCNC(=O)c1ccc(N)cc1
Procaine,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1,"5-hydroxytryptamine receptor 3A;Glutamate receptor ionotropic, NMDA 3A;Sodium channel protein type 10 subunit alpha;Ryanodine receptor 1;Acetylcholine receptor",CCN(CC)CCOC(=O)c1ccc(N)cc1
Procaine benzylpenicillin,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,Beta-lactamase TEM;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1
Procaine merethoxylline,O.[Hg+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[CH2]C(CN=C(O)C1=CC=CC=C1OCC([O-])=O)OCCOC,,CCN(CC)CCOC(=O)c1ccc(N)cc1.O.[CH2]C(CN=C(O)c1ccccc1OCC(=O)[O-])OCCOC.[Hg+]
Procarbazine,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,Sodium channel protein type 5 subunit alpha,CNNCc1ccc(C(=O)NC(C)C)cc1
Procaterol,CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2,Beta-2 adrenergic receptor;D(2) dopamine receptor,CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c2[nH]c(=O)ccc12
Prochlorperazine,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Cytochrome P450 1A2;Tyrosine-protein kinase Fyn;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Pleiotropic ABC efflux transporter of multiple drugs,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Procyclidine,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Histamine H1 receptor;Glutamate [NMDA] receptor,OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1
Profenamine,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12,"Muscarinic acetylcholine receptor M1;Glutamate receptor ionotropic, NMDA 3A;Acetylcholinesterase;Cholinesterase;Solute carrier family 22 member 1;Muscarinic acetylcholine receptor M2;Butyrylcholinesterase",CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21
Proflavine,NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1,Flavin reductase (NADPH);Riboflavin kinase;Riboflavin-binding protein,Nc1ccc2cc3ccc(N)cc3nc2c1
Progesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,"Sodium/nucleoside cotransporter 1;Sigma non-opioid intracellular receptor 1;Multidrug resistance protein 1;Glucocorticoid receptor;Mineralocorticoid receptor;Estrogen receptor;Androgen receptor;Progesterone receptor;Corticosteroid-binding globulin;Sex hormone-binding globulin;Sterol O-acyltransferase 1;Fatty acid-binding protein, intestinal;Fatty acid-binding protein, liver;C-8 sterol isomerase;Steroid 5-alpha-reductase;Cation channel sperm-associated protein 1;Cation channel sperm-associated protein 2;Cation channel sperm-associated protein 3;Cation channel sperm-associated protein 4;Short transient receptor potential channel 5;P2X purinoceptor 3",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Proguanil,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,Bifunctional dihydrofolate reductase-thymidylate synthase;Trace amine-associated receptor 1,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1
Promazine,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,Histamine H1 receptor,CN(C)CCCN1c2ccccc2Sc2ccccc21
Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Cholinesterase;Major prion protein;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;Pleiotropic ABC efflux transporter of multiple drugs;Sodium channel alpha subunits; brain (Types I, II, III);Chloroquine resistance transporter;FAD-linked sulfhydryl oxidase ALR;Calmodulin;Calmodulin-1",CC(CN1c2ccccc2Sc2ccccc21)N(C)C
Propafenone,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1,"Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sodium channel protein type 5 subunit alpha;Sodium channel subunit beta-1;Sodium channel subunit beta-2;Sodium channel subunit beta-3;Sodium channel subunit beta-4;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Aldehyde oxidase;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Cytochrome P450 1A2;Potassium channel subfamily K member 2;Potassium voltage-gated channel subfamily A member 5;Potassium channel subfamily K member 3;Solute carrier family 22 member 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;Solute carrier family 22 member 2;Sulfonylurea receptor 2, Kir6.2",CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
Propanoic acid,CCC(O)=O,,CCC(=O)O
Propantheline,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C
Proparacaine,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC,"Sigma non-opioid intracellular receptor 1;Amine oxidase [flavin-containing] A;Sodium channel protein type 10 subunit alpha;Sodium channel alpha subunits; brain (Types I, II, III)",CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
Propiolactone,O=C1CCO1,Glucocorticoid receptor;Nuclear receptor subfamily 1 group I member 2;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Estrogen receptor beta;Cytochrome P450 2C19;Multidrug and toxin extrusion protein 1,O=C1CCO1
Propiomazine,CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1,D(1A) dopamine receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;D(4) dopamine receptor;Alpha-1B adrenergic receptor,CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2
Propiverine,CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1,Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1
Propofol,CC(C)C1=CC=CC(C(C)C)=C1O,Fatty-acid amide hydrolase 1;Prostaglandin G/H synthase 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Carbonic anhydrase 2;Carbonic anhydrase 1;Cytochrome P450 2C9;Arachidonate 15-lipoxygenase;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-2/beta-2/gamma-2,CC(C)c1cccc(C(C)C)c1O
Propoxycaine,CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC,"Sodium channel alpha subunits; brain (Types I, II, III)",CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC
Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,Sigma non-opioid intracellular receptor 1;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Histamine H1 receptor;Beta-3 adrenergic receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Cytochrome P450 2D6;Voltage-dependent L-type calcium channel subunit alpha-1C;Cytochrome P450 1A2;Solute carrier family 22 member 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Membrane-associated progesterone receptor component 1;D(2) dopamine receptor;Beta-2 adrenergic receptor;Beta-1 adrenergic receptor;Adrenergic receptor beta,CC(C)NCC(O)COc1cccc2ccccc12
Propyl alcohol,CCCO,,CCCO
Propylene glycol,CC(O)CO,,CC(O)CO
Propylhexedrine,CNC(C)CC1CCCCC1,,CNC(C)CC1CCCCC1
Propyliodone,CCCOC(=O)CN1C=C(I)C(=O)C(I)=C1,,CCCOC(=O)Cn1cc(I)c(=O)c(I)c1
Propylparaben,CCCOC(=O)C1=CC=C(O)C=C1,,CCCOC(=O)c1ccc(O)cc1
Propylthiouracil,CCCC1=CC(=O)NC(=S)N1,Thyroid peroxidase;Myeloperoxidase;Type I iodothyronine deiodinase;Taste receptor type 2 member 38,CCCc1cc(=O)[nH]c(=S)[nH]1
Protionamide,CCCC1=CC(=CC=N1)C(N)=S,Polyphenol oxidase 2,CCCc1cc(C(N)=S)ccn1
Protirelin,[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O,Thyrotropin-releasing hormone receptor;Protein Trhr2; Thyrotropin releasing hormone receptor 2; Thyrotropin-releasing hormone receptor 2;Thyrotropin-releasing hormone receptor 2,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1
Protokylol,CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1,Beta-2 adrenergic receptor,CC(Cc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(O)c1
Protriptyline,CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12,Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Adenosine receptor A3,CNCCCC1c2ccccc2C=Cc2ccccc21
Proxibarbal,CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O,,C=CCC1(CC(C)O)C(=O)NC(=O)NC1=O
Prucalopride,COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1,D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;5-hydroxytryptamine receptor 4,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1
Prussian blue,[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N,,N#[C][Fe-4]([C]#N)([C]#N)([C]#N)([C]#N)[C]#N.N#[C][Fe-4]([C]#N)([C]#N)([C]#N)([C]#N)[C]#N.N#[C][Fe-4]([C]#N)([C]#N)([C]#N)([C]#N)[C]#N.[Fe+3].[Fe+3].[Fe+3].[Fe+3]
Pseudoephedrine,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,Beta-2 adrenergic receptor;Alpha-2A adrenergic receptor;Sodium-dependent noradrenaline transporter;Alpha-1A adrenergic receptor,CN[C@@H](C)[C@@H](O)c1ccccc1
Pyrantel,[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1,Acetylcholinesterase,CN1CCCN=C1/C=C/c1cccs1
Pyrazinamide,NC(=O)C1=NC=CN=C1,Cytochrome P450 3A4;Carbonic anhydrase 2;Cyclopropane mycolic acid synthase 1;Amidase; Nicotinamidase; Nicotinamidase/pyrazinamidase; Pyrazinamidase; Pyrazinamidase/nicotinamidase; Pyrazinamidase/nicotinamidase PncA;Cytochrome P450 3A5;3-oxoacyl-ACP synthase; Fatty acid synthase Fas; Probable fatty acid synthase Fas (Fatty acid synthetase),NC(=O)c1cnccn1
Pyridostigmine,CN(C)C(=O)OC1=C[N+](C)=CC=C1,Acetylcholinesterase;Cholinesterase,CN(C)C(=O)Oc1ccc[n+](C)c1
Pyridoxal phosphate,CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O,,Cc1ncc(COP(=O)(O)O)c(C=O)c1O
Pyridoxine,CC1=C(O)C(CO)=C(CO)C=N1,"Serine hydroxymethyltransferase, cytosolic;Pyridoxine-5'-phosphate oxidase;Pyridoxal phosphate phosphatase;Pyridoxal kinase;Cystathionine beta-synthase;Phosphoserine aminotransferase",Cc1ncc(CO)c(CO)c1O
Pyrimethamine,CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1,Muscarinic acetylcholine receptor M1;Dihydrofolate reductase;Cytochrome P450 2C9;Bifunctional dihydrofolate reductase-thymidylate synthase;Solute carrier family 22 member 1;Pteridine reductase 1;Multidrug and toxin extrusion protein 1;Beta-hexosaminidase subunit alpha;Beta-hexosaminidase subunit beta;Multidrug and toxin extrusion protein 2,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1
Pyrithione,[O-][N+]1=C(S)C=CC=C1,"Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;FAD-linked sulfhydryl oxidase ALR;Protein-lysine 6-oxidase;Lysyl oxidase homolog 3;Lysyl oxidase homolog 4;Lysyl oxidase homolog 2",[O-][n+]1ccccc1S
Pyrophosphoric acid,OP(O)(=O)OP(O)(O)=O,,O=P(O)(O)OP(=O)(O)O
Pyruvic acid,CC(=O)C(O)=O,,CC(=O)C(=O)O
Pyrvinium,CN(C)C1=CC2=C(C=C1)[N+](C)=C(\C=C\C1=C(C)N(C(C)=C1)C1=CC=CC=C1)C=C2,"Fumarate reductase;Synaptojanin-2;Synaptojanin-1;Serine hydroxymethyltransferase, mitochondrial",Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1
Quaternium-15,[Cl-].[H]C(Cl)=C([H])C[N+]12CN3CN(CN(C3)C1)C2,,ClC=CC[N+]12CN3CN(CN(C3)C1)C2.[Cl-]
Quazepam,FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2,GABA A receptor alpha-1/beta-1/gamma-2;GABA A receptor alpha-3/beta-1/gamma-2;GABA A receptor alpha-2/beta-1/gamma-2,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21
Quetiapine,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Membrane-associated progesterone receptor component 1;Transporter;Histone H1.0,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
Quinagolide,[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC,Serotonin (5-HT) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Adrenergic receptor alpha-1,CCCN1C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]2Cc3c(O)cccc3C[C@H]21
Quinapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
Quinestrol,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3,Estrogen receptor,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC5CCCC5)ccc4[C@H]3CC[C@@]21C
Quinethazone,CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O,Solute carrier family 12 member 3,CCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1
Quinidine,[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,"Sodium channel protein type 5 subunit alpha;Sodium channel subunit beta-1;Sodium channel subunit beta-2;Sodium channel subunit beta-3;Sodium channel subunit beta-4;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Muscarinic acetylcholine receptor M2;Cholinesterase;Potassium voltage-gated channel subfamily A member 5;Potassium voltage-gated channel subfamily H member 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Potassium voltage-gated channel subfamily A member 7;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Sodium channel alpha subunits; brain (Types I, II, III);Equilibrative nucleoside transporter 4;Potassium voltage-gated channel subfamily D member 2;Potassium channel subfamily T member 1;Cytochrome P450 2D6",C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12
Quinidine barbiturate,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C,,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12.CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
Quinine,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,"Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Hemoglobin subunit alpha;Potassium voltage-gated channel subfamily B member 2;Solute carrier family 22 member 1;Sodium channel alpha subunits; brain (Types I, II, III);Equilibrative nucleoside transporter 4",C=C[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12
Quinupramine,C1CN2CCC1C(C2)N1C2=CC=CC=C2CCC2=CC=CC=C12,"D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Sodium-dependent dopamine transporter;Adenosine receptor A3;Major prion protein;Solute carrier family 22 member 1;Potassium voltage-gated channel subfamily H member 1;Transporter;Pleiotropic ABC efflux transporter of multiple drugs;Solute carrier family 22 member 2;Glutamate NMDA receptor;Muscarinic acetylcholine receptor;Serotonin (5-HT) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Adrenergic receptor alpha-1;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;G protein-activated inward rectifier potassium channel 4;G protein-activated inward rectifier potassium channel 2;Sphingomyelin phosphodiesterase",c1ccc2c(c1)CCc1ccccc1N2C1CN2CCC1CC2
Quinupristin,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1,,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O
Rabeprazole,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1,"Alpha-2B adrenergic receptor;D(3) dopamine receptor;5-hydroxytryptamine receptor 1D;Sodium/potassium-transporting ATPase subunit alpha-1;Adenosine receptor A3;Fatty acid synthase;Potassium-transporting ATPase;Insulin-degrading enzyme;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1;Cytosolic endo-beta-N-acetylglucosaminidase;Sterile alpha and TIR motif-containing protein 1",COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C
Racemethionine,CSCCC(N)C(O)=O,Protein arginine N-methyltransferase 1;S-adenosylmethionine decarboxylase proenzyme;Met repressor;Phenylethanolamine N-methyltransferase;Protein-beta-aspartate methyltransferase,CSCCC(N)C(=O)O
Racephedrine,CN[C@H](C)[C@@H](O)C1=CC=CC=C1,Beta-2 adrenergic receptor,CN[C@H](C)[C@@H](O)c1ccccc1
Radium Ra 223 dichloride,[Cl-].[Cl-].[223Ra++],,[223Ra+2].[Cl-].[Cl-]
Raloxifene,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,"Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Aldehyde oxidase;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Nuclear receptor subfamily 1 group I member 2;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Estrogen receptor;Delta-type opioid receptor;Acetylcholinesterase;Cytochrome P450 2C9;Estrogen receptor beta;G-protein coupled estrogen receptor 1;Interleukin-6;Tyrosine-protein kinase Fyn;Bile acid receptor;Substance-K receptor;Phospholipase D1;Phospholipase D2;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;C-8 sterol isomerase;Cruzipain;Complement C5;HLA class I histocompatibility antigen, A-3 alpha chain",O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
Raltegravir,CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Gag-Pol polyprotein;Integrase;C-C chemokine receptor type 1,Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
Raltitrexed,CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,Thymidylate synthase;Dihydrofolate reductase;Bifunctional dihydrofolate reductase-thymidylate synthase;Folate receptor beta;Proton-coupled folate transporter;Folate transporter 1;Folate receptor alpha,Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1
Ramelteon,CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2,Melatonin receptor type 1A;Melatonin receptor type 1B,CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3
Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
Ranitidine,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O,Histamine H2 receptor;Acetylcholinesterase;Multidrug and toxin extrusion protein 1,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
Ranolazine,COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Voltage-gated sodium channel Nav1.5 cardiac isoform,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Rapacuronium,[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1,Muscle-type nicotinic acetylcholine receptor,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1
Rasagiline,C#CCN[C@@H]1CCC2=CC=CC=C12,Acetylcholinesterase;Amine oxidase [flavin-containing] B;Cholinesterase;Amine oxidase [flavin-containing] A,C#CCN[C@@H]1CCc2ccccc21
Rebamipide,OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C1=CC=C(Cl)C=C1,Cholecystokinin receptor type A,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1
Reboxetine,[H][C@@]1(CNCCO1)[C@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Sodium-dependent dopamine transporter;G protein-activated inward rectifier potassium channel 2;Transporter;Kir3.1/Kir3.2;Kir3.1/Kir3.4,CCOc1ccccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
Regadenoson,CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1,Adenosine receptor A2a;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3,CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Glycine receptor subunit alpha-1;Platelet-derived growth factor receptor beta;Mast/stem cell growth factor receptor Kit;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Angiopoietin-1 receptor;Fibroblast growth factor receptor 1;Bifunctional epoxide hydrolase 2;Vascular endothelial growth factor receptor 3,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Relebactam,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O,Beta-lactamase,O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Relugolix,CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1,Gonadotropin-releasing hormone receptor,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Replicase polyprotein 1ab,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
Remifentanil,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC,Mu-type opioid receptor,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
Remimazolam,COC(=O)CC[C@@H]1N=C(C2=CC=CC=N2)C2=CC(Br)=CC=C2N2C(C)=CN=C12,GABA A receptor alpha-3/beta-2/gamma-2;GABA-A receptor; alpha-1/beta-2/gamma-2;GABA A receptor alpha-2/beta-2/gamma-2;GABA A receptor alpha-5/beta-2/gamma-2;GABA-A receptor; benzodiazepine binding site,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21
Remoxipride,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC,D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;D(3) dopamine receptor;D(4) dopamine receptor;Dopamine receptor,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC
Repaglinide,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O,"ATP-binding cassette sub-family C member 8;Solute carrier organic anion transporter family member 1B1;Solute carrier family 22 member 1;Sulfonylurea receptor 1, Kir6.2;Sulfonylurea receptor 2, Kir6.2",CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O
Rescinnamine,[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,Synaptic vesicular amine transporter,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)C=Cc2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
Reserpine,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,"Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Multidrug resistance protein 1;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;ATP-binding cassette sub-family G member 2;Synaptic vesicular amine transporter;Quinolone resistance protein NorA;Chromaffin granule amine transporter;Sodium channel alpha subunits; brain (Types I, II, III);Sodium-dependent serotonin transporter",COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
Resorcinol,OC1=CC(O)=CC=C1,"Carbonic anhydrase 2;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 14;Carbonic anhydrase 13;Prostaglandin G/H synthase 1;Carbonic anhydrase",Oc1cccc(O)c1
Resorcinol monoacetate,CC(=O)OC1=CC(O)=CC=C1,,CC(=O)Oc1cccc(O)c1
Retapamulin,[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C,,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2C[C@H]3CC[C@@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
Revefenacin,CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine receptor A1;Adenosine kinase;Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;Cytosolic purine 5'-nucleotidase;Inosine-5'-monophosphate dehydrogenase 1;Inosine-5'-monophosphate dehydrogenase 2;DNA topoisomerase 1;NS5B protein,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
Ribociclib,CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1,Cyclin-dependent kinase 2;Cyclin-dependent kinase 6;Cyclin-dependent kinase 4,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1
Riboflavin,CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1,Flavin reductase (NADPH);Riboflavin kinase;Riboflavin-binding protein,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C
Ribostamycin,[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@@H](O)[C@H]1O,,NC[C@H]1O[C@H](O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O
Rifabutin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21,DNA-directed RNA polymerase subunit beta;Bacterial DNA-directed RNA polymerase,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O
Rifampicin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C,Nuclear receptor subfamily 1 group I member 2;Enoyl-[acyl-carrier-protein] reductase [NADH];Bile salt export pump;Caspase-1;Solute carrier organic anion transporter family member 1B1;Lanosterol 14-alpha demethylase;DNA-directed RNA polymerase subunit beta;Arachidonate 15-lipoxygenase;Solute carrier organic anion transporter family member 1A2;Solute carrier organic anion transporter family member 1B3;Glutathione S-transferase omega-1,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Rifamycin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O,Bile salt export pump;Solute carrier organic anion transporter family member 1B1;Solute carrier organic anion transporter family member 1A2;DNA-directed RNA polymerase subunit beta,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Rifapentine,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O,Bacterial DNA-directed RNA polymerase,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Rifaximin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O,Nuclear receptor subfamily 1 group I member 2;Bacterial DNA-directed RNA polymerase,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Rilmenidine,C1CC1C(NC1=NCCO1)C1CC1,Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Nischarin,C1COC(NC(C2CC2)C2CC2)=N1
Rilpivirine,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Potassium voltage-gated channel subfamily H member 2;Reverse transcriptase/RNaseH;Reverse transcriptase;Reverse transcriptase protein,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1
Riluzole,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2,"Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent noradrenaline transporter;Intermediate conductance calcium-activated potassium channel protein 4;Glutamate receptor ionotropic, NMDA 3A;Small conductance calcium-activated potassium channel protein 3;Pteridine reductase 1;Small conductance calcium-activated potassium channel protein 1;Short transient receptor potential channel 5;Small conductance calcium-activated potassium channel protein 2",Nc1nc2ccc(OC(F)(F)F)cc2s1
Rimantadine,CC(N)C12CC3CC(CC(C3)C1)C2,Matrix protein 2;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Polymerase acidic protein,CC(N)C12CC3CC(CC(C3)C1)C2
Rimegepant,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=C1C=CC=N2)C1=C(F)C(F)=CC=C1,Calcitonin gene-related peptide type 1 receptor,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
Rimexolone,[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Rimonabant,CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1,Potassium voltage-gated channel subfamily H member 2;Acetylcholinesterase;Cannabinoid receptor 2;N-arachidonyl glycine receptor;Cannabinoid receptor 1;G-protein coupled receptor 55,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1
Riociguat,COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2,"cAMP-specific 3',5'-cyclic phosphodiesterase 7B;Guanylate cyclase soluble subunit beta-1",COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N
Ripretinib,CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1,Platelet-derived growth factor receptor beta;Vascular endothelial growth factor receptor 2;Macrophage colony-stimulating factor 1 receptor;Angiopoietin-1 receptor;Mast/stem cell growth factor receptor Kit;Platelet-derived growth factor receptor alpha,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Risdiplam,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CCNC2(CC2)C1,,Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1
Risedronic acid,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O,,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Glycine receptor subunit alpha-1;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Transporter;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Serotonin 1 (5-HT1) receptor;Serotonin 2 (5-HT2) receptor;Histone H1.0,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Ritiometan,OC(=O)CSC(SCC(O)=O)SCC(O)=O,,O=C(O)CSC(SCC(=O)O)SCC(=O)O
Ritodrine,C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1,Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1
Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,Mu-type opioid receptor;Cytochrome P450 3A4;Multidrug resistance protein 1;Cytochrome P450 2D6;Nuclear receptor subfamily 1 group I member 2;Kappa-type opioid receptor;Cytochrome P450 2C9;Vasopressin V1a receptor;Gag-Pol polyprotein;Thromboxane-A synthase;Solute carrier family 22 member 1;Substance-K receptor;Cytochrome P450 3A5;Pol polyprotein;UDP-glucuronosyltransferase 1-1;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Protease,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Coagulation factor X;Suppressor of tumorigenicity 14 protein,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
Rivastigmine,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,Acetylcholinesterase;Cholinesterase;Butyrylcholinesterase; Protein Bche;Butyrylcholinesterase,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
Rizatriptan,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Cytochrome P450 2D6;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Serotonin 3 (5-HT3) receptor,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12
Rocuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,Acetylcholine receptor;Acetylcholine receptor; alpha1/beta1/delta/gamma,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1
Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Prostaglandin E2 receptor EP2 subtype;Cytochrome c oxidase subunit 2,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
Roflumilast,FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;cAMP-specific 3',5'-cyclic phosphodiesterase 4D;Phosphodiesterase 4;Phosphodiesterase",O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
Rolapitant,C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,Substance-P receptor,C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Rolitetracycline,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C,Insulin-degrading enzyme;Integrase;DNA repair protein RAD52 homolog,CN(C)[C@@H]1C(O)=C(C(=O)NCN2CCCC2)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
Romidepsin,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Histone deacetylase 5;Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 3;Histone deacetylase 6;Histone deacetylase 7;Histone deacetylase 8;Histone deacetylase 4;Histone deacetylase 9;Bromodomain-containing protein 4;Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2);Histone deacetylase 3/NCoR1;Histone deacetylase,C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O
Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 7;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor,CCCN(CCC)CCc1cccc2c1CC(=O)N2
Ropivacaine,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,Sodium channel protein type 5 subunit alpha;Sodium channel protein type 1 subunit alpha;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 3 subunit alpha;Sodium channel protein type 4 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha;Sodium channel protein type 10 subunit alpha;Potassium channel subfamily K member 3,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Rose bengal,OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12,,O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(=O)c(I)c-2oc2c(I)c(O)c(I)cc12
Rose bengal I-131,OC(=O)C1=C(C(Cl)=C(Cl)C(Cl)=C1Cl)C1=C2C=C([131I])C(=O)C([131I])=C2OC2=C([131I])C(O)=C([131I])C=C12,,O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc([131I])c(=O)c([131I])c-2oc2c([131I])c(O)c([131I])cc12
Rosiglitazone,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1,Potassium voltage-gated channel subfamily H member 2;Carbonic anhydrase 2;Bile salt export pump;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma;Retinoic acid receptor RXR-alpha;Retinoic acid receptor gamma;Thromboxane-A synthase;Peroxisome proliferator-activated receptor delta;Free fatty acid receptor 1;Type-1A angiotensin II receptor;Short transient receptor potential channel 5;Sodium/bile acid cotransporter;CDGSH iron-sulfur domain-containing protein 1;CDGSH iron-sulfur domain-containing protein 2,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
Rosoxacin,CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1,Gamma-aminobutyric acid receptor subunit alpha-2;Sodium-dependent serotonin transporter;Muscarinic acetylcholine receptor M1;DNA gyrase subunit A;DNA gyrase subunit B;Histamine H3 receptor;Gag-Pro-Pol polyprotein;GABA-A receptor; anion channel;CAAX prenyl protease 1;Trypsin,CCn1cc(C(=O)O)c(=O)c2ccc(-c3ccncc3)cc21
Rosuvastatin,CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O,3-hydroxy-3-methylglutaryl-coenzyme A reductase;Phosphodiesterase 6D,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O
Rotigotine,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1,D(1A) dopamine receptor;D(2) dopamine receptor;D(3) dopamine receptor;D(1B) dopamine receptor;D(4) dopamine receptor,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1
Roxadustat,CC1=NC(C(=O)NCC(O)=O)=C(O)C2=C1C=C(OC1=CC=CC=C1)C=C2,Alpha-ketoglutarate-dependent dioxygenase FTO;Egl nine homolog 1;Egl nine homolog 2;Egl nine homolog 3,Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12
Roxithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,50S ribosomal protein L10;Motilin receptor;Alpha-1B adrenergic receptor,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
Rubidium,[Rb],,[Rb]
Rubidium Rb-82,[82Rb+],,[82Rb+]
Rucaparib,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3,Tankyrase-2;Tankyrase-1;Poly [ADP-ribose] polymerase 4;Poly [ADP-ribose] polymerase 10;Poly [ADP-ribose] polymerase 12;Poly [ADP-ribose] polymerase 14;Poly [ADP-ribose] polymerase 15;Poly [ADP-ribose] polymerase 2;Poly [ADP-ribose] polymerase 1;Poly [ADP-ribose] polymerase 3,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1
Rufinamide,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,"Carbonic anhydrase 5A, mitochondrial;Sodium channel alpha subunit",NC(=O)c1cn(Cc2c(F)cccc2F)nn1
Rupatadine,CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1,Histamine H1 receptor;Platelet-activating factor receptor,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1
Rutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
Ruxolitinib,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,"Tyrosine-protein kinase JAK3;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Serine/threonine-protein kinase B-raf;Proto-oncogene tyrosine-protein kinase receptor Ret;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Myosin light chain kinase, smooth muscle;Death-associated protein kinase 3;Histone deacetylase 6;Calcium/calmodulin-dependent protein kinase type 1;Mitogen-activated protein kinase 8;Rho-associated protein kinase 1;Tyrosine-protein kinase JAK1;Serine/threonine-protein kinase PLK1;Death-associated protein kinase 2;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Calcium/calmodulin-dependent protein kinase type II subunit delta;Calcium/calmodulin-dependent protein kinase type II subunit gamma;AP2-associated protein kinase 1;Serine/threonine-protein kinase MARK2;Ribosomal protein S6 kinase alpha-2;Calcium/calmodulin-dependent protein kinase type II subunit beta;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase 17B;Protein kinase C epsilon type;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Serine/threonine-protein kinase 17A;ALK tyrosine kinase receptor;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Dual specificity protein kinase CLK2;Cyclin-G-associated kinase;Calcium/calmodulin-dependent protein kinase type 1D;Activated CDC42 kinase 1;Ribosomal protein S6 kinase alpha-5;Dual specificity protein kinase CLK4;MAP kinase-interacting serine/threonine-protein kinase 2;Calcium/calmodulin-dependent protein kinase type 1G;Inhibitor of nuclear factor kappa-B kinase subunit beta;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;BDNF/NT-3 growth factors receptor;Cyclin-dependent kinase 7;Serine/threonine-protein kinase DCLK3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TYK2;Serine/threonine-protein kinase 25;Serine/threonine-protein kinase RIO1;NT-3 growth factor receptor;Casein kinase II subunit alpha;Casein kinase II subunit alpha';Inhibitor of nuclear factor kappa-B kinase subunit epsilon;Dual specificity mitogen-activated protein kinase kinase 3;Maternal embryonic leucine zipper kinase;Serine/threonine-protein kinase 26;Serine/threonine-protein kinase Nek7;Serine/threonine-protein kinase RIO3;SRSF protein kinase 1;Ankyrin repeat and protein kinase domain-containing protein 1;Myotonin-protein kinase;Leukocyte tyrosine kinase receptor;Serine/threonine-protein kinase PAK 6;Serine/threonine-protein kinase PAK 7;Bone morphogenetic protein receptor type-2;Dual specificity mitogen-activated protein kinase kinase 4;Death-associated protein kinase 1;Serine/threonine-protein kinase DCLK1;Serine/threonine-protein kinase DCLK2;Serine/threonine-protein kinase PAK 4;Serine/threonine-protein kinase PLK3;cGMP-dependent protein kinase 2;Ribosomal protein S6 kinase alpha-1;Ribosomal protein S6 kinase alpha-4;Casein kinase I isoform alpha;Mitogen-activated protein kinase kinase kinase kinase 2;Serine/threonine-protein kinase TBK1;Dual specificity tyrosine-phosphorylation-regulated kinase 1A;Dual specificity tyrosine-phosphorylation-regulated kinase 2;Ephrin type-B receptor 6;Serine/threonine-protein kinase/endoribonuclease IRE1;Rhodopsin kinase;G protein-coupled receptor kinase 4;G protein-coupled receptor kinase 7;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Microtubule-associated serine/threonine-protein kinase 1;Serine/threonine-protein kinase OSR1;Serine/threonine-protein kinase RIO2;SRSF protein kinase 3;STE20/SPS1-related proline-alanine-rich protein kinase;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Serine/threonine-protein kinase ULK1;Serine/threonine-protein kinase ULK2;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Homeodomain-interacting protein kinase 1;Mitogen-activated protein kinase kinase kinase 15;Serine/threonine-protein kinase PLK2;Receptor-interacting serine/threonine-protein kinase 4;Uncharacterized serine/threonine-protein kinase SBK3;Mitogen-activated protein kinase kinase kinase 1;Phosphatidylinositol 4-kinase beta;Serine/threonine-protein kinase SIK3;Bone morphogenetic protein receptor type-1B;Serine/threonine-protein kinase SBK1;Serine/threonine-protein kinase Nek3;Peripheral plasma membrane protein CASK;Serine/threonine-protein kinase VRK2;Serine/threonine-protein kinase TAO2;Leucine-rich repeat serine/threonine-protein kinase 2;Serine/threonine-protein kinase PknB;JAK2/JAK1;JAK3/JAK1;JAK1/TYK2;JAK1/JAK2/TYK2;JAK2/TYK2;Oxysterols receptor LXR-beta",N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Sacubitril,CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O,Neprilysin,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O
Safinamide,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O,"Sodium channel protein type 9 subunit alpha;Amine oxidase [flavin-containing] A;Sigma non-opioid intracellular receptor 1;Amine oxidase [flavin-containing] B;Sodium channel alpha subunits; brain (Types I, II, III)",C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O
Salbutamol,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
Salicylamide,NC(=O)C1=CC=CC=C1O,"Sulfonylurea receptor 2, Kir6.2;Sulfonylurea receptor 1, Kir6.2",NC(=O)c1ccccc1O
Salicylic acid,OC(=O)C1=CC=CC=C1O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Acidic phospholipase A2 3;Gamma-glutamyltranspeptidase 1;Acid-sensing ion channel 3;Nicotinate phosphoribosyltransferase,O=C(O)c1ccccc1O
Salmeterol,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(2) dopamine receptor;D(3) dopamine receptor;Aldehyde oxidase;Beta-3 adrenergic receptor,OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O
Salsalate,OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Arachidonate 5-lipoxygenase;Peroxisome proliferator-activated receptor gamma,O=C(Oc1ccccc1C(=O)O)c1ccccc1O
Samarium (153Sm) lexidronam,[153Sm+3].OP(O)(=O)CN(CCN(CP(O)([O-])=O)CP(O)([O-])=O)CP(O)([O-])=O,,O=P([O-])(O)CN(CCN(CP(=O)([O-])O)CP(=O)(O)O)CP(=O)([O-])O.[153Sm+3]
Samidorphan,NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)C2=C1O,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
Sapropterin,[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O,"Nitric oxide synthase, brain;Phenylalanine-4-hydroxylase",C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)[nH]c(=O)c2N1
Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,Mu-type opioid receptor;Cytochrome P450 3A4;Multidrug resistance protein 1;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;Canalicular multispecific organic anion transporter 1;Sodium-dependent dopamine transporter;Kappa-type opioid receptor;Multidrug resistance-associated protein 1;Delta-type opioid receptor;Vasopressin V1a receptor;Gag-Pol polyprotein;Thromboxane-A synthase;Substance-K receptor;Pol polyprotein;Protease;Chloroquine resistance transporter,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
Sarecycline,[H][C@@]12CC3=C(CN(C)OC)C=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,DNA repair protein RAD52 homolog,CON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Saxagliptin,[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,Cytochrome P450 3A4;Multidrug resistance protein 1;Dipeptidyl peptidase 4;Dipeptidyl peptidase 8;Dipeptidyl peptidase 9,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
Scopolamine,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Muscarinic receptor M1;Muscarinic acetylcholine receptor DM1;Muscarinic acetylcholine receptor,CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12
Secnidazole,CC(O)CN1C(C)=NC=C1N(=O)=O,3-oxoacyl-[acyl-carrier-protein] synthase 3,Cc1ncc([N+](=O)[O-])n1CC(C)O
Secobarbital,CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,Matrix metalloproteinase-9;GABA-A receptor alpha-1/beta-2/gamma-2,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
Segesterone acetate,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],"Cytochrome P450 3A4;Androgen receptor;Steroid 17-alpha-hydroxylase/17,20 lyase;Cytochrome P450 11B1, mitochondrial;Cytochrome P450 11B2, mitochondrial;Cytochrome P450 17A1",C=C1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O
Selegiline,C[C@H](CC1=CC=CC=C1)N(C)CC#C,Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Monoamine oxidase,C#CCN(C)[C@H](C)Cc1ccccc1
Selenic acid,O[Se](O)(=O)=O,,O=[Se](=O)(O)O
Selenious acid,O[Se](O)=O,,O=[Se](O)O
Selenium,[Se],Gamma-butyrobetaine dioxygenase,[Se]
Selenium Sulfide,S=[Se]=S,,S=[Se]=S
Selenomethionine,C[Se]CC[C@H](N)C(O)=O,S-ribosylhomocysteine lyase,C[Se]CC[C@H](N)C(=O)O
Selenomethionine Se-75,C[75Se]CC[C@H](N)C(O)=O,,C[75Se]CC[C@H](N)C(=O)O
Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Prostacyclin receptor,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1
Selinexor,FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F,Exportin-1,O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1
Selpercatinib,COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1,Aurora kinase B;Proto-oncogene tyrosine-protein kinase receptor Ret,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
Selumetinib,CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO,Epidermal growth factor receptor;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21
Semaglutide,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O,Glucagon-like peptide 1 receptor,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Serdexmethylphenidate,[H][C@@]1(CCCCN1C(=O)OC[N+]1=CC=CC(=C1)C(=O)N[C@@H](CO)C([O-])=O)[C@H](C(=O)OC)C1=CC=CC=C1,Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Transporter;Dopamine receptor,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)[O-])c1
Sertaconazole,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl,"Lanosterol 14-alpha demethylase;Indoleamine 2,3-dioxygenase 1",Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1
Sertindole,FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M3;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Alpha-1D adrenergic receptor;D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-1B adrenergic receptor;Adrenergic receptor alpha-1;Serotonin 2 (5-HT2) receptor,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
Sertraline,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2C19;Alpha-1B adrenergic receptor;Melanocortin receptor 5;Membrane-associated progesterone receptor component 1;Transporter;Transcriptional activator protein luxR,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
Setmelanotide,[H]N([H])C(=O)[C@@H]1CSSC[C@H](N([H])C(=O)[C@H](CCCN=C(N([H])[H])N([H])[H])N([H])C(C)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC2=CN=CN2[H])C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN([H])C3=CC=CC=C23)C(=O)N1,Melanocortin receptor 5;Melanocortin receptor 3;Melanocyte-stimulating hormone receptor;Melanocortin receptor 4,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC1=O
Sevelamer,NCC=C.ClCC1CO1,,C=CCN.ClCC1CO1
Sevoflurane,FCOC(C(F)(F)F)C(F)(F)F,Glycine receptor subunit alpha-1;Potassium channel subfamily K member 2;Potassium channel subfamily K member 3;Potassium channel subfamily K member 9;Potassium channel subfamily K member 10;Potassium channel subfamily K member 18;GABA-A receptor; anion channel,FCOC(C(F)(F)F)C(F)(F)F
Sibutramine,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Potassium voltage-gated channel subfamily D member 3;Cytochrome P450 2B6;Solute carrier family 22 member 2,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
Silanol,O[SiH3],Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,O[SiH3]
Sildenafil,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1,"Adenosine receptor A2a;Potassium voltage-gated channel subfamily H member 2;Adenosine receptor A1;Multidrug resistance-associated protein 5;cGMP-specific 3',5'-cyclic phosphodiesterase;Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha;Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A;cAMP-specific 3',5'-cyclic phosphodiesterase 4D;cGMP-dependent 3',5'-cyclic phosphodiesterase;High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A;Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha';High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A;High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A;Alpha-1B adrenergic receptor;Uncharacterized protein;Indoleamine 2,3-dioxygenase 2;Phosphodiesterase 3;Phosphodiesterase 4;Phosphodiesterase 1;Phosphodiesterase 6;Solute carrier organic anion transporter family member 1B3;Phosphodiesterase 2A",CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
Silicon,[Si],,[Si]
Silicon dioxide,O=[Si]=O,,O=[Si]=O
Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F,Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Alpha-1A adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
Silodrate,O.[O--].[O--].[Mg++].[Mg++].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O,,O.O=[Si]([O-])[O-].O=[Si]([O-])[O-].O=[Si]([O-])[O-].[Al+3].[Al+3].[Mg+2].[Mg+2].[O-2].[O-2]
Silver,[Ag],,[Ag]
Silver nitrate,[Ag+].[O-]N(=O)=O,,O=[N+]([O-])[O-].[Ag+]
Silver sulfadiazine,[Ag+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C1=NC=CC=N1,Dihydropteroate synthase;Aurora kinase A,Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+]
Simeprevir,[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C1C=CC(OC)=C2C)C1=NC(=CS1)C(C)C)C(=O)NS(=O)(=O)C1CC1,"Cathepsin S;Hepatitis C virus serine protease, NS3/NS4A;Nonstructural protein NS3-4A;Polyprotein;Genome polyprotein",COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C
Simethicone,O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C,S-ribosylhomocysteine lyase,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O
Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,Nuclear receptor subfamily 1 group I member 3;3-hydroxy-3-methylglutaryl-coenzyme A reductase;Acetylcholinesterase;Cholinesterase,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Sinapultide,CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O,Heat-stable enterotoxin receptor,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
Sincalide,CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Cholecystokinin receptor type A;Gastrin/cholecystokinin type B receptor;Cholecystokinin receptor,CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Siponimod,CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F,Sphingosine 1-phosphate receptor 4;Sphingosine 1-phosphate receptor 3;Sphingosine 1-phosphate receptor 2;Sphingosine 1-phosphate receptor 1;Sphingosine 1-phosphate receptor 5,CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1
Sirolimus,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,Sodium/nucleoside cotransporter 1;Cytochrome P450 3A4;Multidrug resistance protein 1;Peptidyl-prolyl cis-trans isomerase FKBP1A;Cytochrome P450 2C9;Serine/threonine-protein kinase mTOR;Peptidyl-prolyl cis-trans isomerase FKBP3;Cytochrome P450 2C19;Peptidyl-prolyl cis-trans isomerase FKBP1B;Peptidyl-prolyl cis-trans isomerase FKBP5;Programmed cell death protein 4;Eukaryotic translation initiation factor 4E,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
Sitagliptin,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F,Dipeptidyl peptidase 4;Angiotensin-converting enzyme;Prolyl endopeptidase FAP;Dipeptidyl peptidase 8;Dipeptidyl peptidase 9;Dipeptidyl peptidase 2;Dipeptidyl peptidase IV,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sitaxentan,CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl,Endothelin-1 receptor;Endothelin B receptor,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2
"Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)",[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC,,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC.[Na+]
Sodium acetate,[Na+].CC([O-])=O,,CC(=O)[O-].[Na+]
Sodium ascorbate,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,,O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Na+]
Sodium aurothiomalate,[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O,,O=C([O-])CC([S][Au])C(=O)[O-].[Na+].[Na+]
Sodium aurotiosulfate,O.O.[Na+].[Na+].[Na+].[Au+].[O-]S([S-])(=O)=O.[O-]S([S-])(=O)=O,,O.O.O=S(=O)([O-])[S-].O=S(=O)([O-])[S-].[Au+].[Na+].[Na+].[Na+]
Sodium bicarbonate,[Na+].OC([O-])=O,,O=C([O-])O.[Na+]
Sodium bisulfite,[Na+].OS([O-])=O,,O=S([O-])O.[Na+]
Sodium borate,[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2,,[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2
Sodium camphorsulfonate,[Na+].[H][C@]12CC[C@@](CS([O-])(=O)=O)(C(=O)C1)C2(C)C,,CC1(C)[C@H]2CC[C@@]1(CS(=O)(=O)[O-])C(=O)C2.[Na+]
Sodium carbonate,[Na+].[Na+].[O-]C([O-])=O,,O=C([O-])[O-].[Na+].[Na+]
Sodium chloride,[Na+].[Cl-],,[Cl-].[Na+]
Sodium chromate Cr-51,[Na+].[Na+].[O-][51Cr]([O-])(=O)=O,,[Na+].[Na+].[O]=[51Cr](=[O])([O-])[O-]
Sodium citrate,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]
Sodium feredetate,[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4,,O=C([O-])C[N+]12CC[N+]34CC(=O)[O][Fe-2]13([O]C(=O)C2)[O]C(=O)C4.[Na+]
Sodium ferric gluconate complex,[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Na+].[O-2].[O-2].[O-2]
Sodium fluoride,[F-].[Na+],,[F-].[Na+]
Sodium fluorophosphate,[Na+].[Na+].[O-]P([O-])(F)=O,,O=P([O-])([O-])F.[Na+].[Na+]
Sodium glycerophosphate,[Na+].[Na+].OCC(O)COP([O-])([O-])=O,,O=P([O-])([O-])OCC(O)CO.[Na+].[Na+]
Sodium hydroxide,[OH-].[Na+],,[Na+].[OH-]
Sodium iodide,[Na+].[I-],,[I-].[Na+]
Sodium lauryl sulfoacetate,[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,,CCCCCCCCCCCCOC(=O)CS(=O)(=O)[O-].[Na+]
Sodium metavanadate,[Na+].[O-][V](=O)=O,,[Na+].[O]=[V](=[O])[O-]
Sodium molybdate,[Na+].[Na+].[O-][Mo]([O-])(=O)=O,,[Na+].[Na+].[O]=[Mo](=[O])([O-])[O-]
Sodium oxybate,[Na+].OCCCC([O-])=O,,O=C([O-])CCCO.[Na+]
Sodium phosphate P 32,[Na+].[Na+].O[32P]([O-])([O-])=O,,O=[32P]([O-])([O-])O.[Na+].[Na+]
"Sodium phosphate, dibasic",[Na+].[Na+].OP([O-])([O-])=O,,O=P([O-])([O-])O.[Na+].[Na+]
"Sodium phosphate, monobasic",[Na+].OP(O)([O-])=O,Intestinal alkaline phosphatase,O=P([O-])(O)O.[Na+]
Sodium stibogluconate,O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO,,O.O.O.O.O.O.O.O.O.O=C([O-])[C@@H]1[O][Sb]2([O-])([O][Sb]34([OH])[O][C@H]([C@H](O)CO)[C@H]([O]3)[C@H](C(=O)[O-])[O]4)[O][C@H]([C@H](O)CO)[C@@H]1[O]2.[Na+].[Na+].[Na+]
Sodium sulfate,[Na+].[Na+].[O-]S([O-])(=O)=O,Bifunctional epoxide hydrolase 2,O=S(=O)([O-])[O-].[Na+].[Na+]
Sodium sulfide,[Na+].[Na+].[S--],,[Na+].[Na+].[S-2]
Sodium tartrate,[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)C(=O)[O-].[Na+].[Na+]
Sodium tetradecyl sulfate,[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O,,CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)[O-].[Na+]
Sodium zirconium cyclosilicate,[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1,,[Na+].[Na+].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1.[Zr]
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1,NS5B protein;Genome polyprotein,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1
Solifenacin,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1
Solriamfetol,N[C@@H](COC(N)=O)CC1=CC=CC=C1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter,NC(=O)OC[C@H](N)Cc1ccccc1
Somatostatin,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,Mu-type opioid receptor;Delta-type opioid receptor;Somatostatin receptor type 2;Somatostatin receptor type 3;Somatostatin receptor type 5;Somatostatin receptor;Somatostatin receptor type 4;Somatostatin receptor type 1,C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O
Sonidegib,[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1,Sonic hedgehog protein;Smoothened homolog,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Sorafenib,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,"Tyrosine-protein kinase JAK3;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;5-hydroxytryptamine receptor 5A;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Carbonic anhydrase 7;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Cyclin-dependent kinase 2;Insulin receptor;Fibroblast growth factor receptor 3;Tyrosine-protein kinase HCK;High affinity nerve growth factor receptor;Myosin light chain kinase 2, skeletal/cardiac muscle;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Ephrin type-A receptor 8;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;LIM domain kinase 1;Fibroblast growth factor receptor 1;Cyclin-dependent-like kinase 5;Serine/threonine-protein kinase 10;Serine/threonine-protein kinase PLK4;Aurora kinase C;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Mitogen-activated protein kinase 11;Ephrin type-A receptor 5;Ephrin type-A receptor 4;Fibroblast growth factor receptor 2;Mitogen-activated protein kinase 3;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Mitogen-activated protein kinase 12;Tyrosine-protein kinase Fgr;Aurora kinase A;Serine/threonine-protein kinase 36;Ephrin type-A receptor 3;Mitogen-activated protein kinase 14;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Mitogen-activated protein kinase kinase kinase kinase 5;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Ephrin type-A receptor 7;STE20-like serine/threonine-protein kinase;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Cyclin-dependent kinase 15;Bifunctional epoxide hydrolase 2;TGF-beta receptor type-2;Mitogen-activated protein kinase 1;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Ephrin type-B receptor 2;Cyclin-dependent kinase 7;Ribosomal protein S6 kinase alpha-6;Non-receptor tyrosine-protein kinase TNK1;Mitogen-activated protein kinase 13;Cyclin-dependent kinase 17;Cyclin-dependent kinase 14;Mitogen-activated protein kinase kinase kinase MLT;Tyrosine-protein kinase receptor Tie-1;NT-3 growth factor receptor;LIM domain kinase 2;MAP kinase-interacting serine/threonine-protein kinase 1;Serine/threonine-protein kinase NLK;Serine/threonine-protein kinase 33;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Mitogen-activated protein kinase kinase kinase kinase 1;Aurora kinase B;Mitogen-activated protein kinase kinase kinase kinase 4;Tyrosine-protein kinase Mer;Cyclin-dependent kinase 19;Cyclin-dependent kinase 8;Muscle, skeletal receptor tyrosine-protein kinase;Citron Rho-interacting kinase;Myosin-IIIb;Cyclin-dependent kinase 3;Tyrosine-protein kinase Srms;Ephrin type-A receptor 1;Mitogen-activated protein kinase 15;Receptor-interacting serine/threonine-protein kinase 1;Casein kinase I isoform alpha;Cyclin-dependent kinase-like 2;Cyclin-dependent kinase-like 3;Ephrin type-B receptor 6;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Homeodomain-interacting protein kinase 4;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Mitogen-activated protein kinase kinase kinase 19;Homeodomain-interacting protein kinase 1;Serine/threonine-protein kinase TAO2;Dual specificity mitogen-activated protein kinase kinase 5;Myosin light chain kinase 3;Calcium-dependent protein kinase 1;Serine/threonine-protein kinase A-Raf;Purine nucleoside phosphorylase;Receptor-interacting serine/threonine-protein kinase 3",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sorbitol,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO
Sotagliflozin,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1,Sodium/glucose cotransporter 2;Sodium/glucose cotransporter 1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sotalol,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Potassium voltage-gated channel subfamily H member 2,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
Sotorasib,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F,GTPase KRas,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Sparfloxacin,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,Potassium voltage-gated channel subfamily H member 2;Topoisomerase IV;DNA gyrase,C[C@@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1
Spectinomycin,[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2,30S ribosomal protein S12,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O
Spinosad,[H][C@]1(C[C@@]2([H])C=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC.[H][C@]1(C[C@@]2([H])C(C)=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC,Nicotinic acetylcholine receptor,CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C(C)[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1.CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1
Spiramycin,[H][C@@]1(CC[C@@H]([C@@H](C)O1)N(C)C)O[C@H]1\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](O)[C@H](OC)[C@@H](O[C@]2([H])O[C@H](C)[C@@H](O[C@@]3([H])C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@H]1C,Bile salt export pump;Solute carrier organic anion transporter family member 1B1;Solute carrier organic anion transporter family member 1A2;DNA-directed RNA polymerase subunit beta,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
Spirapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,Glucocorticoid receptor;Nuclear receptor subfamily 1 group I member 2;Mineralocorticoid receptor;Androgen receptor;Progesterone receptor;Estrogen receptor beta;Cytochrome P450 2C19;Multidrug and toxin extrusion protein 1,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12
Squalene,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C,Dihydropteroate synthase,CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C
Stannous chloride,[Cl-].[Cl-].[Sn++],,[Cl-].[Cl-].[Sn+2]
Stannous fluoride,F[Sn]F,,[F][Sn][F]
Stanozolol,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C,Cytochrome P450 2D6;Adenosine receptor A3;Estrogen receptor;Androgen receptor;Cytochrome P450 2C9;Cytochrome P450 2C19;Progesterone receptor,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Stavudine,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,Gag-Pol polyprotein;Reverse transcriptase/RNaseH;Reverse transcriptase,Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
Stearic acid,CCCCCCCCCCCCCCCCCC(O)=O,,CCCCCCCCCCCCCCCCCC(=O)O
Steviolbioside,C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(O)=O,,C=C1C[C@@]23CC[C@H]4[C@@](C)(CCC[C@@]4(C)C(=O)O)[C@@H]2CC[C@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C3
Stiripentol,CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1,Cytochrome P450 3A4;Sodium- and chloride-dependent GABA transporter 1;Cytochrome P450 1A2;Cytochrome P450 2C19,CC(C)(C)C(O)/C=C/c1ccc2c(c1)OCO2
Streptomycin,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O,30S ribosomal protein S12,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
Streptozocin,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,30S ribosomal protein S12,CN(N=O)C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O
Strontium chloride,[Cl-].[Cl-].[Sr++],,[Cl-].[Cl-].[Sr+2]
Strontium chloride Sr-89,[Cl-].[Cl-].[89Sr++],,[89Sr+2].[Cl-].[Cl-]
Strontium ranelate,[Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,,N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2]
Succimer,OC(=O)[C@@H](S)[C@@H](S)C(O)=O,,O=C(O)[C@@H](S)[C@@H](S)C(=O)O
Succinic acid,OC(=O)CCC(O)=O,,O=C(O)CCC(=O)O
Succinylcholine,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Neuronal acetylcholine receptor subunit alpha-7;Acetylcholine-binding protein;Acetylcholine receptor subunit delta;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Muscarinic acetylcholine receptor;Nicotinic acetylcholine receptor alpha8 subunit,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
Sucralfate,O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O,Pepsin A-5,O.O=S(=O)(OC[C@H]1O[C@@](COS(=O)(=O)[O][Al]([OH])[OH])(O[C@H]2O[C@H](COS(=O)(=O)[O][Al]([OH])[OH])[C@@H](OS(=O)(=O)[O][Al]([OH])[OH])[C@H](OS(=O)(=O)[O][Al]([OH])[OH])[C@H]2OS(=O)(=O)[O][Al]([OH])[OH])[C@@H](OS(=O)(=O)[O][Al]([OH])[OH])[C@@H]1OS(=O)(=O)[O][Al]([OH])[OH])[O][Al]([OH])[OH].[OH][Al]([OH])[OH]
Sucrose,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Sufentanil,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1,Mu-type opioid receptor;Kappa-type opioid receptor;Delta-type opioid receptor;Solute carrier family 22 member 1;Sigma non-opioid intracellular receptor 1;Opioid receptor,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
Sugammadex,O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,,O=C(O)CCSC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]9CSCCC(=O)O)O[C@@H]8CSCCC(=O)O)O[C@@H]7CSCCC(=O)O)O[C@@H]6CSCCC(=O)O)O[C@@H]5CSCCC(=O)O)O[C@@H]4CSCCC(=O)O)O[C@@H]3CSCCC(=O)O
Sulbactam,[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O,"Beta-lactamase;Beta-lactamase TEM;Beta-lactamase SHV-1;Beta-lactamase OXA-1;Carbapenem-hydrolizing beta-lactamase SFC-1;Beta-lactamase GES-13;Class D beta-lactamase;Serine beta-lactamase-like protein LACTB, mitochondrial;ADC-18 protein;Beta-lactamase 1",CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
Sulconazole,ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,"Alpha-2A adrenergic receptor;Cytochrome P450 3A4;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Adenosine receptor A3;Lanosterol 14-alpha demethylase;Beta-lactamase;Cytochrome P450 2C9;Cytochrome P450 1A2;Cytochrome P450 2C19;Alkaline phosphatase, tissue-nonspecific isozyme;Tyrosine-protein kinase Fyn;Thromboxane-A synthase;Bile acid receptor;Indoleamine 2,3-dioxygenase 1;Substance-K receptor;Indoleamine 2,3-dioxygenase 2;Malate dehydrogenase cytoplasmic ",Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
Sulfabenzamide,NC1=CC=C(C=C1)S(=O)(=O)NC(=O)C1=CC=CC=C1,Dihydrofolate reductase;Dihydropteroate synthase,Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
Sulfacetamide,CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1,Dihydrofolate reductase;Dihydropteroate synthase,CC(=O)NS(=O)(=O)c1ccc(N)cc1
Sulfacytine,CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O,"7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase; Dihydropteroate synthetase",CCn1ccc(NS(=O)(=O)c2ccc(N)cc2)nc1=O
Sulfadiazine,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1,"5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;Dihydroorotate dehydrogenase (quinone), mitochondrial;Dihydropteroate synthase;Aurora kinase A;High affinity choline transporter 1",Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
Sulfadimethoxine,COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1,5-hydroxytryptamine receptor 6,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
Sulfadoxine,COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC,"7,8-dihydro-6-hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase; Dihydropteroate synthetase;6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase",COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
Sulfamerazine,CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1,Dihydropteroate synthase,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
Sulfameter,COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1,Dihydropteroate synthase,COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1
Sulfamethazine,CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1,Dihydropteroate synthase,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1
Sulfamethizole,CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,Dihydropteroate synthase,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
Sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,Bifunctional protein FolC;Dihydropteroate synthase;Dihydrofolate reductase;Pol polyprotein;Endothelin-1 receptor,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
Sulfametopyrazine,COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1,Dihydropteroate synthase,COc1nccnc1NS(=O)(=O)c1ccc(N)cc1
Sulfanilamide,NC1=CC=C(C=C1)S(N)(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Dihydropteroate synthase;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",Nc1ccc(S(N)(=O)=O)cc1
Sulfaphenazole,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1,Cytochrome P450 2C9;Dihydropteroate synthase,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
Sulfapyridine,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Dihydropteroate synthase;Dihydropteroate synthase type-1,Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1
Sulfasalazine,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1,"Carbonic anhydrase 2;Carbonic anhydrase 1;Acetyl-CoA acetyltransferase, mitochondrial;Arachidonate 5-lipoxygenase;Cystine/glutamate transporter;Caspase-1;Thromboxane-A synthase;Interstitial collagenase;Androgen receptor;Proton-coupled folate transporter;Aldose reductase;Mitogen-activated protein kinase 1;Cyclooxygenase;Sodium/bile acid cotransporter",O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Sulfathiazole,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1,Dihydropteroate synthase;Endothelin-1 receptor;Transcriptional activator protein LasR,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
Sulfinpyrazone,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1,Multidrug resistance-associated protein 1;fMet-Leu-Phe receptor;Solute carrier family 22 member 12;Nicotinate phosphoribosyltransferase,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
Sulfisoxazole,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,Dihydropteroate synthase;Endothelin-1 receptor;Endothelin B receptor,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
Sulfoxone,OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1,Mu-type opioid receptor;Cytochrome P450 2D6;Adenosine receptor A3;Kappa-type opioid receptor;Delta-type opioid receptor;C-C chemokine receptor type 5;Opioid receptor,O=S(O)CNc1ccc(S(=O)(=O)c2ccc(NCS(=O)O)cc2)cc1
Sulfur hexafluoride,FS(F)(F)(F)(F)F,,FS(F)(F)(F)(F)F
Sulindac,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Glycine receptor subunit alpha-1;Aldose reductase;Retinoic acid receptor RXR-alpha;72 kDa type IV collagenase;Lactoylglutathione lyase;Prostaglandin E synthase;Complement C5;Bile salt export pump,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)=O)cc1
Sulpiride,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O,"D(2) dopamine receptor;Alpha-2A adrenergic receptor;D(3) dopamine receptor;D(4) dopamine receptor;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 15;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Dopamine receptor;Carbonic anhydrase, alpha family;Carbonate dehydratase",CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
Sultamicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@@]2([H])S(=O)(=O)C1(C)C,Penicillin-binding protein 1A;Angiopoietin-1 receptor;Transient receptor potential cation channel subfamily M member 4;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C
Sulthiame,NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 9;Carbonic anhydrase 6;Carbonic anhydrase 15;Carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase, alpha family;Carbonate dehydratase",NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1
Sultopride,CCN1CCCC1CNC(=O)C1=CC(=CC=C1OC)S(=O)(=O)CC,D(2) dopamine receptor;D(3) dopamine receptor,CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC
Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 3A;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;Multidrug and toxin extrusion protein 1;5-hydroxytryptamine 1D receptor,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"Tyrosine-protein kinase JAK3;Potassium voltage-gated channel subfamily H member 2;Acetylcholinesterase;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Receptor-type tyrosine-protein kinase FLT3;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Ribosomal protein S6 kinase alpha-3;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Insulin-like growth factor 1 receptor;Myosin light chain kinase, smooth muscle;Insulin receptor;Death-associated protein kinase 3;Calcium/calmodulin-dependent protein kinase type 1;Fibroblast growth factor receptor 3;Rho-associated protein kinase 1;Focal adhesion kinase 1;Tyrosine-protein kinase HCK;Tyrosine-protein kinase JAK1;Mitogen-activated protein kinase 10;Death-associated protein kinase 2;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;High affinity nerve growth factor receptor;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Protein kinase C alpha type;Calcium/calmodulin-dependent protein kinase type II subunit delta;Myosin light chain kinase 2, skeletal/cardiac muscle;Calcium/calmodulin-dependent protein kinase type II subunit gamma;AP2-associated protein kinase 1;Serine/threonine-protein kinase MARK2;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;Serine/threonine-protein kinase Nek2;Ribosomal protein S6 kinase alpha-2;5'-AMP-activated protein kinase catalytic subunit alpha-1;Calcium/calmodulin-dependent protein kinase type II subunit beta;Fibroblast growth factor receptor 1;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Cyclin-dependent-like kinase 5;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase 17B;Serine/threonine-protein kinase 10;Tyrosine-protein kinase Fer;Serine/threonine-protein kinase PLK4;Aurora kinase C;Serine/threonine-protein kinase 16;Dual specificity protein kinase TTK;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 5;Fibroblast growth factor receptor 2;Serine/threonine-protein kinase N1;Protein kinase C theta type;Serine/threonine-protein kinase 17A;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;Aurora kinase A;ALK tyrosine kinase receptor;Ephrin type-A receptor 3;BMP-2-inducible protein kinase;Serine/threonine-protein kinase pim-2;Tyrosine-protein kinase FRK;Dual specificity protein kinase CLK1;Dual specificity protein kinase CLK2;Serine/threonine-protein kinase 38-like;Mitogen-activated protein kinase kinase kinase kinase 5;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Ephrin type-B receptor 1;Calcium/calmodulin-dependent protein kinase type 1D;Cyclin-dependent kinase 16;Serine/threonine-protein kinase 4;Activated CDC42 kinase 1;Ribosomal protein S6 kinase alpha-5;STE20-like serine/threonine-protein kinase;Dual specificity protein kinase CLK4;MAP kinase-interacting serine/threonine-protein kinase 2;Mitogen-activated protein kinase 9;Calcium/calmodulin-dependent protein kinase kinase 2;MAP/microtubule affinity-regulating kinase 3;Calcium/calmodulin-dependent protein kinase kinase 1;Calcium/calmodulin-dependent protein kinase type 1G;Epithelial discoidin domain-containing receptor 1;Solute carrier family 22 member 1;Testis-specific serine/threonine-protein kinase 1;3-phosphoinositide-dependent protein kinase 1;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Tyrosine-protein kinase ITK/TSK;Serine/threonine-protein kinase 3;Serine/threonine-protein kinase ULK3;Protein-tyrosine kinase 6;Tyrosine-protein kinase BTK;Tyrosine-protein kinase receptor UFO;BDNF/NT-3 growth factors receptor;Tyrosine-protein kinase receptor TYRO3;Cyclin-dependent kinase 7;Serine/threonine-protein kinase D1;Ribosomal protein S6 kinase beta-1;Serine/threonine-protein kinase N2;RAC-beta serine/threonine-protein kinase;Serine/threonine-protein kinase DCLK3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Serine/threonine-protein kinase Chk1;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Serine/threonine-protein kinase PAK 3;Cyclin-dependent kinase 17;Cyclin-dependent kinase 18;Cyclin-dependent kinase 14;Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha;Phosphatidylinositol 5-phosphate 4-kinase type-2 beta;Myosin light chain kinase family member 4;Wee1-like protein kinase;Serine/threonine-protein kinase 25;Protein-tyrosine kinase 2-beta;Serine/threonine-protein kinase RIO1;Casein kinase I isoform alpha-like;Casein kinase I isoform delta;Casein kinase I isoform gamma-2;Casein kinase I isoform gamma-3;Tyrosine-protein kinase receptor Tie-1;Serine/threonine-protein kinase tousled-like 1;Serine/threonine-protein kinase tousled-like 2;NT-3 growth factor receptor;Casein kinase II subunit alpha;Casein kinase II subunit alpha';Dual specificity tyrosine-phosphorylation-regulated kinase 1B;Inhibitor of nuclear factor kappa-B kinase subunit epsilon;Serine/threonine-protein kinase STK11;Dual specificity mitogen-activated protein kinase kinase 3;Maternal embryonic leucine zipper kinase;MAP kinase-interacting serine/threonine-protein kinase 1;Serine/threonine-protein kinase 26;Serine/threonine-protein kinase Nek7;Eukaryotic translation initiation factor 2-alpha kinase 4;Insulin receptor-related protein;Interleukin-1 receptor-associated kinase 3;Serine/threonine-protein kinase RIO3;Serine/threonine-protein kinase SIK2;SRSF protein kinase 1;SRSF protein kinase 2;Serine/threonine-protein kinase 33;5'-AMP-activated protein kinase catalytic subunit alpha-2;Ankyrin repeat and protein kinase domain-containing protein 1;Discoidin domain-containing receptor 2;Serine/threonine-protein kinase LATS1;Serine/threonine-protein kinase LATS2;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;Serine/threonine-protein kinase PAK 6;Serine/threonine-protein kinase PAK 7;NUAK family SNF1-like kinase 1;Serine/threonine-protein kinase pim-3;Mitogen-activated protein kinase kinase kinase kinase 3;Aurora kinase B;Tyrosine-protein kinase Blk;Bone morphogenetic protein receptor type-2;Serine/threonine-protein kinase BRSK1;Mitogen-activated protein kinase kinase kinase kinase 4;Serine/threonine-protein kinase MARK1;MAP/microtubule affinity-regulating kinase 4;Dual specificity mitogen-activated protein kinase kinase 4;Dual specificity mitogen-activated protein kinase kinase 6;Tyrosine-protein kinase Mer;Calcium/calmodulin-dependent protein kinase type IV;Mitogen-activated protein kinase kinase kinase 9;Mitogen-activated protein kinase kinase kinase 11;Serine/threonine-protein kinase 24;Muscle, skeletal receptor tyrosine-protein kinase;Citron Rho-interacting kinase;Casein kinase I isoform gamma-1;Death-associated protein kinase 1;Serine/threonine-protein kinase DCLK1;Serine/threonine-protein kinase DCLK2;Myosin-IIIa;Myosin-IIIb;Serine/threonine-protein kinase PAK 4;Serine/threonine-protein kinase BRSK2;Serine/threonine-protein kinase SIK1;Mitogen-activated protein kinase 7;Serine/threonine-protein kinase D2;Serine/threonine-protein kinase D3;Interferon-induced, double-stranded RNA-activated protein kinase;Receptor-interacting serine/threonine-protein kinase 1;Tyrosine-protein kinase Fes/Fps;Fibroblast growth factor receptor 4;Ribosomal protein S6 kinase alpha-1;Ribosomal protein S6 kinase alpha-4;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;Casein kinase I isoform alpha;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Serine/threonine-protein kinase TBK1;Interleukin-1 receptor-associated kinase 4;Cyclin-dependent kinase 4;Cyclin-dependent kinase-like 2;Serine/threonine-protein kinase Chk2;Protein delta homolog 1;Dual specificity tyrosine-phosphorylation-regulated kinase 1A;Dual specificity tyrosine-phosphorylation-regulated kinase 2;Ephrin type-B receptor 6;Serine/threonine-protein kinase/endoribonuclease IRE1;Rhodopsin kinase;G protein-coupled receptor kinase 4;G protein-coupled receptor kinase 7;Homeodomain-interacting protein kinase 2;Homeodomain-interacting protein kinase 3;Homeodomain-interacting protein kinase 4;Hormonally up-regulated neu tumor-associated kinase;Serine/threonine-protein kinase ICK;Inhibitor of nuclear factor kappa-B kinase subunit alpha;Interleukin-1 receptor-associated kinase 1;Mitogen-activated protein kinase kinase kinase 13;Mitogen-activated protein kinase kinase kinase 2;Mitogen-activated protein kinase kinase kinase 3;Microtubule-associated serine/threonine-protein kinase 1;Serine/threonine-protein kinase 38;Serine/threonine-protein kinase NIM1;Serine/threonine-protein kinase OSR1;U4/U6 small nuclear ribonucleoprotein Prp4;Serine/threonine-protein kinase RIO2;SRSF protein kinase 3;STE20/SPS1-related proline-alanine-rich protein kinase;Mitogen-activated protein kinase kinase kinase 7;Serine/threonine-protein kinase TAO1;Serine/threonine-protein kinase TAO3;Serine/threonine-protein kinase ULK1;Serine/threonine-protein kinase ULK2;Mitogen-activated protein kinase kinase kinase 19;Homeodomain-interacting protein kinase 1;Mitogen-activated protein kinase kinase kinase 15;Serine/threonine-protein kinase PLK2;Receptor-interacting serine/threonine-protein kinase 4;Uncharacterized serine/threonine-protein kinase SBK3;Serine/threonine-protein kinase 35;Tankyrase-2;Megakaryocyte-associated tyrosine-protein kinase;Bone morphogenetic protein receptor type-1B;Serine/threonine-protein kinase SBK1;Serine/threonine-protein kinase PRP4 homolog;Mitogen-activated protein kinase kinase kinase 12;Serine/threonine-protein kinase Sgk3;SNF-related serine/threonine-protein kinase;Dual specificity mitogen-activated protein kinase kinase 5;Myosin light chain kinase 3;Leucine-rich repeat serine/threonine-protein kinase 2;Dual serine/threonine and tyrosine protein kinase;Calcium-dependent protein kinase 1;Serine/threonine-protein kinase PknB;Bromodomain-containing protein 9;Ephrin type-A receptor 7;Ephrin type-B receptor 4;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Platelet-derived growth factor receptor alpha",CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Suprofen,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Cytochrome P450 2C9,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1
Suvorexant,[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,Orexin receptor type 2;Orexin receptor type 1,Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1
Synthetic camphor,CC1(C)C2CCC1(C)C(=O)C2,,CC12CCC(CC1=O)C2(C)C
Tacrine,NC1=C2CCCCC2=NC2=CC=CC=C12,Sodium-dependent noradrenaline transporter;Aldehyde oxidase;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Acetylcholinesterase;Acetylcholine receptor subunit epsilon;Solute carrier family 22 member 1;Alpha-1A adrenergic receptor;Muscarinic acetylcholine receptor M2;Butyrylcholinesterase; Protein Bche;Choline O-acetyltransferase;Muscarinic acetylcholine receptor M1;Amine oxidase [flavin-containing] A;Cholinesterase;Histamine N-methyltransferase;Butyrylcholinesterase;Glutamate NMDA receptor; GRIN1/GRIN2B;Glutamate NMDA receptor; GRIN1/GRIN2A;Muscarinic acetylcholine receptor;Amyloid beta A4 protein,Nc1c2c(nc3ccccc13)CCCC2
Tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Interleukin-5;Interferon gamma;Peptidyl-prolyl cis-trans isomerase FKBP1A;Interleukin-2;Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform;Serine/threonine-protein kinase mTOR;Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform;Peptidyl-prolyl cis-trans isomerase FKBP1B;Peptidyl-prolyl cis-trans isomerase FKBP5;Splicing factor 3B subunit 3;Peptidyl-prolyl cis-trans isomerase FKBP10,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
Tadalafil,[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1,"Potassium voltage-gated channel subfamily H member 2;cGMP-specific 3',5'-cyclic phosphodiesterase;Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;Acetylcholinesterase;Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha;Phosphodiesterase 6",CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
Tafamidis,OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1,ATP-binding cassette sub-family G member 2;Solute carrier family 22 member 6;Solute carrier family 22 member 8;Transthyretin,O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1
Tafenoquine,COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1,"Adenosine receptor A2a;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;Adenosine kinase;Adenosine deaminase;Mitogen-activated protein kinase kinase kinase 7;Adenosylhomocysteinase;Adenosine A2 receptor;Phosphatidylinositol 4-kinase type 2-alpha;Phosphatidylinositol 4-kinase type 2-beta;Glyceraldehyde-3-phosphate dehydrogenase liver;cAMP-dependent protein kinase A;Histone-lysine N-methyltransferase, H3 lysine-79 specific",COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1
Tafluprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1,Prostaglandin F2-alpha receptor,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O
Talazoparib,CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1,Tankyrase-2;Poly [ADP-ribose] polymerase 4;Poly [ADP-ribose] polymerase 10;Poly [ADP-ribose] polymerase 12;Poly [ADP-ribose] polymerase 15;Poly [ADP-ribose] polymerase 6;Mono [ADP-ribose] polymerase PARP16;Tankyrase-1;Poly [ADP-ribose] polymerase 2;Poly [ADP-ribose] polymerase 1;Poly [ADP-ribose] polymerase 3,Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1
Talbutal,CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,GABA-A receptor; anion channel,C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O
Talc,[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[O-][H],,[Mg+2].[Mg+2].[Mg+2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-].[OH-].[Si+4].[Si+4].[Si+4].[Si+4]
Tamoxifen,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,"Sodium/potassium-transporting ATPase subunit alpha-2;Beta-1 adrenergic receptor;Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Mu-type opioid receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Adenosine receptor A2a;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Beta-3 adrenergic receptor;Sodium-dependent dopamine transporter;Adenosine receptor A1;Adenosine receptor A3;Nuclear receptor subfamily 1 group I member 2;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Kappa-type opioid receptor;Estrogen receptor;Progesterone receptor;Delta-type opioid receptor;Estrogen receptor beta;G-protein coupled estrogen receptor 1;Estrogen-related receptor gamma;Epidermal growth factor receptor;Substance-P receptor;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Receptor tyrosine-protein kinase erbB-2;Thromboxane-A synthase;Steroid hormone receptor ERR1;Substance-K receptor;Androgen receptor;B2 bradykinin receptor;Melanocortin receptor 4;Melanocortin receptor 5;Melanocortin receptor 3;Membrane-associated progesterone receptor component 1;Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform;Alpha-1A adrenergic receptor;C-8 sterol isomerase;Solute carrier family 22 member 2;Emopamil-binding protein-like;Anti-estrogen binding site (AEBS);Transcriptional activator protein luxR",CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Tamsulosin,CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;D(3) dopamine receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Alpha-2B adrenergic receptor;Serotonin 1 (5-HT1) receptor,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
Tannic acid,OC1=CC(=CC(O)=C1O)C(=O)OC1=C(O)C(O)=CC(=C1)C(=O)OC[C@H]1OC(OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H]1OC(=O)C1=CC(OC(=O)C2=CC(O)=C(O)C(O)=C2)=C(O)C(O)=C1,Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Free fatty acid receptor 2;Free fatty acid receptor 3,O=C(OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1
Tapentadol,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1,Mu-type opioid receptor;Sodium-dependent noradrenaline transporter;Solute carrier family 22 member 1,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C
Tapinarof,CC(C)C1=C(O)C=C(\C=C\C2=CC=CC=C2)C=C1O,,CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O
Tasimelteon,CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2,Melatonin receptor type 1A;Melatonin receptor type 1B,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2
Taurine,NCCS(O)(=O)=O,Sodium-dependent noradrenaline transporter;Aldehyde oxidase;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Acetylcholinesterase;Acetylcholine receptor subunit epsilon;Solute carrier family 22 member 1;Alpha-1A adrenergic receptor;Muscarinic acetylcholine receptor M2;Butyrylcholinesterase; Protein Bche;Choline O-acetyltransferase;Muscarinic acetylcholine receptor M1;Amine oxidase [flavin-containing] A;Cholinesterase;Histamine N-methyltransferase;Butyrylcholinesterase;Glutamate NMDA receptor; GRIN1/GRIN2B;Glutamate NMDA receptor; GRIN1/GRIN2A;Muscarinic acetylcholine receptor;Amyloid beta A4 protein,NCCS(=O)(=O)O
Taurocholic acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O,,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Taurolidine,O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1,Toll-like receptor 9;Replicase polyprotein 1ab;Beta-lactamase;Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1,O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1
Tauroursodeoxycholic acid,[H][C@@]12CC[C@H]([C@H](C)CCC(=O)NCCS(O)(=O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@]2([H])C[C@H](O)CC[C@]12C,,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Tavaborole,OB1OCC2=CC(F)=CC=C12,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase;Leucine--tRNA ligase, cytoplasmic;Leucine-tRNA ligase",OB1OCc2cc(F)ccc21
Tazarotene,CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1,Retinoic acid receptor alpha;Retinoic acid receptor beta;Retinoic acid receptor gamma,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Tazemetostat,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,Polycomb protein EED;Histone-lysine N-methyltransferase EZH1;Histone-lysine N-methyltransferase EZH2,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Tazobactam,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O,Beta-lactamase;Beta-lactamase TEM;Beta-lactamase SHV-1;Beta-lactamase 1;IMI-1; IMI-1 carbapenemase;Carbapenem-hydrolizing beta-lactamase SFC-1;Carbepenem-hydrolyzing beta-lactamase KPC;Beta-lactamase GES-13;Class D beta-lactamase,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
Technetium Tc-99m disofenin,[99Tc].CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O,,CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O.[99Tc]
Technetium Tc-99m etidronate,[99Tc].CC(O)(P(O)(O)=O)P(O)(O)=O,,CC(O)(P(=O)(O)O)P(=O)(O)O.[99Tc]
Technetium Tc-99m mebrofenin,[Tc].CC1=CC(C)=C(Br)C(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O,,Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br.[Tc]
Technetium Tc-99m medronate,O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O,,O.O.O=P([O-])([O-])CP(=O)([O-])[O-].[98Tc+4]
Technetium Tc-99m oxidronate,[99Tc].OC(P(O)(O)=O)P(O)(O)=O,,O=P(O)(O)C(O)P(=O)(O)O.[99Tc]
Technetium Tc-99m pertechnetate,O.O.O.O.[98Tc-],,O.O.O.O.[98Tc-]
Technetium Tc-99m pyrophosphate,[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O,,O=P([O-])([O-])OP(=O)([O-])[O-].[99Tc+4]
Technetium Tc-99m sestamibi,[Tc+].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-],,[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Tc+]
Technetium Tc-99m succimer,[99Tc].OC(=O)[C@@H](S)[C@@H](S)C(O)=O,,O=C(O)[C@@H](S)[C@@H](S)C(=O)O.[99Tc]
Technetium Tc-99m sulfur colloid,[99Tc].S1SSSSSSS1,,S1SSSSSSS1.[99Tc]
Technetium Tc-99m tetrofosmin,O.O.[98Tc].CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC,,CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC.O.O.[98Tc]
Tecovirimat,FC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O,Envelope protein F13,O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1
Tedizolid,CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O,,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1
Tedizolid phosphate,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O,DNA topoisomerase 2-alpha,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1
Tegafur,FC1=CN(C2CCCO2)C(=O)NC1=O,,O=c1[nH]c(=O)n(C2CCCO2)cc1F
Tegafur-uracil,O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O,,O=c1[nH]c(=O)n(C2CCCO2)cc1F.O=c1cc[nH]c(=O)[nH]1
Tegaserod,CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2,5-hydroxytryptamine receptor 4;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 3A,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12
Teicoplanin,CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2OC3=C(Cl)C=C(C=C3)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]5NC(=O)[C@@H](CC6=CC=C(OC1=CC4=C2)C(Cl)=C6)NC(=O)[C@H](N)C1=CC=C(O)C(OC2=CC(O)=CC5=C2)=C1)C1=CC=C(O)C(=C1)C1=C(C=C(O)C=C1OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[C@H](NC3=O)C(O)=O,,CCCCCCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(OC4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@H](CO)[C@@H](O)[C@@H]1O
Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,"Plasminogen;Neutrophil elastase;Chymotrypsin-like elastase family member 1;Cathepsin B;Cathepsin L1;Chymase;Lysosomal protective protein;Cathepsin L2;Cathepsin K;Cathepsin S;Hepatitis C virus serine protease, NS3/NS4A;NS3 protease",CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
Telavancin,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O,,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O
Telbivudine,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,Capsid protein;Protein P,Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O
Telithromycin,[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1,Potassium voltage-gated channel subfamily H member 2,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C
Telmisartan,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O,Angiotensin-converting enzyme;Glycine receptor subunit alpha-1;Type-1 angiotensin II receptor;Peroxisome proliferator-activated receptor gamma;Type-2 angiotensin II receptor;Type-1B angiotensin II receptor;Type-1A angiotensin II receptor;Multidrug and toxin extrusion protein 1,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Telotristat ethyl,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1,,CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1
Temazepam,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,Nuclear receptor subfamily 1 group I member 3;GABA-A receptor alpha-1/beta-2/gamma-2,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21
Temocillin,CO[C@]1(NC(=O)C(C(O)=O)C2=CSC=C2)[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21
Temoporfin,OC1=CC=CC(=C1)C-1=C2\CCC(=N2)\C(=C2/N\C(\C=C2)=C(/C2=N/C(/C=C2)=C(\C2=CC=C\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1,,
Temozolomide,CN1N=NC2=C(N=CN2C1=O)C(N)=O,"Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase V;Carbonic anhydrase, alpha family;Carbonate dehydratase",Cn1nnc2c(C(N)=O)ncn2c1=O
Temsirolimus,OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC,Multidrug resistance protein 1;Peptidyl-prolyl cis-trans isomerase FKBP1A;Serine/threonine-protein kinase mTOR;Peptidyl-prolyl cis-trans isomerase FKBP3,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
Tenapanor,CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2,Sodium/hydrogen exchanger 3,CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Teniposide,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1,Multidrug resistance protein 1;DNA topoisomerase 2-alpha;ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 6;Canalicular multispecific organic anion transporter 2,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Tenofovir alafenamide,CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1,,CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1
Tenofovir disoproxil,[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,Protein P;DNA polymerase subunit gamma-1;Capsid protein,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C
Tenoxicam,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
Tepotinib,CN1CCC(COC2=CN=C(N=C2)C2=CC(CN3N=C(C=CC3=O)C3=CC(=CC=C3)C#N)=CC=C2)CC1,Interleukin-1 receptor-associated kinase 4;Hepatocyte growth factor receptor,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1
Terazosin,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1,Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;5-hydroxytryptamine receptor 2A;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Ribosyldihydronicotinamide dehydrogenase [quinone];Solute carrier family 22 member 1,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
Terbinafine,CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;Cytochrome P450 2D6;Squalene monooxygenase;Squalene epoxidase;Membrane-associated progesterone receptor component 1,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
Terbutaline,CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1,Beta-2 adrenergic receptor,CC(C)(C)NCC(O)c1cc(O)cc(O)c1
Terconazole,CC(C)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,Sodium/nucleoside cotransporter 1;5-hydroxytryptamine receptor 4;D(1A) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Alpha-1D adrenergic receptor;Lanosterol 14-alpha demethylase;Acetylcholinesterase;Tyrosine-protein kinase Fyn;Heme oxygenase 2;Arachidonate 15-lipoxygenase;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor,CC(C)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
Terfenadine,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Potassium voltage-gated channel subfamily H member 2;Multidrug resistance protein 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Epidermal growth factor receptor;C-C chemokine receptor type 5;Tyrosine-protein kinase Fyn;Cytochrome P450 2J2;Substance-K receptor;Potassium voltage-gated channel subfamily H member 1;Alpha-1B adrenergic receptor;Heat shock protein HSP 90-alpha;Adrenergic receptor alpha-1;Transcriptional activator protein luxR,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,"Dihydroorotate dehydrogenase (quinone), mitochondrial;Dihydrofolate reductase;Dihydroorotate dehydrogenase",C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1
Terizidone,O=C1NOCC1\N=C\C1=CC=C(\C=N\C2CONC2=O)C=C1,GABA-A receptor alpha-1/beta-2/gamma-2;Transient receptor potential cation channel subfamily M member 3,O=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1
Terpin hydrate,O.CC(C)(O)[C@H]1CC[C@@](C)(O)CC1,,CC(C)(O)[C@H]1CC[C@@](C)(O)CC1.O
Testolactone,[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H],Aromatase,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)OC(=O)CC[C@@H]12
Testosterone,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Sigma non-opioid intracellular receptor 1;Glucocorticoid receptor;Androgen receptor;Aromatase;Corticosteroid-binding globulin;Sex hormone-binding globulin;Lanosterol 14-alpha demethylase;Progesterone receptor;C-8 sterol isomerase;Steroid 5-alpha-reductase;Constitutive androstane receptor,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
Testosterone cypionate,[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Androgen receptor,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
Testosterone enantate benzilic acid hydrazone,[H]N(N=C1CC[C@@]2(C)C(CC[C@@]3([H])[C@]4([H])CC[C@H](OC(=O)CCCCCC)[C@@]4(C)CC[C@]23[H])=C1)C(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=NNC(=O)C(O)(c5ccccc5)c5ccccc5)CC[C@]4(C)[C@H]3CC[C@]12C
Testosterone enanthate,[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Androgen receptor,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Testosterone propionate,[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,Androgen receptor,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Testosterone undecanoate,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Androgen receptor,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Tetrabenazine,COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1,"D(2) dopamine receptor;Alpha-2A adrenergic receptor;Alpha-2C adrenergic receptor;Synaptic vesicular amine transporter;Chromaffin granule amine transporter;Sodium channel alpha subunits; brain (Types I, II, III)",COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2
Tetracaine,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,"Sodium channel protein type 5 subunit alpha;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;Sodium channel protein type 2 subunit alpha;Sodium channel protein type 8 subunit alpha;Sodium channel protein type 9 subunit alpha;Amine oxidase [flavin-containing] A;cGMP-gated cation channel alpha-1;Sodium channel alpha subunits; brain (Types I, II, III)",CCCCNc1ccc(C(=O)OCCN(C)C)cc1
Tetrachlorodecaoxide,O.O=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O,,O.O=O.[O-][Cl+][O-].[O-][Cl+][O-].[O-][Cl+][O-].[O-][Cl+][O-]
Tetracosactide,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O,Melanocortin receptor 4;Adrenocorticotropic hormone receptor,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C
Tetracycline,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,30S ribosomal protein S4;30S ribosomal protein S9,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
Tetracycline phosphate complex,[Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O.[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.O=P(=O)O.O=P(=O)O.O=P(=O)O.O=P(=O)O.O=P(=O)O.O=P(=O)[O-].[Na+]
Tetradecyl hydrogen sulfate (ester),CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O,,CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)O
Tetraferric tricitrate decahydrate,O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,,O.O.O.O.O.O.O.O.O.O.O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].[Fe+3].[Fe+3].[Fe+3].[Fe+3]
Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate,[Cu+].F[B-](F)(F)F.COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-],,F[B-](F)(F)F.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Cu+]
Tetramethylthiuram monosulfide,CN(C)C(=S)SC(=S)N(C)C,,CN(C)C(=S)SC(=S)N(C)C
Tetrofosmin,CCOCCP(CCOCC)CCP(CCOCC)CCOCC,5'-AMP-activated protein kinase subunit beta-1;Dipeptidyl peptidase 4;Solute carrier family 22 member 1;Solute carrier family 22 member 2;Solute carrier family 22 member 3;Mitochondrial complex I (NADH dehydrogenase),CCOCCP(CCOCC)CCP(CCOCC)CCOCC
Tetryzoline,C1CN=C(N1)C1CCCC2=CC=CC=C12,Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Adrenergic receptor alpha,c1ccc2c(c1)CCCC2C1=NCCN1
Tezacaftor,CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO,Cystic fibrosis transmembrane conductance regulator,CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO
Thalidomide,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Tumor necrosis factor;Cereblon isoform 4;Protein cereblon,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
Thallous chloride,[Cl-].[Tl+],,[Cl-].[Tl+]
Thallous chloride Tl-201,Cl[201Tl],,[Cl][201Tl]
Thenalidine,CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1,Urokinase-type plasminogen activator;Prothrombin;Trypsin-1;Suppressor of tumorigenicity 14 protein;Protein arginine N-methyltransferase 1,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1
Thenyldiamine,CN(C)CCN(CC1=CSC=C1)C1=CC=CC=N1,"Histamine H1 receptor;Histamine H4 receptor;Sodium channel alpha subunits; brain (Types I, II, III)",CN(C)CCN(Cc1ccsc1)c1ccccn1
Theophylline,CN1C2=C(NC=N2)C(=O)N(C)C1=O,"Adenosine receptor A2a;cGMP-inhibited 3',5'-cyclic phosphodiesterase A;Adenosine receptor A1;Adenosine receptor A2b;Adenosine receptor A3;cAMP-specific 3',5'-cyclic phosphodiesterase 4A;Alkaline phosphatase, tissue-nonspecific isozyme;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Uncharacterized protein;Adenosine A2 receptor;Adenosine A2b receptor;Adenosine receptor;Heart phosphodiesterase;Adenosine A2a receptor;Transmembrane domain-containing protein TMIGD3",Cn1c(=O)c2[nH]cnc2n(C)c1=O
Thiabendazole,N1C2=CC=CC=C2N=C1C1=CSC=N1,"Peptidyl-prolyl cis-trans isomerase FKBP1A;Cytochrome P450 1A2;Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial;Methionine aminopeptidase 2;Reverse transcriptase/RNaseH;Methionine aminopeptidase;Methionine aminopeptidase 1;Tubulin",c1ccc2[nH]c(-c3cscn3)nc2c1
Thiamine,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N,Thiamine transporter 1;Transketolase;Thiamin pyrophosphokinase 1;Thiamine-triphosphatase;Transketolase-like protein 1;Heat shock protein HSP 90-alpha;Thiamine transporter ThiT,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1
Thiamylal,CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O,GABA-A receptor; anion channel,C=CCC1(C(C)CCC)C(=O)NC(=S)NC1=O
Thiethylperazine,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;Alpha-1A adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Pleiotropic ABC efflux transporter of multiple drugs;FAD-linked sulfhydryl oxidase ALR,CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2
Thimerosal,[Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O,"Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 6;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Adenosine receptor A3;Carbonic anhydrase 4;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Toll-like receptor 9;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Mitogen-activated protein kinase 3;Carbonic anhydrase 13;Beta-lactamase",C[CH2][Hg][S]c1ccccc1C(=O)[O-].[Na+]
Thiohexam,C1CCC(CC1)NSC1=NC2=CC=CC=C2S1,,c1ccc2sc(SNC3CCCCC3)nc2c1
Thiopental,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor; anion channel;Potassium voltage-gated channel subfamily C member 4,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
Thioridazine,CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1,"Nuclear receptor subfamily 1 group I member 3;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Kappa-type opioid receptor;5-hydroxytryptamine receptor 5A;Cytochrome P450 1A2;5-hydroxytryptamine receptor 1E;Epidermal growth factor receptor;Cytochrome P450 2C19;Tyrosine-protein kinase Fyn;Serine/threonine-protein kinase pim-1;Membrane-associated progesterone receptor component 1;Pleiotropic ABC efflux transporter of multiple drugs;Muscarinic acetylcholine receptor;Serotonin 1 (5-HT1) receptor;Adrenergic receptor alpha-2;Dopamine receptor;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor;G protein-activated inward rectifier potassium channel 2",CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
Thiosulfuric acid,OS(O)(=O)=S,,O=S(O)(O)=S
Thiotepa,S=P(N1CC1)(N1CC1)N1CC1,Cytochrome P450 2B6,S=P(N1CC1)(N1CC1)N1CC1
Thiothixene,CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1,D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
Thiram,CN(C)C(=S)SSC(=S)N(C)C,Fatty-acid amide hydrolase 1;Gamma-butyrobetaine dioxygenase;Monoglyceride lipase;Bifunctional protein GlmU;Protein-lysine 6-oxidase;Lysyl oxidase homolog 3;Lysyl oxidase homolog 4;Histone-lysine N-methyltransferase EHMT2;Histone-lysine N-methyltransferase EHMT1;Lysyl oxidase homolog 2,CN(C)C(=S)SSC(=S)N(C)C
Thonzonium,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1,Insulin-degrading enzyme;Dual specificity tyrosine-phosphorylation-regulated kinase 1A,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1
Thonzylamine,COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1,Histamine H1 receptor,COc1ccc(CN(CCN(C)C)c2ncccn2)cc1
Threonine,C[C@@H](O)[C@H](N)C(O)=O,"Sodium channel alpha subunits; brain (Types I, II, III)",C[C@@H](O)[C@H](N)C(=O)O
Thymol,CC(C)C1=CC=C(C)C=C1O,Transient receptor potential cation channel subfamily A member 1;Transient receptor potential cation channel subfamily M member 8;Heat sensitive channel TRPV3,Cc1ccc(C(C)C)c(O)c1
Tiagabine,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,Sodium- and chloride-dependent GABA transporter 1;Sodium- and chloride-dependent betaine transporter,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C
Tiaprofenic acid,CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1,,CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1
Tibolone,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H],Sodium-dependent serotonin transporter;Estrogen receptor;Androgen receptor;Progesterone receptor;Cytochrome P450 2C19;Steryl-sulfatase,C#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
Ticagrelor,CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1,P2Y purinoceptor 12;Equilibrative nucleoside transporter 1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Ticarcillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O,Penicillin-binding protein 1A;Bacterial penicillin-binding protein,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O
Ticlopidine,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Cytochrome P450 2A6;Bile salt export pump;P2Y purinoceptor 12;Cytochrome P450 2C19;Cytochrome P450 2B6;Membrane-associated progesterone receptor component 1,Clc1ccccc1CN1CCc2sccc2C1
Tigecycline,[H][C@@]12CC3=C(C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,DNA repair protein RAD52 homolog,CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Tilarginine,CNC(=N)NCCC[C@H](N)C(O)=O,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 2D6;Proteasome subunit alpha type-1;Sodium/calcium exchanger 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Calmodulin,CNC(=N)NCCC[C@H](N)C(=O)O
Tilbroquinol,CC1=C2C=CC=NC2=C(O)C(Br)=C1,Catechol O-methyltransferase;Botulinum neurotoxin type A;Carbonic anhydrase 15;Amyloid beta A4 protein,Cc1cc(Br)c(O)c2ncccc12
Tiludronic acid,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O,,O=P(O)(O)C(Sc1ccc(Cl)cc1)P(=O)(O)O
Timolol,[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 1A;Beta-3 adrenergic receptor,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
Tinidazole,CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O,3-oxoacyl-[acyl-carrier-protein] synthase 3,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
Tioconazole,ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1,"Lanosterol 14-alpha demethylase;Steroid 17-alpha-hydroxylase/17,20 lyase",Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1
Tioguanine,NC1=NC(=S)C2=C(N1)N=CN2,Prostaglandin G/H synthase 1;Adenosine receptor A3;Multidrug resistance-associated protein 5;Multidrug resistance-associated protein 4;Inosine-5'-monophosphate dehydrogenase 1;Xanthine dehydrogenase/oxidase;Inosine-5'-monophosphate dehydrogenase 2;Hypoxanthine-guanine phosphoribosyltransferase;Mitogen-activated protein kinase 3;Arachidonate 15-lipoxygenase;2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,Nc1nc(=S)c2[nH]cnc2[nH]1
Tiopronin,CC(S)C(=O)NCC(O)=O,Angiotensin-converting enzyme,CC(S)C(=O)NCC(=O)O
Tiotropium,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M5,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12
Tipiracil,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O,Thymidine phosphorylase,N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl
Tipranavir,[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O,Multidrug resistance protein 1;Cathepsin D;Pol polyprotein;CAAX prenyl protease 1 homolog;Cathepsin E;Pepsin A-5,CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1
Tirbanibulin,O=C(CC1=CC=C(C=N1)C1=CC=C(OCCN2CCOCC2)C=C1)NCC1=CC=CC=C1,Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lyn,O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1
Tirofiban,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O,Integrin alpha-IIb/beta-3,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O
Titanium dioxide,O=[Ti]=O,,[O]=[Ti]=[O]
Tivozanib,COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1,Platelet-derived growth factor receptor alpha;Ephrin type-B receptor 2;Platelet-derived growth factor receptor beta;Mast/stem cell growth factor receptor Kit;Receptor-type tyrosine-protein kinase FLT3;Hepatocyte growth factor receptor;Fibroblast growth factor receptor 1;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Tixocortol,[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CS
Tizanidine,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Alpha-2A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Nischarin;Alpha-1A adrenergic receptor;Alpha-1B adrenergic receptor,Clc1ccc2nsnc2c1NC1=NCCN1
Tobramycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,"Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)",NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O
Tocainide,CC(N)C(=O)NC1=C(C)C=CC=C1C,Sodium channel alpha subunit,Cc1cccc(C)c1NC(=O)C(C)N
Tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N,Tyrosine-protein kinase JAK3;Tyrosine-protein kinase ABL1;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Fyn;Proto-oncogene tyrosine-protein kinase receptor Ret;Calcium/calmodulin-dependent protein kinase type 1;Rho-associated protein kinase 1;Tyrosine-protein kinase JAK1;Protein kinase C delta type;Tyrosine-protein kinase JAK2;Rho-associated protein kinase 2;Calcium/calmodulin-dependent protein kinase type II subunit delta;Ribosomal protein S6 kinase alpha-2;Calcium/calmodulin-dependent protein kinase type II subunit alpha;Serine/threonine-protein kinase N1;BMP-2-inducible protein kinase;Calcium/calmodulin-dependent protein kinase type 1D;MAP kinase-interacting serine/threonine-protein kinase 2;Serine/threonine-protein kinase N2;Serine/threonine-protein kinase DCLK3;Serine/threonine-protein kinase 3;Ribosomal protein S6 kinase alpha-6;NUAK family SNF1-like kinase 2;Non-receptor tyrosine-protein kinase TNK1;Non-receptor tyrosine-protein kinase TYK2;Myotonin-protein kinase;Serine/threonine-protein kinase DCLK1;Ribosomal protein S6 kinase alpha-1;Mitogen-activated protein kinase kinase kinase kinase 2;G protein-coupled receptor kinase 7;Serine/threonine-protein kinase ULK3;Leucine-rich repeat serine/threonine-protein kinase 2;Serine/threonine-protein kinase PknB;JAK1/TYK2;JAK1/JAK2/TYK2;JAK2/TYK2;JAK2/JAK1;JAK3/JAK1,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Tolazamide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1,"Arachidonate 15-lipoxygenase;Sulfonylurea receptor 1, Kir6.2",Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
Tolazoline,C(C1=NCCN1)C1=CC=CC=C1,Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;Alpha-2C adrenergic receptor;Trace amine-associated receptor 1;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,c1ccc(CC2=NCCN2)cc1
Tolbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,"Solute carrier family 22 member 6;ATP-sensitive inward rectifier potassium channel 11;Sulfonylurea receptor 1, Kir6.2",CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1
Tolcapone,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O,Transthyretin;Catechol O-methyltransferase;G-protein coupled receptor 35;Krueppel-like factor 10;Bile salt export pump,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
Tolfenamic acid,CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O,,Cc1c(Cl)cccc1Nc1ccccc1C(=O)O
Tolmetin,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Aldose reductase;Lactoylglutathione lyase;Interleukin-8,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Tolnaftate,CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1,5-hydroxytryptamine receptor 2B;Cytochrome P450 2C19;Lanosterol 14-alpha demethylase,Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1
Tolterodine,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C,Potassium voltage-gated channel subfamily H member 2;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1
Tolvaptan,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,Vasopressin V1a receptor;Vasopressin V2 receptor,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1
Topiramate,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,"Sodium channel protein type 5 subunit alpha;Sodium channel protein type 1 subunit alpha;Nuclear receptor subfamily 1 group I member 2;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Sodium channel protein type 2 subunit alpha;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;GABA-A receptor alpha-1/beta-2/gamma-2;Carbonic anhydrase V;Glutamate receptor ionotropic kainate;Glutamate receptor ionotropic AMPA;Carbonic anhydrase, alpha family;Carbonate dehydratase",CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1
Topotecan,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,"Cytochrome P450 3A4;Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Nuclear receptor subfamily 1 group I member 2;ATP-binding cassette sub-family G member 2;Multidrug resistance-associated protein 4;DNA topoisomerase I, mitochondrial;DNA topoisomerase 1;Hypoxia-inducible factor 1-alpha;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;DNA topoisomerase I;ORF 73;UDP-galactopyranose mutase",CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
Torasemide,CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1,Solute carrier family 12 member 1,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
Toremifene,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,5-hydroxytryptamine receptor 6;Estrogen receptor;Estrogen-related receptor gamma;Envelope glycoprotein,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
Trabectedin,[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31,Proto-oncogene tyrosine-protein kinase Src;Nuclear receptor subfamily 1 group I member 2,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4
Tramadol,COC1=CC=CC(=C1)C1(O)CCCCC1CN(C)C,Mu-type opioid receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Kappa-type opioid receptor;Delta-type opioid receptor;Solute carrier family 22 member 1,COc1cccc(C2(O)CCCCC2CN(C)C)c1
Trametinib,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,Multidrug resistance protein 1;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1
Trandolapril,[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,Angiotensin-converting enzyme,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21
Tranexamic acid,NC[C@H]1CC[C@@H](CC1)C(O)=O,,NC[C@H]1CC[C@H](C(=O)O)CC1
Tranylcypromine,NC1CC1C1=CC=CC=C1,Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;Sodium-dependent dopamine transporter;Cytochrome P450 2A6;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Cytochrome P450 2C19;Cytochrome P450 2B6;Cationic trypsin;D(2) dopamine receptor;D(3) dopamine receptor;Lysine-specific histone demethylase 1A;Lysine-specific histone demethylase 1B;7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase,NC1CC1c1ccccc1
Travoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F,Prostaglandin E2 receptor EP3 subtype;Prostaglandin F2-alpha receptor,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O
Trazodone,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 1B;Membrane-associated progesterone receptor component 1;HLA class I histocompatibility antigen, A-3 alpha chain",O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
Treosulfan,CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O,,CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
Treprostinil,[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1,Prostaglandin E2 receptor EP1 subtype;Prostaglandin E2 receptor EP3 subtype;Prostacyclin receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor,CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O
Tretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O,"5-hydroxytryptamine receptor 2B;Adenosine receptor A3;Retinoic acid receptor alpha;11-cis retinol dehydrogenase;Nuclear receptor ROR-alpha;Retinoic acid receptor RXR-alpha;Retinoic acid receptor RXR-beta;Retinoic acid receptor RXR-gamma;Retinoic acid receptor beta;Retinoic acid receptor gamma;Peroxisome proliferator-activated receptor delta;Nuclear receptor ROR-beta;Nuclear receptor ROR-gamma;Mitogen-activated protein kinase 1;Cellular retinoic acid-binding protein 1;Cellular retinoic acid-binding protein 2;Indoleamine 2,3-dioxygenase 2;Nuclear receptor subfamily 2 group E member 1;Nuclear receptor subfamily 2 group C member 2;Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1",CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Triamcinolone,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Glucocorticoid receptor;Annexin A1;Progesterone receptor,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
Triamterene,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,"Solute carrier family 12 member 1;Cytochrome P450 2D6;Caspase-1;Cathepsin G;Pteridine reductase 1;Amiloride-sensitive sodium channel, ENaC",Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
Triazolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12,Cytochrome P450 3A4;Platelet-activating factor receptor;Cholecystokinin receptor type A;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-3;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;GABA-A receptor;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-3/beta-2/gamma-3;GABA A receptor alpha-5/beta-3/gamma-3;GABA A receptor alpha-5/beta-2/gamma-2;GABA A receptor alpha-5/beta-2/gamma-3,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2
Trichlormethiazide,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl,"Carbonic anhydrase 2;Solute carrier family 12 member 3;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13",NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
Trichloroethylene,ClC=C(Cl)Cl,,ClC=C(Cl)Cl
Triclabendazole,CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2,Cruzipain,CSc1nc2cc(Oc3cccc(Cl)c3Cl)c(Cl)cc2[nH]1
Triclocarban,ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1,Bifunctional epoxide hydrolase 2;Epoxide hydrolase; Epoxide hydrolase EphB;Epoxide hydrolase 1,O=C(Nc1ccc(Cl)cc1)Nc1ccc(Cl)c(Cl)c1
Triclofos,OP(O)(=O)OCC(Cl)(Cl)Cl,GABA-A receptor; anion channel,O=P(O)(O)OCC(Cl)(Cl)Cl
Triclosan,OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1,Enoyl-[acyl-carrier-protein] reductase [NADH];Carbonyl reductase [NADPH] 1;Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI;Enoyl-[acyl-carrier-protein] reductase [NADH] FabI;Enoyl-acyl-carrier protein reductase;Enoyl-acyl carrier reductase; Enoyl-acyl carrier reductase ENR;Enoyl-ACP reductase;Enoyl-[acyl-carrier-protein] reductase [NADPH];Enoyl-[acyl-carrier-protein] reductase [NULLDH];78 kDa glucose-regulated protein,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl
Triethylenetetramine,NCCNCCNCCN,,NCCNCCNCCN
Trifarotene,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=CC(=CC=C1OCCO)C1=CC=C(C=C1)C(O)=O,Retinoic acid receptor alpha;Retinoic acid receptor beta;Retinoic acid receptor gamma,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Trifluoperazine,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,"D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Potassium voltage-gated channel subfamily H member 2;3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;Multidrug resistance protein 1;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Muscarinic acetylcholine receptor M3;Alpha-2C adrenergic receptor;D(4) dopamine receptor;Calmodulin;Trypanothione reductase;DNA-dependent protein kinase catalytic subunit;NS3;Beta-glucuronidase;Lysozyme C-1;C-8 sterol isomerase;Pleiotropic ABC efflux transporter of multiple drugs;Emopamil-binding protein-like;Adrenergic receptor alpha-1;Sodium channel alpha subunits; brain (Types I, II, III);Serotonin 2 (5-HT2) receptor",CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
Triflupromazine,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,D(2) dopamine receptor;Multidrug resistance protein 1;5-hydroxytryptamine receptor 2A;Trypanothione reductase;Cholinesterase;Pleiotropic ABC efflux transporter of multiple drugs,CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21
Trifluridine,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F,Thymidine kinase;Thymidylate kinase,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F
Triflusal,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O,Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Carbonic anhydrase 2;Transthyretin;Carbonic anhydrase 1;Dihydrofolate reductase,CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
Triheptanoin,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC
Trihexyphenidyl,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1,Sigma non-opioid intracellular receptor 1;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Cytochrome P450 2D6,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1
Trilaciclib,CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1,Receptor-type tyrosine-protein kinase FLT3;Cyclin-dependent kinase 1;Cyclin-dependent kinase 2;Cyclin-dependent-like kinase 5;Cyclin-dependent kinase 9;Cyclin-dependent kinase 7;NUAK family SNF1-like kinase 2;Serine/threonine-protein kinase Nek10;Cyclin-dependent kinase 6;Cyclin-dependent kinase 4,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1
Trilostane,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O
Trimebutine,CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1,DNA-directed RNA polymerase subunit beta;Bacterial DNA-directed RNA polymerase,CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
Trimetazidine,COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1,"Carnitine O-palmitoyltransferase 1, muscle isoform",COc1ccc(CN2CCNCC2)c(OC)c1OC
Trimethadione,CN1C(=O)OC(C)(C)C1=O,Voltage-dependent T-type calcium channel subunit alpha-1G,CN1C(=O)OC(C)(C)C1=O
Trimethaphan,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1,Neuronal acetylcholine receptor subunit alpha-10;Neuronal acetylcholine receptor subunit alpha-7;Acetylcholine receptor subunit alpha;Nicotinic acetylcholine receptor alpha 5 subunit;Neuronal acetylcholine receptor; alpha3/beta4,O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1
Trimethobenzamide,COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1,Catalase-peroxidase;Enoyl-[acyl-carrier-protein] reductase [NADH];Polyphenol oxidase 2,COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC
Trimethoprim,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,Dihydrofolate reductase;Bifunctional dihydrofolate reductase-thymidylate synthase;Solute carrier family 22 member 1;Dihydrofolate reductase type 1,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC
Trimetrexate,COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC,"Dihydrofolate reductase;Folylpolyglutamate synthase, mitochondrial;Bifunctional dihydrofolate reductase-thymidylate synthase",COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC
Trimipramine,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;Histamine H1 receptor;Sodium-dependent dopamine transporter;Solute carrier family 22 member 1,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
Trioxsalen,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,Adenosine receptor A2a;5-hydroxytryptamine receptor 2C;Amine oxidase [flavin-containing] A,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
Tripelennamine,CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1,Histamine H1 receptor,CN(C)CCN(Cc1ccccc1)c1ccccn1
Triprolidine,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1,Histamine H1 receptor,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
Triptorelin,CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,Gonadotropin-releasing hormone receptor,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Tritoqualine,CCOC1=C(OCC)C(OCC)=C(N)C2=C1C(OC2=O)C1N(C)CCC2=CC3=C(OCO3)C(OC)=C12,,CCOc1c(N)c2c(c(OCC)c1OCC)C(C1c3c(cc4c(c3OC)OCO4)CCN1C)OC2=O
Troglitazone,CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O,"Cytochrome P450 3A4;5-hydroxytryptamine receptor 2B;Adenosine receptor A3;Carbonic anhydrase 2;Bile salt export pump;Cytochrome P450 2C9;Amine oxidase [flavin-containing] B;Amine oxidase [flavin-containing] A;Aldose reductase;Peroxisome proliferator-activated receptor gamma;Tyrosine-protein phosphatase non-receptor type 1;Glycogen [starch] synthase, liver;Thromboxane-A synthase;Mitogen-activated protein kinase 1;Indoleamine 2,3-dioxygenase 2;UDP-glucuronosyltransferase 1-6;Indoleamine 2,3-dioxygenase 1;Polyunsaturated fatty acid lipoxygenase ALOX15",Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
Trolamine,OCCN(CCO)CCO,"Angiotensin-converting enzyme;Glutamate receptor ionotropic, NMDA 1",OCCN(CCO)CCO
Trolamine salicylate,OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O,,O=C(O)c1ccccc1O.OCCN(CCO)CCO
Troleandomycin,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Cytochrome P450 3A4,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
Tromantadine,CN(C)CCOCC(=O)NC12CC3CC(CC(C3)C1)C2,Matrix protein 2;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Polymerase acidic protein,CN(C)CCOCC(=O)NC12CC3CC(CC(C3)C1)C2
Tromethamine,NC(CO)(CO)CO,"D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Aldehyde oxidase;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Cholinesterase;Major prion protein;Solute carrier family 22 member 1;Alpha-1B adrenergic receptor;Pleiotropic ABC efflux transporter of multiple drugs;Sodium channel alpha subunits; brain (Types I, II, III);Chloroquine resistance transporter;FAD-linked sulfhydryl oxidase ALR;Calmodulin;Calmodulin-1",NC(CO)(CO)CO
Tropicamide,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Cytochrome P450 2C9;Cytochrome P450 2C19,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
Tropisetron,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C,5-hydroxytryptamine receptor 4;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 3A;Glycine receptor subunit alpha-1;Glycine receptor subunit alpha-2;Neuronal acetylcholine receptor subunit alpha-7;Glycine receptor subunit beta;Serotonin 3 (5-HT3) receptor;Neuronal acetylcholine receptor; alpha4/beta2;Acetylcholine receptor; alpha1/beta1/delta/gamma;Serotonin 3 receptor (5HT3);5-hydroxytryptamine receptor 3B;Neuronal acetylcholine receptor subunit alpha-3,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2
Trospium,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1,Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M5,O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1
Trovafloxacin,[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O,Sodium-dependent dopamine transporter;Thromboxane-A synthase;Topoisomerase IV;DNA gyrase,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12
Trypan blue free acid,CC1=CC(=CC=C1\N=N\C1=C(C=C2C=C(C=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O,,Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O
Tryptophan,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O,Extracellular calcium-sensing receptor;Myeloperoxidase;Probable G-protein coupled receptor 139,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
Tubocurarine,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3,Muscarinic acetylcholine receptor M2;5-hydroxytryptamine receptor 3A;Neuronal acetylcholine receptor subunit alpha-7;Small conductance calcium-activated potassium channel protein 3;Small conductance calcium-activated potassium channel protein 2;Zinc-activated ligand-gated ion channel;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Acetylcholine receptor subunit alpha;Nicotinic acetylcholine receptor alpha 5 subunit;Neuronal acetylcholine receptor; alpha4/beta2;Acetylcholine receptor;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta4;Acetylcholine receptor; alpha1/beta1/delta/gamma;Serotonin 3 receptor (5HT3);Small conductance calcium-activated potassium channel protein 1;GABA-A receptor; anion channel,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
Tucatinib,CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1,Epidermal growth factor receptor;Receptor tyrosine-protein kinase erbB-4;ERBB2/ERBB3,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1
Tyropanoic acid,CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C(O)=O)=C1I,,CCCC(=O)Nc1c(I)cc(I)c(CC(CC)C(=O)O)c1I
Tyrosine,N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,Large neutral amino acids transporter small subunit 1,N[C@@H](Cc1ccc(O)cc1)C(=O)O
Ubidecarenone,COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O,Mineralocorticoid receptor,COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O
Ubiquinol,COC1=C(OC)C(O)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(C)=C1O,Catechol O-methyltransferase;Botulinum neurotoxin type A;Carbonic anhydrase 15;Amyloid beta A4 protein,COc1c(O)c(C)c(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)c(O)c1OC
Ubrogepant,C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1,Calcitonin gene-related peptide type 1 receptor,C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
Udenafil,CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C,"Multidrug resistance protein 1;cGMP-specific 3',5'-cyclic phosphodiesterase",CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc(=O)c2c([nH]1)c(CCC)nn2C
Ulipristal,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,Progesterone receptor,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Ulobetasol,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Sigma non-opioid intracellular receptor 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;Sodium-dependent dopamine transporter;Cytochrome P450 2D6;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;Alpha-1A adrenergic receptor;CAAX prenyl protease 1;CAAX prenyl protease 2,C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl
Umbralisib,CC(C)OC1=C(F)C=C(C=C1)C1=NN([C@@H](C)C2=C(C3=CC=CC(F)=C3)C(=O)C3=CC(F)=CC=C3O2)C2=C1C(N)=NC=N2,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform;Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;Casein kinase I isoform epsilon",CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Umeclidinium,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2,Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2
Undecoylium chloride iodine complex,[Cl-].CCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,,CCC(=O)OCCNC(=O)C[n+]1ccccc1.[Cl-]
Undecylenic acid,OC(=O)CCCCCCCCC=C,,C=CCCCCCCCCC(=O)O
Unoprostone,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,Prostaglandin E2 receptor EP1 subtype;Prostaglandin D2 receptor 2;Prostaglandin E2 receptor EP3 subtype;Prostacyclin receptor;Thromboxane A2 receptor;Prostaglandin E2 receptor EP2 subtype;Prostaglandin E2 receptor EP4 subtype;Prostaglandin D2 receptor;Prostaglandin F2-alpha receptor;Solute carrier family 22 member 6;Solute carrier family 22 member 20;Cation channel sperm-associated protein 1;Cation channel sperm-associated protein 2;Cation channel sperm-associated protein 3;Cation channel sperm-associated protein 4,CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O
Upadacitinib,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F,Non-receptor tyrosine-protein kinase TYK2;Tyrosine-protein kinase JAK3;Tyrosine-protein kinase JAK1;Tyrosine-protein kinase JAK2,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Uracil mustard,ClCCN(CCCl)C1=CNC(=O)NC1=O,Estrogen receptor,O=c1[nH]cc(N(CCCl)CCCl)c(=O)[nH]1
Urea,NC(N)=O,,NC(N)=O
Urea C-13,N[13C](N)=O,,N[13C](N)=O
Urea C-14,N[14C](N)=O,,N[14C](N)=O
Urethane,CCOC(N)=O,"Mu-type opioid receptor;Potassium voltage-gated channel subfamily H member 2;Kappa-type opioid receptor;Glutamate receptor ionotropic, NMDA 3A;Neuronal acetylcholine receptor subunit alpha-10;Delta-type opioid receptor;Opioid receptor",CCOC(N)=O
Uridine triacetate,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1C=CC(=O)NC1=O,,CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
Ursodeoxycholic acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Vaborbactam,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1,Beta-lactamase;Beta-lactamase TEM;Beta-lactamase SHV-1;Beta-lactamase 1;IMI-1; IMI-1 carbapenemase;Carbapenem-hydrolizing beta-lactamase SFC-1;Carbepenem-hydrolyzing beta-lactamase KPC;Beta-lactamase GES-13;Class D beta-lactamase,O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1
Valaciclovir,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O,DNA polymerase catalytic subunit,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21
Valbenazine,COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1,Synaptic vesicular amine transporter,COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
Valdecoxib,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,"Prostaglandin G/H synthase 2;Prostaglandin G/H synthase 1;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2B;Carbonic anhydrase 2;Carbonic anhydrase 1;Carbonic anhydrase 4;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase 3;Carbonic anhydrase 6;Carbonic anhydrase 14;Cytochrome c oxidase subunit 2;Carbonic anhydrase 13;Carbonic anhydrase;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Cytochrome c oxidase subunit 1;Carbonic anhydrase, alpha family;Carbonate dehydratase",Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Valganciclovir,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O,DNA polymerase catalytic subunit,CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21
Valine,CC(C)[C@H](N)C(O)=O,Large neutral amino acids transporter small subunit 1,CC(C)[C@H](N)C(=O)O
Valproate bismuth,[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O,,CCCC(CCC)C(=O)[O-].CCCC(CCC)C(=O)[O-].CCCC(CCC)C(=O)[O-].[Bi+3]
Valproic acid,CCCC(CCC)C(O)=O,,CCCC(CCC)C(=O)O
Valrubicin,[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1,DNA topoisomerase 2-alpha,CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O,Type-1 angiotensin II receptor;Type-1B angiotensin II receptor;Type-1A angiotensin II receptor;Angiotensin II receptor (AT-1) type-1,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Vanadium,[V],,[V]
Vancomycin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,Alpha-2A adrenergic receptor;D-alanyl-D-alanine dipeptidase;UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Vandetanib,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1,"Macrophage-stimulating protein receptor;Platelet-derived growth factor receptor beta;Tyrosine-protein kinase ABL1;Mast/stem cell growth factor receptor Kit;Epidermal growth factor receptor;Proto-oncogene tyrosine-protein kinase Src;Tyrosine-protein kinase Lck;Tyrosine-protein kinase Yes;Tyrosine-protein kinase Fyn;Ephrin type-A receptor 2;Receptor-type tyrosine-protein kinase FLT3;Proto-oncogene tyrosine-protein kinase receptor Ret;Vascular endothelial growth factor receptor 1;Vascular endothelial growth factor receptor 2;Vascular endothelial growth factor receptor 3;Macrophage colony-stimulating factor 1 receptor;Platelet-derived growth factor receptor alpha;Receptor tyrosine-protein kinase erbB-2;Phosphorylase b kinase gamma catalytic chain, liver/testis isoform;Fibroblast growth factor receptor 3;Tyrosine-protein kinase HCK;Receptor tyrosine-protein kinase erbB-4;Rho-associated protein kinase 2;Tyrosine-protein kinase CSK;Angiopoietin-1 receptor;Ephrin type-A receptor 8;Hepatocyte growth factor receptor;Tyrosine-protein kinase Lyn;5'-AMP-activated protein kinase catalytic subunit alpha-1;Fibroblast growth factor receptor 1;Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform;Serine/threonine-protein kinase 10;Serine/threonine-protein kinase PLK4;Aurora kinase C;Abelson tyrosine-protein kinase 2;Ephrin type-A receptor 5;Ephrin type-A receptor 4;Fibroblast growth factor receptor 2;Ephrin type-A receptor 6;TRAF2 and NCK-interacting protein kinase;Casein kinase I isoform epsilon;Tyrosine-protein kinase Fgr;ALK tyrosine kinase receptor;Ephrin type-A receptor 3;Tyrosine-protein kinase FRK;Mitogen-activated protein kinase kinase kinase kinase 5;Mitogen-activated protein kinase kinase kinase 4;Cyclin-G-associated kinase;Receptor-interacting serine/threonine-protein kinase 2;Ephrin type-B receptor 1;Ephrin type-A receptor 7;STE20-like serine/threonine-protein kinase;MAP kinase-interacting serine/threonine-protein kinase 2;Epithelial discoidin domain-containing receptor 1;Ephrin type-B receptor 4;Serine/threonine-protein kinase receptor R3;Activin receptor type-1;Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2;Protein-tyrosine kinase 6;Tyrosine-protein kinase BTK;Tyrosine-protein kinase receptor UFO;Tyrosine-protein kinase receptor TYRO3;Ephrin type-B receptor 2;Cyclin-dependent kinase 7;Ribosomal protein S6 kinase beta-1;Ribosomal protein S6 kinase alpha-6;Mitogen-activated protein kinase kinase kinase MLT;Tyrosine-protein kinase receptor Tie-1;Tyrosine-protein kinase TXK;MAP kinase-interacting serine/threonine-protein kinase 1;Serine/threonine-protein kinase SIK2;Serine/threonine-protein kinase 33;Serine/threonine-protein kinase TNNI3K;Discoidin domain-containing receptor 2;Chaperone activity of bc1 complex-like, mitochondrial;Serine/threonine-protein kinase MRCK gamma;Leukocyte tyrosine kinase receptor;Mitogen-activated protein kinase kinase kinase kinase 1;Mitogen-activated protein kinase kinase kinase kinase 3;Tyrosine-protein kinase Blk;Mitogen-activated protein kinase kinase kinase kinase 4;Tyrosine-protein kinase Mer;Serine/threonine-protein kinase MRCK alpha;Serine/threonine-protein kinase MRCK beta;Citron Rho-interacting kinase;AarF domain-containing protein kinase 4;Serine/threonine-protein kinase SIK1;Tyrosine-protein kinase Srms;Dual specificity testis-specific protein kinase 1;Ephrin type-A receptor 1;Tubulin alpha-1A chain;Mitogen-activated protein kinase 6;Fibroblast growth factor receptor 4;Ribosomal protein S6 kinase alpha-1;Mitogen-activated protein kinase kinase kinase kinase 2;Misshapen-like kinase 1;Interleukin-1 receptor-associated kinase 4;Ephrin type-B receptor 6;Hormonally up-regulated neu tumor-associated kinase;Interleukin-1 receptor-associated kinase 1;Serine/threonine-protein kinase ULK3;Mitogen-activated protein kinase kinase kinase 19;Receptor-interacting serine/threonine-protein kinase 4;Serine/threonine-protein kinase 35;Receptor tyrosine-protein kinase erbB-3;Serine/threonine-protein kinase SIK3;Bone morphogenetic protein receptor type-1B;Serine/threonine-protein kinase 32A;Dual specificity mitogen-activated protein kinase kinase 5",COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1
Vanillyl butyl ether,CCCCOCC1=CC(OC)=C(O)C=C1,,CCCCOCc1ccc(O)c(OC)c1
Vardenafil,CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1,"cGMP-specific 3',5'-cyclic phosphodiesterase;Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha;Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A;cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A;cGMP-dependent 3',5'-cyclic phosphodiesterase;High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A;Phosphodiesterase 3;Phosphodiesterase 4;Phosphodiesterase 1",CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12
Varenicline,C1C2CNCC1C1=C2C=C2N=CC=NC2=C1,Neuronal acetylcholine receptor subunit alpha-7;Neuronal acetylcholine receptor; alpha2/beta2;Neuronal acetylcholine receptor; alpha3/beta2;Neuronal acetylcholine receptor; alpha3/beta4;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Acetylcholine receptor; alpha1/beta1/delta/gamma;Neuronal acetylcholine receptor; alpha2/beta4;Acetylcholine receptor,c1cnc2cc3c(cc2n1)C1CNCC3C1
Vasopressin,NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O.NC1CSSCC(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O,Vasopressin V1a receptor;Vasopressin V1b receptor;Vasopressin V2 receptor;Oxytocin receptor;Vasopressin V1 receptor,NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Vecuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Neuronal acetylcholine receptor; alpha2/beta4;Acetylcholine receptor;Neuronal acetylcholine receptor; alpha4/beta2;Neuronal acetylcholine receptor; alpha4/beta4;Acetylcholine receptor; alpha1/beta1/delta/gamma,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
Velpatasvir,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC=C(N1)C1=CC=C2C(COC3=CC4=C(C=CC5=C4NC(=N5)[C@@H]4CC[C@H](C)N4C(=O)[C@@H](NC(=O)OC)C(C)C)C=C23)=C1,Nonstructural protein 5A;Genome polyprotein,COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,"RAF proto-oncogene serine/threonine-protein kinase;Serine/threonine-protein kinase B-raf;Vascular endothelial growth factor receptor 2;Mitogen-activated protein kinase kinase kinase MLT;Serine/threonine-protein kinase A-Raf;GTPase KRas;Ferrochelatase, mitochondrial",CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Venetoclax,CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1,Bcl-2-like protein 1;Apoptosis regulator Bcl-W;Apoptosis regulator Bcl-2,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Venlafaxine,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Sodium-dependent dopamine transporter;Alpha-1A adrenergic receptor;Transporter,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
Verapamil,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,"Sodium channel protein type 5 subunit alpha;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Cytochrome P450 3A4;Multidrug resistance protein 1;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;D(3) dopamine receptor;Histamine H2 receptor;Aldehyde oxidase;Alpha-1D adrenergic receptor;Voltage-dependent L-type calcium channel subunit alpha-1C;Multidrug resistance-associated protein 1;ATP-binding cassette sub-family G member 2;Carbonic anhydrase 1;G protein-activated inward rectifier potassium channel 2;Voltage-dependent T-type calcium channel subunit alpha-1H;Voltage-dependent L-type calcium channel subunit alpha-1S;Potassium voltage-gated channel subfamily A member 10;Potassium voltage-gated channel subfamily A member 3;Potassium voltage-gated channel subfamily C member 2;Solute carrier family 22 member 1;Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;Potassium voltage-gated channel subfamily A member 7;Alpha-1B adrenergic receptor;Membrane-associated progesterone receptor component 1;Alpha-1A adrenergic receptor;Translocator protein;Muscarinic acetylcholine receptor M2;Solute carrier family 22 member 2;Sodium channel alpha subunits; brain (Types I, II, III);Voltage-gated L-type calcium channel;Equilibrative nucleoside transporter 4;Chloroquine resistance transporter;Two pore calcium channel protein 1;Two pore calcium channel protein 2",COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
Vericiguat,COC(=O)NC1=C(N)N=C(N=C1N)C1=NN(CC2=CC=CC=C2F)C2=C1C=C(F)C=N2,Guanylate cyclase soluble subunit beta-1,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N
Vernakalant,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1,Sodium channel protein type 5 subunit alpha;Potassium voltage-gated channel subfamily H member 2;Potassium voltage-gated channel subfamily D member 2;Potassium voltage-gated channel subfamily A member 5,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC
Verteporfin,COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C,,C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC
Vibegron,[H][C@@]1(CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)[C@H](O)C1=CC=CC=C1,Beta-3 adrenergic receptor,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21
Vidarabine,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,"DNA polymerase catalytic subunit;Deoxycytidine kinase;DNA polymerase alpha catalytic subunit;Ribonucleoside-diphosphate reductase large subunit;Ribonucleoside-diphosphate reductase subunit M2;Deoxyguanosine kinase, mitochondrial;Ribose-phosphate pyrophosphokinase 1;Dipeptidyl peptidase 4;Adenylate cyclase type V;Adenosylhomocysteinase ",Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Vigabatrin,NC(CCC(O)=O)C=C,"4-aminobutyrate aminotransferase, mitochondrial;Gamma-amino-N-butyrate transaminase",C=CC(N)CCC(=O)O
Vilanterol,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O
Vilazodone,NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1,D(2) dopamine receptor;Sodium-dependent serotonin transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 7;D(3) dopamine receptor;Histamine H1 receptor;5-hydroxytryptamine receptor 4;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 2A;Acetylcholinesterase;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 1D;D(4) dopamine receptor;5-hydroxytryptamine receptor 6;Serotonin 3 (5-HT3) receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1
Vildagliptin,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N,Prolyl endopeptidase FAP;Dipeptidyl peptidase 8;Dipeptidyl peptidase 9;Dipeptidyl peptidase IV;Dipeptidyl peptidase 4,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2
Viloxazine,CCOC1=CC=CC=C1OCC1CNCCO1,Sodium-dependent serotonin transporter;Sodium-dependent dopamine transporter;Transporter;Sodium-dependent noradrenaline transporter,CCOc1ccccc1OCC1CNCCO1
Vinblastine,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC,Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Multidrug resistance-associated protein 1;Multidrug resistance-associated protein 7;Thromboxane-A synthase;Arachidonate 15-lipoxygenase;Amine oxidase [flavin-containing] B;Tubulin beta,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Vincristine,[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC,Multidrug resistance protein 1;Canalicular multispecific organic anion transporter 1;Multidrug resistance-associated protein 1;Multidrug resistance-associated protein 7;Tubulin;Tubulin beta,CC[C@]1(O)C[C@@H]2C[N@@](CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Vindesine,[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC,Cytochrome P450 3A4,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Vinflunine,CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC,Tubulin beta,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)C[N@](Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
Vinorelbine,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC,Cytochrome P450 3A4;Substance-K receptor;Tubulin beta,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Viomycin,[H][C@@]1(C[C@H](O)NC(=N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)CCCN)=C\NC(N)=O,"Indoleamine 2,3-dioxygenase 1",N=C1N[C@@H](O)C[C@H]([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC2=O)N1
Vismodegib,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1,Sonic hedgehog protein;Smoothened homolog,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Vitamin A,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C,Glutathione S-transferase P;Alpha-tocopherol transfer protein,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1
Vitamin E,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C,Glutathione S-transferase P;Alpha-tocopherol transfer protein,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
Voclosporin,[H][C@@]1([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O)C(C)C,Peptidyl-prolyl cis-trans isomerase A,C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
Vonoprazan,CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1,Potassium-transporting ATPase,CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1
Vorapaxar,[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC,Proteinase-activated receptor 1,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1
Voriconazole,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,"Cytochrome P450 3A4;Lanosterol 14-alpha demethylase;Cytochrome P450 2C9;Cytochrome P450 2C19;14-alpha sterol demethylase Cyp51A;14-alpha sterol demethylase;Cytochrome P450 11A1;Cholesterol side-chain cleavage enzyme, mitochondrial;Cholesterol 24-hydroxylase",C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
Vorinostat,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,Histone deacetylase 5;Histone deacetylase 2;Histone deacetylase 1;Histone deacetylase 3;Histone deacetylase 6;Histone deacetylase 7;Histone deacetylase 8;Histone deacetylase 4;Histone deacetylase 9;Leukotriene A-4 hydrolase;Histone deacetylase 10;HD2 type histone deacetylase HDA106; Histone deacetylase 2b; Uncharacterized protein;Histone deacetylase;Histone deacetylase-like amidohydrolase;Histone deacetylase 11;Lysine-specific demethylase 4E;Bromodomain-containing protein 4;Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2);Histone deacetylase 3/NCoR1;Histone deacetylase 1/3/5/8;Histone deacetylase (HDAC1 and HDAC2),O=C(CCCCCCC(=O)Nc1ccccc1)NO
Vortioxetine,CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;Histamine H1 receptor;Histamine H2 receptor;5-hydroxytryptamine receptor 5A;Sodium-dependent serotonin transporter;Sodium-dependent dopamine transporter;5-hydroxytryptamine receptor 3A;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 7;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 1B,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
Voxelotor,CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1,Cytochrome P450 3A4;Cytochrome P450 2C8;Cytochrome P450 2C9;hemoglobin subunit alpha,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O
Voxilaprevir,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C,Genome polyprotein,CC[C@@H]1[C@@H]2CN(C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]3C[C@H]3CCCCC(F)(F)c3nc4ccc(OC)cc4nc3O2)[C@@H]1C(=O)N[C@]1(C(=O)NS(=O)(=O)C2(C)CC2)C[C@H]1C(F)F
Warfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,Cytochrome P450 3A4;Cytochrome P450 2C9;Vitamin K epoxide reductase complex subunit 1;Proprotein convertase subtilisin/kexin type 7;Vitamin K epoxide reductase complex subunit 1-like protein 1,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Xamoterol,OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;Beta-3 adrenergic receptor,O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1
Xanthinol,CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C,,CN(CCO)CC(O)Cn1cnc2c1c(=O)n(C)c(=O)n2C
Xenon Xe-127,[127Xe],,[127Xe]
Xenon Xe-129,[129Xe],,[129Xe]
Xenon-133,[133Xe],,[133Xe]
Ximelagatran,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1,Urokinase-type plasminogen activator;Plasminogen;Coagulation factor X;Tissue-type plasminogen activator;Coagulation factor VII;Vitamin K-dependent protein C;Cationic trypsin;Coagulation factor XI;Prothrombin,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1
Xylometazoline,CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C,Alpha-2A adrenergic receptor;Alpha-1A adrenergic receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Adrenergic receptor alpha-2;Adrenergic receptor alpha-1;Adrenergic receptor alpha;Alpha-2B adrenergic receptor,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
Xylose,OC[C@@H](O)[C@H](O)[C@@H](O)C=O,,O=C[C@H](O)[C@@H](O)[C@H](O)CO
Yohimbine,[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,"D(2) dopamine receptor;Alpha-2A adrenergic receptor;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Cytochrome P450 2D6;Adenosine receptor A3;Alpha-1D adrenergic receptor;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;DNA topoisomerase 1;5-hydroxytryptamine receptor 2A;Voltage-dependent L-type calcium channel subunit alpha-1C;Adrenergic receptor alpha-2;Dopamine receptor;Sodium channel alpha subunits; brain (Types I, II, III);Alpha-2 adrenergic receptor;Dual specificity phosphatase Cdc25A",COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O
Yttrium Y-90,[90Y],,[90Y]
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Cytochrome P450 3A4;Adenosine receptor A3;Cytochrome P450 2C9;Cysteinyl leukotriene receptor 1;Cytosolic phospholipase A2;Epidermal growth factor receptor;Peroxisome proliferator-activated receptor gamma;Thromboxane-A synthase;Mitogen-activated protein kinase 3;Cysteinyl leukotriene receptor 2;Mitogen-activated protein kinase 14;Leukotriene B4 receptor 1;Bifunctional epoxide hydrolase 2;Mitogen-activated protein kinase 1;Solute carrier family 22 member 2;Multidrug and toxin extrusion protein 1;Multidrug and toxin extrusion protein 2;Sodium/bile acid cotransporter;Prostaglandin E synthase,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Deoxycytidine kinase;Reverse transcriptase/RNaseH,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1
Zaleplon,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-2,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
Zanamivir,[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Neuraminidase;Sialidase 3;Sialidase 2;Sialidase-4,CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1N=C(N)N
Zanubrutinib,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1,Tyrosine-protein kinase BTK,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
Zeaxanthin,C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1
Ziconotide,[H][C@]12CSSC[C@]3([H])NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC[C@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC3=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N2,Voltage-dependent N-type calcium channel subunit alpha-1B;Voltage-dependent P/Q-type calcium channel subunit alpha-1A,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O
Zidovudine,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,"Sigma non-opioid intracellular receptor 1;5-hydroxytryptamine receptor 2A;Thymidine kinase, cytosolic;Thymidylate kinase;Pol polyprotein;Reverse transcriptase/RNaseH;Gag-Pro-Pol polyprotein;Reverse transcriptase;Thymidine kinase;Reverse transcriptase protein",Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Arachidonate 5-lipoxygenase;Arachidonate 15-lipoxygenase;Cysteinyl leukotriene receptor 2;Leukotriene A-4 hydrolase;Leukotriene B4 receptor 1;Arachidonate 5-lipoxygenase-activating protein;Bifunctional epoxide hydrolase 2;Prostaglandin E synthase,CC(c1cc2ccccc2s1)N(O)C(N)=O
Zimelidine,CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1,D(2) dopamine receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter,CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1
Zinc,[Zn],,[Zn]
Zinc acetate,[Zn++].CC([O-])=O.CC([O-])=O,,CC(=O)[O-].CC(=O)[O-].[Zn+2]
Zinc ascorbate,[Zn++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,,O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Zn+2]
Zinc chloride,[Cl-].[Cl-].[Zn++],,[Cl-].[Cl-].[Zn+2]
Zinc dibutyldithiocarbamate,[Zn++].CCCCN(CCCC)C([S-])=S.CCCCN(CCCC)C([S-])=S,,CCCCN(CCCC)C(=S)[S-].CCCCN(CCCC)C(=S)[S-].[Zn+2]
Zinc gluconate,[Zn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O,,O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Zn+2]
Zinc oxide,O=[Zn],Soluble guanylate cyclase,[O]=[Zn]
Zinc phenolsulfonate,[Zn++].OC1=CC=C(C=C1)S([O-])(=O)=O.OC1=CC=C(C=C1)S([O-])(=O)=O,,O=S(=O)([O-])c1ccc(O)cc1.O=S(=O)([O-])c1ccc(O)cc1.[Zn+2]
Zinc sulfate,[Zn++].[O-]S([O-])(=O)=O,,O=S(=O)([O-])[O-].[Zn+2]
Ziprasidone,ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Potassium voltage-gated channel subfamily H member 2;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2B;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E;Transporter;Adrenergic receptor alpha-1;Histone H1.0,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
Zirconium chloride hydroxide,O[Zr]Cl,,[OH][Zr][Cl]
Zofenopril,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1,Angiotensin-converting enzyme,C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@@H](Sc2ccccc2)C[C@H]1C(=O)O
"Zoledronate D,L-Lysine Monohydrate",O.NCCCCC(N)C(O)=O.OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,,NCCCCC(N)C(=O)O.O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O
Zoledronic acid,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,,O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O
Zolmitriptan,CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12,5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1F;5-hydroxytryptamine receptor 1E;D(2) dopamine receptor;D(1A) dopamine receptor;Adrenergic receptor alpha-2,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12
Zolpidem,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Multidrug resistance protein 1;Translocator protein;Gamma-aminobutyric acid receptor subunit alpha-5;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-2/beta-3/gamma-2;GABA-A receptor alpha-3/beta-3/gamma-2;GABA-A receptor alpha-1/beta-3/gamma-2;GABA-A receptor; anion channel;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-6/beta-2/gamma-2;GABA-A receptor; alpha-1/beta-2/gamma-2;GABA A receptor alpha-2/beta-2/gamma-2;CAAX prenyl protease 2,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,"Sodium channel protein type 1 subunit alpha;Carbonic anhydrase 2;Voltage-dependent T-type calcium channel subunit alpha-1G;Carbonic anhydrase 1;Carbonic anhydrase 4;Amine oxidase [flavin-containing] B;Carbonic anhydrase 9;Carbonic anhydrase 12;Carbonic anhydrase 5A, mitochondrial;Carbonic anhydrase 5B, mitochondrial;Carbonic anhydrase 7;Carbonic anhydrase;Carbonic anhydrase 6;Carbonic anhydrase 14;Carbonic anhydrase 13;Carbonic anhydrase 15;Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase;Alpha carbonic anhydrase;Astrosclerin-3;Beta-carbonic anhydrase 1;Delta carbonic anhydrase;Carbonic anhydrase V;Carbonic anhydrase 3;Amine oxidase [flavin-containing];Carbonic anhydrase, alpha family;Carbonate dehydratase",NS(=O)(=O)Cc1noc2ccccc12
Zopiclone,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,GABA-A receptor; anion channel;GABA-A receptor alpha-1/beta-2/gamma-2;GABA-A receptor alpha-5/beta-3/gamma-2;GABA-A receptor alpha-1/beta-2/gamma-3;GABA A receptor alpha-3/beta-2/gamma-2;GABA A receptor alpha-3/beta-2/gamma-3;GABA A receptor alpha-5/beta-3/gamma-3;GABA A receptor alpha-5/beta-2/gamma-2;GABA A receptor alpha-5/beta-2/gamma-3,CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1
Zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,Beta-1 adrenergic receptor;Beta-2 adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor;Alpha-2A adrenergic receptor;Sodium-dependent serotonin transporter;Sodium-dependent noradrenaline transporter;5-hydroxytryptamine receptor 1A;5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 2C;5-hydroxytryptamine receptor 6;5-hydroxytryptamine receptor 7;Alpha-1A adrenergic receptor;Alpha-2B adrenergic receptor;D(3) dopamine receptor;D(1B) dopamine receptor;Histamine H1 receptor;Histamine H2 receptor;Histamine H4 receptor;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M4;Muscarinic acetylcholine receptor M5;5-hydroxytryptamine receptor 1B;5-hydroxytryptamine receptor 1D;Alpha-2C adrenergic receptor;Sodium-dependent dopamine transporter;D(4) dopamine receptor;5-hydroxytryptamine receptor 3A;Alpha-1B adrenergic receptor;5-hydroxytryptamine receptor 5A;5-hydroxytryptamine receptor 1E,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21
Zucapsaicin,COC1=C(O)C=CC(CNC(=O)CCCC\C=C/C(C)C)=C1,Transient receptor potential cation channel subfamily V member 1,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O
Zuclopenthixol,OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1,5-hydroxytryptamine receptor 2A;5-hydroxytryptamine receptor 6;Alpha-1A adrenergic receptor;D(1A) dopamine receptor;D(2) dopamine receptor,OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1
Zytron,COP(=S)(NC(C)C)OC1=CC=C(Cl)C=C1Cl,,COP(=S)(NC(C)C)Oc1ccc(Cl)cc1Cl
alpha-Amyl cinnamaldehyde,CCCCC\C(C=O)=C\C1=CC=CC=C1,,CCCCC/C(C=O)=C/c1ccccc1
alpha-Arbutin,OC[C@H]1O[C@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,Tyrosinase;Polyphenol oxidase 2,OC[C@H]1O[C@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O
alpha-Linolenic acid,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,"Prostaglandin G/H synthase 1;Aromatase;Peroxisome proliferator-activated receptor alpha;Peroxisome proliferator-activated receptor gamma;Fatty acid-binding protein, heart;Peroxisome proliferator-activated receptor delta;Free fatty acid receptor 1;Tissue factor;Prostaglandin G/H synthase 2",CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O
alpha-Tocopherol succinate,[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@]1(C)CCC2=C(C)C(OC(=O)CCC(O)=O)=C(C)C(C)=C2O1,,Cc1c(C)c2c(c(C)c1OC(=O)CCC(=O)O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
gamma-Aminobutyric acid,NCCCC(O)=O,Sodium- and chloride-dependent GABA transporter 1;Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit rho-1;Sodium- and chloride-dependent GABA transporter 3;Sodium- and chloride-dependent betaine transporter;Sodium- and chloride-dependent GABA transporter 2;Gamma-aminobutyric acid receptor subunit gamma-1;Gamma-aminobutyric acid type B receptor subunit 1,NCCCC(=O)O
gamma-Hydroxybutyric acid,OCCCC(O)=O,Sodium- and chloride-dependent GABA transporter 1;Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit rho-1;Sodium- and chloride-dependent GABA transporter 3;Sodium- and chloride-dependent betaine transporter;Sodium- and chloride-dependent GABA transporter 2;Gamma-aminobutyric acid receptor subunit gamma-1;Gamma-aminobutyric acid type B receptor subunit 1,O=C(O)CCCO
p-Phenylenediamine,NC1=CC=C(N)C=C1,Histamine H1 receptor,Nc1ccc(N)cc1
